tternquist · April 21, 2026 15:21
diff --git a/trials_slim.jsonl b/trials_slim.jsonl
 {"nctId": "NCT00883051", "briefTitle": "Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment", "officialTitle": "A Double Blind Randomized Placebo-Controlled Parallel Group Dose-Ranging Study of Oral COL-144 in the Acute Treatment of Migraine", "overallStatus": "COMPLETED", "startDate": "2009-07", "completionDate": "2010-02", "leadSponsor": "Eli Lilly and Company", "collaborators": ["CoLucid Pharmaceuticals"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 512, "briefSummary": "The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.", "conditions": ["Migraine Disorders"], "keywords": ["COL-144", "acute treatment", "migraine"], "interventions": [{"type": "DRUG", "name": "Lasmiditan", "otherNames": ["LY573144"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Migraine Disorders"], "meshInterventions": ["lasmiditan"], "hasResults": true, "classifyText": "Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment Migraine Disorders COL-144 acute treatment migraine Lasmiditan Placebo Migraine Disorders lasmiditan The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation."}
 {"nctId": "NCT00190762", "briefTitle": "A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma", "officialTitle": "A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma", "overallStatus": "COMPLETED", "startDate": "2001-10", "completionDate": "2005-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 240, "briefSummary": "Based on results from earlier clinical trials, Pemetrexed may have antitumor activity as a first-line agent in the treatment of mesothelioma. Given this, it is hypothesized that Pemetrexed may be active in second-line mesothelioma in which the standard treatment is best supportive care. This study will compare survival of previously treated patients with malignant pleural mesothelioma who receive Pemetrexed plus best supportive care to the survival of similar patients who receive best supportive care alone.", "conditions": ["Mesothelioma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pemetrexed", "otherNames": []}], "meshConditions": ["Mesothelioma"], "meshInterventions": ["Pemetrexed"], "hasResults": false, "classifyText": "A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma Mesothelioma Pemetrexed Mesothelioma Pemetrexed Based on results from earlier clinical trials, Pemetrexed may have antitumor activity as a first-line agent in the treatment of mesothelioma. Given this, it is hypothesized that Pemetrexed may be active in second-line mesothelioma in which the standard treatment is best supportive care. This study will compare survival of previously treated patients with malignant pleural mesothelioma who receive Pemetrexed plus best supportive care to the survival of similar patients who receive best supportive care alone."}
 {"nctId": "NCT02111096", "briefTitle": "A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus", "officialTitle": "A Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of LY2409021 Compared to Sitagliptin in Subjects With Type 2 Diabetes Mellitus", "overallStatus": "TERMINATED", "startDate": "2014-04", "completionDate": "2015-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 174, "briefSummary": "The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks).", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2409021", "otherNames": []}, {"type": "DRUG", "name": "Sitagliptin", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Metformin", "otherNames": []}, {"type": "DRUG", "name": "Sulfonylurea", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["adomeglivant", "Sitagliptin Phosphate", "Metformin", "Sulfonylurea Compounds"], "hasResults": true, "classifyText": "A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2 LY2409021 Sitagliptin Placebo Metformin Sulfonylurea Diabetes Mellitus, Type 2 adomeglivant Sitagliptin Phosphate Metformin Sulfonylurea Compounds The intent of this study is to assess the safety of LY2409021 in participants with Type 2 diabetes mellitus taking metformin and sulfonylurea as prescribed by their personal physician. The study treatment is expected to last 12 months (52 weeks)."}
 {"nctId": "NCT03535194", "briefTitle": "A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)", "officialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2", "overallStatus": "COMPLETED", "startDate": "2018-06-26", "completionDate": "2020-06-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1484, "briefSummary": "The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.", "conditions": ["Psoriasis"], "keywords": ["Interleukin-23 (IL-23)"], "interventions": [{"type": "DRUG", "name": "Mirikizumab", "otherNames": ["LY3074828"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Secukinumab", "otherNames": []}], "meshConditions": ["Psoriasis"], "meshInterventions": ["mirikizumab", "secukinumab"], "hasResults": true, "classifyText": "A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Psoriasis Interleukin-23 (IL-23) Mirikizumab Placebo Secukinumab Psoriasis mirikizumab secukinumab The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis."}
 {"nctId": "NCT03977974", "briefTitle": "A Study of LY3526318 in Healthy Participants", "officialTitle": "A Safety, Tolerability, Pharmacokinetic, and Pilot Food Effect Study of Single- and Multiple-Ascending Doses of LY3526318 in Healthy Participants", "overallStatus": "TERMINATED", "startDate": "2019-06-21", "completionDate": "2020-03-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 76, "briefSummary": "The main purpose of this study is to learn more about the safety and side effects of LY3526318 when given by mouth to healthy participants. The study will have two parts. Each participant will enroll in only one part. For each participant, Part A will last up to 28 days and Part B will last up to 51 days, including screening and follow-up.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3526318", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": true, "classifyText": "A Study of LY3526318 in Healthy Participants Healthy LY3526318 Placebo The main purpose of this study is to learn more about the safety and side effects of LY3526318 when given by mouth to healthy participants. The study will have two parts. Each participant will enroll in only one part. For each participant, Part A will last up to 28 days and Part B will last up to 51 days, including screening and follow-up."}
 {"nctId": "NCT05757531", "briefTitle": "A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants", "officialTitle": "Disposition of [14C]-LY3437943 Following Subcutaneous Administration in Healthy Male Participants", "overallStatus": "COMPLETED", "startDate": "2023-03-17", "completionDate": "2023-06-23", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 7, "briefSummary": "The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air.\n\nThe study will last up to approximately 15 weeks including the screening period of 28 days.", "conditions": ["Healthy"], "keywords": ["Radioactive", "ADME"], "interventions": [{"type": "DRUG", "name": "[\u00b9\u2074C]-LY3437943", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants Healthy Radioactive ADME [\u00b9\u2074C]-LY3437943 The main purpose of this study is to is to look at how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it in healthy male participants. This study will involve a single dose of 14C radiolabeled LY3437943. his means that a radioactive tracer substance, C14, will be incorporated into the study drug to investigate the study drug and its breakdown products and to find out how much of these pass from blood into urine, feces and expired air.\n\nThe study will last up to approximately 15 weeks including the screening period of 28 days."}
 {"nctId": "NCT06568042", "briefTitle": "Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy", "officialTitle": "A Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study Evaluating LY3848575 in Chronic Neuropathic Pain Associated With Distal Sensory Polyneuropathy", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2024-08-22", "completionDate": "2026-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 450, "briefSummary": "The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.\n\nParticipation may last up to 30 weeks including screening.", "conditions": ["Neuropathic Pain", "Distal Sensory Polyneuropathy"], "keywords": ["Peripheral Neuropathy", "Diabetic Peripheral Neuropathy", "Chemotherapy Induced Peripheral Neuropathy", "HIV Induced Peripheral Neuropathy"], "interventions": [{"type": "DRUG", "name": "LY3848575", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Neuralgia", "Peripheral Nervous System Diseases"], "meshInterventions": [], "hasResults": false, "classifyText": "Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy Neuropathic Pain Distal Sensory Polyneuropathy Peripheral Neuropathy Diabetic Peripheral Neuropathy Chemotherapy Induced Peripheral Neuropathy HIV Induced Peripheral Neuropathy LY3848575 Placebo Neuralgia Peripheral Nervous System Diseases The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their feet and moves up the leg to just below the knee.\n\nParticipation may last up to 30 weeks including screening."}
 {"nctId": "NCT01341470", "briefTitle": "A Study of LY2495655 in Healthy Subjects", "officialTitle": "A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2495655 in Japanese Subjects", "overallStatus": "COMPLETED", "startDate": "2011-05", "completionDate": "2012-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 47, "briefSummary": "The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of LY2495655 administered subcutaneously and intravenously in Japanese subjects.", "conditions": ["Healthy Volunteer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2495655", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": ["landogrozumab"], "hasResults": true, "classifyText": "A Study of LY2495655 in Healthy Subjects Healthy Volunteer LY2495655 Placebo landogrozumab The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of LY2495655 administered subcutaneously and intravenously in Japanese subjects."}
 {"nctId": "NCT00191113", "briefTitle": "Somatropin Treatment to Final Height in Turner Syndrome", "officialTitle": "Humatrope Treatment to Final Height in Turner's Syndrome", "overallStatus": "COMPLETED", "startDate": "1989-02", "completionDate": "2007-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 154, "briefSummary": "A randomized, controlled trial in girls with Turner syndrome at least 7 years old and younger than 13 at study entry, to determine the efficacy and safety of Humatrope (somatropin) treatment in promoting linear growth to final height.", "conditions": ["Turner Syndrome"], "keywords": ["syndrome", "Turner", "Turner's", "height", "growth", "growth hormone", "somatropin", "short stature", "short", "hearing", "glucose metabolism"], "interventions": [{"type": "DRUG", "name": "Somatropin", "otherNames": ["Humatrope", "Growth hormone"]}, {"type": "DRUG", "name": "Ethinyl estradiol", "otherNames": []}, {"type": "DRUG", "name": "Medroxyprogesterone acetate", "otherNames": []}], "meshConditions": ["Turner Syndrome", "Syndrome", "Dwarfism"], "meshInterventions": ["Human Growth Hormone", "Growth Hormone", "Ethinyl Estradiol", "Medroxyprogesterone Acetate"], "hasResults": true, "classifyText": "Somatropin Treatment to Final Height in Turner Syndrome Turner Syndrome syndrome Turner Turner's height growth growth hormone somatropin short stature short hearing glucose metabolism Somatropin Ethinyl estradiol Medroxyprogesterone acetate Turner Syndrome Syndrome Dwarfism Human Growth Hormone Growth Hormone Ethinyl Estradiol Medroxyprogesterone Acetate A randomized, controlled trial in girls with Turner syndrome at least 7 years old and younger than 13 at study entry, to determine the efficacy and safety of Humatrope (somatropin) treatment in promoting linear growth to final height."}
 {"nctId": "NCT01736254", "briefTitle": "A Study of Evacetrapib in Healthy Participants", "officialTitle": "Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2012-12", "completionDate": "2013-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 24, "briefSummary": "The purpose of this study is to determine whether concentrations of the study drug (evacetrapib) in the blood stream is the same or is different when the person is also taking gemfibrozil (a drug used to lower lipid levels). Each participant will receive gemfibrozil alone, evacetrapib alone, and both drugs in combination. There is no washout period between doses. The safety of both of the study drugs given together will be evaluated. Information about any side effects that may have occurred will also be collected. This study will last approximately 36 days.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Evacetrapib", "otherNames": ["LY2484595"]}, {"type": "DRUG", "name": "Gemfibrozil", "otherNames": []}], "meshConditions": [], "meshInterventions": ["evacetrapib", "Gemfibrozil"], "hasResults": true, "classifyText": "A Study of Evacetrapib in Healthy Participants Healthy Volunteers Evacetrapib Gemfibrozil evacetrapib Gemfibrozil The purpose of this study is to determine whether concentrations of the study drug (evacetrapib) in the blood stream is the same or is different when the person is also taking gemfibrozil (a drug used to lower lipid levels). Each participant will receive gemfibrozil alone, evacetrapib alone, and both drugs in combination. There is no washout period between doses. The safety of both of the study drugs given together will be evaluated. Information about any side effects that may have occurred will also be collected. This study will last approximately 36 days."}
 {"nctId": "NCT01837641", "briefTitle": "A Study of LY3002813 in Participants With Alzheimer's Disease", "officialTitle": "A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease", "overallStatus": "COMPLETED", "startDate": "2013-05-03", "completionDate": "2016-08-24", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 63, "briefSummary": "The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813. Study participants will be healthy or will have mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild to moderate AD.\n\nThere will be seven groups of study participants. Five groups will receive a single dose of LY3002813 or placebo (no drug), followed by up to 4 multiple doses of LY3002813 or placebo given as an injection into a vein. Approximately 12 weeks will pass between the single dose and the first multiple dose. One group of participants will receive a single dose of LY3002813 given as an injection under the skin. One group of participants will receive a single dose of LY3002813 given as an injection into a vein.", "conditions": ["Alzheimer Disease"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "LY3002813-IV", "otherNames": []}, {"type": "BIOLOGICAL", "name": "LY3002813-SC", "otherNames": []}, {"type": "DRUG", "name": "Placebo-IV", "otherNames": []}], "meshConditions": ["Alzheimer Disease"], "meshInterventions": [], "hasResults": true, "classifyText": "A Study of LY3002813 in Participants With Alzheimer's Disease Alzheimer Disease LY3002813-IV LY3002813-SC Placebo-IV Alzheimer Disease The study will evaluate the safety of LY3002813 by looking at adverse events. The study will also look at the effect the body has on LY3002813. Study participants will be healthy or will have mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild to moderate AD.\n\nThere will be seven groups of study participants. Five groups will receive a single dose of LY3002813 or placebo (no drug), followed by up to 4 multiple doses of LY3002813 or placebo given as an injection into a vein. Approximately 12 weeks will pass between the single dose and the first multiple dose. One group of participants will receive a single dose of LY3002813 given as an injection under the skin. One group of participants will receive a single dose of LY3002813 given as an injection into a vein."}
 {"nctId": "NCT02152631", "briefTitle": "A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer", "officialTitle": "JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2014-10-03", "completionDate": "2026-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 453, "briefSummary": "The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.", "conditions": ["Non Small Cell Lung Cancer"], "keywords": ["Therapy, Platinum, Kras +"], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Erlotinib", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["abemaciclib", "Erlotinib Hydrochloride"], "hasResults": true, "classifyText": "A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer Non Small Cell Lung Cancer Therapy, Platinum, Kras + Abemaciclib Erlotinib Carcinoma, Non-Small-Cell Lung abemaciclib Erlotinib Hydrochloride The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer."}
 {"nctId": "NCT02595736", "briefTitle": "A Study of LY3200327 in Healthy Participants", "officialTitle": "A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3200327 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2015-11", "completionDate": "2016-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 52, "briefSummary": "The purpose of this study is to look at the safety and tolerability of single doses of LY3200327 when given to healthy male and female participants either by injection under the skin or by drip into a vein. The study will help determine how the drug behaves inside the body and how long it takes to disappear from the body. The study will also look for anti-drug antibodies and how these may affect how LY3200327 acts in your body.\n\nThe study is expected to last approximately 12 weeks (with screening evaluations up to 4 weeks prior).", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo (SC)", "otherNames": []}, {"type": "DRUG", "name": "LY3200327 (SC)", "otherNames": []}, {"type": "DRUG", "name": "LY3200327 (IV)", "otherNames": []}, {"type": "DRUG", "name": "Placebo (IV)", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3200327 in Healthy Participants Healthy Placebo (SC) LY3200327 (SC) LY3200327 (IV) Placebo (IV) The purpose of this study is to look at the safety and tolerability of single doses of LY3200327 when given to healthy male and female participants either by injection under the skin or by drip into a vein. The study will help determine how the drug behaves inside the body and how long it takes to disappear from the body. The study will also look for anti-drug antibodies and how these may affect how LY3200327 acts in your body.\n\nThe study is expected to last approximately 12 weeks (with screening evaluations up to 4 weeks prior)."}
 {"nctId": "NCT00415363", "briefTitle": "Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy", "officialTitle": "A Double-blind, Randomized, Placebo-controlled Multicentre Phase II Study of Maintenance Enzastaurin Following Whole Brain Radiation Therapy in the Treatment of Brain Metastases From Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2006-12", "completionDate": "2011-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 109, "briefSummary": "This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer. Approximately 108 patients will be randomly assigned to receive either enzastaurin or placebo after having completed whole brain radiotherapy.", "conditions": ["Non Small Cell Lung Cancer", "Small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "enzastaurin", "otherNames": ["LY317615"]}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Small Cell Lung Carcinoma"], "meshInterventions": ["enzastaurin"], "hasResults": true, "classifyText": "Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy Non Small Cell Lung Cancer Small Cell Lung Cancer enzastaurin placebo Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma enzastaurin This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer. Approximately 108 patients will be randomly assigned to receive either enzastaurin or placebo after having completed whole brain radiotherapy."}
 {"nctId": "NCT06890611", "briefTitle": "A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants", "officialTitle": "A Phase 1, Relative Bioavailability Study of Bimagrumab (LY3985863) Test and Reference Materials, and Bimagrumab Test Material Coadministration and Coformulation With Tirzepatide (LY900042), in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2025-03-25", "completionDate": "2025-09-26", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 125, "briefSummary": "The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Bimagrumab", "otherNames": ["LY3985863", "BYM338", "VER201"]}, {"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Bimagrumab + Tirzepatide Coformulation", "otherNames": ["LY900042"]}], "meshConditions": [], "meshInterventions": ["bimagrumab", "Tirzepatide"], "hasResults": false, "classifyText": "A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants Healthy Bimagrumab Tirzepatide Bimagrumab + Tirzepatide Coformulation bimagrumab Tirzepatide The main purpose of this study is to evaluate the body concentration of different forms of bimagrumab, administered alone or with tirzepatide. Participation in the study will last about 4.5 months, including screening and follow-up."}
 {"nctId": "NCT00190944", "briefTitle": "Effects of Teriparatide on Distal Radius Fracture Healing", "officialTitle": "Effects of Teriparatide on Distal Radius Fracture Healing", "overallStatus": "COMPLETED", "startDate": "2004-12", "completionDate": "2007-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 105, "briefSummary": "Effects of Teriparatide on Distal Radius Fracture Healing", "conditions": ["Colles' Fracture"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Teriparatide", "otherNames": []}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Colles' Fracture"], "meshInterventions": ["Teriparatide"], "hasResults": false, "classifyText": "Effects of Teriparatide on Distal Radius Fracture Healing Colles' Fracture Teriparatide placebo Colles' Fracture Teriparatide Effects of Teriparatide on Distal Radius Fracture Healing"}
 {"nctId": "NCT02340104", "briefTitle": "A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants", "officialTitle": "An Absolute Bioavailability Study of Baricitinib in Healthy Subjects Using the Intravenous Tracer Method", "overallStatus": "COMPLETED", "startDate": "2015-01", "completionDate": "2015-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 8, "briefSummary": "The purpose of this study is to compare how much baricitinib (study drug) gets into the blood stream when it is given as a single dose (in tablet form) and as an intravenous infusion (injection given directly into a vein via a small needle). Each participant in the study will make four visits to the investigator site over the course of about 6 weeks.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104"]}, {"type": "DRUG", "name": "[^13C4D3^15N]-baricitinib", "otherNames": ["[^13C4D3^15N]-LY3009104"]}], "meshConditions": [], "meshInterventions": ["baricitinib"], "hasResults": true, "classifyText": "A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants Healthy Volunteers Baricitinib [^13C4D3^15N]-baricitinib baricitinib The purpose of this study is to compare how much baricitinib (study drug) gets into the blood stream when it is given as a single dose (in tablet form) and as an intravenous infusion (injection given directly into a vein via a small needle). Each participant in the study will make four visits to the investigator site over the course of about 6 weeks."}
 {"nctId": "NCT01885078", "briefTitle": "An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis", "officialTitle": "A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis", "overallStatus": "COMPLETED", "startDate": "2013-06-27", "completionDate": "2020-11-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 2877, "briefSummary": "The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study.\n\nThe study provides 7 years of additional treatment with baricitinib.", "conditions": ["Rheumatoid Arthritis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY 3009104", "INCB 028050"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Arthritis, Rheumatoid"], "meshInterventions": ["baricitinib"], "hasResults": true, "classifyText": "An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis Rheumatoid Arthritis Baricitinib Placebo Arthritis, Rheumatoid baricitinib The purpose of this study is to investigate the long-term safety and any side effects of baricitinib in participants who have completed a previous baricitinib rheumatoid arthritis study.\n\nThe study provides 7 years of additional treatment with baricitinib."}
 {"nctId": "NCT02265705", "briefTitle": "A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy", "overallStatus": "COMPLETED", "startDate": "2014-10", "completionDate": "2017-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 290, "briefSummary": "The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as baricitinib in participants with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy.", "conditions": ["Rheumatoid Arthritis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104", "INCB 028050"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Arthritis, Rheumatoid"], "meshInterventions": ["baricitinib"], "hasResults": true, "classifyText": "A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA) Rheumatoid Arthritis Baricitinib Placebo Arthritis, Rheumatoid baricitinib The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as baricitinib in participants with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy."}
 {"nctId": "NCT00320541", "briefTitle": "A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer", "officialTitle": "A Randomized Phase II Trial of Paclitaxel and Bevacizumab Versus Gemcitabine, Paclitaxel, and Bevacizumab as First Line Treatment for Locally Advanced or Metastatic Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2006-05", "completionDate": "2012-08", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Genentech, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 187, "briefSummary": "This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer", "conditions": ["Breast Cancer"], "keywords": ["Breast Cancer", "Cancer of Breast", "Cancer of the breast", "Breast Neoplasms"], "interventions": [{"type": "DRUG", "name": "gemcitabine", "otherNames": ["LY188011", "Gemzar"]}, {"type": "DRUG", "name": "paclitaxel", "otherNames": ["Taxol"]}, {"type": "DRUG", "name": "bevacizumab", "otherNames": ["Avastin"]}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Gemcitabine", "Paclitaxel", "Bevacizumab"], "hasResults": true, "classifyText": "A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer Breast Cancer Breast Cancer Cancer of Breast Cancer of the breast Breast Neoplasms gemcitabine paclitaxel bevacizumab Breast Neoplasms Gemcitabine Paclitaxel Bevacizumab This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer"}
 {"nctId": "NCT05999968", "briefTitle": "Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment", "officialTitle": "A Phase 1b Study of Abemaciclib Plus Darolutamide in Men With Metastatic Castration-Resistant Prostate Cancer", "overallStatus": "COMPLETED", "startDate": "2024-01-12", "completionDate": "2026-01-21", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Bayer"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 10, "briefSummary": "The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with darolutamide to participants with prostate cancer that has spread after initial treatment. Participation may last up to 32 months.", "conditions": ["Prostatic Neoplasms"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Darolutamide", "otherNames": []}, {"type": "DRUG", "name": "LHRH agonist/antagonist", "otherNames": []}], "meshConditions": ["Prostatic Neoplasms"], "meshInterventions": ["abemaciclib", "darolutamide", "Gonadotropin-Releasing Hormone"], "hasResults": false, "classifyText": "Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment Prostatic Neoplasms Abemaciclib Darolutamide LHRH agonist/antagonist Prostatic Neoplasms abemaciclib darolutamide Gonadotropin-Releasing Hormone The main purpose of this study is to learn more about the safety and tolerability of abemaciclib when given in combination with darolutamide to participants with prostate cancer that has spread after initial treatment. Participation may last up to 32 months."}
 {"nctId": "NCT06594159", "briefTitle": "A Study of LY4065967 in Healthy Japanese Participants", "officialTitle": "A Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of LY4065967, to Evaluate the Effect of LY4065967 on the Pharmacokinetics of Rosuvastatin in Healthy Japanese Participants", "overallStatus": "COMPLETED", "startDate": "2024-10-22", "completionDate": "2025-03-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 59, "briefSummary": "The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants. Blood tests will be performed to check how much LY4065967 and rosuvastatin get into the bloodstream and how long it takes the body to eliminate it. This is a 3-part study and will last approximately 2 weeks excluding screening period for each part.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY4065967", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Rosuvastatin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Rosuvastatin Calcium"], "hasResults": false, "classifyText": "A Study of LY4065967 in Healthy Japanese Participants Healthy LY4065967 Placebo Rosuvastatin Rosuvastatin Calcium The purpose of this study is to obtain safety and tolerability data of the study drug known as LY4065967 and rosuvastatin in healthy Japanese participants. Blood tests will be performed to check how much LY4065967 and rosuvastatin get into the bloodstream and how long it takes the body to eliminate it. This is a 3-part study and will last approximately 2 weeks excluding screening period for each part."}
 {"nctId": "NCT00768391", "briefTitle": "Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available", "officialTitle": "Phase I Study of Anti-Platelet Derived Growth Factor Receptor Alpha (PDGFRa) Monoclonal Antibody IMC-3G3 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom no Standard Therapy is Available", "overallStatus": "COMPLETED", "startDate": "2006-12", "completionDate": "2010-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": null, "enrollment": 20, "briefSummary": "The purpose of this study is to determine if IMC-3G3 is safe for patients, and also to determine the best dose of IMC-3G3 to give to patients.", "conditions": ["Solid Tumors"], "keywords": ["Tumors", "Lymphoma", "Antibodies, Monoclonal"], "interventions": [{"type": "BIOLOGICAL", "name": "IMC-3G3", "otherNames": []}], "meshConditions": ["Neoplasms", "Lymphoma"], "meshInterventions": ["olaratumab"], "hasResults": false, "classifyText": "Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available Solid Tumors Tumors Lymphoma Antibodies, Monoclonal IMC-3G3 Neoplasms Lymphoma olaratumab The purpose of this study is to determine if IMC-3G3 is safe for patients, and also to determine the best dose of IMC-3G3 to give to patients."}
 {"nctId": "NCT04342897", "briefTitle": "A Study of LY3127804 in Participants With COVID-19", "officialTitle": "A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients Who Are Hospitalized With Pneumonia and Presumed or Confirmed COVID-19", "overallStatus": "TERMINATED", "startDate": "2020-04-20", "completionDate": "2020-10-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 95, "briefSummary": "A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19.", "conditions": ["COVID-19", "Pneumonia"], "keywords": ["Corona Virus Disease 19 (COVID-19)", "2019 Novel Coronavirus (2019 n-COV)", "Severe Acute Respiratory Syndrome (SARS)", "Pulmonary Disease", "SARS-CoV-2"], "interventions": [{"type": "DRUG", "name": "LY3127804", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["COVID-19", "Pneumonia", "Severe Acute Respiratory Syndrome", "Lung Diseases"], "meshInterventions": ["zansecimab"], "hasResults": true, "classifyText": "A Study of LY3127804 in Participants With COVID-19 COVID-19 Pneumonia Corona Virus Disease 19 (COVID-19) 2019 Novel Coronavirus (2019 n-COV) Severe Acute Respiratory Syndrome (SARS) Pulmonary Disease SARS-CoV-2 LY3127804 Placebo COVID-19 Pneumonia Severe Acute Respiratory Syndrome Lung Diseases zansecimab A randomized, double-blind, placebo-controlled, clinical trial of LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19."}
 {"nctId": "NCT05696847", "briefTitle": "A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity", "officialTitle": "A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With Obesity", "overallStatus": "COMPLETED", "startDate": "2023-02-07", "completionDate": "2025-01-16", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 28, "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period.", "conditions": ["Obesity"], "keywords": ["Pediatrics", "Obesity", "Chronic weight management"], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Obesity"], "meshInterventions": ["Tirzepatide"], "hasResults": true, "classifyText": "A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity Obesity Pediatrics Obesity Chronic weight management Tirzepatide Placebo Obesity Tirzepatide The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity. The blood tests will be performed to investigate how the body processes the study drug in these participants. For each participant, the study will last about approximately 13 weeks excluding the screening period."}
 {"nctId": "NCT01430091", "briefTitle": "A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet", "officialTitle": "Relative Bioavailability of a Prasugrel Paediatric Orally Disintegrating Tablet Formulation Compared to the Tablet in Healthy Adult Subjects", "overallStatus": "COMPLETED", "startDate": "2011-09", "completionDate": "2011-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 18, "briefSummary": "This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment.", "conditions": ["Sickle Cell Disease"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Prasugrel (clinical formulation)", "otherNames": ["LY640315", "Effient\u00ae", "Efient\u00ae"]}, {"type": "DRUG", "name": "Prasugrel (Orally Disintegrating Tablet [ODT])", "otherNames": ["LY640315", "Effient\u00ae", "Efient\u00ae"]}], "meshConditions": ["Anemia, Sickle Cell"], "meshInterventions": ["Prasugrel Hydrochloride"], "hasResults": true, "classifyText": "A Relative Bioavailability Study of a Prasugrel Orally Disintegrating Tablet Sickle Cell Disease Prasugrel (clinical formulation) Prasugrel (Orally Disintegrating Tablet [ODT]) Anemia, Sickle Cell Prasugrel Hydrochloride This study compares the clinical tablet formulation of prasugrel taken orally with an orally disintegrating tablet (ODT) taken orally. The study will evaluate the amount of prasugrel active metabolite circulating in the blood for each treatment."}
 {"nctId": "NCT00279214", "briefTitle": "Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock", "officialTitle": "An Evaluation of Vasopressor Requirement, Hemodynamic Response and Measures of Tissue Perfusion With the Administration of Drotrecogin Alfa (Activated) as Part of Physician-Directed Therapy in Patients With Septic Shock", "overallStatus": "COMPLETED", "startDate": "2005-11", "completionDate": "2007-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 43, "briefSummary": "The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated).", "conditions": ["Sepsis", "Septic Shock"], "keywords": [], "interventions": [{"type": "DRUG", "name": "drotrecogin alfa (activated)", "otherNames": []}], "meshConditions": ["Sepsis", "Shock, Septic"], "meshInterventions": ["drotrecogin alfa activated"], "hasResults": true, "classifyText": "Hemodynamic and Perfusion Response to Drotrecogin Alfa (Activated) in Patients With Septic Shock Sepsis Septic Shock drotrecogin alfa (activated) Sepsis Shock, Septic drotrecogin alfa activated The study will evaluate the vasopressor requirement, hemodynamic response and measures of tissue perfusion in patients with septic shock receiving an infusion of drotrecogin alfa (activated) compared to patients not receiving drotrecogin alfa (activated)."}
 {"nctId": "NCT00551538", "briefTitle": "24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine", "officialTitle": "Twenty-Four-Hour Plasma Glucose Profiles Observed in Patients With Type 2 Diabetes During Therapy Consisting of Oral Agent(s) Plus Twice-Daily Insulin Lispro Low Mixture or Once-Daily Insulin Glargine", "overallStatus": "COMPLETED", "startDate": "2003-05", "completionDate": "2004-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 15, "briefSummary": "The purpose of this study is to determine if twice-daily Lispro low mixture (75/25) will result in lower post prandial blood glucose readings versus once-daily glargine plus oral diabetic medications.", "conditions": ["Type 2 Diabetes"], "keywords": ["Diabetes", "Diabetic", "Insulin", "Glargine", "Lispro"], "interventions": [{"type": "DRUG", "name": "Lispro mix 75/25", "otherNames": []}, {"type": "DRUG", "name": "Glargine", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Insulin Resistance"], "meshInterventions": ["Insulin Glargine"], "hasResults": false, "classifyText": "24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine Type 2 Diabetes Diabetes Diabetic Insulin Glargine Lispro Lispro mix 75/25 Glargine Diabetes Mellitus, Type 2 Diabetes Mellitus Insulin Resistance Insulin Glargine The purpose of this study is to determine if twice-daily Lispro low mixture (75/25) will result in lower post prandial blood glucose readings versus once-daily glargine plus oral diabetic medications."}
 {"nctId": "NCT00988858", "briefTitle": "A Study of Advanced or Metastatic Non-small Cell Lung Cancer", "officialTitle": "A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2009-11", "completionDate": "2014-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 55, "briefSummary": "The primary purpose of this study is to evaluate the efficacy and safety of LY2603618 in combination with pemetrexed and any side effects that might be associated with it along with determining the effects of LY2603618 in combination with pemetrexed in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC).", "conditions": ["Non Small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2603618", "otherNames": []}, {"type": "DRUG", "name": "Pemetrexed", "otherNames": ["Alimta", "LY231514"]}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["LY2603618", "Pemetrexed"], "hasResults": true, "classifyText": "A Study of Advanced or Metastatic Non-small Cell Lung Cancer Non Small Cell Lung Cancer LY2603618 Pemetrexed Carcinoma, Non-Small-Cell Lung LY2603618 Pemetrexed The primary purpose of this study is to evaluate the efficacy and safety of LY2603618 in combination with pemetrexed and any side effects that might be associated with it along with determining the effects of LY2603618 in combination with pemetrexed in participants with advanced or metastatic Non-small Cell Lung Cancer (NSCLC)."}
 {"nctId": "NCT02891226", "briefTitle": "A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease", "officialTitle": "A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)", "overallStatus": "COMPLETED", "startDate": "2016-12-14", "completionDate": "2021-02-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 191, "briefSummary": "The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease.", "conditions": ["Crohn's Disease"], "keywords": ["inflammatory bowel disease", "IL-23", "biologic"], "interventions": [{"type": "DRUG", "name": "Mirikizumab", "otherNames": ["LY3074828"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Crohn Disease", "Inflammatory Bowel Diseases"], "meshInterventions": ["mirikizumab"], "hasResults": true, "classifyText": "A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease Crohn's Disease inflammatory bowel disease IL-23 biologic Mirikizumab Placebo Crohn Disease Inflammatory Bowel Diseases mirikizumab The purpose of this study is to evaluate the safety and effectiveness of the study drug Mirikizumab in participants with active Crohn's Disease."}
 {"nctId": "NCT03338010", "briefTitle": "A Study of LY2963016 Compared to Lantus\u00ae in Adult Chinese Participants With Type 2 Diabetes Mellitus", "officialTitle": "A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus\u00ae in Adult Chinese Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2018-03-22", "completionDate": "2020-03-18", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 536, "briefSummary": "The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus\u00ae in insulin na\u00efve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications (OAMs). Participants will continue their OAMs throughout the study.", "conditions": ["Type 2 Diabetes"], "keywords": ["Insulin glargine"], "interventions": [{"type": "DRUG", "name": "LY2963016", "otherNames": []}, {"type": "DRUG", "name": "Lantus\u00ae", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["LY2963016 insulin glargine", "Insulin Glargine"], "hasResults": true, "classifyText": "A Study of LY2963016 Compared to Lantus\u00ae in Adult Chinese Participants With Type 2 Diabetes Mellitus Type 2 Diabetes Insulin glargine LY2963016 Lantus\u00ae Diabetes Mellitus, Type 2 LY2963016 insulin glargine Insulin Glargine The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus\u00ae in insulin na\u00efve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications (OAMs). Participants will continue their OAMs throughout the study."}
 {"nctId": "NCT01246960", "briefTitle": "A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer", "officialTitle": "Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach", "overallStatus": "COMPLETED", "startDate": "2011-04", "completionDate": "2014-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 168, "briefSummary": "The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer.", "conditions": ["Stomach Cancer", "Esophageal Cancer"], "keywords": ["cancer", "stomach", "esophagus", "gastroesophageal"], "interventions": [{"type": "BIOLOGICAL", "name": "Ramucirumab", "otherNames": ["LY3009806", "IMC-1121B"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Oxaliplatin", "otherNames": []}, {"type": "DRUG", "name": "Leucovorin", "otherNames": []}, {"type": "DRUG", "name": "5-Fluorouracil", "otherNames": ["5-FU"]}], "meshConditions": ["Stomach Neoplasms", "Esophageal Neoplasms", "Neoplasms"], "meshInterventions": ["Ramucirumab", "Oxaliplatin", "Leucovorin", "Fluorouracil"], "hasResults": true, "classifyText": "A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer Stomach Cancer Esophageal Cancer cancer stomach esophagus gastroesophageal Ramucirumab Placebo Oxaliplatin Leucovorin 5-Fluorouracil Stomach Neoplasms Esophageal Neoplasms Neoplasms Ramucirumab Oxaliplatin Leucovorin Fluorouracil The purpose of this study is to determine whether ramucirumab when used in conjunction with chemotherapy treatment can help participants with stomach, esophagus, and gastroesophageal cancer."}
 {"nctId": "NCT00721162", "briefTitle": "Study of Ramucirumab in Ovarian Cancer", "officialTitle": "A Phase 2, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma", "overallStatus": "COMPLETED", "startDate": "2008-08", "completionDate": "2015-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 60, "briefSummary": "The purpose of this study is to determine if ramucirumab given as monotherapy is effective in the treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.", "conditions": ["Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma"], "keywords": ["Ovarian Cancer,", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma"], "interventions": [{"type": "BIOLOGICAL", "name": "Ramucirumab", "otherNames": ["IMC-1121B"]}], "meshConditions": ["Ovarian Neoplasms", "Fallopian Tube Neoplasms"], "meshInterventions": ["Ramucirumab"], "hasResults": true, "classifyText": "Study of Ramucirumab in Ovarian Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Carcinoma Ovarian Cancer, Fallopian Tube Cancer Primary Peritoneal Carcinoma Ramucirumab Ovarian Neoplasms Fallopian Tube Neoplasms Ramucirumab The purpose of this study is to determine if ramucirumab given as monotherapy is effective in the treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma."}
 {"nctId": "NCT03886948", "briefTitle": "A Study of Injections of LY3074828 in Healthy Participants", "officialTitle": "A Safety, Tolerability, and Pharmacokinetic Study of Injections of LY3074828 Solution Using Investigational 1-mL Pre-filled Syringes and Investigational 1-mL Autoinjector in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2019-03-27", "completionDate": "2019-10-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 66, "briefSummary": "The purpose of this study is to learn about the effects of LY3074828 when given as an injection just under the skin by two different devices. The study will last about 12 weeks for each participant.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3074828", "otherNames": []}, {"type": "DEVICE", "name": "Pre-filled syringe (PFS)", "otherNames": []}, {"type": "DEVICE", "name": "Autoinjector (AI)", "otherNames": []}], "meshConditions": [], "meshInterventions": ["mirikizumab"], "hasResults": true, "classifyText": "A Study of Injections of LY3074828 in Healthy Participants Healthy LY3074828 Pre-filled syringe (PFS) Autoinjector (AI) mirikizumab The purpose of this study is to learn about the effects of LY3074828 when given as an injection just under the skin by two different devices. The study will last about 12 weeks for each participant."}
 {"nctId": "NCT06916078", "briefTitle": "A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function", "officialTitle": "A Phase 1, Multicenter, Sequential-Design, Single-Dose, Open-Label Study of Lepodisiran in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic Impairment", "overallStatus": "RECRUITING", "startDate": "2025-04-23", "completionDate": "2026-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 33, "briefSummary": "The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants.\n\nThe study will last up to approximately 9 weeks, excluding screening.", "conditions": ["Liver Dysfunction", "Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Lepodisiran", "otherNames": ["LY3819469"]}], "meshConditions": ["Liver Diseases"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function Liver Dysfunction Healthy Lepodisiran Liver Diseases The main purpose of this study is to evaluate how much lepodisiran gets into the blood stream and how long it takes the body to get rid of it when given as a subcutaneous (SC) injection under the skin to participants with mild, moderate, or severe liver function impairment compared to participants with normal liver function. The study will also evaluate how well lepodisiran is tolerated and what side effects may occur in these participants.\n\nThe study will last up to approximately 9 weeks, excluding screening."}
 {"nctId": "NCT01746017", "briefTitle": "A Study of LY2922470 in Healthy Participants and Participants With Diabetes", "officialTitle": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY2922470 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2012-12", "completionDate": "2013-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 26, "briefSummary": "The aim of this trial is to evaluate the safety of the study drug in healthy participant and participant with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.\n\nThe study consists of two parts. Part A will study healthy participants in up to 4 dosing periods over approximately 6 weeks. Part B will study participants with diabetes in up to 3 dosing periods over approximately 5 weeks.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "LY2922470", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["LY2922470"], "hasResults": true, "classifyText": "A Study of LY2922470 in Healthy Participants and Participants With Diabetes Diabetes Mellitus, Type 2 Placebo LY2922470 Diabetes Mellitus, Type 2 LY2922470 The aim of this trial is to evaluate the safety of the study drug in healthy participant and participant with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.\n\nThe study consists of two parts. Part A will study healthy participants in up to 4 dosing periods over approximately 6 weeks. Part B will study participants with diabetes in up to 3 dosing periods over approximately 5 weeks."}
 {"nctId": "NCT01865084", "briefTitle": "A Study of Tadalafil for Duchenne Muscular Dystrophy", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy", "overallStatus": "TERMINATED", "startDate": "2013-09", "completionDate": "2016-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 331, "briefSummary": "The main purpose of this study is to determine if tadalafil can slow the decline in walking ability of boys who have Duchenne muscular dystrophy (DMD). The study will also assess the safety of tadalafil and any side effects that might be associated with it in boys who have DMD. Participants will receive study treatment (tadalafil or placebo) for the first 48 weeks of the study, and can then continue into an open label extension (OLE) that consists of two periods during which all participants will receive tadalafil. In OLE period 1, all participants will receive tadalafil for 48 weeks. Participants completing OLE period 1 will continue into OLE period 2 and will receive tadalafil for at least another 48 weeks.", "conditions": ["Muscular Dystrophy, Duchenne"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tadalafil", "otherNames": ["LY450190", "Cialis"]}, {"type": "DRUG", "name": "Placebo", "otherNames": ["Administered orally"]}], "meshConditions": ["Muscular Dystrophy, Duchenne"], "meshInterventions": ["Tadalafil"], "hasResults": true, "classifyText": "A Study of Tadalafil for Duchenne Muscular Dystrophy Muscular Dystrophy, Duchenne Tadalafil Placebo Muscular Dystrophy, Duchenne Tadalafil The main purpose of this study is to determine if tadalafil can slow the decline in walking ability of boys who have Duchenne muscular dystrophy (DMD). The study will also assess the safety of tadalafil and any side effects that might be associated with it in boys who have DMD. Participants will receive study treatment (tadalafil or placebo) for the first 48 weeks of the study, and can then continue into an open label extension (OLE) that consists of two periods during which all participants will receive tadalafil. In OLE period 1, all participants will receive tadalafil for 48 weeks. Participants completing OLE period 1 will continue into OLE period 2 and will receive tadalafil for at least another 48 weeks."}
 {"nctId": "NCT01430104", "briefTitle": "A Study of Teriparatide in Japanese Osteoporosis Patients", "officialTitle": "A Study to Assess the Effects on Serum Calcium When Teriparatide is Used With Active Vitamin D in Osteoporosis Patients", "overallStatus": "COMPLETED", "startDate": "2011-08", "completionDate": "2011-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 30, "briefSummary": "The purpose of this trial is to assess the effects on serum calcium when teriparatide is used with active vitamin D in osteoporosis patients.\n\nThis study consists of a Screening Period, a 14-day Lead-in Period, a 28-day Treatment Period, and a 7-day Follow-up Period. Patients will take vitamin D and calcium supplementation from the Lead-in Period throughout the study. During the Treatment Period, daily administration of teriparatide will be added.", "conditions": ["Osteoporosis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Teriparatide", "otherNames": ["LY333334", "Forteo", "Forsteo"]}, {"type": "DRUG", "name": "Aspara-CA 600 mg", "otherNames": []}, {"type": "DRUG", "name": "Alfarol 1.0 \u00b5g", "otherNames": []}], "meshConditions": ["Osteoporosis"], "meshInterventions": ["Teriparatide"], "hasResults": true, "classifyText": "A Study of Teriparatide in Japanese Osteoporosis Patients Osteoporosis Teriparatide Aspara-CA 600 mg Alfarol 1.0 \u00b5g Osteoporosis Teriparatide The purpose of this trial is to assess the effects on serum calcium when teriparatide is used with active vitamin D in osteoporosis patients.\n\nThis study consists of a Screening Period, a 14-day Lead-in Period, a 28-day Treatment Period, and a 7-day Follow-up Period. Patients will take vitamin D and calcium supplementation from the Lead-in Period throughout the study. During the Treatment Period, daily administration of teriparatide will be added."}
 {"nctId": "NCT00190658", "briefTitle": "Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome", "officialTitle": "Safety and Efficacy of Humatrope in Pediatric Patients With Genetic Short Stature (SHOX Gene Defect)", "overallStatus": "COMPLETED", "startDate": "2000-02", "completionDate": "2010-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 75, "briefSummary": "This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreated prepubertal patients with SHOX deficiency. Both groups will be compared to a somatropin-treated group of girls with Turner syndrome. After the second year patients in the control group have the option to receive treatment as well. All patients will optionally be treated until they achieved adult height.", "conditions": ["Failure to Thrive"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Somatropin (rDNA origin) for injection", "otherNames": []}], "meshConditions": ["Failure to Thrive"], "meshInterventions": ["Human Growth Hormone", "WW Domain-Containing Oxidoreductase"], "hasResults": false, "classifyText": "Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome Failure to Thrive Somatropin (rDNA origin) for injection Failure to Thrive Human Growth Hormone WW Domain-Containing Oxidoreductase This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreated prepubertal patients with SHOX deficiency. Both groups will be compared to a somatropin-treated group of girls with Turner syndrome. After the second year patients in the control group have the option to receive treatment as well. All patients will optionally be treated until they achieved adult height."}
 {"nctId": "NCT01777191", "briefTitle": "Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis", "officialTitle": "Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis", "overallStatus": "COMPLETED", "startDate": "2013-03", "completionDate": "2015-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 204, "briefSummary": "The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.", "conditions": ["Plaque Psoriasis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Ixekizumab Auto-Injector", "otherNames": ["LY2439821"]}, {"type": "DRUG", "name": "Ixekizumab Prefilled Syringe", "otherNames": ["LY2439821"]}], "meshConditions": [], "meshInterventions": ["ixekizumab"], "hasResults": true, "classifyText": "Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis Plaque Psoriasis Ixekizumab Auto-Injector Ixekizumab Prefilled Syringe ixekizumab The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension."}
 {"nctId": "NCT01129674", "briefTitle": "A Long-Term, Open-Label, Study on Schizophrenia", "officialTitle": "A Long-Term, Open-Label, Multicenter Study of LY2140023 Compared to Atypical Antipsychotic Standard of Care in Patients With DSM-IV-TR Schizophrenia", "overallStatus": "TERMINATED", "startDate": "2010-06", "completionDate": "2012-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1210, "briefSummary": "The primary purpose of the study is to help answer the following research questions:\n\nHow LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period.\n\nWhether LY 2140023 can help patients with Schizophrenia.", "conditions": ["Schizophrenia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2140023", "otherNames": ["mGlu 2/3 Prodrug II"]}, {"type": "DRUG", "name": "Olanzapine", "otherNames": ["Zyprexa", "LY170053"]}, {"type": "DRUG", "name": "Aripiprazole", "otherNames": []}, {"type": "DRUG", "name": "Risperidone", "otherNames": []}, {"type": "DRUG", "name": "Quetiapine", "otherNames": []}], "meshConditions": ["Schizophrenia"], "meshInterventions": ["LY 2140023", "Olanzapine", "Aripiprazole", "Risperidone", "Quetiapine Fumarate"], "hasResults": false, "classifyText": "A Long-Term, Open-Label, Study on Schizophrenia Schizophrenia LY2140023 Olanzapine Aripiprazole Risperidone Quetiapine Schizophrenia LY 2140023 Olanzapine Aripiprazole Risperidone Quetiapine Fumarate The primary purpose of the study is to help answer the following research questions:\n\nHow LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period.\n\nWhether LY 2140023 can help patients with Schizophrenia."}
 {"nctId": "NCT00785538", "briefTitle": "A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available", "officialTitle": "Phase I Study of Anti-Insulin-Like Growth Factor-I Receptor (IGF-IR) Monoclonal Antibody IMC-A12 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom No Standard Therapy is Available", "overallStatus": "COMPLETED", "startDate": "2005-10", "completionDate": "2011-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 24, "briefSummary": "The purpose of this study is to determine if IMC-A12 is safe for participants, and also to determine the best dose of IMC-A12 to give to participants.", "conditions": ["Advanced Solid Tumors"], "keywords": ["Tumors", "Antibodies, Monoclonal"], "interventions": [{"type": "BIOLOGICAL", "name": "IMC-A12", "otherNames": ["Cixutumumab", "LY3012217"]}, {"type": "BIOLOGICAL", "name": "IMC-A12", "otherNames": ["Cixutumumab", "LY3012217"]}, {"type": "BIOLOGICAL", "name": "IMC-A12", "otherNames": ["Cixutumumab", "LY3012217"]}, {"type": "BIOLOGICAL", "name": "IMC-A12", "otherNames": ["Cixutumumab", "LY3012217"]}, {"type": "BIOLOGICAL", "name": "IMC-A12", "otherNames": ["Cixutumumab", "LY3012217"]}, {"type": "BIOLOGICAL", "name": "IMC-A12", "otherNames": ["Cixutumumab", "LY3012217"]}], "meshConditions": ["Neoplasms"], "meshInterventions": ["cixutumumab"], "hasResults": true, "classifyText": "A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available Advanced Solid Tumors Tumors Antibodies, Monoclonal IMC-A12 IMC-A12 IMC-A12 IMC-A12 IMC-A12 IMC-A12 Neoplasms cixutumumab The purpose of this study is to determine if IMC-A12 is safe for participants, and also to determine the best dose of IMC-A12 to give to participants."}
 {"nctId": "NCT03743285", "briefTitle": "A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)", "officialTitle": "An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2018-11-14", "completionDate": "2019-01-28", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["NA"], "primaryPurpose": "DEVICE_FEASIBILITY", "enrollment": 10, "briefSummary": "The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes. The purpose of this study is to assess the safety of the AID system and to test whether the AID System functions as designed. The study will last about 3 months with up to 6 days of inpatient time.", "conditions": ["Type 1 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DEVICE", "name": "AID System", "otherNames": ["LY8888AU"]}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["LY275585"]}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin Lispro"], "hasResults": false, "classifyText": "A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D) Type 1 Diabetes Mellitus AID System Insulin Lispro Diabetes Mellitus, Type 1 Insulin Lispro The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes. The purpose of this study is to assess the safety of the AID system and to test whether the AID System functions as designed. The study will last about 3 months with up to 6 days of inpatient time."}
 {"nctId": "NCT00191347", "briefTitle": "A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer", "officialTitle": "A Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2004-10", "completionDate": "2005-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 30, "briefSummary": "This study is designed to determine the efficacy of the biweekly pemetrexed/gemcitabine regimen when given to patients with metastatic breast cancer. Each agent has well demonstrated antitumor activity in patients with locally advanced or metastatic breast cancer. In addition, in the phase I combination trial of the two agents, a durable tumor response was seen in one out of three heavily pretreated breast cancer patients (Adjei et al. 2000). Therefore, it is reasonable to expect that the combination of pemetrexed and gemcitabine administered may be associated with considerably more anti-tumor activity than either agent alone. If such activity is seen in this study, randomized studies comparing this combination with other active agents or combinations of active agents will be considered.", "conditions": ["Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": []}, {"type": "DRUG", "name": "gemcitabine", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Pemetrexed", "Gemcitabine"], "hasResults": false, "classifyText": "A Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer Breast Cancer pemetrexed gemcitabine Breast Neoplasms Pemetrexed Gemcitabine This study is designed to determine the efficacy of the biweekly pemetrexed/gemcitabine regimen when given to patients with metastatic breast cancer. Each agent has well demonstrated antitumor activity in patients with locally advanced or metastatic breast cancer. In addition, in the phase I combination trial of the two agents, a durable tumor response was seen in one out of three heavily pretreated breast cancer patients (Adjei et al. 2000). Therefore, it is reasonable to expect that the combination of pemetrexed and gemcitabine administered may be associated with considerably more anti-tumor activity than either agent alone. If such activity is seen in this study, randomized studies comparing this combination with other active agents or combinations of active agents will be considered."}
 {"nctId": "NCT01401543", "briefTitle": "A Bioavailability Study of LY2452473 and Tadalafil", "officialTitle": "LY2452473 Formulation Exploratory Bioavailability Study", "overallStatus": "COMPLETED", "startDate": "2011-07", "completionDate": "2011-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 24, "briefSummary": "This study compares LY2452473 taken orally as a 5 milligram (mg) capsule at the same time as a 5 mg tadalafil tablet with three different combination tablets (LY900010) of 5 mg LY2452473 and 5 mg tadalafil taken orally. The study will evaluate the amount of LY2452473 and tadalafil circulating in the blood for each treatment. Side effects will be documented. This study is approximately 34 days not including screening.", "conditions": ["Erectile Dysfunction"], "keywords": ["testosterone", "energy", "libido", "erectile function", "weak muscles"], "interventions": [{"type": "DRUG", "name": "LY2452473", "otherNames": []}, {"type": "DRUG", "name": "Tadalafil", "otherNames": ["LY450190", "Cialis"]}, {"type": "DRUG", "name": "LY900010", "otherNames": []}], "meshConditions": ["Erectile Dysfunction"], "meshInterventions": ["LY2452473", "Tadalafil"], "hasResults": true, "classifyText": "A Bioavailability Study of LY2452473 and Tadalafil Erectile Dysfunction testosterone energy libido erectile function weak muscles LY2452473 Tadalafil LY900010 Erectile Dysfunction LY2452473 Tadalafil This study compares LY2452473 taken orally as a 5 milligram (mg) capsule at the same time as a 5 mg tadalafil tablet with three different combination tablets (LY900010) of 5 mg LY2452473 and 5 mg tadalafil taken orally. The study will evaluate the amount of LY2452473 and tadalafil circulating in the blood for each treatment. Side effects will be documented. This study is approximately 34 days not including screening."}
 {"nctId": "NCT01284335", "briefTitle": "A Safety Study in Participants With Advanced Solid Tumors", "officialTitle": "A Phase 1 Multicenter, Dose-escalation Study of LY573636-sodium in Combination With 1) Gemcitabine HCl or 2) Docetaxel or 3) Temozolomide or 4) Cisplatin, or 5) Erlotinib in Patients With Advanced Solid Tumors", "overallStatus": "TERMINATED", "startDate": "2008-07", "completionDate": "2016-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 234, "briefSummary": "The purpose of this study is to determine a safe dose of LY573636 (tasisulam) when used in 5 separate combinations with an approved cancer medication for treating participants with advanced cancer. Data from this study will be reviewed for any side effects or anti-tumor activity that may be associated with the LY573636 combination treatments.", "conditions": ["Advanced Solid Tumors"], "keywords": ["Advanced solid tumors", "Unresectable", "Metastatic", "Limited treatment options", "Measurable or nonmeasurable disease"], "interventions": [{"type": "DRUG", "name": "Gemcitabine", "otherNames": ["LY18011"]}, {"type": "DRUG", "name": "Docetaxel", "otherNames": []}, {"type": "DRUG", "name": "Temozolomide", "otherNames": []}, {"type": "DRUG", "name": "Cisplatin", "otherNames": []}, {"type": "DRUG", "name": "Erlotinib", "otherNames": []}, {"type": "DRUG", "name": "LY573636", "otherNames": ["Tasisulam", "LY573636-sodium"]}], "meshConditions": ["Neoplasm Metastasis"], "meshInterventions": ["Gemcitabine", "Docetaxel", "Temozolomide", "Cisplatin", "Erlotinib Hydrochloride", "N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide"], "hasResults": true, "classifyText": "A Safety Study in Participants With Advanced Solid Tumors Advanced Solid Tumors Advanced solid tumors Unresectable Metastatic Limited treatment options Measurable or nonmeasurable disease Gemcitabine Docetaxel Temozolomide Cisplatin Erlotinib LY573636 Neoplasm Metastasis Gemcitabine Docetaxel Temozolomide Cisplatin Erlotinib Hydrochloride N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide The purpose of this study is to determine a safe dose of LY573636 (tasisulam) when used in 5 separate combinations with an approved cancer medication for treating participants with advanced cancer. Data from this study will be reviewed for any side effects or anti-tumor activity that may be associated with the LY573636 combination treatments."}
 {"nctId": "NCT01958489", "briefTitle": "A Study of Evacetrapib in Japanese and Non-Japanese Participants", "officialTitle": "Effect of Evacetrapib on the Pharmacokinetics of Pravastatin in Healthy Japanese and Non-Japanese Subjects", "overallStatus": "COMPLETED", "startDate": "2013-10", "completionDate": "2014-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 24, "briefSummary": "The main purpose of this study is to look at the effect of evacetrapib on pravastatin levels in the blood when both drugs are taken at the same time. The study will also assess how well the body handles evacetrapib and pravastatin when given at the same time.\n\nThis study has two periods in fixed order. Each participant will enroll in both periods. This study will last approximately 25 days, not including screening.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Evacetrapib", "otherNames": ["LY2484595"]}, {"type": "DRUG", "name": "Pravastatin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["evacetrapib", "Pravastatin"], "hasResults": true, "classifyText": "A Study of Evacetrapib in Japanese and Non-Japanese Participants Healthy Volunteers Evacetrapib Pravastatin evacetrapib Pravastatin The main purpose of this study is to look at the effect of evacetrapib on pravastatin levels in the blood when both drugs are taken at the same time. The study will also assess how well the body handles evacetrapib and pravastatin when given at the same time.\n\nThis study has two periods in fixed order. Each participant will enroll in both periods. This study will last approximately 25 days, not including screening."}
 {"nctId": "NCT03750643", "briefTitle": "A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis", "officialTitle": "Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis", "overallStatus": "COMPLETED", "startDate": "2018-11-29", "completionDate": "2021-09-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 128, "briefSummary": "The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts. Each participant will enroll in one part. The study will last 12 to 24 weeks, depending on part.", "conditions": ["Dermatitis, Atopic"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3454738", "otherNames": []}, {"type": "DRUG", "name": "LY3454738", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Dermatitis, Atopic"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis Dermatitis, Atopic LY3454738 LY3454738 Placebo Dermatitis, Atopic The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts. Each participant will enroll in one part. The study will last 12 to 24 weeks, depending on part."}
 {"nctId": "NCT00233025", "briefTitle": "Duloxetine Versus Placebo in the Treatment of FMS", "officialTitle": "Duloxetine 60/120mg Versus Placebo in the Treatment of Fibromyalgia Syndrome", "overallStatus": "COMPLETED", "startDate": "2005-09", "completionDate": "2007-06", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Boehringer Ingelheim"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 320, "briefSummary": "To test the hypothesis that the efficacy and safety of duloxetine has beneficial effects of the reduction of pain severity as measured by the average pain item of the BPI and the PGI-I in patients with fibromyalgia syndrome.", "conditions": ["Fibromyalgia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Fibromyalgia"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Duloxetine Versus Placebo in the Treatment of FMS Fibromyalgia Duloxetine Placebo Fibromyalgia Duloxetine Hydrochloride To test the hypothesis that the efficacy and safety of duloxetine has beneficial effects of the reduction of pain severity as measured by the average pain item of the BPI and the PGI-I in patients with fibromyalgia syndrome."}
 {"nctId": "NCT03155997", "briefTitle": "Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer", "officialTitle": "A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2017-07-12", "completionDate": "2029-05", "leadSponsor": "Eli Lilly and Company", "collaborators": ["NSABP Foundation Inc"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 5637, "briefSummary": "The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.", "conditions": ["Breast Cancer"], "keywords": ["early stage breast cancer", "cyclin-dependent kinase (CDK)"], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Standard Adjuvant Endocrine Therapy", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["abemaciclib"], "hasResults": true, "classifyText": "Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer Breast Cancer early stage breast cancer cyclin-dependent kinase (CDK) Abemaciclib Standard Adjuvant Endocrine Therapy Breast Neoplasms abemaciclib The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer."}
 {"nctId": "NCT01237587", "briefTitle": "A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome", "officialTitle": "Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome", "overallStatus": "COMPLETED", "startDate": "2011-03", "completionDate": "2017-11-28", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 184, "briefSummary": "The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS).\n\nThis trial consists of two distinct study periods. A blinded treatment period of 13 weeks and an open label extension period of 26 weeks.", "conditions": ["Fibromyalgia"], "keywords": ["Adolescents", "Juvenile Primary Fibromyalgia Syndrome"], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": ["LY248686"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Fibromyalgia"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": true, "classifyText": "A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome Fibromyalgia Adolescents Juvenile Primary Fibromyalgia Syndrome Duloxetine Placebo Fibromyalgia Duloxetine Hydrochloride The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS).\n\nThis trial consists of two distinct study periods. A blinded treatment period of 13 weeks and an open label extension period of 26 weeks."}
 {"nctId": "NCT04819100", "briefTitle": "A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)", "officialTitle": "LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib Following Definitive Locoregional Treatment in Participants With Stage IB-IIIA RET Fusion-Positive NSCLC", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2021-12-20", "completionDate": "2028-05", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Loxo Oncology, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 152, "briefSummary": "The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years.", "conditions": ["Carcinoma, Non-Small-Cell Lung"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Selpercatinib", "otherNames": ["LY3527723", "LOXO-292"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["selpercatinib"], "hasResults": false, "classifyText": "A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) Carcinoma, Non-Small-Cell Lung Selpercatinib Placebo Carcinoma, Non-Small-Cell Lung selpercatinib The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had surgery or radiation. Participants who are assigned to placebo and stop the study drug because their disease comes back or gets worse have the option to potentially crossover to selpercatinib. Participation could last up to three years."}
 {"nctId": "NCT00105092", "briefTitle": "Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer.", "officialTitle": "A Phase II Evaluation of Oral Enzastaurin HCl in Second-and Third- Line Treatment of Patients With Non-Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2005-03", "completionDate": "2007-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 50, "briefSummary": "Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy.", "conditions": ["Non-Small-Cell Lung Carcinoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Enzastaurin HCL", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["enzastaurin"], "hasResults": false, "classifyText": "Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer. Non-Small-Cell Lung Carcinoma Enzastaurin HCL Carcinoma, Non-Small-Cell Lung enzastaurin Enzastaurin given daily to patients with non-small cell lung cancer who have failed at least one prior therapy."}
 {"nctId": "NCT00065533", "briefTitle": "Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer", "officialTitle": "Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2003-05", "completionDate": "2005-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 92, "briefSummary": "The purposes of this study are to determine the safety of pemetrexed and any side effects that might be associated with it, whether pemetrexed can help patients with breast cancer and how much pemetrexed should be given to patients.", "conditions": ["Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Pemetrexed"], "hasResults": false, "classifyText": "Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer Breast Cancer pemetrexed Breast Neoplasms Pemetrexed The purposes of this study are to determine the safety of pemetrexed and any side effects that might be associated with it, whether pemetrexed can help patients with breast cancer and how much pemetrexed should be given to patients."}
 {"nctId": "NCT01687998", "briefTitle": "A Study of Evacetrapib in High-Risk Vascular Disease", "officialTitle": "Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes", "overallStatus": "TERMINATED", "startDate": "2012-10", "completionDate": "2016-07", "leadSponsor": "Eli Lilly and Company", "collaborators": ["The Cleveland Clinic"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 12092, "briefSummary": "The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).", "conditions": ["Cardiovascular Diseases"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Evacetrapib", "otherNames": ["LY2484595"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Cardiovascular Diseases"], "meshInterventions": ["evacetrapib"], "hasResults": true, "classifyText": "A Study of Evacetrapib in High-Risk Vascular Disease Cardiovascular Diseases Evacetrapib Placebo Cardiovascular Diseases evacetrapib The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD)."}
 {"nctId": "NCT02718898", "briefTitle": "A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis", "officialTitle": "A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients With Moderate-to-Severe Genital Psoriasis", "overallStatus": "COMPLETED", "startDate": "2016-04", "completionDate": "2018-02-21", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 149, "briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.", "conditions": ["Genital Psoriasis", "Psoriasis"], "keywords": ["genital"], "interventions": [{"type": "DRUG", "name": "Ixekizumab", "otherNames": ["LY2439821"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Psoriasis"], "meshInterventions": ["ixekizumab"], "hasResults": true, "classifyText": "A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Genital Psoriasis Psoriasis genital Ixekizumab Placebo Psoriasis ixekizumab The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis."}
 {"nctId": "NCT02747004", "briefTitle": "A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer", "officialTitle": "A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2016-09-14", "completionDate": "2026-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 234, "briefSummary": "The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.", "conditions": ["Metastatic Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Tamoxifen", "otherNames": []}, {"type": "DRUG", "name": "Prophylactic Loperamide", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["abemaciclib", "Tamoxifen"], "hasResults": true, "classifyText": "A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer Metastatic Breast Cancer Abemaciclib Tamoxifen Prophylactic Loperamide Breast Neoplasms abemaciclib Tamoxifen The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer."}
 {"nctId": "NCT03459612", "briefTitle": "A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants", "officialTitle": "A Phase I, Randomized, Subject- and Investigator-Blind, Placebo-Controlled, 4-Period Cross-Over Study Assessing the Duration of Effect of Lasmiditan on Simulated Driving Performance in Healthy Volunteers", "overallStatus": "COMPLETED", "startDate": "2018-03-26", "completionDate": "2018-06-23", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 68, "briefSummary": "The purpose of this study is to evaluate the effect of lasmiditan on simulated driving performance in healthy participants. Participants are expected to complete each of four study periods, which will last a total of about 10 days. During this time, participants will remain in the clinical research unit. Screening must be completed within 28 days before the start of the study. Follow-up will be completed about one week after discharge.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Lasmiditan", "otherNames": ["LY573144"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Diphenhydramine", "otherNames": []}], "meshConditions": [], "meshInterventions": ["lasmiditan", "Diphenhydramine"], "hasResults": true, "classifyText": "A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants Healthy Lasmiditan Placebo Diphenhydramine lasmiditan Diphenhydramine The purpose of this study is to evaluate the effect of lasmiditan on simulated driving performance in healthy participants. Participants are expected to complete each of four study periods, which will last a total of about 10 days. During this time, participants will remain in the clinical research unit. Screening must be completed within 28 days before the start of the study. Follow-up will be completed about one week after discharge."}
 {"nctId": "NCT07222332", "briefTitle": "A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)", "officialTitle": "A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Preserve Beta Cell Function in Participants Newly Diagnosed With Type 1 Diabetes Aged \u22651 to <36 Years", "overallStatus": "RECRUITING", "startDate": "2026-02-05", "completionDate": "2028-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 300, "briefSummary": "The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.", "conditions": ["Diabetes Mellitus, Type 1"], "keywords": ["T1DM", "Children", "New-onset", "Beta-cell Function"], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["baricitinib"], "hasResults": false, "classifyText": "A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE) Diabetes Mellitus, Type 1 T1DM Children New-onset Beta-cell Function Baricitinib Placebo Diabetes Mellitus, Type 1 baricitinib The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks."}
 {"nctId": "NCT01640834", "briefTitle": "Study of LY2409021 in Participants With Type 1 Diabetes", "officialTitle": "Pilot Study of the Effects of LY2409021 in Patients With Type 1 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2012-07", "completionDate": "2012-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 20, "briefSummary": "This study involves taking a single dose of 100 milligrams (mg) or 300 mg LY2409021 or placebo (an inactive medicine) taken as up to 3 capsules by mouth. The study will evaluate if this drug will reduce the amount of insulin a type 1 diabetic needs over 24 hours. This study includes a 7-day hospitalization period at the clinical research unit (CRU) and will involve screening within 30 days of the start of the study as well as telephone consultations within 5 days after discharge from the CRU.", "conditions": ["Diabetes Mellitus, Type 1"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2409021", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Glucagon", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["adomeglivant", "Glucagon"], "hasResults": true, "classifyText": "Study of LY2409021 in Participants With Type 1 Diabetes Diabetes Mellitus, Type 1 LY2409021 Placebo Glucagon Diabetes Mellitus, Type 1 adomeglivant Glucagon This study involves taking a single dose of 100 milligrams (mg) or 300 mg LY2409021 or placebo (an inactive medicine) taken as up to 3 capsules by mouth. The study will evaluate if this drug will reduce the amount of insulin a type 1 diabetic needs over 24 hours. This study includes a 7-day hospitalization period at the clinical research unit (CRU) and will involve screening within 30 days of the start of the study as well as telephone consultations within 5 days after discharge from the CRU."}
 {"nctId": "NCT00744991", "briefTitle": "A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma", "officialTitle": "A Phase 2, Open-Label, Multicenter Study of Single-Agent Enzastaurin in Patients With Relapsed Cutaneous T-Cell Lymphoma", "overallStatus": "COMPLETED", "startDate": "2008-09", "completionDate": "2010-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 25, "briefSummary": "The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.", "conditions": ["Cutaneous T-Cell Lymphoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Enzastaurin", "otherNames": ["LY317615"]}], "meshConditions": ["Lymphoma, T-Cell, Cutaneous"], "meshInterventions": ["enzastaurin"], "hasResults": true, "classifyText": "A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma Cutaneous T-Cell Lymphoma Enzastaurin Lymphoma, T-Cell, Cutaneous enzastaurin The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies."}
 {"nctId": "NCT01469013", "briefTitle": "Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of Baricitinib (LY3009104) in Japanese Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy", "overallStatus": "COMPLETED", "startDate": "2011-11", "completionDate": "2013-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 145, "briefSummary": "This is a Phase 2b, outpatient, randomized, double-blinded (with a single-blind extension), placebo-controlled, dose-ranging, parallel-group study of baricitinib (LY3009104) in Japanese participants with active rheumatoid arthritis (RA) on background methotrexate (MTX) therapy. Baricitinib will be orally administered once a day with background methotrexate \\[6 to 16 milligrams (mg)/week\\] therapy for 12 weeks in the double-blind treatment period (1, 2, 4 or 8 mg/day, or placebo), and for 52 weeks in the single-blind extension period (4 or 8 mg/day).", "conditions": ["Arthritis, Rheumatoid"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": ["Sugar pill"]}, {"type": "DRUG", "name": "Baricitinib", "otherNames": ["JAK1/JAK2 inhibitor", "JAK1 inhibitor", "JAK2 inhibitor", "NCB028050", "LY3009104"]}, {"type": "DRUG", "name": "Baricitinib", "otherNames": ["JAK1/JAK2 inhibitor", "JAK1 inhibitor", "JAK2 inhibitor", "NCB028050", "LY3009104"]}, {"type": "DRUG", "name": "Baricitinib", "otherNames": ["JAK1/JAK2 inhibitor", "JAK1 inhibitor", "JAK2 inhibitor", "NCB028050", "LY3009104"]}, {"type": "DRUG", "name": "Methotrexate", "otherNames": []}], "meshConditions": ["Arthritis, Rheumatoid"], "meshInterventions": ["Sugars", "baricitinib", "Methotrexate"], "hasResults": true, "classifyText": "Oral Baricitinib (LY3009104)Treatment in Japanese Participants With Active Rheumatoid Arthritis on Background Methotrexate Therapy Arthritis, Rheumatoid Placebo Baricitinib Baricitinib Baricitinib Methotrexate Arthritis, Rheumatoid Sugars baricitinib Methotrexate This is a Phase 2b, outpatient, randomized, double-blinded (with a single-blind extension), placebo-controlled, dose-ranging, parallel-group study of baricitinib (LY3009104) in Japanese participants with active rheumatoid arthritis (RA) on background methotrexate (MTX) therapy. Baricitinib will be orally administered once a day with background methotrexate \\[6 to 16 milligrams (mg)/week\\] therapy for 12 weeks in the double-blind treatment period (1, 2, 4 or 8 mg/day, or placebo), and for 52 weeks in the single-blind extension period (4 or 8 mg/day)."}
 {"nctId": "NCT01722825", "briefTitle": "Study of LY2157299 in Japanese Participants With Cancer", "officialTitle": "Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors", "overallStatus": "COMPLETED", "startDate": "2012-11", "completionDate": "2014-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 12, "briefSummary": "The main purpose of this study is to evaluate the safety and side effects of LY2157299 in Japanese participants with advanced cancer or cancer that has spread to other parts of the body.", "conditions": ["Neoplasms", "Neoplasm Metastasis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2157299", "otherNames": []}], "meshConditions": ["Neoplasms", "Neoplasm Metastasis"], "meshInterventions": ["LY-2157299"], "hasResults": false, "classifyText": "Study of LY2157299 in Japanese Participants With Cancer Neoplasms Neoplasm Metastasis LY2157299 Neoplasms Neoplasm Metastasis LY-2157299 The main purpose of this study is to evaluate the safety and side effects of LY2157299 in Japanese participants with advanced cancer or cancer that has spread to other parts of the body."}
 {"nctId": "NCT01872910", "briefTitle": "A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal", "officialTitle": "Evaluation of the Acute Analgesic Efficacy of a Single Dose of LY3023703 in Patients With Postsurgical Dental Pain: A Parallel, Double-Blind, Randomized, Placebo and Positive Control Study", "overallStatus": "COMPLETED", "startDate": "2013-06", "completionDate": "2013-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 124, "briefSummary": "The main purpose of this study is to test if a single dose of LY3023703 relieves pain after wisdom teeth removal. The study will last about one week for each participant, not including screening.", "conditions": ["Acute Pain"], "keywords": ["Wisdom tooth extraction"], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "LY3023703", "otherNames": ["LY3023703 phosphate"]}, {"type": "DRUG", "name": "Celecoxib", "otherNames": []}], "meshConditions": ["Acute Pain"], "meshInterventions": ["Celecoxib"], "hasResults": true, "classifyText": "A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal Acute Pain Wisdom tooth extraction Placebo LY3023703 Celecoxib Acute Pain Celecoxib The main purpose of this study is to test if a single dose of LY3023703 relieves pain after wisdom teeth removal. The study will last about one week for each participant, not including screening."}
 {"nctId": "NCT06028425", "briefTitle": "A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants", "officialTitle": "A Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of LOXO-783 in Healthy Adult Subjects", "overallStatus": "COMPLETED", "startDate": "2023-09-01", "completionDate": "2023-12-23", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Loxo Oncology, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 42, "briefSummary": "The main purpose of this study is to measure how much of LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered in fasting and fed states in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783. Participation could last up to 63 days including screening period.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LOXO-783", "otherNames": ["LY3849524"]}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study to Evaluate the Effect of Food on LOXO-783 in Healthy Participants Healthy LOXO-783 The main purpose of this study is to measure how much of LOXO-783 is in the bloodstream and how the body handles and eliminates LOXO-783 when administered in fasting and fed states in healthy participants. The study will also evaluate the safety and tolerability of LOXO-783. Participation could last up to 63 days including screening period."}
 {"nctId": "NCT00763724", "briefTitle": "Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults", "officialTitle": "A Propensity-Matched Retrospective Cohort Study of Antidepressant Drug Exposure and Risk of Suicide Attempt in Adults From a Large U.S. Managed Care Population", "overallStatus": "COMPLETED", "startDate": "2008-06", "completionDate": "2009-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "OBSERVATIONAL", "phases": [], "primaryPurpose": null, "enrollment": 254432, "briefSummary": "The primary objective of the study is to estimate the incidence of suicide attempts resulting in a medical encounter or hospitalization in seven propensity matched cohorts of subjects: patients treated with duloxetine for depression, patients treated with one of three other antidepressants or antidepressant classes (venlafaxine, SSRIs, or TCAs) for depression, patients treated with multiple antidepressants for depression (either concurrently or consecutively), depressed patients with no pharmacologic treatment, and a non-depressed general population sample.", "conditions": ["Depression", "Suicide"], "keywords": [], "interventions": [], "meshConditions": ["Depression", "Suicide"], "meshInterventions": [], "hasResults": false, "classifyText": "Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults Depression Suicide Depression Suicide The primary objective of the study is to estimate the incidence of suicide attempts resulting in a medical encounter or hospitalization in seven propensity matched cohorts of subjects: patients treated with duloxetine for depression, patients treated with one of three other antidepressants or antidepressant classes (venlafaxine, SSRIs, or TCAs) for depression, patients treated with multiple antidepressants for depression (either concurrently or consecutively), depressed patients with no pharmacologic treatment, and a non-depressed general population sample."}
 {"nctId": "NCT00191178", "briefTitle": "Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes", "officialTitle": "Pilot Study Investigating the Effects of Insulin Lispro Low Mixture Therapy Compared With Insulin Glargine on Perceived Mood Symptoms in Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2003-08", "completionDate": "2005-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 60, "briefSummary": "This study investigates the influence of two different insulin regimens, twice-daily insulin lispro low mix (LM) and once-daily insulin glargine, on perceived physical, mood, and cognitive symptoms as well as cognitive-motor task performance in patients with type 2 diabetes.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "insulin lispro protamine suspension:insulin lispro rDNA origin low mix", "otherNames": []}, {"type": "DRUG", "name": "insulin glargine", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Insulin Glargine"], "hasResults": false, "classifyText": "Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes Type 2 Diabetes insulin lispro protamine suspension:insulin lispro rDNA origin low mix insulin glargine Diabetes Mellitus, Type 2 Insulin Glargine This study investigates the influence of two different insulin regimens, twice-daily insulin lispro low mix (LM) and once-daily insulin glargine, on perceived physical, mood, and cognitive symptoms as well as cognitive-motor task performance in patients with type 2 diabetes."}
 {"nctId": "NCT00386815", "briefTitle": "Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma", "officialTitle": "Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma", "overallStatus": "COMPLETED", "startDate": "2006-10", "completionDate": "2007-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 20, "briefSummary": "To investigate safety of pemetrexed combined with cisplatin for chemo therapy-naive patients with malignant pleural mesothelioma", "conditions": ["Malignant Pleural Mesothelioma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": []}, {"type": "DRUG", "name": "cisplatin", "otherNames": []}], "meshConditions": ["Mesothelioma, Malignant"], "meshInterventions": ["Pemetrexed", "Cisplatin"], "hasResults": false, "classifyText": "Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Malignant Pleural Mesothelioma pemetrexed cisplatin Mesothelioma, Malignant Pemetrexed Cisplatin To investigate safety of pemetrexed combined with cisplatin for chemo therapy-naive patients with malignant pleural mesothelioma"}
 {"nctId": "NCT06948435", "briefTitle": "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1", "officialTitle": "A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)", "overallStatus": "RECRUITING", "startDate": "2025-04-30", "completionDate": "2027-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 487, "briefSummary": "GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight.", "conditions": ["Hypertension", "Overweight or Obesity"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Orforglipron", "otherNames": ["LY3502970"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Hypertension", "Overweight", "Obesity"], "meshInterventions": ["orforglipron"], "hasResults": false, "classifyText": "A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 Hypertension Overweight or Obesity Orforglipron Placebo Hypertension Overweight Obesity orforglipron GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hypertension in participants with obesity or overweight."}
 {"nctId": "NCT00406848", "briefTitle": "A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients", "officialTitle": "Duloxetine Versus Placebo in the Long-Term Treatment of Patients With Late-Life Major Depression", "overallStatus": "COMPLETED", "startDate": "2006-11", "completionDate": "2009-11", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Boehringer Ingelheim"], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 370, "briefSummary": "The purpose of this study is to compare the efficacy and safety of duloxetine 60 mg once daily to placebo on depression in elderly patients (greater than or equal to 65 years of age). Patients who do not respond in the first 13 weeks will be eligible for rescue using pre-defined criteria. Patients randomized to duloxetine 60 mg/day meeting the rescue criteria will be increased to 120 mg/day. Patients randomized to the placebo arm meeting the rescue criteria will be assigned to duloxetine 60 mg/day.", "conditions": ["Major Depressive Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "duloxetine hydrochloride", "otherNames": ["LY248686, Cymbalta"]}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Depressive Disorder, Major"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": true, "classifyText": "A Study Comparing the Efficacy and Safety of Duloxetine and Placebo for the Treatment of Depression in Elderly Patients Major Depressive Disorder duloxetine hydrochloride placebo Depressive Disorder, Major Duloxetine Hydrochloride The purpose of this study is to compare the efficacy and safety of duloxetine 60 mg once daily to placebo on depression in elderly patients (greater than or equal to 65 years of age). Patients who do not respond in the first 13 weeks will be eligible for rescue using pre-defined criteria. Patients randomized to duloxetine 60 mg/day meeting the rescue criteria will be increased to 120 mg/day. Patients randomized to the placebo arm meeting the rescue criteria will be assigned to duloxetine 60 mg/day."}
 {"nctId": "NCT02624778", "briefTitle": "A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD", "officialTitle": "A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease", "overallStatus": "COMPLETED", "startDate": "2015-12-22", "completionDate": "2019-08-28", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 61, "briefSummary": "The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813. Study participants will have mild cognitive impairment (MCI) due to AD or mild to moderate AD.\n\nThe study involves 3 parts.\n\n* Part A in which participants will receive a single dose of LY3002813 or placebo (no drug).\n* Part B in which participants will receive multiple doses of LY3002813 or placebo for 24 weeks.\n* Part C in which participants will receive multiple doses of LY3002813 or placebo for up to 72 weeks.\n\nDrug will be given as an intravenous infusion (injection into a vein). For Parts A, B and C, the study will last approximately 72 weeks, not including screening of approximately 56 days. The study is for research purposes only and is not intended to treat any medical condition.", "conditions": ["Alzheimer Disease"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "LY3002813", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Alzheimer Disease"], "meshInterventions": [], "hasResults": true, "classifyText": "A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD Alzheimer Disease LY3002813 Placebo Alzheimer Disease The study will evaluate the effect of LY3002813 on brain scans. The study will evaluate the safety of LY3002813 by looking at adverse events (side effects). The study will also look at the effect the body has on LY3002813. Study participants will have mild cognitive impairment (MCI) due to AD or mild to moderate AD.\n\nThe study involves 3 parts.\n\n* Part A in which participants will receive a single dose of LY3002813 or placebo (no drug).\n* Part B in which participants will receive multiple doses of LY3002813 or placebo for 24 weeks.\n* Part C in which participants will receive multiple doses of LY3002813 or placebo for up to 72 weeks.\n\nDrug will be given as an intravenous infusion (injection into a vein). For Parts A, B and C, the study will last approximately 72 weeks, not including screening of approximately 56 days. The study is for research purposes only and is not intended to treat any medical condition."}
 {"nctId": "NCT00191243", "briefTitle": "Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer", "officialTitle": "A Randomized Phase II Study Comparing Single-Agent Docetaxel to Alternating Docetaxel-Gemcitabine as Primary Chemotherapy in Patients With Metastatic Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2002-03", "completionDate": "2009-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 237, "briefSummary": "Randomized,non-blinded,multi-center study in patients with metastatic breast cancer.Patients will be treated with docetaxel or docetaxel-gemcitabine.\n\nAim of the study is to assess the optimal dosage and safety in this setting.", "conditions": ["Breast Cancer"], "keywords": ["breast cancer"], "interventions": [{"type": "DRUG", "name": "Gemcitabine", "otherNames": ["LY188011", "Gemzar"]}, {"type": "DRUG", "name": "docetaxel", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Gemcitabine", "Docetaxel"], "hasResults": false, "classifyText": "Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer Breast Cancer breast cancer Gemcitabine docetaxel Breast Neoplasms Gemcitabine Docetaxel Randomized,non-blinded,multi-center study in patients with metastatic breast cancer.Patients will be treated with docetaxel or docetaxel-gemcitabine.\n\nAim of the study is to assess the optimal dosage and safety in this setting."}
 {"nctId": "NCT04867785", "briefTitle": "A Study of LY3437943 in Participants With Type 2 Diabetes", "officialTitle": "A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes", "overallStatus": "COMPLETED", "startDate": "2021-05-13", "completionDate": "2022-10-27", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 281, "briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3437943", "otherNames": []}, {"type": "DRUG", "name": "Dulaglutide", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["retatrutide", "dulaglutide"], "hasResults": true, "classifyText": "A Study of LY3437943 in Participants With Type 2 Diabetes Type 2 Diabetes LY3437943 Dulaglutide Placebo Diabetes Mellitus, Type 2 retatrutide dulaglutide The main purpose of this study is to evaluate the efficacy and safety of LY3437943 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 43 weeks."}
 {"nctId": "NCT00487240", "briefTitle": "Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes", "officialTitle": "Comparison of Two Basal Insulin Analogs (Insulin Lispro Protamine Suspension and Insulin Detemir) in Basal-Bolus Therapy for Patients With Type 1 Diabetes", "overallStatus": "COMPLETED", "startDate": "2007-06", "completionDate": "2008-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 387, "briefSummary": "The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives.", "conditions": ["Diabetes Mellitus, Type 1"], "keywords": ["diabetes", "type 1"], "interventions": [{"type": "DRUG", "name": "Insulin Lispro Protamine Suspension", "otherNames": ["ILPS", "NPL", "Humalog", "LY275585"]}, {"type": "DRUG", "name": "Insulin Levemir", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1", "Diabetes Mellitus"], "meshInterventions": ["Insulin Lispro"], "hasResults": true, "classifyText": "Comparison of Two Basal Insulin Therapies for Patients With Type 1 Diabetes Diabetes Mellitus, Type 1 diabetes type 1 Insulin Lispro Protamine Suspension Insulin Levemir Diabetes Mellitus, Type 1 Diabetes Mellitus Insulin Lispro The purpose of this study is to examine the efficacy and safety of insulin lispro protamine suspension (ILPS) as compared to insulin detemir as basal insulin combined with mealtime insulin therapy in patients with type 1 diabetes. A gatekeeper strategy will be employed for sequentially testing the secondary objectives."}
 {"nctId": "NCT00191685", "briefTitle": "Duloxetine in the Treatment of Melancholic Depression", "officialTitle": "Duloxetine in the Treatment of Melancholic Depression: An 8-Week Open-Label Dose Study", "overallStatus": "COMPLETED", "startDate": "2004-05", "completionDate": "2005-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 200, "briefSummary": "The purpose of this study is to determine the optimal treatment strategy for MDD patients with melancholic features who do not respond to a standard daily dose. This study will allow investigators to mimic standard clinical practice. During the first 2 weeks of treatment, clinical evaluation of individual patient tolerability and efficacy will enable the dose of duloxetine to be adjusted. Patients allocated to the Flex group may have their daily dose of duloxetine adjusted in the attempt to elicit a clinical response.", "conditions": ["Depressive Disorder, Major"], "keywords": [], "interventions": [{"type": "DRUG", "name": "duloxetine", "otherNames": []}], "meshConditions": ["Depressive Disorder, Major"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Duloxetine in the Treatment of Melancholic Depression Depressive Disorder, Major duloxetine Depressive Disorder, Major Duloxetine Hydrochloride The purpose of this study is to determine the optimal treatment strategy for MDD patients with melancholic features who do not respond to a standard daily dose. This study will allow investigators to mimic standard clinical practice. During the first 2 weeks of treatment, clinical evaluation of individual patient tolerability and efficacy will enable the dose of duloxetine to be adjusted. Patients allocated to the Flex group may have their daily dose of duloxetine adjusted in the attempt to elicit a clinical response."}
 {"nctId": "NCT00191308", "briefTitle": "Molecular Profiling in Lung Cancer Patients", "officialTitle": "Molecular Profiling and Safety Study of Operable Lung Cancer Patients Treated With Alimta Combined With Cisplatin as Neoadjuvant Chemotherapy", "overallStatus": "COMPLETED", "startDate": "2005-05", "completionDate": "2010-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 30, "briefSummary": "The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in participants' blood and tumor tissue to see if there is any link between the levels or changes in the genes and how participants with lung cancer respond to pemetrexed and cisplatin treatment.", "conditions": ["Non-Small Cell Lung Cancer", "Carcinoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514", "Alimta"]}, {"type": "DRUG", "name": "cisplatin", "otherNames": []}, {"type": "PROCEDURE", "name": "Radical Non-Small Cell Lung Cancer (NSCLC) surgery", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Carcinoma"], "meshInterventions": ["Pemetrexed", "Cisplatin", "Surgical Procedures, Operative"], "hasResults": true, "classifyText": "Molecular Profiling in Lung Cancer Patients Non-Small Cell Lung Cancer Carcinoma pemetrexed cisplatin Radical Non-Small Cell Lung Cancer (NSCLC) surgery Carcinoma, Non-Small-Cell Lung Carcinoma Pemetrexed Cisplatin Surgical Procedures, Operative The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in participants' blood and tumor tissue to see if there is any link between the levels or changes in the genes and how participants with lung cancer respond to pemetrexed and cisplatin treatment."}
 {"nctId": "NCT02770521", "briefTitle": "A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants", "officialTitle": "A Study to Evaluate the Safety and Tolerability of Subcutaneous Treprostinil and Pharmacokinetics of a Novel LY900014 Formulation in Healthy Japanese Subjects", "overallStatus": "COMPLETED", "startDate": "2016-05", "completionDate": "2016-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 23, "briefSummary": "The aims of this study are to evaluate:\n\n* The safety and tolerability of a single dose of treprostinil given subcutaneously (as an injection just under the skin)\n* The pharmacokinetic profile (how the body absorbs, breaks down, and gets rid of) of a single subcutaneous dose of a new LY900014 formulation in healthy Japanese participants.\n\nThe study has two parts. Participants may only enroll in one part.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Treprostinil", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "LY900014", "otherNames": ["Ultra-Rapid Lispro"]}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": []}], "meshConditions": [], "meshInterventions": ["treprostinil", "Insulin Lispro"], "hasResults": true, "classifyText": "A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants Healthy Treprostinil Placebo LY900014 Insulin Lispro treprostinil Insulin Lispro The aims of this study are to evaluate:\n\n* The safety and tolerability of a single dose of treprostinil given subcutaneously (as an injection just under the skin)\n* The pharmacokinetic profile (how the body absorbs, breaks down, and gets rid of) of a single subcutaneous dose of a new LY900014 formulation in healthy Japanese participants.\n\nThe study has two parts. Participants may only enroll in one part."}
 {"nctId": "NCT06297616", "briefTitle": "A Study of LY3841136 in Japanese Participants With Obesity or Overweight", "officialTitle": "A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3841136 Monotherapy, and LY3841136 in Combination With Tirzepatide, in Japanese Participants With Obesity or Overweight", "overallStatus": "COMPLETED", "startDate": "2024-04-15", "completionDate": "2025-11-21", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 128, "briefSummary": "The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits.", "conditions": ["Obesity", "Overweight"], "keywords": ["Obesity Disease", "Metabolic Disorders", "Body Weight Loss"], "interventions": [{"type": "DRUG", "name": "LY3841136", "otherNames": []}, {"type": "DRUG", "name": "LY3841136-Placebo", "otherNames": []}, {"type": "DRUG", "name": "Tirzepatide", "otherNames": []}, {"type": "DRUG", "name": "Tirzepatide-Placebo", "otherNames": []}], "meshConditions": ["Obesity", "Overweight", "Metabolic Diseases"], "meshInterventions": ["Tirzepatide"], "hasResults": false, "classifyText": "A Study of LY3841136 in Japanese Participants With Obesity or Overweight Obesity Overweight Obesity Disease Metabolic Disorders Body Weight Loss LY3841136 LY3841136-Placebo Tirzepatide Tirzepatide-Placebo Obesity Overweight Metabolic Diseases Tirzepatide The main purpose of this study is to learn about the side effects of LY3841136 alone and in combination with tirzepatide, when given to Japanese participants with obese or overweight. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Part A of the study will last about 28 weeks and may include up to 17 visits. Part B of the study will last about 40 weeks and may include up to 29 visits."}
 {"nctId": "NCT06354660", "briefTitle": "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)", "officialTitle": "A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)", "overallStatus": "COMPLETED", "startDate": "2024-04-10", "completionDate": "2026-02-20", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 537, "briefSummary": "The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.", "conditions": ["Diabetes Type 2"], "keywords": ["Glucose Metabolism Disorders", "Metabolic Diseases", "Endocrine System Diseases"], "interventions": [{"type": "DRUG", "name": "Retatrutide", "otherNames": ["LY3437943"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2", "Glucose Metabolism Disorders", "Metabolic Diseases", "Endocrine System Diseases"], "meshInterventions": ["retatrutide"], "hasResults": false, "classifyText": "Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Diabetes Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Retatrutide Placebo Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases retatrutide The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits."}
 {"nctId": "NCT01695239", "briefTitle": "A Study of Ixekizumab in Participants With Active Psoriatic Arthritis", "officialTitle": "A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis", "overallStatus": "COMPLETED", "startDate": "2012-12", "completionDate": "2017-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 417, "briefSummary": "This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.", "conditions": ["Psoriasis, Arthritic"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Ixekizumab", "otherNames": ["LY2439821"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Adalimumab", "otherNames": []}], "meshConditions": ["Arthritis, Psoriatic"], "meshInterventions": ["ixekizumab", "Adalimumab"], "hasResults": true, "classifyText": "A Study of Ixekizumab in Participants With Active Psoriatic Arthritis Psoriasis, Arthritic Ixekizumab Placebo Adalimumab Arthritis, Psoriatic ixekizumab Adalimumab This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis."}
 {"nctId": "NCT01591317", "briefTitle": "Study of Prasugrel in Korean Healthy Male Volunteers", "officialTitle": "Single and Multiple Dose Pharmacokinetics and Pharmacodynamics of Prasugrel (LY640315) in Korean Healthy Male Subjects", "overallStatus": "COMPLETED", "startDate": "2009-03", "completionDate": "2009-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 30, "briefSummary": "The purpose of this study is to investigate how the body processes prasugrel and how prasugrel affects blood clotting in healthy Korean men. Three different dosing regimens of prasugrel will be given. Information on side effects will also be collected.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Prasugrel", "otherNames": ["LY640315", "Effient", "Efient", "Prasita"]}], "meshConditions": [], "meshInterventions": ["Prasugrel Hydrochloride"], "hasResults": true, "classifyText": "Study of Prasugrel in Korean Healthy Male Volunteers Healthy Volunteers Prasugrel Prasugrel Hydrochloride The purpose of this study is to investigate how the body processes prasugrel and how prasugrel affects blood clotting in healthy Korean men. Three different dosing regimens of prasugrel will be given. Information on side effects will also be collected."}
 {"nctId": "NCT00515697", "briefTitle": "A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma", "officialTitle": "Phase II Single Arm Study of IMC-1121B in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy", "overallStatus": "COMPLETED", "startDate": "2007-11", "completionDate": "2011-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 39, "briefSummary": "The purpose of this study is to determine whether ramucirumab is effective treatment in participants with metastatic renal cell carcinoma who have developed progressive disease or become intolerant to tyrosine kinase inhibitor therapy.", "conditions": ["Metastatic Renal Cell Carcinoma"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "Ramucirumab", "otherNames": ["IMC-1121B", "LY3009806"]}], "meshConditions": ["Carcinoma, Renal Cell"], "meshInterventions": ["Ramucirumab"], "hasResults": true, "classifyText": "A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma Metastatic Renal Cell Carcinoma Ramucirumab Carcinoma, Renal Cell Ramucirumab The purpose of this study is to determine whether ramucirumab is effective treatment in participants with metastatic renal cell carcinoma who have developed progressive disease or become intolerant to tyrosine kinase inhibitor therapy."}
 {"nctId": "NCT02240433", "briefTitle": "A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)", "officialTitle": "A Phase 1b Study of LY2157299 in Combination With Sorafenib in Patients With Unresectable Hepatocellular Carcinoma", "overallStatus": "COMPLETED", "startDate": "2014-11-12", "completionDate": "2019-12-25", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 9, "briefSummary": "The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.", "conditions": ["Hepatocellular Carcinoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2157299", "otherNames": []}, {"type": "DRUG", "name": "Sorafenib", "otherNames": []}], "meshConditions": ["Carcinoma, Hepatocellular"], "meshInterventions": ["LY-2157299", "Sorafenib"], "hasResults": false, "classifyText": "A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) Hepatocellular Carcinoma LY2157299 Sorafenib Carcinoma, Hepatocellular LY-2157299 Sorafenib The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants."}
 {"nctId": "NCT01621178", "briefTitle": "A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)", "officialTitle": "A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease", "overallStatus": "COMPLETED", "startDate": "2012-07", "completionDate": "2016-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 577, "briefSummary": "The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.", "conditions": ["Type 2 Diabetes", "Chronic Kidney Disease"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Insulin glargine", "otherNames": []}, {"type": "DRUG", "name": "Insulin lispro", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2", "Renal Insufficiency, Chronic"], "meshInterventions": ["dulaglutide", "Insulin Glargine", "Insulin Lispro"], "hasResults": true, "classifyText": "A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Type 2 Diabetes Chronic Kidney Disease Dulaglutide Insulin glargine Insulin lispro Diabetes Mellitus, Type 2 Renal Insufficiency, Chronic dulaglutide Insulin Glargine Insulin Lispro The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease."}
 {"nctId": "NCT01748552", "briefTitle": "A Study of LY2922083 in Healthy Participants and Participants With Diabetes", "officialTitle": "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY2922083 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2012-12", "completionDate": "2013-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 36, "briefSummary": "The aim of this trial is to evaluate the safety of the study drug in healthy participants and participants with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.\n\nThe study consists of two parts. Part A will study healthy participants in up to 3 dosing periods over approximately 6 weeks. Part B will study participants with diabetes in up to 3 dosing periods over approximately 6 weeks.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "LY2922083", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["LY2922083"], "hasResults": true, "classifyText": "A Study of LY2922083 in Healthy Participants and Participants With Diabetes Diabetes Mellitus, Type 2 Placebo LY2922083 Diabetes Mellitus, Type 2 LY2922083 The aim of this trial is to evaluate the safety of the study drug in healthy participants and participants with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.\n\nThe study consists of two parts. Part A will study healthy participants in up to 3 dosing periods over approximately 6 weeks. Part B will study participants with diabetes in up to 3 dosing periods over approximately 6 weeks."}
 {"nctId": "NCT00035035", "briefTitle": "A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.", "officialTitle": "A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.", "overallStatus": "COMPLETED", "startDate": null, "completionDate": null, "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": null, "briefSummary": "Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body.", "conditions": ["Pancreatic Neoplasms", "Metastases, Neoplasm"], "keywords": ["Pancreas", "Cancer", "Unresectable or Metastatic Cancer of the Pancreas", "Alimta"], "interventions": [{"type": "DRUG", "name": "GEMZAR", "otherNames": []}, {"type": "DRUG", "name": "ALIMTA", "otherNames": []}], "meshConditions": ["Pancreatic Neoplasms", "Neoplasm Metastasis", "Neoplasms"], "meshInterventions": ["Gemcitabine", "Pemetrexed"], "hasResults": false, "classifyText": "A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. Pancreatic Neoplasms Metastases, Neoplasm Pancreas Cancer Unresectable or Metastatic Cancer of the Pancreas Alimta GEMZAR ALIMTA Pancreatic Neoplasms Neoplasm Metastasis Neoplasms Gemcitabine Pemetrexed Definition: This study will compare the drug GEMZAR to a combination of GEMZAR plus ALIMTA for the treatment of cancer of the pancreas. Patients may be able to participate in this study if they have cancer in their pancreas that cannot be removed by surgery OR that has spread to a new site in their body."}
 {"nctId": "NCT00088491", "briefTitle": "Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia", "officialTitle": "A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in the Maintenance Therapy of Patients With Schizophrenia", "overallStatus": "COMPLETED", "startDate": "2004-06", "completionDate": "2006-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1205, "briefSummary": "This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine; evaluate different doses of IM olanzapine depot; and determine the blood levels of IM olanzapine depot in patients at different points in time after an injection.", "conditions": ["Schizophrenic Disorders"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Intramuscular Olanzapine Depot", "otherNames": []}, {"type": "DRUG", "name": "Oral Olanzapine", "otherNames": []}], "meshConditions": ["Schizophrenia"], "meshInterventions": ["Olanzapine"], "hasResults": false, "classifyText": "Comparison of Intramuscular Olanzapine Depot to Oral Olanzapine and Low-Dose Depot in Patients With Schizophrenia Schizophrenic Disorders Intramuscular Olanzapine Depot Oral Olanzapine Schizophrenia Olanzapine This is a randomized, double-blind study to determine how well intramuscular (IM) olanzapine depot works compared to oral olanzapine; evaluate the safety and tolerability of IM olanzapine depot compared to oral olanzapine; evaluate different doses of IM olanzapine depot; and determine the blood levels of IM olanzapine depot in patients at different points in time after an injection."}
 {"nctId": "NCT01965782", "briefTitle": "A Study of [14C]-LY3023703 in Healthy Participants", "officialTitle": "Disposition of [14C]-LY3023703 Following Oral Administration in Healthy Subjects", "overallStatus": "TERMINATED", "startDate": "2013-10", "completionDate": "2013-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 18, "briefSummary": "This type of study is called a radiolabeled study. For this study, LY3023703 (study drug) has been specially prepared to contain radiolabeled carbon \\[14C\\]. \\[14C\\] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered to healthy men. Information about any side effects that may occur will also be collected. This study will last up to 15 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "[^14C]-LY3023703", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": true, "classifyText": "A Study of [14C]-LY3023703 in Healthy Participants Healthy Volunteers [^14C]-LY3023703 This type of study is called a radiolabeled study. For this study, LY3023703 (study drug) has been specially prepared to contain radiolabeled carbon \\[14C\\]. \\[14C\\] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered to healthy men. Information about any side effects that may occur will also be collected. This study will last up to 15 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study."}
 {"nctId": "NCT03559270", "briefTitle": "A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis", "officialTitle": "A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis", "overallStatus": "TERMINATED", "startDate": "2018-06-27", "completionDate": "2022-06-13", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Incyte Corporation"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 374, "briefSummary": "This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD).", "conditions": ["Atopic Dermatitis"], "keywords": ["eczema", "atopic eczema"], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104"]}], "meshConditions": ["Dermatitis, Atopic", "Eczema"], "meshInterventions": ["baricitinib"], "hasResults": true, "classifyText": "A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Atopic Dermatitis eczema atopic eczema Baricitinib Dermatitis, Atopic Eczema baricitinib This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD)."}
 {"nctId": "NCT01602224", "briefTitle": "A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)", "officialTitle": "A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma", "overallStatus": "COMPLETED", "startDate": "2012-07", "completionDate": "2014-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 220, "briefSummary": "The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past. Tabalumab will be given in combination with standard doses of two other drugs that are often used to treat MM. Study doctors will collect information about the effectiveness and side effects of this therapy.", "conditions": ["Multiple Myeloma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Dexamethasone", "otherNames": []}, {"type": "DRUG", "name": "Bortezomib", "otherNames": []}, {"type": "BIOLOGICAL", "name": "Tabalumab", "otherNames": ["LY2127399"]}], "meshConditions": ["Multiple Myeloma"], "meshInterventions": ["Dexamethasone", "Bortezomib", "tabalumab"], "hasResults": true, "classifyText": "A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) Multiple Myeloma Placebo Dexamethasone Bortezomib Tabalumab Multiple Myeloma Dexamethasone Bortezomib tabalumab The purpose of this study is to evaluate an investigational drug called tabalumab in participants with Multiple Myeloma (MM) who have tried at least one other therapy in the past. Tabalumab will be given in combination with standard doses of two other drugs that are often used to treat MM. Study doctors will collect information about the effectiveness and side effects of this therapy."}
 {"nctId": "NCT04049123", "briefTitle": "A Study of LY900014 in Healthy Chinese Participants", "officialTitle": "A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Following Single Dose Administration in Healthy Chinese Subjects", "overallStatus": "COMPLETED", "startDate": "2019-11-18", "completionDate": "2020-10-23", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 15, "briefSummary": "The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014 and the effect of LY900014 on blood sugar levels. For each participant, the study will consist of 3 periods and will last about 51 days.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY900014", "otherNames": ["Ultra-Rapid Lispro"]}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["LY275585", "Humalog"]}], "meshConditions": [], "meshInterventions": ["Insulin Lispro"], "hasResults": true, "classifyText": "A Study of LY900014 in Healthy Chinese Participants Healthy LY900014 Insulin Lispro Insulin Lispro The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014 and the effect of LY900014 on blood sugar levels. For each participant, the study will consist of 3 periods and will last about 51 days."}
 {"nctId": "NCT05929066", "briefTitle": "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight", "officialTitle": "A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2023-07-10", "completionDate": "2026-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 2300, "briefSummary": "The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.", "conditions": ["Obesity", "Overweight", "Osteoarthritis, Knee", "Obstructive Sleep Apnea"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Retatrutide", "otherNames": ["LY3437943"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Obesity", "Overweight", "Osteoarthritis, Knee", "Sleep Apnea, Obstructive"], "meshInterventions": ["retatrutide"], "hasResults": false, "classifyText": "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight Obesity Overweight Osteoarthritis, Knee Obstructive Sleep Apnea Retatrutide Placebo Obesity Overweight Osteoarthritis, Knee Sleep Apnea, Obstructive retatrutide The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks."}
 {"nctId": "NCT05893797", "briefTitle": "A Study of LY8888AX in Participants Using a Connected Insulin Management Platform", "officialTitle": "Assessment of Participant Adherence and Glucose Control While Using a Connected Insulin Management Platform", "overallStatus": "COMPLETED", "startDate": "2023-10-05", "completionDate": "2024-09-16", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["NA"], "primaryPurpose": "TREATMENT", "enrollment": 36, "briefSummary": "The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country.", "conditions": ["Type 1 Diabetes", "Type 2 Diabetes", "Type 2 Diabetes Treated With Insulin"], "keywords": ["T1D", "T2D"], "interventions": [{"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["Humalog Tempo Pen"]}, {"type": "DEVICE", "name": "Tempo Smart Button", "otherNames": []}, {"type": "DEVICE", "name": "Dexcom G6 CGM", "otherNames": []}, {"type": "DEVICE", "name": "Glooko Research Mobile App (RMA)", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1", "Diabetes Mellitus, Type 2"], "meshInterventions": ["Insulin Lispro"], "hasResults": true, "classifyText": "A Study of LY8888AX in Participants Using a Connected Insulin Management Platform Type 1 Diabetes Type 2 Diabetes Type 2 Diabetes Treated With Insulin T1D T2D Insulin Lispro Tempo Smart Button Dexcom G6 CGM Glooko Research Mobile App (RMA) Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Insulin Lispro The main purpose of this study is to assess participant adherence and glucose control while using a connected insulin management platform. Approximately 50 participants will be enrolled in each country."}
 {"nctId": "NCT03590860", "briefTitle": "A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure)", "officialTitle": "A Safety, Tolerability, and Pharmacokinetic Study of Single and Multiple Ascending Doses of LY3322207 in Healthy Subjects and Subjects With Hypertension on ACE I/ARB Therapy", "overallStatus": "TERMINATED", "startDate": "2018-07-13", "completionDate": "2019-01-17", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 62, "briefSummary": "The purpose of this study is to investigate the safety of the study drug known as LY3322207. Participants must be healthy or must have hypertension (high blood pressure). Participants with hypertension may already be taking a common drug to reduce blood pressure called an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).", "conditions": ["Hypertension"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3322207", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Hypertension"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure) Hypertension LY3322207 Placebo Hypertension The purpose of this study is to investigate the safety of the study drug known as LY3322207. Participants must be healthy or must have hypertension (high blood pressure). Participants with hypertension may already be taking a common drug to reduce blood pressure called an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB)."}
 {"nctId": "NCT01908582", "briefTitle": "A Study of Evacetrapib and Rifampin in Healthy Participants", "officialTitle": "Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2013-07", "completionDate": "2013-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 26, "briefSummary": "The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of the two drugs, given together, will also be evaluated. The study will also look at blood cholesterol levels and levels of a hormone called cortisol before and after taking rifampin. Information about any side effects that may occur will also be collected.\n\nFor each participant, this study will include 2 periods in fixed order. The study will last approximately 29 days.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Evacetrapib", "otherNames": ["LY2484595"]}, {"type": "DRUG", "name": "Rifampin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["evacetrapib", "Rifampin"], "hasResults": true, "classifyText": "A Study of Evacetrapib and Rifampin in Healthy Participants Healthy Volunteers Evacetrapib Rifampin evacetrapib Rifampin The main purpose of this study is to determine how much evacetrapib gets into the blood stream and how long it takes the body to get rid of it when given with rifampin. The safety and tolerability of the two drugs, given together, will also be evaluated. The study will also look at blood cholesterol levels and levels of a hormone called cortisol before and after taking rifampin. Information about any side effects that may occur will also be collected.\n\nFor each participant, this study will include 2 periods in fixed order. The study will last approximately 29 days."}
 {"nctId": "NCT07392190", "briefTitle": "A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin", "officialTitle": "A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes", "overallStatus": "RECRUITING", "startDate": "2026-02-10", "completionDate": "2028-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 900, "briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.\n\nParticipation in the study will last about 80 weeks.", "conditions": ["Overweight", "Obesity"], "keywords": ["Amylin receptor agonist"], "interventions": [{"type": "DRUG", "name": "Eloralintide", "otherNames": ["LY3841136"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Overweight", "Obesity"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin Overweight Obesity Amylin receptor agonist Eloralintide Placebo Overweight Obesity The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.\n\nParticipation in the study will last about 80 weeks."}
 {"nctId": "NCT01618916", "briefTitle": "A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol", "officialTitle": "A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Japanese and Non-Japanese Subjects With Elevated LDL-C", "overallStatus": "COMPLETED", "startDate": "2012-06", "completionDate": "2013-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 51, "briefSummary": "This is a phase 1 study in otherwise healthy participants with high LDL cholesterol. Following multiple doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body will be evaluated. Participants will participate in the study for approximately 3 months not including screening. Screening is required within 42 days prior to the start of the study.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3015014", "otherNames": []}, {"type": "OTHER", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": ["frovocimab"], "hasResults": true, "classifyText": "A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol Healthy Volunteers LY3015014 Placebo frovocimab This is a phase 1 study in otherwise healthy participants with high LDL cholesterol. Following multiple doses of LY3015014, the safety and tolerability of the drug, how the body handles the drug, and the drug's effect on the body will be evaluated. Participants will participate in the study for approximately 3 months not including screening. Screening is required within 42 days prior to the start of the study."}
 {"nctId": "NCT00550927", "briefTitle": "Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer", "officialTitle": "A Phase 1 Safety Evaluation of Oral Enzastaurin in Combination With Bevacizumab in Patients With Advanced/Metastatic Cancer", "overallStatus": "COMPLETED", "startDate": "2006-11", "completionDate": "2012-09", "leadSponsor": "Eli Lilly and Company", "collaborators": ["National Cancer Institute (NCI)"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 42, "briefSummary": "RATIONALE: Enzastaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Enzastaurin and bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving enzastaurin together with bevacizumab may kill more cancer cells.\n\nPURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin and bevacizumab in treating patients with locally advanced or metastatic cancer.", "conditions": ["Unspecified Adult Solid Tumor, Protocol Specific"], "keywords": ["unspecified adult solid tumor, protocol specific"], "interventions": [{"type": "BIOLOGICAL", "name": "bevacizumab", "otherNames": []}, {"type": "DRUG", "name": "enzastaurin hydrochloride", "otherNames": []}, {"type": "OTHER", "name": "diagnostic laboratory biomarker analysis", "otherNames": []}, {"type": "OTHER", "name": "pharmacological study", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Bevacizumab"], "hasResults": false, "classifyText": "Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer Unspecified Adult Solid Tumor, Protocol Specific unspecified adult solid tumor, protocol specific bevacizumab enzastaurin hydrochloride diagnostic laboratory biomarker analysis pharmacological study Bevacizumab RATIONALE: Enzastaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Enzastaurin and bevacizumab may also stop the growth of cancer cells by blocking blood flow to the cancer. Giving enzastaurin together with bevacizumab may kill more cancer cells.\n\nPURPOSE: This phase I trial is studying the side effects and best dose of enzastaurin and bevacizumab in treating patients with locally advanced or metastatic cancer."}
 {"nctId": "NCT07073170", "briefTitle": "A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus", "officialTitle": "A Phase 1, Participant- and Investigator-Blind, Placebo-Controlled, Multiple-Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Daily Doses of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2025-07-25", "completionDate": "2026-01-27", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 36, "briefSummary": "The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3549492", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus Type 2 Diabetes LY3549492 Placebo Diabetes Mellitus, Type 2 The main purpose of this study is to investigate LY3549492 in Chinese participants with type 2 diabetes. Participation in the study will last about 18 weeks."}
 {"nctId": "NCT01556594", "briefTitle": "Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia", "officialTitle": "Phase II Study to Investigate the Safety and Efficacy of 2 Dose Levels of a Novel Glucagon Formulation Compared to Commercially Available Glucagon in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia", "overallStatus": "COMPLETED", "startDate": "2012-03", "completionDate": "2012-07", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Locemia Solutions ULC"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 18, "briefSummary": "In this study, participants with Type 1 diabetes received insulin through an infusion into a vein to reduce their blood glucose, and then received nasal glucagon (NG) or glucagon for injection under the skin, and their blood glucose was measured for 3 hours.\n\nThe main objective of this study was to evaluate the safety and efficacy of intranasal and subcutaneous glucagon (SC) in reversing insulin-induced hypoglycemia in participants with type 1 diabetes.", "conditions": ["Hypoglycemia"], "keywords": ["Hypoglycemia", "Diabetes mellitus"], "interventions": [{"type": "DRUG", "name": "Nasal Glucagon 1 mg", "otherNames": ["Dry Powder Nasal Glucagon", "AMG504-1", "LY900018"]}, {"type": "DRUG", "name": "Nasal Glucagon 2 mg", "otherNames": ["Dry Powder Nasal Glucagon", "AMG504-1", "LY900018"]}, {"type": "DRUG", "name": "SC Glucagon", "otherNames": ["Glucagon", "Glucagon for injection (rDNA origin)"]}, {"type": "DRUG", "name": "Nasal Glucagon 3 mg", "otherNames": ["Dry Powder Nasal Glucagon", "AMG504-1", "LY900018"]}], "meshConditions": ["Hypoglycemia", "Diabetes Mellitus"], "meshInterventions": ["Glucagon", "Injections"], "hasResults": true, "classifyText": "Safety and Efficacy of a Novel Glucagon Formulation in Type 1 Diabetic Patients Following Insulin-induced Hypoglycemia Hypoglycemia Hypoglycemia Diabetes mellitus Nasal Glucagon 1 mg Nasal Glucagon 2 mg SC Glucagon Nasal Glucagon 3 mg Hypoglycemia Diabetes Mellitus Glucagon Injections In this study, participants with Type 1 diabetes received insulin through an infusion into a vein to reduce their blood glucose, and then received nasal glucagon (NG) or glucagon for injection under the skin, and their blood glucose was measured for 3 hours.\n\nThe main objective of this study was to evaluate the safety and efficacy of intranasal and subcutaneous glucagon (SC) in reversing insulin-induced hypoglycemia in participants with type 1 diabetes."}
 {"nctId": "NCT02981342", "briefTitle": "A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma", "officialTitle": "An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma", "overallStatus": "COMPLETED", "startDate": "2017-01-12", "completionDate": "2018-11-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 106, "briefSummary": "The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).", "conditions": ["Pancreatic Ductal Adenocarcinoma"], "keywords": ["pancreatic cancer"], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "LY3023414", "otherNames": []}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": ["LY188011"]}, {"type": "DRUG", "name": "Capecitabine", "otherNames": []}], "meshConditions": ["Pancreatic Neoplasms"], "meshInterventions": ["abemaciclib", "LY3023414", "Gemcitabine", "Capecitabine"], "hasResults": true, "classifyText": "A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma pancreatic cancer Abemaciclib LY3023414 Gemcitabine Capecitabine Pancreatic Neoplasms abemaciclib LY3023414 Gemcitabine Capecitabine The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC)."}
 {"nctId": "NCT05110794", "briefTitle": "A Multiple-Dose Study of LY3502970 in Healthy Participants", "officialTitle": "A Phase 1 Multiple Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of LY3502970 in Fed and Fasted Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2021-11-05", "completionDate": "2022-02-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 33, "briefSummary": "The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in fed and fasted states. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study will last up to 49 days excluding the screening period.", "conditions": ["Healthy"], "keywords": ["Food", "Food Effect"], "interventions": [{"type": "DRUG", "name": "LY3502970", "otherNames": []}], "meshConditions": [], "meshInterventions": ["orforglipron"], "hasResults": false, "classifyText": "A Multiple-Dose Study of LY3502970 in Healthy Participants Healthy Food Food Effect LY3502970 orforglipron The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in healthy participants in fed and fasted states. The study will also evaluate the safety and tolerability of LY3502970 in these participants. The study will last up to 49 days excluding the screening period."}
 {"nctId": "NCT06916091", "briefTitle": "A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight", "officialTitle": "A Phase 1, Investigator- and Participant-Blinded, Placebo Controlled, Randomized, Single Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight", "overallStatus": "COMPLETED", "startDate": "2025-04-21", "completionDate": "2025-09-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 30, "briefSummary": "The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it.\n\nThe study will last approximately 10 weeks excluding a screening period.", "conditions": ["Obesity", "Overweight"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Eloralintide", "otherNames": ["LY3841136"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Obesity", "Overweight"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight Obesity Overweight Eloralintide Placebo Obesity Overweight The purpose of this study is to evaluate how well Eloralintide (LY3841136) is tolerated and what side effects may occur in overweight and obese Chinese participants. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much Eloralintide gets into the bloodstream and how long it takes the body to eliminate it.\n\nThe study will last approximately 10 weeks excluding a screening period."}
 {"nctId": "NCT01408888", "briefTitle": "A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes", "officialTitle": "Study to Evaluate the Effect of LY2189265 on Sitagliptin Pharmacokinetics in Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2011-08", "completionDate": "2012-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 29, "briefSummary": "The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together.\n\nThe duration of participation in this study is expected to be approximately 61 days. The study requires 2 clinic confinements (one of 2 nights and one of 19 nights duration).\n\nThe study involves 3 injections, subcutaneous, of 1.5 milligrams (mg) LY2189265 and 18 daily doses of 100 mg sitagliptin tablets administered orally.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "LY2189265", "otherNames": ["Dulaglutide"]}, {"type": "DRUG", "name": "Sitagliptin", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide", "Sitagliptin Phosphate"], "hasResults": true, "classifyText": "A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes Diabetes Mellitus, Type 2 LY2189265 Sitagliptin Diabetes Mellitus, Type 2 dulaglutide Sitagliptin Phosphate The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together.\n\nThe duration of participation in this study is expected to be approximately 61 days. The study requires 2 clinic confinements (one of 2 nights and one of 19 nights duration).\n\nThe study involves 3 injections, subcutaneous, of 1.5 milligrams (mg) LY2189265 and 18 daily doses of 100 mg sitagliptin tablets administered orally."}
 {"nctId": "NCT00594568", "briefTitle": "Effect of LY450139 on the Long Term Progression of Alzheimer's Disease", "officialTitle": "Effect of \u03b3-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo", "overallStatus": "COMPLETED", "startDate": "2008-03", "completionDate": "2011-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1537, "briefSummary": "Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta-amyloid (\u03b2-amyloid), a sticky protein in the brain that forms amyloid plaques. At autopsy, AD patients are required to have these amyloid plaques in the brain in order to have a definitive diagnosis of AD. Inhibiting the enzyme gamma-secretase (\u03b3-secretase) lowers the production of \u03b2-amyloid. Semagacestat (LY450139) is a functional \u03b3-secretase inhibitor and was shown to lower \u03b2-amyloid in blood and spinal fluid in humans tested thus far and in blood, spinal fluid, and brain in animals tested thus far. This study used several different tests to measure the effect of semagacestat on both \u03b2-amyloid and amyloid plaques for some participants. The build-up of amyloid plaques was measured by a brain scan that takes a picture of amyloid plaques in the brain. Other tests measured the overall function of the brain and brain size in some participants. In this trial, participants who initially received placebo (inactive sugar pill) were, at a certain point in the study, switched over to active drug, semagacestat. In other words, all participants could eventually receive active drug. Participation could last approximately 2 years. Participants taking approved AD medications were permitted to participate in this study and continue taking these medications during the study. All participants who completed this study had the option to continue receiving semagacestat by participating in an open-label study.\n\nPreliminary results from this study (H6L-MC-LFAN \\[LFAN\\]) and another similar study (H6L-MC-LFBC \\[LFBC; NCT00762411\\]) showed semagacestat did not slow disease progression and was associated with worsening of clinical measures of cognition and the ability to perform activities of daily living. Study drug was stopped in all studies. Studies LFAN, LFBC, and open-label H6L-MC-LFBF (LFBF; NCT01035138) were amended to continue collecting safety data, including cognitive scores, for at least 7 months. The Clinical Trial Registry (CTR) will reflect results of analyses from the original LFAN protocol in addition to those from the amended LFAN protocol.", "conditions": ["Alzheimer's Disease"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY450139", "otherNames": ["semagacestat"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Alzheimer Disease"], "meshInterventions": ["N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide"], "hasResults": true, "classifyText": "Effect of LY450139 on the Long Term Progression of Alzheimer's Disease Alzheimer's Disease LY450139 Placebo Alzheimer Disease N2-((2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-N1-((7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-L-alaninamide Alzheimer's disease (AD) is a fatal degenerative disease of the brain for which there is no cure. AD causes brain cells to die. AD is thought to be caused by an excess of beta-amyloid (\u03b2-amyloid), a sticky protein in the brain that forms amyloid plaques. At autopsy, AD patients are required to have these amyloid plaques in the brain in order to have a definitive diagnosis of AD. Inhibiting the enzyme gamma-secretase (\u03b3-secretase) lowers the production of \u03b2-amyloid. Semagacestat (LY450139) is a functional \u03b3-secretase inhibitor and was shown to lower \u03b2-amyloid in blood and spinal fluid in humans tested thus far and in blood, spinal fluid, and brain in animals tested thus far. This study used several different tests to measure the effect of semagacestat on both \u03b2-amyloid and amyloid plaques for some participants. The build-up of amyloid plaques was measured by a brain scan that takes a picture of amyloid plaques in the brain. Other tests measured the overall function of the brain and brai"}
 {"nctId": "NCT01703091", "briefTitle": "A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer", "officialTitle": "A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy", "overallStatus": "COMPLETED", "startDate": "2012-12", "completionDate": "2016-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 197, "briefSummary": "The purpose of this study is to evaluate the effects of ramucirumab in combination with docetaxel in participants with Stage IV non-small cell lung cancer who have had disease progression during or after one prior first-line platinum-based chemotherapy with or without maintenance therapy for advanced/metastatic disease.", "conditions": ["Non-small Cell Lung Cancer Metastatic"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Ramucirumab", "otherNames": ["LY 3009806", "IMC-1121B", "Cyramza\u00ae"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Docetaxel", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Ramucirumab", "Docetaxel"], "hasResults": true, "classifyText": "A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Non-small Cell Lung Cancer Metastatic Ramucirumab Placebo Docetaxel Ramucirumab Docetaxel The purpose of this study is to evaluate the effects of ramucirumab in combination with docetaxel in participants with Stage IV non-small cell lung cancer who have had disease progression during or after one prior first-line platinum-based chemotherapy with or without maintenance therapy for advanced/metastatic disease."}
 {"nctId": "NCT00760747", "briefTitle": "Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD)", "officialTitle": "A Randomized, Controlled, Open-Label Comparison Study of the Efficacy and Safety of Slow Transitioning Compared With Fast Transitioning From a Stimulant Medication to Atomoxetine in Pediatric and Adolescent Outpatients With DSM-IV Attention-Deficit/Hyperactivity Disorder (ADHD)", "overallStatus": "COMPLETED", "startDate": "2008-09", "completionDate": "2010-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 112, "briefSummary": "Children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who are not tolerating or not responding well to stimulant therapy will be included in this study. Two different strategies for transition from Stimulant to Atomoxetine will be used: Slow (10 weeks) and fast (2 weeks). Changes in ADHD symptoms and tolerability of medication will be compared between the two different switching approaches.", "conditions": ["Attention Deficit Hyperactivity Disorder"], "keywords": ["ADHD", "Children", "Stimulant", "Atomoxetine", "Adolescents"], "interventions": [{"type": "DRUG", "name": "Atomoxetine", "otherNames": ["LY139603", "Strattera"]}], "meshConditions": ["Attention Deficit Disorder with Hyperactivity"], "meshInterventions": ["Atomoxetine Hydrochloride"], "hasResults": true, "classifyText": "Comparison of Slow and Fast Transition From Stimulants to Atomoxetine in Children and Adolescents With Attention Deficit/Hyperactivity Disorder(ADHD) Attention Deficit Hyperactivity Disorder ADHD Children Stimulant Atomoxetine Adolescents Atomoxetine Attention Deficit Disorder with Hyperactivity Atomoxetine Hydrochloride Children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who are not tolerating or not responding well to stimulant therapy will be included in this study. Two different strategies for transition from Stimulant to Atomoxetine will be used: Slow (10 weeks) and fast (2 weeks). Changes in ADHD symptoms and tolerability of medication will be compared between the two different switching approaches."}
 {"nctId": "NCT00451555", "briefTitle": "Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer", "officialTitle": "A Randomized, Double-Blind, Phase II Trial of Fulvestrant Plus Enzastaurin Versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2007-04-11", "completionDate": "2018-10-18", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 156, "briefSummary": "The primary purpose of this study is to help answer the following research question: whether enzastaurin given together with fulvestrant can help participants who have breast cancer and make the tumor smaller or disappear and for how long.", "conditions": ["Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "enzastaurin", "otherNames": ["LY317615"]}, {"type": "DRUG", "name": "placebo", "otherNames": []}, {"type": "DRUG", "name": "fulvestrant", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["enzastaurin", "Fulvestrant"], "hasResults": true, "classifyText": "Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer Breast Cancer enzastaurin placebo fulvestrant Breast Neoplasms enzastaurin Fulvestrant The primary purpose of this study is to help answer the following research question: whether enzastaurin given together with fulvestrant can help participants who have breast cancer and make the tumor smaller or disappear and for how long."}
 {"nctId": "NCT02766517", "briefTitle": "Biomarker Study in Participants With Migraine", "officialTitle": "LY2951742 Biomarker Study in Patients With Migraine", "overallStatus": "COMPLETED", "startDate": "2016-09-28", "completionDate": "2017-01-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["EARLY_PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 37, "briefSummary": "This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo. This study NCT02766517 will evaluate how certain biomarkers may be related to the participant's response in study NCT02163993. The study will last about five days.", "conditions": ["Migraine Disorders"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Capsaicin", "otherNames": []}], "meshConditions": ["Migraine Disorders"], "meshInterventions": ["Capsaicin"], "hasResults": true, "classifyText": "Biomarker Study in Participants With Migraine Migraine Disorders Capsaicin Migraine Disorders Capsaicin This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo. This study NCT02766517 will evaluate how certain biomarkers may be related to the participant's response in study NCT02163993. The study will last about five days."}
 {"nctId": "NCT05469126", "briefTitle": "A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants", "officialTitle": "A Phase 1, Open-label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Clarithromycin on the Pharmacokinetics of LY3502970 in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2022-08-01", "completionDate": "2022-11-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 26, "briefSummary": "The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with clarithromycin in healthy participants. This study will last up to approximately 85 days for each participant.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3502970", "otherNames": []}, {"type": "DRUG", "name": "Clarithromycin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["orforglipron", "Clarithromycin"], "hasResults": false, "classifyText": "A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants Healthy LY3502970 Clarithromycin orforglipron Clarithromycin The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with clarithromycin in healthy participants. This study will last up to approximately 85 days for each participant."}
 {"nctId": "NCT04495478", "briefTitle": "A Study of Ramucirumab (LY3009806) in Healthy Participants", "officialTitle": "A Single-Dose Study in Healthy Participants to Characterize Ramucirumab Pharmacokinetics and Investigate Injection Site Reactions Following an Intravenous Infusion or Subcutaneous Administration of Ramucirumab", "overallStatus": "COMPLETED", "startDate": "2020-07-30", "completionDate": "2021-05-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 50, "briefSummary": "This study evaluates a new formulation of ramucirumab, a drug approved for several types of cancer.\n\nIn this study of healthy participants, a small amount of ramucirumab will be given by injection either into a vein or just under the skin. Study doctors will measure the amount of ramucirumab in the bloodstream.\n\nSide effects and tolerability will be documented. The study will last for about 16 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Ramucirumab - IV", "otherNames": ["LY3009806"]}, {"type": "DRUG", "name": "Placebo - IV", "otherNames": []}, {"type": "DRUG", "name": "Ramucirumab - SC", "otherNames": ["LY3009806"]}, {"type": "DRUG", "name": "Placebo - SC", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Ramucirumab"], "hasResults": true, "classifyText": "A Study of Ramucirumab (LY3009806) in Healthy Participants Healthy Ramucirumab - IV Placebo - IV Ramucirumab - SC Placebo - SC Ramucirumab This study evaluates a new formulation of ramucirumab, a drug approved for several types of cancer.\n\nIn this study of healthy participants, a small amount of ramucirumab will be given by injection either into a vein or just under the skin. Study doctors will measure the amount of ramucirumab in the bloodstream.\n\nSide effects and tolerability will be documented. The study will last for about 16 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study."}
 {"nctId": "NCT07174336", "briefTitle": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)", "officialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)", "overallStatus": "RECRUITING", "startDate": "2025-12-22", "completionDate": "2033-05", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Pfizer"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 920, "briefSummary": "The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.", "conditions": ["Breast Neoplasms", "Neoplasm Metastasis"], "keywords": ["STX-478", "PI3K"], "interventions": [{"type": "DRUG", "name": "LY4064809", "otherNames": ["STX-478", "Tersolisib"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Ribociclib", "otherNames": []}, {"type": "DRUG", "name": "Palbociclib", "otherNames": []}, {"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Anastrozole", "otherNames": []}, {"type": "DRUG", "name": "Letrozole", "otherNames": []}, {"type": "DRUG", "name": "Exemestane", "otherNames": []}, {"type": "DRUG", "name": "Fulvestrant", "otherNames": []}], "meshConditions": ["Breast Neoplasms", "Neoplasm Metastasis"], "meshInterventions": ["STX-478", "ribociclib", "palbociclib", "abemaciclib", "Anastrozole", "Letrozole", "exemestane", "Fulvestrant"], "hasResults": false, "classifyText": "A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) Breast Neoplasms Neoplasm Metastasis STX-478 PI3K LY4064809 Placebo Ribociclib Palbociclib Abemaciclib Anastrozole Letrozole Exemestane Fulvestrant Breast Neoplasms Neoplasm Metastasis STX-478 ribociclib palbociclib abemaciclib Anastrozole Letrozole exemestane Fulvestrant The purpose of the study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects."}
 {"nctId": "NCT05564039", "briefTitle": "A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)", "officialTitle": "A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes", "overallStatus": "COMPLETED", "startDate": "2022-11-30", "completionDate": "2024-08-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 282, "briefSummary": "The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Dulaglutide", "otherNames": ["LY2189265"]}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Tirzepatide", "dulaglutide"], "hasResults": true, "classifyText": "A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Type 2 Diabetes Tirzepatide Dulaglutide Diabetes Mellitus, Type 2 Tirzepatide dulaglutide The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes."}
 {"nctId": "NCT03915964", "briefTitle": "A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis", "officialTitle": "A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis", "overallStatus": "COMPLETED", "startDate": "2019-04-25", "completionDate": "2025-05-28", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Incyte Corporation"], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 2663, "briefSummary": "This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.", "conditions": ["Rheumatoid Arthritis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104"]}, {"type": "DRUG", "name": "TNF Inhibitor", "otherNames": ["Etanercept", "Adalimumab"]}], "meshConditions": ["Arthritis, Rheumatoid"], "meshInterventions": ["baricitinib", "Tumor Necrosis Factor Inhibitors", "Etanercept", "Adalimumab"], "hasResults": false, "classifyText": "A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis Rheumatoid Arthritis Baricitinib TNF Inhibitor Arthritis, Rheumatoid baricitinib Tumor Necrosis Factor Inhibitors Etanercept Adalimumab This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis."}
 {"nctId": "NCT01663857", "briefTitle": "A Study LY2228820 for Recurrent Ovarian Cancer", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer", "overallStatus": "COMPLETED", "startDate": "2012-07", "completionDate": "2018-05-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 118, "briefSummary": "A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy.", "conditions": ["Epithelial Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2228820", "otherNames": []}, {"type": "DRUG", "name": "Carboplatin", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": ["Gemzar", "LY188011"]}], "meshConditions": ["Carcinoma, Ovarian Epithelial", "Fallopian Tube Neoplasms"], "meshInterventions": ["ralimetinib", "Carboplatin", "Gemcitabine"], "hasResults": true, "classifyText": "A Study LY2228820 for Recurrent Ovarian Cancer Epithelial Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cancer LY2228820 Carboplatin Placebo Gemcitabine Carcinoma, Ovarian Epithelial Fallopian Tube Neoplasms ralimetinib Carboplatin Gemcitabine A study for women with ovarian cancer that has returned at least 6 months after platinum-based chemotherapy."}
 {"nctId": "NCT00985712", "briefTitle": "A Study on the Effect of 2 Pen Devices on HbA1c", "officialTitle": "A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults With Type 1 Diabetes: Novel Pen With Memory Function (HumaPen Memoir) vs. Conventional Pen Without Memory Function (HumaPen Luxura)", "overallStatus": "COMPLETED", "startDate": "2009-10", "completionDate": "2011-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 263, "briefSummary": "The purpose of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections achieves superior glycemic control, when compared to the conventional HumaPen Luxura without memory function.", "conditions": ["Diabetes Mellitus, Type 1"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["Humalog", "LY275585"]}, {"type": "DRUG", "name": "Huminsulin Regular", "otherNames": ["Huminsulin Normal", "LY041001"]}, {"type": "DEVICE", "name": "HumaPen Memoir", "otherNames": []}, {"type": "DEVICE", "name": "HumaPen Luxura", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin Lispro"], "hasResults": true, "classifyText": "A Study on the Effect of 2 Pen Devices on HbA1c Diabetes Mellitus, Type 1 Insulin Lispro Huminsulin Regular HumaPen Memoir HumaPen Luxura Diabetes Mellitus, Type 1 Insulin Lispro The purpose of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections achieves superior glycemic control, when compared to the conventional HumaPen Luxura without memory function."}
 {"nctId": "NCT03341312", "briefTitle": "A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)", "officialTitle": "A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog\u00ae in Patients With T2DM", "overallStatus": "COMPLETED", "startDate": "2017-11-13", "completionDate": "2018-03-31", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 36, "briefSummary": "The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014, and the effect of LY900014 on blood sugar levels following a standard meal. For each participant, the study will consist of 4 periods and will last approximately 12 weeks from screening to final study follow up.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "LY900014", "otherNames": ["Ultra-Rapid Lispro"]}, {"type": "BIOLOGICAL", "name": "Insulin Lispro", "otherNames": ["LY275585", "Humalog"]}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Insulin Lispro"], "hasResults": true, "classifyText": "A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM) Diabetes Mellitus, Type 2 LY900014 Insulin Lispro Diabetes Mellitus, Type 2 Insulin Lispro The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014, and the effect of LY900014 on blood sugar levels following a standard meal. For each participant, the study will consist of 4 periods and will last approximately 12 weeks from screening to final study follow up."}
 {"nctId": "NCT03758430", "briefTitle": "A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes", "officialTitle": "Technology-supported, Meal-centric, Insulin Dosing for Optimized Post-prandial Glucose Control", "overallStatus": "COMPLETED", "startDate": "2019-02-06", "completionDate": "2020-08-07", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Joslin Diabetes Center"], "studyType": "OBSERVATIONAL", "phases": [], "primaryPurpose": null, "enrollment": 28, "briefSummary": "The main purpose of this study is to determine whether combining meal, glucose, and insulin data in a web-based system will improve management of type 1 diabetes (T1D). No study drug will be given. The study will last about 18 weeks.", "conditions": ["Diabetes Mellitus, Type 1"], "keywords": [], "interventions": [{"type": "OTHER", "name": "Meal-Tagging App", "otherNames": []}, {"type": "DEVICE", "name": "Fitness Tracker", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Fitness Trackers"], "hasResults": false, "classifyText": "A Study of Technology to Improve Glucose Control in Participants With Type 1 Diabetes Diabetes Mellitus, Type 1 Meal-Tagging App Fitness Tracker Diabetes Mellitus, Type 1 Fitness Trackers The main purpose of this study is to determine whether combining meal, glucose, and insulin data in a web-based system will improve management of type 1 diabetes (T1D). No study drug will be given. The study will last about 18 weeks."}
 {"nctId": "NCT01440478", "briefTitle": "The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects", "officialTitle": "Impact of Variations in Urinary pH on the Pharmacokinetics of LY2140023 and LY404039 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2011-09", "completionDate": "2011-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 30, "briefSummary": "This study is designed to explore the effect of increased and decreased urinary pH on the single pharmacokinetic (PK) dose of LY2140023 and its active metabolite LY404039. All participants will receive the three treatments in a randomized order.", "conditions": ["Healthy Subjects"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2140023", "otherNames": []}, {"type": "DRUG", "name": "Ammonium chloride", "otherNames": []}, {"type": "DRUG", "name": "Sodium bicarbonate", "otherNames": []}], "meshConditions": [], "meshInterventions": ["LY 2140023", "Ammonium Chloride", "Sodium Bicarbonate"], "hasResults": false, "classifyText": "The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects Healthy Subjects LY2140023 Ammonium chloride Sodium bicarbonate LY 2140023 Ammonium Chloride Sodium Bicarbonate This study is designed to explore the effect of increased and decreased urinary pH on the single pharmacokinetic (PK) dose of LY2140023 and its active metabolite LY404039. All participants will receive the three treatments in a randomized order."}
 {"nctId": "NCT04031885", "briefTitle": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer", "officialTitle": "A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases", "overallStatus": "TERMINATED", "startDate": "2019-08-14", "completionDate": "2020-08-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 4, "briefSummary": "The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond.", "conditions": ["Metastatic Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Fulvestrant", "otherNames": []}, {"type": "DRUG", "name": "Standard Chemotherapy", "otherNames": ["Capecitabine", "Docetaxel", "Nab paclitaxel", "Paclitaxel"]}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["abemaciclib", "Fulvestrant", "Capecitabine", "Docetaxel", "Taxes", "Paclitaxel"], "hasResults": true, "classifyText": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer Metastatic Breast Cancer Abemaciclib Fulvestrant Standard Chemotherapy Breast Neoplasms abemaciclib Fulvestrant Capecitabine Docetaxel Taxes Paclitaxel The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial could last up to 31 months, depending on your cancer type and how you and your tumor respond."}
 {"nctId": "NCT01394952", "briefTitle": "Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)", "officialTitle": "The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)", "overallStatus": "COMPLETED", "startDate": "2011-07-22", "completionDate": "2018-08-21", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 9901, "briefSummary": "The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.", "conditions": ["Cardiovascular Disease", "Diabetes Mellitus, Type 2"], "keywords": ["Cardiovascular disease", "Diabetes Mellitus", "Dulaglutide"], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Cardiovascular Diseases", "Diabetes Mellitus, Type 2", "Diabetes Mellitus"], "meshInterventions": ["dulaglutide"], "hasResults": true, "classifyText": "Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) Cardiovascular Disease Diabetes Mellitus, Type 2 Cardiovascular disease Diabetes Mellitus Dulaglutide Dulaglutide Placebo Cardiovascular Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus dulaglutide The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen."}
 {"nctId": "NCT01606748", "briefTitle": "A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin", "officialTitle": "An Open-Label, Non-controlled, Non-randomized Sequential Design, Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin in Patients With Advanced Solid Cancers", "overallStatus": "COMPLETED", "startDate": "2012-08", "completionDate": "2016-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 35, "briefSummary": "The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug interactions between necitumumab and gemcitabine-cisplatin.", "conditions": ["Malignant Solid Tumor"], "keywords": ["Advanced Malignant Solid Tumors", "Solid Cancers", "Non-small Cell Lung Cancer", "NSCLC", "Breast Cancer"], "interventions": [{"type": "BIOLOGICAL", "name": "Necitumumab", "otherNames": ["IMC-11F8", "LY3012211"]}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": ["Gemzar\u00ae", "LY188011"]}, {"type": "DRUG", "name": "Cisplatin", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Breast Neoplasms"], "meshInterventions": ["necitumumab", "Gemcitabine", "Cisplatin"], "hasResults": true, "classifyText": "A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin Malignant Solid Tumor Advanced Malignant Solid Tumors Solid Cancers Non-small Cell Lung Cancer NSCLC Breast Cancer Necitumumab Gemcitabine Cisplatin Carcinoma, Non-Small-Cell Lung Breast Neoplasms necitumumab Gemcitabine Cisplatin The purpose of this study is to investigate the pharmacokinetics (PK) of necitumumab in combination with gemcitabine-cisplatin in participants with advanced malignant solid tumors and to assess the potential for drug-drug interactions between necitumumab and gemcitabine-cisplatin."}
 {"nctId": "NCT01389752", "briefTitle": "A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects", "officialTitle": "Effect of Activated Charcoal on the Pharmacokinetics of LY2216684 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2011-07", "completionDate": "2011-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 22, "briefSummary": "The study involves a single oral dose of 18 mg (2 x 9mg tablets) LY2216684 taken on 2 occasions, once with activated charcoal and once without activated charcoal.\n\nThe study will evaluate the effect of charcoal on the absorption of LY2216684. Side effects will be documented. There will be 2 study periods each lasting up to 5 days. There will be at least 7 days between the two doses and a follow up will occur at least 7 days after the last dose. Screening is required within 30 days prior to the start of the study.", "conditions": ["Depressive Disorder, Major"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2216684", "otherNames": []}, {"type": "DRUG", "name": "Activated Charcoal", "otherNames": []}], "meshConditions": ["Depressive Disorder, Major"], "meshInterventions": ["alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol", "Charcoal"], "hasResults": true, "classifyText": "A Study to Evaluate the Effect of Activated Charcoal on the Absorption of LY2216684 in Healthy Subjects Depressive Disorder, Major LY2216684 Activated Charcoal Depressive Disorder, Major alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol Charcoal The study involves a single oral dose of 18 mg (2 x 9mg tablets) LY2216684 taken on 2 occasions, once with activated charcoal and once without activated charcoal.\n\nThe study will evaluate the effect of charcoal on the absorption of LY2216684. Side effects will be documented. There will be 2 study periods each lasting up to 5 days. There will be at least 7 days between the two doses and a follow up will occur at least 7 days after the last dose. Screening is required within 30 days prior to the start of the study."}
 {"nctId": "NCT03310411", "briefTitle": "A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants", "officialTitle": "A Randomized, Double-Blind, Four-Period, Crossover Study to Evaluate the Cardiovascular Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2017-10-17", "completionDate": "2017-12-23", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 40, "briefSummary": "The purpose of this study is to assess whether taking lasmiditan and sumatriptan together will have any additional effects on heart rate and blood pressure compared to taking lasmiditan and sumatriptan individually. This study will also look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it when these two drugs are taken together.\n\nThis study will last about 21 days, not including the screening. Participants will spend 16 days/15 nights in the clinical research unit (CRU) followed by follow-up. Screening is required within 28 days prior to the start of the study.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Lasmiditan", "otherNames": ["LY573144"]}, {"type": "DRUG", "name": "Sumatriptan", "otherNames": []}, {"type": "DRUG", "name": "Placebo for Lasmiditan", "otherNames": []}, {"type": "DRUG", "name": "Placebo for Sumatriptan", "otherNames": []}], "meshConditions": [], "meshInterventions": ["lasmiditan", "Sumatriptan"], "hasResults": true, "classifyText": "A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants Healthy Lasmiditan Sumatriptan Placebo for Lasmiditan Placebo for Sumatriptan lasmiditan Sumatriptan The purpose of this study is to assess whether taking lasmiditan and sumatriptan together will have any additional effects on heart rate and blood pressure compared to taking lasmiditan and sumatriptan individually. This study will also look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it when these two drugs are taken together.\n\nThis study will last about 21 days, not including the screening. Participants will spend 16 days/15 nights in the clinical research unit (CRU) followed by follow-up. Screening is required within 28 days prior to the start of the study."}
 {"nctId": "NCT01159938", "briefTitle": "A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes", "officialTitle": "The Effect of Postprandial Hyperglycemia on the Arterial Stiffness in Patients With Type 2 Diabetes", "overallStatus": "COMPLETED", "startDate": "2010-10", "completionDate": "2013-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": null, "enrollment": 72, "briefSummary": "This Study is looking at whether high blood glucose levels after a meal affect arterial stiffness more or less than low blood glucose levels, and whether certain cardiovascular markers influence the outcome of this.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Lispro", "otherNames": ["Humalog", "LY275585"]}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Insulin Lispro"], "hasResults": true, "classifyText": "A Study of Postprandial Hyperglycemia in Participants With Type 2 Diabetes Diabetes Mellitus, Type 2 Lispro Diabetes Mellitus, Type 2 Insulin Lispro This Study is looking at whether high blood glucose levels after a meal affect arterial stiffness more or less than low blood glucose levels, and whether certain cardiovascular markers influence the outcome of this."}
 {"nctId": "NCT00734604", "briefTitle": "A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.", "officialTitle": "A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men With Erectile Dysfunction.", "overallStatus": "COMPLETED", "startDate": "2008-08", "completionDate": "2009-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 378, "briefSummary": "The primary purpose of the study is to help answer whether tadalafil taken once a day can help improve the psychological outcomes (such as sexual self confidence, spontaneity and time concerns) compared to sildenafil taken as needed in patients with erectile dysfunction (ED).", "conditions": ["Erectile Dysfunction"], "keywords": [], "interventions": [{"type": "DRUG", "name": "tadalafil once a day [T(OaD)]", "otherNames": ["Cialis", "LY450190"]}, {"type": "DRUG", "name": "sildenafil citrate as needed [S(PRN)]", "otherNames": []}, {"type": "DRUG", "name": "tadalafil as needed [T(PRN)]", "otherNames": ["Cialis", "LY450190"]}], "meshConditions": ["Erectile Dysfunction"], "meshInterventions": ["Tadalafil", "Sildenafil Citrate", "Health Services Needs and Demand"], "hasResults": true, "classifyText": "A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes. Erectile Dysfunction tadalafil once a day [T(OaD)] sildenafil citrate as needed [S(PRN)] tadalafil as needed [T(PRN)] Erectile Dysfunction Tadalafil Sildenafil Citrate Health Services Needs and Demand The primary purpose of the study is to help answer whether tadalafil taken once a day can help improve the psychological outcomes (such as sexual self confidence, spontaneity and time concerns) compared to sildenafil taken as needed in patients with erectile dysfunction (ED)."}
 {"nctId": "NCT05433584", "briefTitle": "A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes", "officialTitle": "A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2022-08-01", "completionDate": "2027-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 780, "briefSummary": "This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.", "conditions": ["Type 2 Diabetes"], "keywords": ["T2D", "Diabetes"], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Antihyperglycemic medication", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2", "Diabetes Mellitus"], "meshInterventions": ["Tirzepatide"], "hasResults": false, "classifyText": "A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes Type 2 Diabetes T2D Diabetes Tirzepatide Antihyperglycemic medication Diabetes Mellitus, Type 2 Diabetes Mellitus Tirzepatide This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early."}
 {"nctId": "NCT03861052", "briefTitle": "A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes", "officialTitle": "A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2019-05-07", "completionDate": "2021-03-31", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 636, "briefSummary": "The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Dulaglutide", "otherNames": ["LY2189265"]}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Tirzepatide", "dulaglutide"], "hasResults": true, "classifyText": "A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes Type 2 Diabetes Tirzepatide Dulaglutide Diabetes Mellitus, Type 2 Tirzepatide dulaglutide The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective and safe compared to dulaglutide in participants with type 2 diabetes in Japan."}
 {"nctId": "NCT00849901", "briefTitle": "A Study in the Treatment of Children and Adolescents With Major Depressive Disorder", "officialTitle": "A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder", "overallStatus": "COMPLETED", "startDate": "2009-03", "completionDate": "2011-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 337, "briefSummary": "The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)", "conditions": ["Major Depressive Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "duloxetine", "otherNames": ["LY248686", "Cymbalta"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "fluoxetine", "otherNames": ["LY110140", "Prozac"]}], "meshConditions": ["Depressive Disorder, Major"], "meshInterventions": ["Duloxetine Hydrochloride", "Fluoxetine"], "hasResults": true, "classifyText": "A Study in the Treatment of Children and Adolescents With Major Depressive Disorder Major Depressive Disorder duloxetine Placebo fluoxetine Depressive Disorder, Major Duloxetine Hydrochloride Fluoxetine The purpose of this study is to assess whether duloxetine is superior to placebo in the treatment of children and adolescents with major depressive disorder (MDD)"}
 {"nctId": "NCT04158700", "briefTitle": "A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer", "officialTitle": "Phase 1b/2 Study of LY3200882 and Pembrolizumab in Patients With Advanced Cancer", "overallStatus": "WITHDRAWN", "startDate": "2019-12-05", "completionDate": "2023-05-11", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Merck Sharp & Dohme LLC"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 0, "briefSummary": "The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-\u03b2 (TGF\u03b2) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body.", "conditions": ["Advanced Cancer"], "keywords": ["TGF-beta", "Urothelial carcinoma", "Hepatocellular carcinoma", "Non-small cell lung cancer", "TGF- beta receptor type I inhibitor"], "interventions": [{"type": "DRUG", "name": "LY3200882", "otherNames": []}, {"type": "DRUG", "name": "Pembrolizumab", "otherNames": []}], "meshConditions": ["Camurati-Engelmann Syndrome", "Carcinoma, Transitional Cell", "Carcinoma, Hepatocellular", "Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["pembrolizumab"], "hasResults": false, "classifyText": "A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer Advanced Cancer TGF-beta Urothelial carcinoma Hepatocellular carcinoma Non-small cell lung cancer TGF- beta receptor type I inhibitor LY3200882 Pembrolizumab Camurati-Engelmann Syndrome Carcinoma, Transitional Cell Carcinoma, Hepatocellular Carcinoma, Non-Small-Cell Lung pembrolizumab The main purpose of this study is to see if the drug LY3200882 which is an inhibitor of transforming growth factor-\u03b2 (TGF\u03b2) receptor 1 in combination with pembrolizumab is safe and effective in participants with cancer that has spread to other parts of the body."}
 {"nctId": "NCT02171130", "briefTitle": "Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia", "officialTitle": "A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes", "overallStatus": "COMPLETED", "startDate": "2014-05", "completionDate": "2015-08", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Locemia Solutions ULC"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 129, "briefSummary": "Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of nasal glucagon (AMG504-1) in treating episodes of hypoglycemia. The population will be enriched to include participants who suffer from impaired hypoglycemia awareness.", "conditions": ["Hypoglycemia", "Diabetes Mellitus", "Drug-Specific Antibodies"], "keywords": ["Diabetes Mellitus", "Hypoglycemia", "Glucagon", "Anti-glucagon Antibody", "Immunogenicity"], "interventions": [{"type": "DRUG", "name": "Nasal Glucagon", "otherNames": ["Dry-Mist Nasal Glucagon", "AMG504-1", "LY900018"]}], "meshConditions": ["Hypoglycemia", "Diabetes Mellitus"], "meshInterventions": [], "hasResults": true, "classifyText": "Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia Hypoglycemia Diabetes Mellitus Drug-Specific Antibodies Diabetes Mellitus Hypoglycemia Glucagon Anti-glucagon Antibody Immunogenicity Nasal Glucagon Hypoglycemia Diabetes Mellitus Up to two hundred (200) adult participants with type 1 diabetes (T1D) aged 18 to 75 years will be selected for inclusion in the study. The target is to obtain treatment response and user-experience data following use of nasal glucagon (AMG504-1) in treating episodes of hypoglycemia. The population will be enriched to include participants who suffer from impaired hypoglycemia awareness."}
 {"nctId": "NCT04648865", "briefTitle": "A Study of LY3537031 in Healthy Participants", "officialTitle": "A Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3537031 in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2020-12-09", "completionDate": "2021-06-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 40, "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of LY3537031 in healthy participants. The blood tests will be performed to check how much LY3537031 gets into the bloodstream, how long the body takes to eliminate it and how body handles LY3537031. Each participant will receive a single dose of LY3537031 or placebo. The study will last up to approximately 71 days for each participant, including screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3537031", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3537031 in Healthy Participants Healthy LY3537031 Placebo The main purpose of this study is to evaluate the safety and tolerability of LY3537031 in healthy participants. The blood tests will be performed to check how much LY3537031 gets into the bloodstream, how long the body takes to eliminate it and how body handles LY3537031. Each participant will receive a single dose of LY3537031 or placebo. The study will last up to approximately 71 days for each participant, including screening."}
 {"nctId": "NCT00088036", "briefTitle": "Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder", "officialTitle": "Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo", "overallStatus": "COMPLETED", "startDate": "2004-02", "completionDate": "2006-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 450, "briefSummary": "The purpose of the protocol is to evaluate the efficacy and safety of olanzapine compared with placebo in patients with Borderline Personality Disorder (BPD).", "conditions": ["Borderline Personality Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Olanzapine", "otherNames": []}], "meshConditions": ["Borderline Personality Disorder"], "meshInterventions": ["Olanzapine"], "hasResults": false, "classifyText": "Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder Borderline Personality Disorder Olanzapine Borderline Personality Disorder Olanzapine The purpose of the protocol is to evaluate the efficacy and safety of olanzapine compared with placebo in patients with Borderline Personality Disorder (BPD)."}
 {"nctId": "NCT03616795", "briefTitle": "Study of LY3154207 in Healthy Participants", "officialTitle": "Disposition of [14C]-LY3154207 Following Oral Administration in Healthy Male Subjects", "overallStatus": "COMPLETED", "startDate": "2018-08-09", "completionDate": "2018-11-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 8, "briefSummary": "The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3154207. This means that a radioactive substance C14 will be incorporated into the study drug, to investigate the study drug and its breakdown products, to find out how much of these pass from blood into urine, feces and expired air. The study will last about 4 weeks. Screening is required within 28 days prior to the start of the study and follow up is required approximately 7 days after discharge.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3154207", "otherNames": []}, {"type": "DRUG", "name": "[14C]-LY3154207", "otherNames": []}], "meshConditions": [], "meshInterventions": ["LY3154207"], "hasResults": false, "classifyText": "Study of LY3154207 in Healthy Participants Healthy LY3154207 [14C]-LY3154207 LY3154207 The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will involve a single dose of 14C radiolabelled LY3154207. This means that a radioactive substance C14 will be incorporated into the study drug, to investigate the study drug and its breakdown products, to find out how much of these pass from blood into urine, feces and expired air. The study will last about 4 weeks. Screening is required within 28 days prior to the start of the study and follow up is required approximately 7 days after discharge."}
 {"nctId": "NCT00085956", "briefTitle": "Effects of Arzoxifene on Bone Mass and the Uterus", "officialTitle": "Effects of Arzoxifene on Bone Mineral Density and Endometrial Histology in Postmenopausal Women.", "overallStatus": "COMPLETED", "startDate": "2004-04", "completionDate": "2007-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "PREVENTION", "enrollment": 300, "briefSummary": "The purposes of this study are to determine:\n\n* The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women.\n* The effects of arzoxifene on the uterus (womb) in postmenopausal women.\n* The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density.\n* The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk.\n* The safety of arzoxifene and any side effects that might be associated with its use.", "conditions": ["Postmenopausal Bone Loss"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Arzoxifene", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Osteoporosis, Postmenopausal"], "meshInterventions": ["LY 353381"], "hasResults": false, "classifyText": "Effects of Arzoxifene on Bone Mass and the Uterus Postmenopausal Bone Loss Arzoxifene Placebo Osteoporosis, Postmenopausal LY 353381 The purposes of this study are to determine:\n\n* The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women.\n* The effects of arzoxifene on the uterus (womb) in postmenopausal women.\n* The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density.\n* The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk.\n* The safety of arzoxifene and any side effects that might be associated with its use."}
 {"nctId": "NCT03706365", "briefTitle": "A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer", "officialTitle": "A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2018-11-26", "completionDate": "2026-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 393, "briefSummary": "This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.", "conditions": ["Prostate Cancer"], "keywords": ["Metastatic Castration Resistant Prostate Cancer", "mCRPC"], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Abiraterone acetate", "otherNames": []}, {"type": "DRUG", "name": "Prednisone", "otherNames": []}], "meshConditions": ["Prostatic Neoplasms"], "meshInterventions": ["abemaciclib", "Abiraterone Acetate", "Prednisone"], "hasResults": true, "classifyText": "A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer Prostate Cancer Metastatic Castration Resistant Prostate Cancer mCRPC Abemaciclib Placebo Abiraterone acetate Prednisone Prostatic Neoplasms abemaciclib Abiraterone Acetate Prednisone This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation."}
 {"nctId": "NCT04427501", "briefTitle": "A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness", "officialTitle": "A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness", "overallStatus": "COMPLETED", "startDate": "2020-06-17", "completionDate": "2023-02-21", "leadSponsor": "Eli Lilly and Company", "collaborators": ["AbCellera Biologics Inc.", "Shanghai Junshi Bioscience Co., Ltd."], "studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 3307, "briefSummary": "The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.\n\nPediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 22), open-label addendum to evaluate the pharmacokinetics and safety of LY3819253 and LY3832479. Enrollment began on March 31, 2021, and completed on September 24, 2021.\n\nPediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 23), open-label addendum to evaluate the pharmacokinetics and safety of LY3853113. Enrollment began on August 19, 2022, and completed on February 21, 2023.", "conditions": ["COVID-19"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3819253", "otherNames": ["LY-CoV555", "Bamlanivimab"]}, {"type": "DRUG", "name": "LY3832479", "otherNames": ["LY-CoV016", "Etesevimab"]}, {"type": "DRUG", "name": "LY3853113", "otherNames": ["bebtelovimab"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["COVID-19"], "meshInterventions": ["bamlanivimab", "etesevimab", "bebtelovimab"], "hasResults": true, "classifyText": "A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness COVID-19 LY3819253 LY3832479 LY3853113 Placebo COVID-19 bamlanivimab etesevimab bebtelovimab The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.\n\nPediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 22), open-label addendum to evaluate the pharmacokinetics and safety of LY3819253 and LY3832479. Enrollment began on March 31, 2021, and completed on September 24, 2021.\n\nPediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 23), open-label addendum to evaluate the pharmacokinetics and safety of LY3853113. Enrollment began on August 19, 2022, and completed on Februa"}
 {"nctId": "NCT01450098", "briefTitle": "A Study of LY2484595 in Healthy Subjects", "officialTitle": "Single Dose LY2484595 Tablet Formulations to Determine the Impact of Dose Level, Food, and Ethnicity on the Pharmacokinetics in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2011-10", "completionDate": "2011-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 39, "briefSummary": "The purpose of this study will be to evaluate the safety of a single dose of LY2484595 and to compare the amount of LY2484595 in the blood of healthy non-Asian subjects, Chinese subjects, and first-generation Japanese subjects after receiving a single oral dose of LY2484595 in a fasted state, after eating a low-fat meal, and after eating a high-fat meal.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2484595 Reference Formulation (RF)", "otherNames": ["Evacetrapib"]}, {"type": "DRUG", "name": "LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)", "otherNames": ["Evacetrapib"]}], "meshConditions": [], "meshInterventions": ["evacetrapib"], "hasResults": true, "classifyText": "A Study of LY2484595 in Healthy Subjects Healthy Volunteers LY2484595 Reference Formulation (RF) LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG) evacetrapib The purpose of this study will be to evaluate the safety of a single dose of LY2484595 and to compare the amount of LY2484595 in the blood of healthy non-Asian subjects, Chinese subjects, and first-generation Japanese subjects after receiving a single oral dose of LY2484595 in a fasted state, after eating a low-fat meal, and after eating a high-fat meal."}
 {"nctId": "NCT01890967", "briefTitle": "A Study of LY3015014 in Participants With High Cholesterol", "officialTitle": "A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia", "overallStatus": "COMPLETED", "startDate": "2013-06", "completionDate": "2014-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 527, "briefSummary": "This study is designed to define the amount and duration of cholesterol lowering and to assess the safety and tolerability of different dose regimens of LY3015014 in participants with high cholesterol. The study will also investigate how the body processes the drug and how the drug affects the body. Participants will remain on a stable diet and will continue taking cholesterol-lowering medications (statins with or without ezetimibe). After signing the informed consent document, the participant will complete a screening/run-in period that will last at most 8 weeks. Then, the treatment period will last approximately 16 weeks. After the treatment period, the participants will complete a follow-up period lasting approximately 8 weeks for a total study duration ranging from approximately 25 to 32 weeks.", "conditions": ["Hypercholesterolemia"], "keywords": ["low density lipoprotein, heterozygous familial hypercholesterolemia, polygenic hypercholesterolemia"], "interventions": [{"type": "DRUG", "name": "LY3015014", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Statin", "otherNames": ["atorvastatin", "simvastatin", "rosuvastatin", "pravastatin", "lovastatin", "fluvastatin", "pitavastatin"]}, {"type": "DRUG", "name": "Ezetimibe", "otherNames": []}], "meshConditions": ["Hypercholesterolemia"], "meshInterventions": ["frovocimab", "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "Atorvastatin", "Simvastatin", "Rosuvastatin Calcium", "Pravastatin", "Lovastatin", "Fluvastatin", "pitavastatin", "Ezetimibe"], "hasResults": true, "classifyText": "A Study of LY3015014 in Participants With High Cholesterol Hypercholesterolemia low density lipoprotein, heterozygous familial hypercholesterolemia, polygenic hypercholesterolemia LY3015014 Placebo Statin Ezetimibe Hypercholesterolemia frovocimab Hydroxymethylglutaryl-CoA Reductase Inhibitors Atorvastatin Simvastatin Rosuvastatin Calcium Pravastatin Lovastatin Fluvastatin pitavastatin Ezetimibe This study is designed to define the amount and duration of cholesterol lowering and to assess the safety and tolerability of different dose regimens of LY3015014 in participants with high cholesterol. The study will also investigate how the body processes the drug and how the drug affects the body. Participants will remain on a stable diet and will continue taking cholesterol-lowering medications (statins with or without ezetimibe). After signing the informed consent document, the participant will complete a screening/run-in period that will last at most 8 weeks. Then, the treatment period will last approximately 16 weeks. After the treatment period, the participants will complete a follow-up period lasting approximately 8 weeks for a total study duration ranging from approximately 25 to 32 weeks."}
 {"nctId": "NCT03849612", "briefTitle": "A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus", "officialTitle": "An Early Feasibility Study to Evaluate Basal Initialization Parameters in an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2019-02-21", "completionDate": "2019-03-27", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["NA"], "primaryPurpose": "DEVICE_FEASIBILITY", "enrollment": 10, "briefSummary": "The purpose of this study is to evaluate whether an Automated Insulin Delivery (AID) System is safe to use and functions as intended with personalized basal insulin rates and when basal insulin rates are increased.", "conditions": ["Type 1 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DEVICE", "name": "AID System", "otherNames": ["LY8888AU"]}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["LY275585"]}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin Lispro"], "hasResults": false, "classifyText": "A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus AID System Insulin Lispro Diabetes Mellitus, Type 1 Insulin Lispro The purpose of this study is to evaluate whether an Automated Insulin Delivery (AID) System is safe to use and functions as intended with personalized basal insulin rates and when basal insulin rates are increased."}
 {"nctId": "NCT01007032", "briefTitle": "A Study of IMC-A12 in Advanced Solid Tumors", "officialTitle": "A Phase 1 Study Evaluating the Safety and Pharmacokinetic Profiles of IMC-A12 Administered Every 2 Weeks or Every 3 Weeks to Japanese Patients With Advanced Solid Tumors", "overallStatus": "COMPLETED", "startDate": "2009-11", "completionDate": "2015-04", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Parexel", "Medidata Solutions"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 21, "briefSummary": "In this study, participants will initially receive intravenous (IV) cixutumumab (IMC-A12) every 2 weeks or every 3 weeks for 6 weeks (one cycle). After the first cycle, participants experiencing a best overall response of complete response, partial response, or stable disease will continue to receive cixutumumab at their cohort dose and schedule until there is evidence of progressive disease (PD), or until other withdrawal criteria are met. Participants will be enrolled at one study center, located in the National Cancer Center Hospital - East, Kashiwa, Japan. Approximately 20-30 participants are anticipated.", "conditions": ["Tumors"], "keywords": ["anti-IGF-IR", "monoclonal", "solid tumor", "insulin-like growth factor"], "interventions": [{"type": "BIOLOGICAL", "name": "Cixutumumab", "otherNames": ["IMC-A12", "LY3012217"]}], "meshConditions": ["Neoplasms"], "meshInterventions": ["cixutumumab"], "hasResults": true, "classifyText": "A Study of IMC-A12 in Advanced Solid Tumors Tumors anti-IGF-IR monoclonal solid tumor insulin-like growth factor Cixutumumab Neoplasms cixutumumab In this study, participants will initially receive intravenous (IV) cixutumumab (IMC-A12) every 2 weeks or every 3 weeks for 6 weeks (one cycle). After the first cycle, participants experiencing a best overall response of complete response, partial response, or stable disease will continue to receive cixutumumab at their cohort dose and schedule until there is evidence of progressive disease (PD), or until other withdrawal criteria are met. Participants will be enrolled at one study center, located in the National Cancer Center Hospital - East, Kashiwa, Japan. Approximately 20-30 participants are anticipated."}
 {"nctId": "NCT00055432", "briefTitle": "Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer", "officialTitle": null, "overallStatus": "TERMINATED", "startDate": null, "completionDate": null, "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": null, "briefSummary": "This study hopes to evaluate whether the combination of Gemzar plus Alimta will have any beneficial effects for patients with recurrent platinum-sensitive or platinum-resistant ovarian or peritoneal cancer. Treatments are weekly for two weeks, with the 3rd week off and will be repeated every 21 days. Side effects and the overall safety of the treatment will also be monitored and evaluated. In addition, a Quality of Life questionnaire is part of this study to help measure patient perceived benefits or drawbacks to this treatment regimen.", "conditions": ["Ovarian Cancer", "Peritoneal Cancer"], "keywords": ["recurrent ovarian cancer", "platinum-resistant", "platinum-sensitive", "folate receptor antagonist"], "interventions": [{"type": "DRUG", "name": "Gemzar and Alimta", "otherNames": []}], "meshConditions": ["Ovarian Neoplasms"], "meshInterventions": ["Gemcitabine", "Pemetrexed"], "hasResults": false, "classifyText": "Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer Ovarian Cancer Peritoneal Cancer recurrent ovarian cancer platinum-resistant platinum-sensitive folate receptor antagonist Gemzar and Alimta Ovarian Neoplasms Gemcitabine Pemetrexed This study hopes to evaluate whether the combination of Gemzar plus Alimta will have any beneficial effects for patients with recurrent platinum-sensitive or platinum-resistant ovarian or peritoneal cancer. Treatments are weekly for two weeks, with the 3rd week off and will be repeated every 21 days. Side effects and the overall safety of the treatment will also be monitored and evaluated. In addition, a Quality of Life questionnaire is part of this study to help measure patient perceived benefits or drawbacks to this treatment regimen."}
 {"nctId": "NCT03929744", "briefTitle": "A Study of LY3502970 in Healthy Participants", "officialTitle": "A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2019-06-12", "completionDate": "2020-11-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 133, "briefSummary": "The main purposes of this study are to determine:\n\n* The safety of LY3502970 and any side effects that might be associated with it.\n* How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it.\n\nThis study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3502970", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Atorvastatin", "otherNames": []}, {"type": "DRUG", "name": "Simvastatin", "otherNames": []}, {"type": "DRUG", "name": "Midazolam", "otherNames": []}], "meshConditions": [], "meshInterventions": ["orforglipron", "Atorvastatin", "Simvastatin", "Midazolam"], "hasResults": false, "classifyText": "A Study of LY3502970 in Healthy Participants Healthy LY3502970 Placebo Atorvastatin Simvastatin Midazolam orforglipron Atorvastatin Simvastatin Midazolam The main purposes of this study are to determine:\n\n* The safety of LY3502970 and any side effects that might be associated with it.\n* How much LY3502970 gets into the bloodstream and how long it takes the body to get rid of it.\n\nThis study has 5 parts (A, B, C, D, and E). Parts A and D involve a single dose of LY3502970 and will last about 15 days. Part B and E involve multiple doses of LY3502970 and will last about 4 weeks. Part C involves two single doses of LY3502970 and will last about 29 days. Each participant will enroll in only one part. Screening must be completed within 28 days before study start. This study is for research purposes only, and is not intended to treat any medical condition."}
 {"nctId": "NCT06258174", "briefTitle": "A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants", "officialTitle": "A Phase I, Open-Label, Randomized, 2-Way Crossover Study to Compare the PK of Pirtobrutinib (LOXO-305) Tablets", "overallStatus": "COMPLETED", "startDate": "2021-09-28", "completionDate": "2021-12-22", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Loxo Oncology, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 28, "briefSummary": "The main purpose of this study is to compare two different formulations (mixtures) of pirtobrutinib (LOXO-305) in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will be collected. The study will last up to 65 days.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pirtobrutinib", "otherNames": ["LOXO-305", "LY3527727"]}], "meshConditions": [], "meshInterventions": ["pirtobrutinib"], "hasResults": true, "classifyText": "A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants Healthy Pirtobrutinib pirtobrutinib The main purpose of this study is to compare two different formulations (mixtures) of pirtobrutinib (LOXO-305) in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will be collected. The study will last up to 65 days."}
 {"nctId": "NCT07269210", "briefTitle": "A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia", "officialTitle": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3561774 (Solbinsiran) in Adults With Severe Hypertriglyceridemia", "overallStatus": "RECRUITING", "startDate": "2025-12-08", "completionDate": "2027-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 60, "briefSummary": "The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections.", "conditions": ["Severe Hypertriglyceridemia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Solbinsiran", "otherNames": ["LY3561774"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Hypertriglyceridemia"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia Severe Hypertriglyceridemia Solbinsiran Placebo Hypertriglyceridemia The purpose of this study is to evaluate the safety and efficacy of solbinsiran in lowering triglycerides and other lipid measures compared to placebo in participants with severe hypertriglyceridemia. Participants will receive two subcutaneous injections."}
 {"nctId": "NCT00191165", "briefTitle": "Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency", "officialTitle": "Efficacy and Safety of a High Dosage Compared to the Label Dosage of Humatrope in Early Pubertal Stage Children With Growth Hormone Deficiency", "overallStatus": "COMPLETED", "startDate": "2004-03", "completionDate": "2008-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 27, "briefSummary": "Multi-center, randomized, controlled, open-label, phase III study comparing the effects of two different dosages of somatropin treatment (in-label or doubled) after 12 and 24 months of treatment, on height velocity in early pubertal children with growth hormone deficiency (GHD). The study will be conducted in Italy. Approximately 26 subjects will participate in this study, distributed as 13 in the in-label dosage group (group A) and 13 in the doubled dosage group (group B).", "conditions": ["Growth Hormone Deficiency"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Somatropin", "otherNames": ["LY137998", "Humatrope"]}, {"type": "DRUG", "name": "Somatropin", "otherNames": ["LY137998", "Humatrope"]}], "meshConditions": ["Dwarfism, Pituitary"], "meshInterventions": ["Human Growth Hormone", "Growth Hormone"], "hasResults": true, "classifyText": "Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency Growth Hormone Deficiency Somatropin Somatropin Dwarfism, Pituitary Human Growth Hormone Growth Hormone Multi-center, randomized, controlled, open-label, phase III study comparing the effects of two different dosages of somatropin treatment (in-label or doubled) after 12 and 24 months of treatment, on height velocity in early pubertal children with growth hormone deficiency (GHD). The study will be conducted in Italy. Approximately 26 subjects will participate in this study, distributed as 13 in the in-label dosage group (group A) and 13 in the doubled dosage group (group B)."}
 {"nctId": "NCT02898077", "briefTitle": "A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer", "officialTitle": "A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine", "overallStatus": "COMPLETED", "startDate": "2017-03-02", "completionDate": "2021-04-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 440, "briefSummary": "The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer.", "conditions": ["Gastroesophageal Junction Adenocarcinoma", "Gastric Adenocarcinoma"], "keywords": ["Second line", "Angiogenesis", "Vascular endothelial growth factor receptor 2"], "interventions": [{"type": "DRUG", "name": "Ramucirumab", "otherNames": ["LY3009806"]}, {"type": "DRUG", "name": "Paclitaxel", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Ramucirumab", "Paclitaxel"], "hasResults": true, "classifyText": "A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Gastroesophageal Junction Adenocarcinoma Gastric Adenocarcinoma Second line Angiogenesis Vascular endothelial growth factor receptor 2 Ramucirumab Paclitaxel Placebo Ramucirumab Paclitaxel The purpose of this study is to evaluate the efficacy of the study drug known as ramucirumab in participants with gastric and gastroesophageal cancer."}
 {"nctId": "NCT06003465", "briefTitle": "A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices", "officialTitle": "A Relative Bioavailability Study to Compare the Pharmacokinetics of LY3437943 Administered Subcutaneously by a Test Device (Test Formulation) Versus Reference Device (Reference Formulation) in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2023-08-29", "completionDate": "2024-02-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 57, "briefSummary": "The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 16 weeks, including screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3437943", "otherNames": []}, {"type": "DEVICE", "name": "Test", "otherNames": []}, {"type": "DEVICE", "name": "Reference", "otherNames": []}], "meshConditions": [], "meshInterventions": ["retatrutide"], "hasResults": false, "classifyText": "A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices Healthy LY3437943 Test Reference retatrutide The main purpose of this study is to look at the amount of the study drug, LY3437943, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of LY3437943 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 16 weeks, including screening."}
 {"nctId": "NCT06400472", "briefTitle": "A Study of LY4170156 in Participants With Selected Advanced Solid Tumors", "officialTitle": "A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor \u03b1-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors", "overallStatus": "RECRUITING", "startDate": "2024-05-20", "completionDate": "2027-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 495, "briefSummary": "The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.", "conditions": ["Ovarian Neoplasms", "Endometrial Neoplasms", "Uterine Cervical Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Triple Negative Breast Neoplasms", "Pancreatic Neoplasm", "Colorectal Neoplasms"], "keywords": ["Folate receptor alpha", "NSCLC", "Ovarian cancer", "Cervical cancer", "Endometrial cancer", "Solid tumor", "Lung cancer", "Breast cancer", "Pancreatic cancer", "Colorectal cancer", "Anti-drug conjugate", "Phase I", "Chemotherapy", "sofe-m"], "interventions": [{"type": "DRUG", "name": "LY4170156", "otherNames": ["sofetabart mipitecan"]}, {"type": "DRUG", "name": "bevacizumab", "otherNames": []}, {"type": "DRUG", "name": "carboplatin", "otherNames": []}, {"type": "DRUG", "name": "Itraconazole", "otherNames": []}, {"type": "DRUG", "name": "pembrolizumab", "otherNames": []}], "meshConditions": ["Ovarian Neoplasms", "Endometrial Neoplasms", "Uterine Cervical Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Triple Negative Breast Neoplasms", "Pancreatic Neoplasms", "Colorectal Neoplasms", "Lung Neoplasms", "Breast Neoplasms"], "meshInterventions": ["Bevacizumab", "Carboplatin", "Itraconazole", "pembrolizumab"], "hasResults": false, "classifyText": "A Study of LY4170156 in Participants With Selected Advanced Solid Tumors Ovarian Neoplasms Endometrial Neoplasms Uterine Cervical Neoplasms Carcinoma, Non-Small-Cell Lung Triple Negative Breast Neoplasms Pancreatic Neoplasm Colorectal Neoplasms Folate receptor alpha NSCLC Ovarian cancer Cervical cancer Endometrial cancer Solid tumor Lung cancer Breast cancer Pancreatic cancer Colorectal cancer Anti-drug conjugate Phase I Chemotherapy sofe-m LY4170156 bevacizumab carboplatin Itraconazole pembrolizumab Ovarian Neoplasms Endometrial Neoplasms Uterine Cervical Neoplasms Carcinoma, Non-Small-Cell Lung Triple Negative Breast Neoplasms Pancreatic Neoplasms Colorectal Neoplasms Lung Neoplasms Breast Neoplasms Bevacizumab Carboplatin Itraconazole pembrolizumab The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years."}
 {"nctId": "NCT04840901", "briefTitle": "A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants", "officialTitle": "A Phase 1, Open-Label, Single-Dose Bioequivalence Study of Injections of Lebrikizumab Using a 2-mL Pre-Filled Syringe With Needle Safety Device and an Investigational 2-mL Autoinjector in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2021-06-02", "completionDate": "2022-02-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 242, "briefSummary": "The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that gets into the blood stream and how long it takes the body to get rid of lebrikizumab (LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe with needle safety device (PFS-NSD). The safety and tolerability of lebrikizumab will also be evaluated. The study will last up to 102 days.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Lebrikizumab", "otherNames": ["LY3650150"]}], "meshConditions": [], "meshInterventions": ["lebrikizumab"], "hasResults": true, "classifyText": "A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants Healthy Lebrikizumab lebrikizumab The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that gets into the blood stream and how long it takes the body to get rid of lebrikizumab (LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe with needle safety device (PFS-NSD). The safety and tolerability of lebrikizumab will also be evaluated. The study will last up to 102 days."}
 {"nctId": "NCT00063128", "briefTitle": "Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus.", "officialTitle": "Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2003-04", "completionDate": "2004-04", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Alkermes, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 119, "briefSummary": "This is a research study of a study drug known as LY041001 or human insulin inhalation powder (HIIP). HIIP is a powder form of insulin made to be inhaled through the mouth and into the lungs using a special handheld device.", "conditions": ["Diabetes Mellitus, Type 1"], "keywords": [], "interventions": [{"type": "DRUG", "name": "insulin", "otherNames": ["LY041001"]}, {"type": "DRUG", "name": "human insulin inhalation powder (HIIP)", "otherNames": ["LY041001"]}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin"], "hasResults": false, "classifyText": "Safety and Efficacy of Human Insulin Inhalation Powder in Patients With Type 1 Diabetes Mellitus. Diabetes Mellitus, Type 1 insulin human insulin inhalation powder (HIIP) Diabetes Mellitus, Type 1 Insulin This is a research study of a study drug known as LY041001 or human insulin inhalation powder (HIIP). HIIP is a powder form of insulin made to be inhaled through the mouth and into the lungs using a special handheld device."}
 {"nctId": "NCT00034593", "briefTitle": "A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium", "officialTitle": null, "overallStatus": "COMPLETED", "startDate": null, "completionDate": null, "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": null, "briefSummary": "Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.", "conditions": ["Urologic Neoplasms"], "keywords": ["Bladder cancer", "metastatic", "transitional cell carcinoma of the urothelium"], "interventions": [{"type": "DRUG", "name": "ALIMTA", "otherNames": []}, {"type": "DRUG", "name": "gemcitabine", "otherNames": []}], "meshConditions": ["Urologic Neoplasms", "Urinary Bladder Neoplasms", "Neoplasm Metastasis"], "meshInterventions": ["Pemetrexed", "Gemcitabine"], "hasResults": false, "classifyText": "A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Urologic Neoplasms Bladder cancer metastatic transitional cell carcinoma of the urothelium ALIMTA gemcitabine Urologic Neoplasms Urinary Bladder Neoplasms Neoplasm Metastasis Pemetrexed Gemcitabine Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body."}
 {"nctId": "NCT00385671", "briefTitle": "An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain", "officialTitle": "An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin Among Patients With Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain", "overallStatus": "COMPLETED", "startDate": "2006-09", "completionDate": "2009-11", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Boehringer Ingelheim"], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 407, "briefSummary": "To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to gabapentin.", "conditions": ["Diabetic Neuropathy, Painful"], "keywords": [], "interventions": [{"type": "DRUG", "name": "duloxetine hydrochloride", "otherNames": ["LY248686", "Cymbalta"]}, {"type": "DRUG", "name": "pregabalin", "otherNames": []}, {"type": "DRUG", "name": "gabapentin", "otherNames": []}], "meshConditions": ["Diabetic Neuropathies"], "meshInterventions": ["Duloxetine Hydrochloride", "Pregabalin", "Gabapentin"], "hasResults": true, "classifyText": "An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Diabetic Neuropathy, Painful duloxetine hydrochloride pregabalin gabapentin Diabetic Neuropathies Duloxetine Hydrochloride Pregabalin Gabapentin To test the non-inferiority of duloxetine monotherapy as a treatment for the management of diabetic peripheral neuropathic pain as compared to pregabalin treatment among patients who have not had an adequate response to gabapentin."}
 {"nctId": "NCT00190671", "briefTitle": "A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients", "officialTitle": "A Phase 1/2 Dose-Escalating Study of ALIMTA and Cyclophosphamide Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2005-06", "completionDate": "2008-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 103, "briefSummary": "This is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer. A single arm Phase 1 dose finding (establish maximum tolerated dose) study precedes the randomized phase 2 portion.", "conditions": ["Breast Cancer"], "keywords": ["Advanced Breast Cancer"], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514", "Alimta"]}, {"type": "DRUG", "name": "cyclophosphamide", "otherNames": []}, {"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514", "Alimta"]}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Pemetrexed", "Cyclophosphamide"], "hasResults": true, "classifyText": "A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients Breast Cancer Advanced Breast Cancer pemetrexed cyclophosphamide pemetrexed Breast Neoplasms Pemetrexed Cyclophosphamide This is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer. A single arm Phase 1 dose finding (establish maximum tolerated dose) study precedes the randomized phase 2 portion."}
 {"nctId": "NCT05723198", "briefTitle": "A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata", "officialTitle": "A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of Baricitinib in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata", "overallStatus": "RECRUITING", "startDate": "2023-02-27", "completionDate": "2030-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 595, "briefSummary": "The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.\n\nThe study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period.", "conditions": ["Areata Alopecia", "Alopecia", "Hypotrichosis", "Hair Diseases", "Skin Diseases", "Pathological Conditions, Anatomical"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Alopecia", "Hypotrichosis", "Hair Diseases", "Skin Diseases", "Pathological Conditions, Anatomical"], "meshInterventions": ["baricitinib"], "hasResults": false, "classifyText": "A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata Areata Alopecia Alopecia Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Baricitinib Placebo Alopecia Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical baricitinib The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.\n\nThe study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Follow-up period."}
 {"nctId": "NCT05960851", "briefTitle": "A Study of LY3871801 in Healthy Asian and Non-Asian Participants", "officialTitle": "A Phase I, Participant- and Investigator-Blind, Single-center Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LY3871801 in Healthy Asian and Non-Asian Participants", "overallStatus": "COMPLETED", "startDate": "2023-08-09", "completionDate": "2023-10-25", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 32, "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of LY3871801 when administered as multiple doses in Healthy Asian and Non-Asian Participants. The study will also evaluate the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it in these participants. The study will be conducted in two parts (A \\& B). The study will last up to approximately 24 days excluding the screening period.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3871801", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3871801 in Healthy Asian and Non-Asian Participants Healthy LY3871801 Placebo The main purpose of this study is to evaluate the safety and tolerability of LY3871801 when administered as multiple doses in Healthy Asian and Non-Asian Participants. The study will also evaluate the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it in these participants. The study will be conducted in two parts (A \\& B). The study will last up to approximately 24 days excluding the screening period."}
 {"nctId": "NCT00803231", "briefTitle": "Follow-up Data of Patients Treated With XIGRIS\u00ae in France", "officialTitle": "Follow-up Data of Patients Treated With XIGRIS\u00ae DROTRECOGIN ALFA (ACTIVATED) in France", "overallStatus": "COMPLETED", "startDate": "2008-11", "completionDate": "2009-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "OBSERVATIONAL", "phases": [], "primaryPurpose": null, "enrollment": 1004, "briefSummary": "The transparency commission wishes that the laboratory Lilly France sets up a follow-up study describing the conditions of use of Xigris\u00ae in France.\n\nThe purpose of this study is to describe the characteristics of the treated patients, the conditions of drug use, in particular the conditions of treatment initiation and the clinical development of the patients during normal clinical practice, in particular rate and cause of mortality within one month.", "conditions": ["Sepsis"], "keywords": [], "interventions": [], "meshConditions": ["Sepsis"], "meshInterventions": [], "hasResults": false, "classifyText": "Follow-up Data of Patients Treated With XIGRIS\u00ae in France Sepsis Sepsis The transparency commission wishes that the laboratory Lilly France sets up a follow-up study describing the conditions of use of Xigris\u00ae in France.\n\nThe purpose of this study is to describe the characteristics of the treated patients, the conditions of drug use, in particular the conditions of treatment initiation and the clinical development of the patients during normal clinical practice, in particular rate and cause of mortality within one month."}
 {"nctId": "NCT01463631", "briefTitle": "A Study of LY3007113 in Participants With Advanced Cancer", "officialTitle": "A Phase 1 Study of LY3007113, a p38 MAPK Inhibitor, in Patients With Advanced Cancer", "overallStatus": "COMPLETED", "startDate": "2011-12", "completionDate": "2013-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 27, "briefSummary": "This study evaluates the safety and tolerability of different doses of an experimental treatment in participants with advanced cancer.", "conditions": ["Metastatic Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3007113", "otherNames": []}], "meshConditions": ["Neoplasm Metastasis"], "meshInterventions": [], "hasResults": true, "classifyText": "A Study of LY3007113 in Participants With Advanced Cancer Metastatic Cancer LY3007113 Neoplasm Metastasis This study evaluates the safety and tolerability of different doses of an experimental treatment in participants with advanced cancer."}
 {"nctId": "NCT02109029", "briefTitle": "A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue", "officialTitle": "Use of Open-Flow Microperfusion to Measure LY2605541 and Human Insulin Concentrations in Adipose Tissue Interstitial Fluid", "overallStatus": "COMPLETED", "startDate": "2014-04", "completionDate": "2015-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 24, "briefSummary": "LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, and to measure the quantity of LY2605541 in fat tissue. The study has two parts. It involves intravenous (IV) infusion of the investigational drug and a procedure to measure concentrations in the fat tissue. Both parts of the study will be conducted in participants with type 1 diabetes mellitus (T1DM). Part A and B of the study might take up to 7 weeks to complete.", "conditions": ["Diabetes Mellitus, Type 1"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Insulin Peglispro", "otherNames": ["LY2605541"]}, {"type": "DRUG", "name": "Human Insulin", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["basal insulin peglispro", "LY2605541", "Insulin"], "hasResults": true, "classifyText": "A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue Diabetes Mellitus, Type 1 Insulin Peglispro Human Insulin Diabetes Mellitus, Type 1 basal insulin peglispro LY2605541 Insulin LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, and to measure the quantity of LY2605541 in fat tissue. The study has two parts. It involves intravenous (IV) infusion of the investigational drug and a procedure to measure concentrations in the fat tissue. Both parts of the study will be conducted in participants with type 1 diabetes mellitus (T1DM). Part A and B of the study might take up to 7 weeks to complete."}
 {"nctId": "NCT00191802", "briefTitle": "Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients", "officialTitle": "Compliance With and Acceptance of Teriparatide Pen Injection in Severely Osteoporotic Patients [CATS]", "overallStatus": "COMPLETED", "startDate": "2003-09", "completionDate": "2005-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 120, "briefSummary": "The purposes of this study are to evaluate the acceptance of the subcutaneous drug teriparatide over 6 months of therapy in patients with severe osteoporosis in Canada, and to evaluate how often such patients are actually able to use the injection; to obtain additional safety data (side effect data) that will supplement the existing database of adverse events that have been reported to-date in clinical trials by patients treated with teriparatide; to document the prior use of other osteoporosis therapies in this patient population, and ongoing use of other osteoporosis therapies during the study; and to describe the baseline demographics and disease state of these severely osteoporotic patients.The purposes of the study extension are to continue to assess the acceptance of the subcutaneous drug teriparatide over up to 18 months of therapy in patients with severe osteoporosis in Canada, and to continue to assess how often such patients are actually able to use the injection; to obtain additional safety data (side effects) that will supplement the existing database of adverse events that have been reported to date in clinical trials by patients treated with teriparatide.", "conditions": ["Osteoporosis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "teriparatide", "otherNames": []}], "meshConditions": ["Osteoporosis"], "meshInterventions": ["Teriparatide"], "hasResults": false, "classifyText": "Compliance and Acceptance of Teriparatide Injection in Severely Osteoporotic Patients Osteoporosis teriparatide Osteoporosis Teriparatide The purposes of this study are to evaluate the acceptance of the subcutaneous drug teriparatide over 6 months of therapy in patients with severe osteoporosis in Canada, and to evaluate how often such patients are actually able to use the injection; to obtain additional safety data (side effect data) that will supplement the existing database of adverse events that have been reported to-date in clinical trials by patients treated with teriparatide; to document the prior use of other osteoporosis therapies in this patient population, and ongoing use of other osteoporosis therapies during the study; and to describe the baseline demographics and disease state of these severely osteoporotic patients.The purposes of the study extension are to continue to assess the acceptance of the subcutaneous drug teriparatide over up to 18 months of therapy in patients with severe osteoporosis in Canada, and to continue to assess how often such patients are actually able to use the injection; to obtain a"}
 {"nctId": "NCT04437511", "briefTitle": "A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)", "officialTitle": "Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2020-06-19", "completionDate": "2028-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1736, "briefSummary": "The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.\n\nAdditional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.\n\nTrial participants who were dosed with donanemab in the main study will be enrolled to a 3-year follow up addendum. No study drug will be administered during this follow up.", "conditions": ["Alzheimer Disease"], "keywords": ["Alzheimer's", "Dementia", "Cognitive Impairment", "Amyloid Plaque"], "interventions": [{"type": "DRUG", "name": "Donanemab", "otherNames": ["LY3002813"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Alzheimer Disease", "Dementia", "Cognitive Dysfunction", "Plaque, Amyloid"], "meshInterventions": ["donanemab"], "hasResults": true, "classifyText": "A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Alzheimer Disease Alzheimer's Dementia Cognitive Impairment Amyloid Plaque Donanemab Placebo Alzheimer Disease Dementia Cognitive Dysfunction Plaque, Amyloid donanemab The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.\n\nAdditional participants will be enrolled to an addendum safety cohort. The participants will be administered open-label donanemab.\n\nTrial participants who were dosed with donanemab in the main study will be enrolled to a 3-year follow up addendum. No study drug will be administered during this follow up."}
 {"nctId": "NCT00311532", "briefTitle": "Observational Study of Pergolide Mesylate and Cardiac Valvulopathy", "officialTitle": "Observational Study to Determine the Incidence of New-Onset Valvulopathy in Patients Treated With Pergolide as Second-Line Therapy for Parkinson's Disease", "overallStatus": "COMPLETED", "startDate": "2006-03", "completionDate": "2007-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "OBSERVATIONAL", "phases": [], "primaryPurpose": null, "enrollment": 200, "briefSummary": "The primary objective of this study is to estimate the incidence of new-onset valvulopathy, determined by baseline and follow-up echocardiograms, in patients with Parkinson's Disease who are receiving pergolide as second-line therapy.\n\nThe secondary objective of the study is to estimate the prevalence of valvulopathy, as determined by baseline echocardiograms, among all patients who have Parkinson's Disease and are being considered for pergolide as second-line therapy.", "conditions": ["Parkinson Disease"], "keywords": [], "interventions": [], "meshConditions": ["Parkinson Disease"], "meshInterventions": [], "hasResults": false, "classifyText": "Observational Study of Pergolide Mesylate and Cardiac Valvulopathy Parkinson Disease Parkinson Disease The primary objective of this study is to estimate the incidence of new-onset valvulopathy, determined by baseline and follow-up echocardiograms, in patients with Parkinson's Disease who are receiving pergolide as second-line therapy.\n\nThe secondary objective of the study is to estimate the prevalence of valvulopathy, as determined by baseline echocardiograms, among all patients who have Parkinson's Disease and are being considered for pergolide as second-line therapy."}
 {"nctId": "NCT01871493", "briefTitle": "A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants", "officialTitle": "A Phase 1 Study to Evaluate the Pharmacokinetics of LY2605541 Injection and Insulin Lispro Injection Administered as Mixture or as Individual Components in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2013-06", "completionDate": "2013-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 40, "briefSummary": "The main purpose of this study is to evaluate how the body absorbs and removes LY2605541, insulin lispro, and a mixture of both from the blood. The study has two parts. Participants may enroll in only one part. Each part has four treatment periods in a fixed order. The study will last approximately 8 weeks, not including screening. Screening is required within 28 days prior to the start of the study.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2605541", "otherNames": []}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["Humalog"]}], "meshConditions": [], "meshInterventions": ["LY2605541", "Insulin Lispro"], "hasResults": false, "classifyText": "A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants Healthy Volunteers LY2605541 Insulin Lispro LY2605541 Insulin Lispro The main purpose of this study is to evaluate how the body absorbs and removes LY2605541, insulin lispro, and a mixture of both from the blood. The study has two parts. Participants may enroll in only one part. Each part has four treatment periods in a fixed order. The study will last approximately 8 weeks, not including screening. Screening is required within 28 days prior to the start of the study."}
 {"nctId": "NCT01015287", "briefTitle": "A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction", "officialTitle": "A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pretreatment At the Time of Diagnosis in Patients With Non-ST-Elevation Myocardial Infarction (NSTEMI): The ACCOAST Study", "overallStatus": "COMPLETED", "startDate": "2009-12", "completionDate": "2013-02", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Daiichi Sankyo Co., Ltd."], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 4033, "briefSummary": "The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary angiography/percutaneous coronary intervention (PCI).", "conditions": ["Acute Coronary Syndromes"], "keywords": ["Acute Coronary Syndromes", "Heart Disease", "Percutaneous Coronary Intervention", "P2Y12", "NSTEMI"], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Prasugrel", "otherNames": ["LY640315", "Efient", "Effient", "CS-747"]}], "meshConditions": ["Acute Coronary Syndrome", "Heart Diseases", "Non-ST Elevated Myocardial Infarction"], "meshInterventions": ["Prasugrel Hydrochloride"], "hasResults": true, "classifyText": "A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction Acute Coronary Syndromes Acute Coronary Syndromes Heart Disease Percutaneous Coronary Intervention P2Y12 NSTEMI Placebo Prasugrel Acute Coronary Syndrome Heart Diseases Non-ST Elevated Myocardial Infarction Prasugrel Hydrochloride The purpose of this trial is to investigate the potential benefits/risks regarding pretreatment with prasugrel in non-ST-elevation myocardial infarction (NSTEMI) participants with elevated troponin scheduled for coronary angiography/percutaneous coronary intervention (PCI)."}
 {"nctId": "NCT02163993", "briefTitle": "A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache", "officialTitle": "A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients With Episodic Migraine", "overallStatus": "COMPLETED", "startDate": "2014-07-07", "completionDate": "2018-02-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 414, "briefSummary": "The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.", "conditions": ["Migraine Headache"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Galcanezumab", "otherNames": ["LY2951742"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Migraine Disorders"], "meshInterventions": ["galcanezumab"], "hasResults": true, "classifyText": "A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache Migraine Headache Galcanezumab Placebo Migraine Disorders galcanezumab The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches."}
 {"nctId": "NCT00408993", "briefTitle": "Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China", "officialTitle": "Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China", "overallStatus": "COMPLETED", "startDate": "2006-12", "completionDate": "2008-02", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Boehringer Ingelheim"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 215, "briefSummary": "To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy.", "conditions": ["Diabetic Neuropathies"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine Hydrochloride", "otherNames": ["LY248686", "Cymbalta"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetic Neuropathies"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": true, "classifyText": "Duloxetine Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain in China Diabetic Neuropathies Duloxetine Hydrochloride Placebo Diabetic Neuropathies Duloxetine Hydrochloride To determine if duloxetine 60mg up to 120mg daily can work in treating pain from Diabetic Neuropathy."}
 {"nctId": "NCT04840914", "briefTitle": "A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction", "officialTitle": "A Single-Dose Study Evaluating Different Dose Levels and Subcutaneous Infusion Durations on Safety, Pharmacokinetics, and Pharmacodynamics of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction", "overallStatus": "COMPLETED", "startDate": "2021-06-01", "completionDate": "2024-05-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 44, "briefSummary": "The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits.", "conditions": ["Chronic Heart Failure With Reduced Ejection Fraction"], "keywords": ["Heart Failure"], "interventions": [{"type": "DRUG", "name": "LY3461767", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Heart Failure"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction Chronic Heart Failure With Reduced Ejection Fraction Heart Failure LY3461767 Placebo Heart Failure The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF). The study will last up to 3 months and may include 5 visits."}
 {"nctId": "NCT00044421", "briefTitle": "Treatment of Peripheral Neuropathy in Patients With Diabetes", "officialTitle": "LY333531 Treatment of Peripheral Neuropathy in Patients With Diabetes", "overallStatus": "COMPLETED", "startDate": "2002-07", "completionDate": "2006-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 400, "briefSummary": "The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes.", "conditions": ["Diabetic Neuropathies", "Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Ruboxistaurin mesylate", "otherNames": []}], "meshConditions": ["Diabetic Neuropathies", "Diabetes Mellitus"], "meshInterventions": [], "hasResults": false, "classifyText": "Treatment of Peripheral Neuropathy in Patients With Diabetes Diabetic Neuropathies Diabetes Mellitus Ruboxistaurin mesylate Diabetic Neuropathies Diabetes Mellitus The purpose of this protocol is to determine if an investigational drug is effective in treating nerve malfunction in diabetes."}
 {"nctId": "NCT00097214", "briefTitle": "Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)", "officialTitle": "A Phase II Trial of Carboplatin Plus Cetuximab for the Treatment of Stage IIIb/IV Non-Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2004-11", "completionDate": "2007-04", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Bristol-Myers Squibb"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 57, "briefSummary": "This is a phase II study in previously untreated subjects with histologically or cytologically proven stage IIIB/IV NSCLC designed to determine the efficacy of first line treatment with carboplatin and cetuximab.", "conditions": ["Non-small Cell Lung Cancer"], "keywords": ["NSCLC", "Non-small", "Lung", "IIIB", "IV", "Carboplatin", "Cetuximab", "Stage IIIB non-small cell lung cancer", "Stage IV non-small cell lung cancer"], "interventions": [{"type": "DRUG", "name": "Carboplatin", "otherNames": ["Paraplatin"]}, {"type": "BIOLOGICAL", "name": "Cetuximab", "otherNames": ["erbitux"]}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Carboplatin", "Cetuximab"], "hasResults": false, "classifyText": "Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) Non-small Cell Lung Cancer NSCLC Non-small Lung IIIB IV Carboplatin Cetuximab Stage IIIB non-small cell lung cancer Stage IV non-small cell lung cancer Carboplatin Cetuximab Carcinoma, Non-Small-Cell Lung Carboplatin Cetuximab This is a phase II study in previously untreated subjects with histologically or cytologically proven stage IIIB/IV NSCLC designed to determine the efficacy of first line treatment with carboplatin and cetuximab."}
 {"nctId": "NCT03988114", "briefTitle": "A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer", "officialTitle": "A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors", "overallStatus": "WITHDRAWN", "startDate": "2019-09-16", "completionDate": "2023-03-23", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 0, "briefSummary": "The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) advanced breast cancer that have certain disease characteristics.", "conditions": ["Metastatic Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Nonsteroidal Aromatase Inhibitor (NSAI)", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["abemaciclib"], "hasResults": false, "classifyText": "A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer Metastatic Breast Cancer Abemaciclib Nonsteroidal Aromatase Inhibitor (NSAI) Breast Neoplasms abemaciclib The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) advanced breast cancer that have certain disease characteristics."}
 {"nctId": "NCT03363906", "briefTitle": "A Study of Dulaglutide in Healthy Participants", "officialTitle": "Relative Bioavailability of an Investigational Single Dose of Dulaglutide After Subcutaneous Administration by a Single Dose Pen Compared to a Prefilled Syringe in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2017-12-07", "completionDate": "2018-06-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 27, "briefSummary": "The purpose of this study is to evaluate a new formulation of dulaglutide (study drug) administered under the skin as one injection using a single dose pen compared to three injections using a pre filled syringe.\n\nThis study will evaluate how much of the study drug enters the body and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.\n\nThe study will last about 84 days, including screening and will require overnight stays in the clinical research unit (CRU).", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Dulaglutide (Reference)", "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Dulaglutide (Test)", "otherNames": ["LY2189265"]}], "meshConditions": [], "meshInterventions": ["dulaglutide"], "hasResults": true, "classifyText": "A Study of Dulaglutide in Healthy Participants Healthy Dulaglutide (Reference) Dulaglutide (Test) dulaglutide The purpose of this study is to evaluate a new formulation of dulaglutide (study drug) administered under the skin as one injection using a single dose pen compared to three injections using a pre filled syringe.\n\nThis study will evaluate how much of the study drug enters the body and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected.\n\nThe study will last about 84 days, including screening and will require overnight stays in the clinical research unit (CRU)."}
 {"nctId": "NCT01158404", "briefTitle": "Notch Inhibitor in Advanced Cancer", "officialTitle": "Phase 1 Study of a Notch Inhibitor in Patients With Advanced Cancer", "overallStatus": "COMPLETED", "startDate": "2010-07", "completionDate": "2012-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 35, "briefSummary": "The objective of this phase 1 study is to evaluate the safety and tolerability of Notch Inhibitor in participants with advanced cancer. This study includes dose escalation and dose confirmation components.", "conditions": ["Advanced Cancer"], "keywords": ["Metastatic Cancer", "Solid Tumors"], "interventions": [{"type": "DRUG", "name": "LY900009 - Dose Escalation Phase (Part A)", "otherNames": ["Notch Inhibitor"]}, {"type": "DRUG", "name": "LY900009 - Dose Confirmation Phase (Part B)", "otherNames": ["Notch Inhibitor"]}], "meshConditions": ["Neoplasm Metastasis"], "meshInterventions": [], "hasResults": true, "classifyText": "Notch Inhibitor in Advanced Cancer Advanced Cancer Metastatic Cancer Solid Tumors LY900009 - Dose Escalation Phase (Part A) LY900009 - Dose Confirmation Phase (Part B) Neoplasm Metastasis The objective of this phase 1 study is to evaluate the safety and tolerability of Notch Inhibitor in participants with advanced cancer. This study includes dose escalation and dose confirmation components."}
 {"nctId": "NCT03027284", "briefTitle": "A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer", "officialTitle": "A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer", "overallStatus": "COMPLETED", "startDate": "2017-02-03", "completionDate": "2020-03-17", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 19, "briefSummary": "The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer.", "conditions": ["Advanced Cancer", "Metastatic Cancer", "Biliary Tract Carcinoma", "Cholangiocarcinoma", "Gall Bladder Carcinoma", "Solid Tumor", "Non-Hodgkin's Lymphoma"], "keywords": ["Neoplasm"], "interventions": [{"type": "DRUG", "name": "Merestinib", "otherNames": ["LY2801653"]}, {"type": "DRUG", "name": "Cisplatin", "otherNames": []}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": ["LY188011"]}], "meshConditions": ["Neoplasm Metastasis", "Cholangiocarcinoma", "Gallbladder Neoplasms", "Lymphoma, Non-Hodgkin", "Neoplasms"], "meshInterventions": ["merestinib", "Cisplatin", "Gemcitabine"], "hasResults": false, "classifyText": "A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer Advanced Cancer Metastatic Cancer Biliary Tract Carcinoma Cholangiocarcinoma Gall Bladder Carcinoma Solid Tumor Non-Hodgkin's Lymphoma Neoplasm Merestinib Cisplatin Gemcitabine Neoplasm Metastasis Cholangiocarcinoma Gallbladder Neoplasms Lymphoma, Non-Hodgkin Neoplasms merestinib Cisplatin Gemcitabine The main purpose of this study is to evaluate tolerability of merestinib monotherapy or in combination with other anti-cancer agents in Japanese participants with advanced and/or metastatic cancer."}
 {"nctId": "NCT01794000", "briefTitle": "A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)", "officialTitle": "A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.", "overallStatus": "TERMINATED", "startDate": "2013-04", "completionDate": "2015-12", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Daiichi Sankyo"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 341, "briefSummary": "The main purpose of the study is to evaluate the efficacy and safety of the study drug known as prasugrel for the reduction of Vaso-Occlusive Crisis events in pediatric participants with sickle cell disease. The study will also investigate reduction in daily pain in children who have sickle cell disease.", "conditions": ["Sickle Cell Disease"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Prasugrel", "otherNames": ["LY640315", "Effient", "Efient"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Anemia, Sickle Cell"], "meshInterventions": ["Prasugrel Hydrochloride"], "hasResults": true, "classifyText": "A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD) Sickle Cell Disease Prasugrel Placebo Anemia, Sickle Cell Prasugrel Hydrochloride The main purpose of the study is to evaluate the efficacy and safety of the study drug known as prasugrel for the reduction of Vaso-Occlusive Crisis events in pediatric participants with sickle cell disease. The study will also investigate reduction in daily pain in children who have sickle cell disease."}
 {"nctId": "NCT02778100", "briefTitle": "A Study of Nasal Glucagon in Participants With a Common Cold", "officialTitle": "A Phase 1 Study to Evaluate the Effects of Common Cold and of Concomitant Administration of Nasal Decongestant on the Pharmacokinetics and Pharmacodynamics of a Novel Glucagon Formulation in Otherwise Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2013-03", "completionDate": "2013-04", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Locemia Solutions ULC"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 36, "briefSummary": "The main purpose of this study is to evaluate the safety of nasal glucagon (NG) in participants with a common cold, some of whom will also take a nasal decongestant. The study will investigate how the body processes NG and the effect of NG on the body. The study will last up to 30 days for each participant.", "conditions": ["Common Cold"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Nasal Glucagon", "otherNames": ["LY900018", "AMG 504-1"]}, {"type": "DRUG", "name": "Oxymetazoline", "otherNames": []}], "meshConditions": ["Common Cold"], "meshInterventions": ["Oxymetazoline"], "hasResults": true, "classifyText": "A Study of Nasal Glucagon in Participants With a Common Cold Common Cold Nasal Glucagon Oxymetazoline Common Cold Oxymetazoline The main purpose of this study is to evaluate the safety of nasal glucagon (NG) in participants with a common cold, some of whom will also take a nasal decongestant. The study will investigate how the body processes NG and the effect of NG on the body. The study will last up to 30 days for each participant."}
 {"nctId": "NCT06635057", "briefTitle": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan", "officialTitle": "A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants With Type 2 Diabetes During Ramadan", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2024-10-11", "completionDate": "2026-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 130, "briefSummary": "The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.", "conditions": ["Type 2 Diabetes"], "keywords": ["Ramadan", "Fasting"], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}], "meshConditions": ["Diabetes Mellitus, Type 2", "Fasting"], "meshInterventions": ["Tirzepatide"], "hasResults": false, "classifyText": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan Type 2 Diabetes Ramadan Fasting Tirzepatide Diabetes Mellitus, Type 2 Fasting Tirzepatide The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month."}
 {"nctId": "NCT07215312", "briefTitle": "A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin", "officialTitle": "A Phase 2, Randomized, Open-Label, Comparator-Controlled Trial to Evaluate the Efficacy and Safety of LY3938577 in Study Participants, With Type 2 Diabetes Previously Treated With Basal Insulin", "overallStatus": "RECRUITING", "startDate": "2025-10-13", "completionDate": "2026-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 100, "briefSummary": "The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Glycemic control", "Hypoglycemia", "Hyperglycemia"], "interventions": [{"type": "DRUG", "name": "LY3938577", "otherNames": []}, {"type": "DRUG", "name": "Degludec", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2", "Hypoglycemia", "Hyperglycemia"], "meshInterventions": ["insulin degludec"], "hasResults": false, "classifyText": "A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin Diabetes Mellitus, Type 2 Glycemic control Hypoglycemia Hyperglycemia LY3938577 Degludec Diabetes Mellitus, Type 2 Hypoglycemia Hyperglycemia insulin degludec The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks."}
 {"nctId": "NCT03214367", "briefTitle": "A Study of LY900014 in Participants With Type 1 Diabetes", "officialTitle": "A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D", "overallStatus": "COMPLETED", "startDate": "2017-07-17", "completionDate": "2019-08-22", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1392, "briefSummary": "The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).", "conditions": ["Type 1 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY900014", "otherNames": ["Ultra-Rapid Lispro"]}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["Humalog"]}, {"type": "DRUG", "name": "Insulin Glargine", "otherNames": []}, {"type": "DRUG", "name": "Insulin Degludec", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin Lispro", "Insulin Glargine", "insulin degludec"], "hasResults": true, "classifyText": "A Study of LY900014 in Participants With Type 1 Diabetes Type 1 Diabetes Mellitus LY900014 Insulin Lispro Insulin Glargine Insulin Degludec Diabetes Mellitus, Type 1 Insulin Lispro Insulin Glargine insulin degludec The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D)."}
 {"nctId": "NCT00207116", "briefTitle": "An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma", "officialTitle": "An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma", "overallStatus": "COMPLETED", "startDate": "2005-09", "completionDate": "2006-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 120, "briefSummary": "The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer", "conditions": ["Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis"], "keywords": ["Metastatic Non Small Cell Lung Cancer"], "interventions": [{"type": "DRUG", "name": "Cetuximab", "otherNames": ["Erbitux"]}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Neoplasm Metastasis"], "meshInterventions": ["Cetuximab"], "hasResults": false, "classifyText": "An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma Carcinoma, Non-Small-Cell Lung Neoplasm Metastasis Metastatic Non Small Cell Lung Cancer Cetuximab Carcinoma, Non-Small-Cell Lung Neoplasm Metastasis Cetuximab The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer"}
 {"nctId": "NCT00190606", "briefTitle": "Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence", "officialTitle": "Efficacy and Safety of Duloxetine Compared With Placebo,Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects With Moderate to Sever Stress Urinary Incontinence", "overallStatus": "COMPLETED", "startDate": "2002-01", "completionDate": "2006-04", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Boehringer Ingelheim"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 200, "briefSummary": "The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence", "conditions": ["Urinary Stress Incontinence"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": []}, {"type": "PROCEDURE", "name": "Pelvic Floor Muscle Training (PFMT)", "otherNames": []}, {"type": "PROCEDURE", "name": "Imitation PFMT", "otherNames": []}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Urinary Incontinence, Stress"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence Urinary Stress Incontinence Duloxetine Pelvic Floor Muscle Training (PFMT) Imitation PFMT placebo Urinary Incontinence, Stress Duloxetine Hydrochloride The study is a comparison of the efficacy and safety of duloxetine and pelvic floor muscle training with that of placebo in patients with moderate to severe stress urinary incontinence"}
 {"nctId": "NCT00781911", "briefTitle": "A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer", "officialTitle": "A Phase 2, Multicenter, Two Tier Study of IMC-A12 in Combination With Depot Octreotide in Patients With Metastatic, Well or Moderately Differentiated Carcinoid or Islet Cell Carcinoma", "overallStatus": "COMPLETED", "startDate": "2009-02", "completionDate": "2016-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 43, "briefSummary": "Determine the 6-month progression free survival (PFS) rate associated with cixutumumab in combination with depot octreotide acetate (octreotide) in participants with metastatic neuroendocrine tumors.", "conditions": ["Carcinoma", "Neuroendocrine Tumors"], "keywords": ["Islet Cell", "CARCINOMA, ISLET CELL", "Octreotide", "depot octreotide acetate", "Insulin-Like Growth Factor (IGF) 1", "Metastatic, Carcinoid or Islet Cell", "Neuroendocrine Tumors"], "interventions": [{"type": "BIOLOGICAL", "name": "Cixutumumab", "otherNames": ["IMC-A12", "LY3012217"]}, {"type": "DRUG", "name": "depot octreotide", "otherNames": ["SMS 201-995"]}], "meshConditions": ["Carcinoma", "Neuroendocrine Tumors", "Carcinoma, Islet Cell", "Neoplasm Metastasis", "Carcinoid Tumor"], "meshInterventions": ["cixutumumab", "Octreotide"], "hasResults": true, "classifyText": "A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer Carcinoma Neuroendocrine Tumors Islet Cell CARCINOMA, ISLET CELL Octreotide depot octreotide acetate Insulin-Like Growth Factor (IGF) 1 Metastatic, Carcinoid or Islet Cell Neuroendocrine Tumors Cixutumumab depot octreotide Carcinoma Neuroendocrine Tumors Carcinoma, Islet Cell Neoplasm Metastasis Carcinoid Tumor cixutumumab Octreotide Determine the 6-month progression free survival (PFS) rate associated with cixutumumab in combination with depot octreotide acetate (octreotide) in participants with metastatic neuroendocrine tumors."}
 {"nctId": "NCT01897493", "briefTitle": "A Study of Evacetrapib and Digoxin in Healthy Participants", "officialTitle": "Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2013-07", "completionDate": "2013-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 16, "briefSummary": "The main purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with the study drug evacetrapib. This study will also look at the effect of evacetrapib on the removal of digoxin from the body by the kidneys. Information about any side effects that may occur will be collected. This study will last approximately 33 days for each participant, not including screening.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Evacetrapib", "otherNames": ["LY2484595"]}, {"type": "DRUG", "name": "Digoxin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["evacetrapib", "Digoxin"], "hasResults": true, "classifyText": "A Study of Evacetrapib and Digoxin in Healthy Participants Healthy Volunteers Evacetrapib Digoxin evacetrapib Digoxin The main purpose of this study is to determine how much digoxin gets into the blood stream and how long it takes the body to get rid of it when given with the study drug evacetrapib. This study will also look at the effect of evacetrapib on the removal of digoxin from the body by the kidneys. Information about any side effects that may occur will be collected. This study will last approximately 33 days for each participant, not including screening."}
 {"nctId": "NCT02435433", "briefTitle": "A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein", "officialTitle": "Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib", "overallStatus": "COMPLETED", "startDate": "2015-07-20", "completionDate": "2021-11-19", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 399, "briefSummary": "The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be randomized to ramucirumab or placebo in a 2:1 ratio (Main Global Cohort and China Maximized Extended Enrollment \\[MEE\\] Cohort). Participants may also receive ramucirumab if eligible to be enrolled in Open-Label Expansion (OLE) Cohort.", "conditions": ["Hepatocellular Carcinoma"], "keywords": ["liver cancer"], "interventions": [{"type": "DRUG", "name": "Ramucirumab", "otherNames": ["Cyramza", "LY3009806"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Carcinoma, Hepatocellular", "Liver Neoplasms"], "meshInterventions": ["Ramucirumab"], "hasResults": true, "classifyText": "A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Hepatocellular Carcinoma liver cancer Ramucirumab Placebo Carcinoma, Hepatocellular Liver Neoplasms Ramucirumab The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein. Participants will be randomized to ramucirumab or placebo in a 2:1 ratio (Main Global Cohort and China Maximized Extended Enrollment \\[MEE\\] Cohort). Participants may also receive ramucirumab if eligible to be enrolled in Open-Label Expansion (OLE) Cohort."}
 {"nctId": "NCT00231725", "briefTitle": "Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin", "officialTitle": "Complaints Associated With Use of Pre-Filled Pen B When Used by Patients With Type 2 Diabetes on Twice-Daily Insulin Therapy", "overallStatus": "COMPLETED", "startDate": "2005-09", "completionDate": "2006-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": null, "enrollment": 370, "briefSummary": "Trial of new insulin injection pen called Pre-filled Pen B by type 2 diabetics in take home situations. Patients must use insulin lispro injection \\[rDNA origin\\] Low Mix twice daily during the trial.", "conditions": ["Type 2 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "insulin lispro injection [rDNA origin] Low Mix", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Insulin Lispro"], "hasResults": false, "classifyText": "Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin Type 2 Diabetes Mellitus insulin lispro injection [rDNA origin] Low Mix Diabetes Mellitus, Type 2 Insulin Lispro Trial of new insulin injection pen called Pre-filled Pen B by type 2 diabetics in take home situations. Patients must use insulin lispro injection \\[rDNA origin\\] Low Mix twice daily during the trial."}
 {"nctId": "NCT00055250", "briefTitle": "A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer", "officialTitle": "A Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of Gemcitabine Plus LY293111 Compared to Gemcitabine Plus Placebo in Patients With Locally Advanced or Metastatic Pancreatic Cancer", "overallStatus": "COMPLETED", "startDate": "2003-01", "completionDate": "2005-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 130, "briefSummary": "The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer.", "conditions": ["Pancreatic Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Gemcitabine", "otherNames": []}, {"type": "DRUG", "name": "LY293111", "otherNames": []}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Pancreatic Neoplasms"], "meshInterventions": ["Gemcitabine", "LY 293111"], "hasResults": false, "classifyText": "A Study With LY293111, Gemcitabine and Placebo in Patients With Pancreatic Cancer Pancreatic Cancer Gemcitabine LY293111 placebo Pancreatic Neoplasms Gemcitabine LY 293111 The purpose of this study is to determine the effectiveness and side effects of LY293111 given in combination with gemcitabine in patients with pancreatic cancer."}
 {"nctId": "NCT01337596", "briefTitle": "A Study of LY2951742 in Healthy Volunteers", "officialTitle": "A Safety, Tolerability, and Pharmacokinetic Study of Single, Escalating Subcutaneous Doses of LY2951742 in Healthy Volunteers", "overallStatus": "COMPLETED", "startDate": "2011-04", "completionDate": "2012-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "OTHER", "enrollment": 63, "briefSummary": "To evaluate the safety and tolerability of LY2951742 given as single or multiple subcutaneous injection in healthy male subjects", "conditions": ["Migraines"], "keywords": ["pain", "neuropathic pain", "headaches"], "interventions": [{"type": "DRUG", "name": "LY2951742", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Migraine Disorders", "Pain", "Neuralgia", "Headache"], "meshInterventions": ["galcanezumab"], "hasResults": true, "classifyText": "A Study of LY2951742 in Healthy Volunteers Migraines pain neuropathic pain headaches LY2951742 Placebo Migraine Disorders Pain Neuralgia Headache galcanezumab To evaluate the safety and tolerability of LY2951742 given as single or multiple subcutaneous injection in healthy male subjects"}
 {"nctId": "NCT05074420", "briefTitle": "A Study of Baricitinib (LY3009104) in Children With COVID-19", "officialTitle": "A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19", "overallStatus": "TERMINATED", "startDate": "2021-12-21", "completionDate": "2024-11-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 6, "briefSummary": "The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose.", "conditions": ["Covid19", "Corona Virus Infection"], "keywords": ["coronavirus"], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104"]}], "meshConditions": ["COVID-19", "Coronavirus Infections"], "meshInterventions": ["baricitinib"], "hasResults": false, "classifyText": "A Study of Baricitinib (LY3009104) in Children With COVID-19 Covid19 Corona Virus Infection coronavirus Baricitinib COVID-19 Coronavirus Infections baricitinib The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose."}
 {"nctId": "NCT02860780", "briefTitle": "A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer", "officialTitle": "A Phase 1 Dose-Escalation Study of LY2606368 in Combination With Ralimetinib in Patients With Advanced or Metastatic Cancer", "overallStatus": "COMPLETED", "startDate": "2016-08-10", "completionDate": "2017-05-15", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 9, "briefSummary": "The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.", "conditions": ["Advanced Cancer", "Metastatic Cancer", "Colorectal Cancer", "Non-small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "prexasertib", "otherNames": ["LY2606368"]}, {"type": "DRUG", "name": "ralimetinib", "otherNames": ["LY2228820"]}], "meshConditions": ["Neoplasm Metastasis", "Colorectal Neoplasms", "Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["prexasertib", "ralimetinib"], "hasResults": false, "classifyText": "A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer Advanced Cancer Metastatic Cancer Colorectal Cancer Non-small Cell Lung Cancer prexasertib ralimetinib Neoplasm Metastasis Colorectal Neoplasms Carcinoma, Non-Small-Cell Lung prexasertib ralimetinib The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer."}
 {"nctId": "NCT02335346", "briefTitle": "An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)", "officialTitle": "An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Osteoarthritis and Knee Pain", "overallStatus": "COMPLETED", "startDate": "2015-01", "completionDate": "2016-03", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Shionogi"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 93, "briefSummary": "The purpose of this study is to assess the safety and efficacy of duloxetine in participants with osteoarthritis and knee pain. The study will last for 1 year.", "conditions": ["Osteoarthritis of the Knee"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": ["LY248686", "Cymbalta"]}], "meshConditions": ["Osteoarthritis, Knee"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": true, "classifyText": "An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480) Osteoarthritis of the Knee Duloxetine Osteoarthritis, Knee Duloxetine Hydrochloride The purpose of this study is to assess the safety and efficacy of duloxetine in participants with osteoarthritis and knee pain. The study will last for 1 year."}
 {"nctId": "NCT00050206", "briefTitle": "Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder", "officialTitle": "Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder", "overallStatus": "COMPLETED", "startDate": "2002-11", "completionDate": "2005-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 130, "briefSummary": "The purpose of this study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of mania in bipolar disorder in adolescents. Both the potential benefits and side effects of olanzapine will be evaluated throughout this trial.", "conditions": ["Bipolar Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Olanzapine", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Bipolar Disorder"], "meshInterventions": ["Olanzapine"], "hasResults": false, "classifyText": "Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Bipolar Disorder Olanzapine Placebo Bipolar Disorder Olanzapine The purpose of this study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of mania in bipolar disorder in adolescents. Both the potential benefits and side effects of olanzapine will be evaluated throughout this trial."}
 {"nctId": "NCT00985504", "briefTitle": "A Study of Patients With Major Depressive Disorder and Residual Apathy", "officialTitle": "A Phase 4, 8-week, Double-blind, Randomized Study Comparing Switching to Duloxetine or Escitalopram in Patients With Major Depressive Disorder and Residual Apathy in the Absence of Depressed Mood", "overallStatus": "COMPLETED", "startDate": "2009-09", "completionDate": "2010-12", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Boehringer Ingelheim"], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 483, "briefSummary": "The purpose of this study is to provide a comparison of the apathy, depression, and functional outcomes associated with switching to duloxetine or escitalopram in patients who have previously responded to treatment with a selective serotonin reuptake inhibitor (SSRI) for major depressive disorder and who have residual apathy in the absence of depressed mood.", "conditions": ["Major Depressive Disorder"], "keywords": ["Major Depressive Disorder", "Apathy", "Duloxetine Hydrochloride", "SSRI", "Escitalopram"], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": ["Cymbalta", "LY248686"]}, {"type": "DRUG", "name": "Escitalopram", "otherNames": []}], "meshConditions": ["Depressive Disorder, Major", "Lethargy"], "meshInterventions": ["Duloxetine Hydrochloride", "Escitalopram"], "hasResults": true, "classifyText": "A Study of Patients With Major Depressive Disorder and Residual Apathy Major Depressive Disorder Major Depressive Disorder Apathy Duloxetine Hydrochloride SSRI Escitalopram Duloxetine Escitalopram Depressive Disorder, Major Lethargy Duloxetine Hydrochloride Escitalopram The purpose of this study is to provide a comparison of the apathy, depression, and functional outcomes associated with switching to duloxetine or escitalopram in patients who have previously responded to treatment with a selective serotonin reuptake inhibitor (SSRI) for major depressive disorder and who have residual apathy in the absence of depressed mood."}
 {"nctId": "NCT01263093", "briefTitle": "A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel", "officialTitle": "Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of R-130964, the Active Metabolite of Clopidogrel, in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2010-12", "completionDate": "2011-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 47, "briefSummary": "The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect each other in the body. Information about any side effects that may occur will also be collected.", "conditions": ["Major Depressive Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Clopidogrel", "otherNames": []}, {"type": "DRUG", "name": "LY2216684", "otherNames": []}], "meshConditions": ["Depressive Disorder, Major"], "meshInterventions": ["Clopidogrel", "alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol"], "hasResults": true, "classifyText": "A Pharmacokinetic Study on the Effect of LY2216684 on the Active Metabolite of Clopidogrel Major Depressive Disorder Clopidogrel LY2216684 Depressive Disorder, Major Clopidogrel alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol The purpose of this study is to measure how much of the study drugs (clopidogrel and LY2216684) reach the blood stream and how long it takes the body to dispose of them and to determine how clopidogrel and LY2216684 might affect each other in the body. Information about any side effects that may occur will also be collected."}
 {"nctId": "NCT01005680", "briefTitle": "A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer", "officialTitle": "A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer.", "overallStatus": "COMPLETED", "startDate": "2009-11", "completionDate": "2012-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 256, "briefSummary": "The purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC).", "conditions": ["Non Small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pemetrexed", "otherNames": ["Alimta", "LY231514"]}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": ["Gemzar", "LY188011"]}, {"type": "DRUG", "name": "Cisplatin", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Pemetrexed", "Gemcitabine", "Cisplatin"], "hasResults": true, "classifyText": "A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer Non Small Cell Lung Cancer Pemetrexed Gemcitabine Cisplatin Carcinoma, Non-Small-Cell Lung Pemetrexed Gemcitabine Cisplatin The purpose of this study is to compare the efficacy and safety of two different chemotherapy types in the first line treatment of advanced Non-Small Cell Lung Cancer (NSCLC)."}
 {"nctId": "NCT00436280", "briefTitle": "Chemotherapy for Participants With Lymphoma", "officialTitle": "An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine and Oxaliplatin Plus Enzastaurin as Treatment for Patients With Relapsed Diffuse Large B-Cell Lymphoma", "overallStatus": "COMPLETED", "startDate": "2007-02", "completionDate": "2012-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 68, "briefSummary": "The primary purpose of this study is to help answer the following research questions:\n\n* To assess whether Enzastaurin combined with rituximab, gemcitabine and oxaliplatin (R-GEMOX) can help participants with Diffuse Large B-Cell Lymphoma (DLBCL) remain free from disease and thus live longer.\n* To assess for any side effects that might be associated with enzastaurin and R-GEMOX .\n* To look at the characteristics and levels of certain genes and proteins to learn more about DLBCL and how enzastaurin works in the body.\n* To look at the level of enzastaurin in the body and how long it remains.", "conditions": ["Lymphoma, Large Cell, Diffuse"], "keywords": [], "interventions": [{"type": "DRUG", "name": "enzastaurin", "otherNames": ["LY317615"]}, {"type": "DRUG", "name": "gemcitabine", "otherNames": ["LY188011, Gemzar"]}, {"type": "DRUG", "name": "rituximab", "otherNames": []}, {"type": "DRUG", "name": "oxaliplatin", "otherNames": []}], "meshConditions": ["Lymphoma, Large B-Cell, Diffuse"], "meshInterventions": ["enzastaurin", "Gemcitabine", "Rituximab", "Oxaliplatin"], "hasResults": true, "classifyText": "Chemotherapy for Participants With Lymphoma Lymphoma, Large Cell, Diffuse enzastaurin gemcitabine rituximab oxaliplatin Lymphoma, Large B-Cell, Diffuse enzastaurin Gemcitabine Rituximab Oxaliplatin The primary purpose of this study is to help answer the following research questions:\n\n* To assess whether Enzastaurin combined with rituximab, gemcitabine and oxaliplatin (R-GEMOX) can help participants with Diffuse Large B-Cell Lymphoma (DLBCL) remain free from disease and thus live longer.\n* To assess for any side effects that might be associated with enzastaurin and R-GEMOX .\n* To look at the characteristics and levels of certain genes and proteins to learn more about DLBCL and how enzastaurin works in the body.\n* To look at the level of enzastaurin in the body and how long it remains."}
 {"nctId": "NCT00332202", "briefTitle": "PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin", "officialTitle": "A Phase 3 Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin", "overallStatus": "COMPLETED", "startDate": "2006-06", "completionDate": "2013-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "PREVENTION", "enrollment": 758, "briefSummary": "This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily.\n\nThis is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1.", "conditions": ["Non Hodgkin Lymphoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "enzastaurin", "otherNames": ["LY317615"]}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Lymphoma, Non-Hodgkin"], "meshInterventions": ["enzastaurin"], "hasResults": true, "classifyText": "PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin Non Hodgkin Lymphoma enzastaurin placebo Lymphoma, Non-Hodgkin enzastaurin This clinical research study is to investigate the prevention of relapse in patients with diffuse large B cell lymphoma (DLBCL) using enzastaurin daily.\n\nThis is a randomised trial which compares Enzastaurin to Placebo (dummy treatment), the chance of receiving Enzastaurin is 2 to 1."}
 {"nctId": "NCT03433677", "briefTitle": "A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes", "officialTitle": "A Prospective, Randomized, Double-Blind, Crossover Comparison Evaluating Compatibility and Safety of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Patients With Type 1 Diabetes (PRONTO-Pump)", "overallStatus": "COMPLETED", "startDate": "2018-02-21", "completionDate": "2018-09-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 49, "briefSummary": "The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.", "conditions": ["Diabetes Type 1"], "keywords": ["insulin pump"], "interventions": [{"type": "DRUG", "name": "LY900014", "otherNames": ["Ultra-Rapid Lispro"]}, {"type": "DRUG", "name": "Insulin lispro", "otherNames": ["Humalog"]}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin Lispro"], "hasResults": true, "classifyText": "A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes Diabetes Type 1 insulin pump LY900014 Insulin lispro Diabetes Mellitus, Type 1 Insulin Lispro The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes."}
 {"nctId": "NCT04640077", "briefTitle": "A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)", "officialTitle": "Donanemab Follow-On Study: Safety, Tolerability, And Efficacy in Symptomatic Alzheimer's Disease With Validation of Remote Neuropsychological Assessments", "overallStatus": "COMPLETED", "startDate": "2020-11-23", "completionDate": "2024-02-27", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 95, "briefSummary": "The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over videoconferencing", "conditions": ["Alzheimer Disease", "Dementia", "Brain Diseases", "Central Nervous System Diseases", "Cognitive Impairment"], "keywords": [], "interventions": [{"type": "OTHER", "name": "No Intervention", "otherNames": []}, {"type": "DRUG", "name": "donanemab", "otherNames": ["LY3002813"]}], "meshConditions": ["Alzheimer Disease", "Dementia", "Brain Diseases", "Central Nervous System Diseases", "Cognitive Dysfunction"], "meshInterventions": ["donanemab"], "hasResults": true, "classifyText": "A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Cognitive Impairment No Intervention donanemab Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Cognitive Dysfunction donanemab The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over videoconferencing"}
 {"nctId": "NCT01520220", "briefTitle": "Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms", "officialTitle": "A Phase 1 Study of LY2784544 Testing Alternative Dosing Regimens in Patients With Myeloproliferative Neoplasms", "overallStatus": "COMPLETED", "startDate": "2012-06-11", "completionDate": "2017-02-24", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 100, "briefSummary": "The purpose of this study is to determine a dose of LY2784544 that may be safely administered to participants with myeloproliferative neoplasms.", "conditions": ["Myeloproliferative Neoplasms of", "Polycythemia Vera", "Essential Thrombocythemia", "Myelofibrosis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2784544", "otherNames": []}], "meshConditions": ["Polycythemia Vera", "Thrombocythemia, Essential", "Primary Myelofibrosis"], "meshInterventions": ["LY2784544"], "hasResults": false, "classifyText": "Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms Myeloproliferative Neoplasms of Polycythemia Vera Essential Thrombocythemia Myelofibrosis LY2784544 Polycythemia Vera Thrombocythemia, Essential Primary Myelofibrosis LY2784544 The purpose of this study is to determine a dose of LY2784544 that may be safely administered to participants with myeloproliferative neoplasms."}
 {"nctId": "NCT03830281", "briefTitle": "A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy", "officialTitle": "A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion", "overallStatus": "COMPLETED", "startDate": "2019-02-14", "completionDate": "2020-01-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 471, "briefSummary": "The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).", "conditions": ["Type 1 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Ultra-Rapid Lispro", "otherNames": ["LY900014", "Insulin lispro"]}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["Humalog", "LY275585"]}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin Lispro"], "hasResults": true, "classifyText": "A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy Type 1 Diabetes Mellitus Ultra-Rapid Lispro Insulin Lispro Diabetes Mellitus, Type 1 Insulin Lispro The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D)."}
 {"nctId": "NCT00437294", "briefTitle": "Enzastaurin in Combination of Capecitabine to Treat Breast Cancer", "officialTitle": "A Double-Blind, Randomized, Phase 2 Trial of Capecitabine Plus Enzastaurin Versus Capecitabine Plus Placebo in Patients With Metastatic or Recurrent Breast Cancer Previously Treated With an Anthracycline and a Taxane", "overallStatus": "TERMINATED", "startDate": "2007-03", "completionDate": "2009-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 86, "briefSummary": "The purpose of this study is to determine whether the combination of enzastaurin and capecitabine is more effective than the combination of placebo and capecitabine in treating participants with breast cancer who were previously treated with an anthracycline and a taxane.", "conditions": ["Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "enzastaurin", "otherNames": ["LY317615"]}, {"type": "DRUG", "name": "placebo", "otherNames": []}, {"type": "DRUG", "name": "capecitabine", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["enzastaurin", "Capecitabine"], "hasResults": true, "classifyText": "Enzastaurin in Combination of Capecitabine to Treat Breast Cancer Breast Cancer enzastaurin placebo capecitabine Breast Neoplasms enzastaurin Capecitabine The purpose of this study is to determine whether the combination of enzastaurin and capecitabine is more effective than the combination of placebo and capecitabine in treating participants with breast cancer who were previously treated with an anthracycline and a taxane."}
 {"nctId": "NCT01667900", "briefTitle": "A Study of Dulaglutide in Chinese Participants", "officialTitle": "Pharmacokinetics of a Single Dulaglutide Dose in Healthy Chinese Subjects and of Multiple Dulaglutide Doses in Chinese Patients With T2DM", "overallStatus": "COMPLETED", "startDate": "2012-08", "completionDate": "2014-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 58, "briefSummary": "This is a study of dulaglutide in Chinese participants. The purpose of the study is to determine how the body processes dulaglutide and how dulaglutide affects the body. This study has 2 parts: Part A - single dose of dulaglutide administered to healthy participants in 2 of 3 study periods. There is a minimum 28-day washout between periods. Part A will last approximately 16 weeks. Part B - multiple doses of dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM). Part B will last approximately 15 weeks.\n\nDoses of 0.5 milligrams (mg), 0.75 mg, and 1.5 mg of dulaglutide will be evaluated in this study.", "conditions": ["Diabetes Mellitus, Type 2", "Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide"], "hasResults": true, "classifyText": "A Study of Dulaglutide in Chinese Participants Diabetes Mellitus, Type 2 Healthy Volunteers Dulaglutide Placebo Diabetes Mellitus, Type 2 dulaglutide This is a study of dulaglutide in Chinese participants. The purpose of the study is to determine how the body processes dulaglutide and how dulaglutide affects the body. This study has 2 parts: Part A - single dose of dulaglutide administered to healthy participants in 2 of 3 study periods. There is a minimum 28-day washout between periods. Part A will last approximately 16 weeks. Part B - multiple doses of dulaglutide administered to participants with Type 2 diabetes mellitus (T2DM). Part B will last approximately 15 weeks.\n\nDoses of 0.5 milligrams (mg), 0.75 mg, and 1.5 mg of dulaglutide will be evaluated in this study."}
 {"nctId": "NCT06045000", "briefTitle": "Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants", "officialTitle": "A Phase 1 Study to Assess the Excretion Balance, Pharmacokinetics, and Metabolism of [14C]-DC-806 in Healthy Male Participants", "overallStatus": "COMPLETED", "startDate": "2023-09-14", "completionDate": "2023-10-02", "leadSponsor": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 8, "briefSummary": "The primary objective of this study is to investigate the rate and routes of excretion, including the mass balance, after single oral dose administration of DC-806 containing 3.7 MBq (100 \u03bcCi) of \\[14C\\]-DC-806 in urine and feces.", "conditions": ["Healthy Volunteers"], "keywords": ["DC-806", "Mass Balance"], "interventions": [{"type": "DRUG", "name": "DC-806", "otherNames": []}, {"type": "DRUG", "name": "[14C]-DC-806", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male Participants Healthy Volunteers DC-806 Mass Balance DC-806 [14C]-DC-806 The primary objective of this study is to investigate the rate and routes of excretion, including the mass balance, after single oral dose administration of DC-806 containing 3.7 MBq (100 \u03bcCi) of \\[14C\\]-DC-806 in urine and feces."}
 {"nctId": "NCT06864026", "briefTitle": "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)", "officialTitle": "A Phase 4, Prospective, Open-Label, Single-Arm Study to Assess the Effectiveness of Tirzepatide After Initiation of Ixekizumab in Adult Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice.", "overallStatus": "RECRUITING", "startDate": "2025-03-06", "completionDate": "2027-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 200, "briefSummary": "The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.\n\nThe study will last up to 12 months.", "conditions": ["Psoriatic Arthritis", "Overweight or Obesity"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}], "meshConditions": ["Arthritis, Psoriatic", "Overweight", "Obesity"], "meshInterventions": ["Tirzepatide"], "hasResults": false, "classifyText": "A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) Psoriatic Arthritis Overweight or Obesity Tirzepatide Arthritis, Psoriatic Overweight Obesity Tirzepatide The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.\n\nThe study will last up to 12 months."}
 {"nctId": "NCT00058968", "briefTitle": "A Study for the Treatment of Painful Diabetic Neuropathy", "officialTitle": "Duloxetine Versus Placebo in the Treatment of Patients With Painful Diabetic Neuropathy", "overallStatus": "COMPLETED", "startDate": "2002-10", "completionDate": "2005-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 660, "briefSummary": "The purpose of the study is to determine if duloxetine can help patients with painful diabetic neuropathy.", "conditions": ["Diabetic Neuropathy, Painful"], "keywords": ["neuropathy", "pain", "diabetes", "chronic pain", "persistent pain", "leg pain", "peripheral neuropathy", "foot pain", "painful neuropathy", "diabetic neuropathy"], "interventions": [{"type": "DRUG", "name": "Duloxetine hydrochloride", "otherNames": []}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Diabetic Neuropathies", "Pain", "Diabetes Mellitus", "Chronic Pain", "Peripheral Nervous System Diseases", "Neuropathy, Painful"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "A Study for the Treatment of Painful Diabetic Neuropathy Diabetic Neuropathy, Painful neuropathy pain diabetes chronic pain persistent pain leg pain peripheral neuropathy foot pain painful neuropathy diabetic neuropathy Duloxetine hydrochloride placebo Diabetic Neuropathies Pain Diabetes Mellitus Chronic Pain Peripheral Nervous System Diseases Neuropathy, Painful Duloxetine Hydrochloride The purpose of the study is to determine if duloxetine can help patients with painful diabetic neuropathy."}
 {"nctId": "NCT00191568", "briefTitle": "Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer", "officialTitle": "A Phase II Trial of Adjuvant Treatment With Gemcitabine and Oxaliplatin Followed by Concomitant Gemcitabine and Radiation Therapy in Patients With Resected Pancreatic Adenocarcinoma", "overallStatus": "COMPLETED", "startDate": "2002-10", "completionDate": "2007-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 45, "briefSummary": "A non-randomized phase II study to determine the efficacy and safety of the combination of Gemcitabine and Oxaliplatin followed by Gemcitabine and radiotherapy in patients with surgically resected pancreatic cancer.", "conditions": ["Pancreatic Neoplasms"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Gemcitabine", "otherNames": []}, {"type": "DRUG", "name": "Oxaliplatin", "otherNames": []}, {"type": "PROCEDURE", "name": "Radiotherapy", "otherNames": []}], "meshConditions": ["Pancreatic Neoplasms"], "meshInterventions": ["Gemcitabine", "Oxaliplatin", "Radiotherapy"], "hasResults": false, "classifyText": "Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer Pancreatic Neoplasms Gemcitabine Oxaliplatin Radiotherapy Pancreatic Neoplasms Gemcitabine Oxaliplatin Radiotherapy A non-randomized phase II study to determine the efficacy and safety of the combination of Gemcitabine and Oxaliplatin followed by Gemcitabine and radiotherapy in patients with surgically resected pancreatic cancer."}
 {"nctId": "NCT04881747", "briefTitle": "A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants", "officialTitle": "Bioequivalence of Lasmiditan Oral Disintegrating Tablet Compared to Current Immediate-Release Tablet Formulation to Support Treatment of Migraine", "overallStatus": "COMPLETED", "startDate": "2021-05-14", "completionDate": "2021-07-24", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 47, "briefSummary": "The main purpose of this study is to compare the amount of lasmiditan that gets into the blood stream and how long it takes the body to get rid of it, when given as a oral-disintegrating (OD) tablet compared to immediate-release (IR) tablet formulation. The information about any adverse effects experienced will be collected and the tolerability of lasmiditan when administered as OD tablet will also be evaluated.\n\nScreening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 5 weeks, including screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Lasmiditan", "otherNames": ["LY573144"]}], "meshConditions": [], "meshInterventions": ["lasmiditan"], "hasResults": true, "classifyText": "A Study to Compare Two Different Formulations of Lasmiditan in Healthy Participants Healthy Lasmiditan lasmiditan The main purpose of this study is to compare the amount of lasmiditan that gets into the blood stream and how long it takes the body to get rid of it, when given as a oral-disintegrating (OD) tablet compared to immediate-release (IR) tablet formulation. The information about any adverse effects experienced will be collected and the tolerability of lasmiditan when administered as OD tablet will also be evaluated.\n\nScreening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be about 5 weeks, including screening."}
 {"nctId": "NCT01965808", "briefTitle": "A Study of LY2157299 in Healthy Participants", "officialTitle": "Effect of Food on the Pharmacokinetics of LY2157299 Monohydrate in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2013-10", "completionDate": "2013-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 16, "briefSummary": "Participants in this study will receive two oral doses of 150 milligram (mg) LY2157299 taken at least 4 days apart. One dose will be given without food. One dose will be given with a high fat meal. The study will evaluate the effect of a high fat meal on how much of the drug gets into the blood stream. Side effects will be documented. This study will last approximately 15 days not including screening. Screening is required within 30 days prior to the start of the study.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2157299", "otherNames": []}], "meshConditions": [], "meshInterventions": ["LY-2157299"], "hasResults": false, "classifyText": "A Study of LY2157299 in Healthy Participants Healthy Volunteers LY2157299 LY-2157299 Participants in this study will receive two oral doses of 150 milligram (mg) LY2157299 taken at least 4 days apart. One dose will be given without food. One dose will be given with a high fat meal. The study will evaluate the effect of a high fat meal on how much of the drug gets into the blood stream. Side effects will be documented. This study will last approximately 15 days not including screening. Screening is required within 30 days prior to the start of the study."}
 {"nctId": "NCT02518113", "briefTitle": "A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL", "officialTitle": "A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients", "overallStatus": "COMPLETED", "startDate": "2015-10-01", "completionDate": "2018-01-15", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 36, "briefSummary": "The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).", "conditions": ["T-cell Acute Lymphoblastic Leukemia", "T-cell Lymphoblastic Lymphoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3039478", "otherNames": []}, {"type": "DRUG", "name": "Dexamethasone", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Precursor T-Cell Lymphoblastic Leukemia-Lymphoma"], "meshInterventions": ["crenigacestat", "Dexamethasone"], "hasResults": true, "classifyText": "A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL T-cell Acute Lymphoblastic Leukemia T-cell Lymphoblastic Lymphoma LY3039478 Dexamethasone Placebo Precursor T-Cell Lymphoblastic Leukemia-Lymphoma crenigacestat Dexamethasone The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL)."}
 {"nctId": "NCT00190723", "briefTitle": "A Study of LY317615 in Patients With Brain Tumors", "officialTitle": "A Phase II Trial of LY317615 in Patients With Recurrent High-Grade Gliomas", "overallStatus": "COMPLETED", "startDate": "2002-10", "completionDate": "2006-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 120, "briefSummary": "1. The safety of LY317615 and any side effects that might be associated with the drug.\n2. Whether LY317615, can help patients with brain tumors.", "conditions": ["Malignant Glioma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Enzastaurin", "otherNames": []}], "meshConditions": ["Glioma"], "meshInterventions": ["enzastaurin"], "hasResults": false, "classifyText": "A Study of LY317615 in Patients With Brain Tumors Malignant Glioma Enzastaurin Glioma enzastaurin 1. The safety of LY317615 and any side effects that might be associated with the drug.\n2. Whether LY317615, can help patients with brain tumors."}
 {"nctId": "NCT01237899", "briefTitle": "Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance", "officialTitle": "Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance After Multiple Oral Dosing of LY2623091 in Healthy Volunteers", "overallStatus": "COMPLETED", "startDate": "2010-10", "completionDate": "2011-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "OTHER", "enrollment": 32, "briefSummary": "The purpose of this study is to investigate the safety and tolerability of LY2623091 after multiple oral dosing in healthy men and women of non-childbearing potential. Two cohorts of 16 subjects will participate in 2 dosing periods. Treatment assignment will be double-blind for LY2623091 and placebo (negative control), and open label for eplerenone (positive control).", "conditions": ["Chronic Kidney Disease"], "keywords": ["Kidney", "Renal"], "interventions": [{"type": "DRUG", "name": "LY2623091", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Eplerenone", "otherNames": []}], "meshConditions": ["Renal Insufficiency, Chronic"], "meshInterventions": ["Eplerenone"], "hasResults": true, "classifyText": "Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance Chronic Kidney Disease Kidney Renal LY2623091 Placebo Eplerenone Renal Insufficiency, Chronic Eplerenone The purpose of this study is to investigate the safety and tolerability of LY2623091 after multiple oral dosing in healthy men and women of non-childbearing potential. Two cohorts of 16 subjects will participate in 2 dosing periods. Treatment assignment will be double-blind for LY2623091 and placebo (negative control), and open label for eplerenone (positive control)."}
 {"nctId": "NCT00129220", "briefTitle": "Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder", "officialTitle": "Placebo- and Haloperidol-Controlled Double-Blind Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder", "overallStatus": "COMPLETED", "startDate": "2005-07", "completionDate": "2009-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 224, "briefSummary": "The purpose of this study is to confirm the efficacy of olanzapine in the treatment of manic or mixed symptoms associated with bipolar I disorder.", "conditions": ["Bipolar Disorder"], "keywords": ["Manic or mixed episode associated with bipolar I disorder"], "interventions": [{"type": "DRUG", "name": "olanzapine", "otherNames": ["LY170053", "Zyprexa"]}, {"type": "DRUG", "name": "haloperidol", "otherNames": []}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Bipolar Disorder", "Mania"], "meshInterventions": ["Olanzapine", "Haloperidol"], "hasResults": true, "classifyText": "Trial of Olanzapine in Patients With Manic or Mixed Episode of Bipolar I Disorder Bipolar Disorder Manic or mixed episode associated with bipolar I disorder olanzapine haloperidol placebo Bipolar Disorder Mania Olanzapine Haloperidol The purpose of this study is to confirm the efficacy of olanzapine in the treatment of manic or mixed symptoms associated with bipolar I disorder."}
 {"nctId": "NCT00034489", "briefTitle": "A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.", "officialTitle": "A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.", "overallStatus": "COMPLETED", "startDate": null, "completionDate": null, "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": null, "briefSummary": "This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs.", "conditions": ["Breast Neoplasms"], "keywords": ["metastatic breast cancer", "combination therapy", "Alimta"], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": []}, {"type": "DRUG", "name": "gemcitabine", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Pemetrexed", "Gemcitabine"], "hasResults": false, "classifyText": "A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. Breast Neoplasms metastatic breast cancer combination therapy Alimta pemetrexed gemcitabine Breast Neoplasms Pemetrexed Gemcitabine This is a study to explore how well the combination of LY231514 and Gemcitabine work together in patients with breast cancer that has spread beyond the location of the original tumor. Patients must have previously received treatment with anthracycline and taxane chemotherapy drugs."}
 {"nctId": "NCT07241390", "briefTitle": "A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)", "officialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease", "overallStatus": "RECRUITING", "startDate": "2025-12-01", "completionDate": "2031-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 7140, "briefSummary": "The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.", "conditions": ["Atherosclerosis Cardiovascular Disease", "Chronic Kidney Disease"], "keywords": ["Heart Disease", "Kidney Disease", "Outcomes", "Stroke"], "interventions": [{"type": "DRUG", "name": "Orforglipron", "otherNames": ["LY3502970"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Renal Insufficiency, Chronic", "Heart Diseases", "Kidney Diseases", "Stroke"], "meshInterventions": ["orforglipron"], "hasResults": false, "classifyText": "A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes) Atherosclerosis Cardiovascular Disease Chronic Kidney Disease Heart Disease Kidney Disease Outcomes Stroke Orforglipron Placebo Renal Insufficiency, Chronic Heart Diseases Kidney Diseases Stroke orforglipron The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years."}
 {"nctId": "NCT05929079", "briefTitle": "A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight", "officialTitle": "A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight: A Randomized Double-Blind, Placebo-Controlled Trial", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2023-07-11", "completionDate": "2026-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1000, "briefSummary": "The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.", "conditions": ["Type 2 Diabetes", "Obesity", "Overweight", "Obstructive Sleep Apnea"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Retatrutide", "otherNames": ["LY3437943"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2", "Obesity", "Overweight", "Sleep Apnea, Obstructive"], "meshInterventions": ["retatrutide"], "hasResults": false, "classifyText": "A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight Type 2 Diabetes Obesity Overweight Obstructive Sleep Apnea Retatrutide Placebo Diabetes Mellitus, Type 2 Obesity Overweight Sleep Apnea, Obstructive retatrutide The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits."}
 {"nctId": "NCT01682135", "briefTitle": "A Study in Participants With Advanced Solid Tumors", "officialTitle": "Phase I Study of Ramucirumab in Patients With Advanced Solid Tumors", "overallStatus": "COMPLETED", "startDate": "2012-11", "completionDate": "2015-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 28, "briefSummary": "This trial is testing ramucirumab (LY3009806) administered to Chinese participants with advanced solid tumors that are resistant to standard therapy or for whom no standard therapy is available. The purpose of this study is to evaluate how safe ramucirumab is and whether it causes any side effects. The study will also measure how much ramucirumab gets into the blood stream and how long it takes the body to get rid of it.", "conditions": ["Solid Tumor"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "Ramucirumab", "otherNames": ["IMC-1121B", "LY3009806"]}], "meshConditions": [], "meshInterventions": ["Ramucirumab"], "hasResults": true, "classifyText": "A Study in Participants With Advanced Solid Tumors Solid Tumor Ramucirumab Ramucirumab This trial is testing ramucirumab (LY3009806) administered to Chinese participants with advanced solid tumors that are resistant to standard therapy or for whom no standard therapy is available. The purpose of this study is to evaluate how safe ramucirumab is and whether it causes any side effects. The study will also measure how much ramucirumab gets into the blood stream and how long it takes the body to get rid of it."}
 {"nctId": "NCT03126591", "briefTitle": "A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma", "officialTitle": "An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments", "overallStatus": "COMPLETED", "startDate": "2017-07-03", "completionDate": "2023-02-21", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Merck Sharp & Dohme LLC"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 41, "briefSummary": "The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma.", "conditions": ["Soft Tissue Sarcoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Olaratumab", "otherNames": ["LY3012207"]}, {"type": "DRUG", "name": "Pembrolizumab (KEYTRUDA\u00ae)", "otherNames": ["MK3475"]}], "meshConditions": ["Sarcoma"], "meshInterventions": ["olaratumab", "pembrolizumab"], "hasResults": true, "classifyText": "A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma Soft Tissue Sarcoma Olaratumab Pembrolizumab (KEYTRUDA\u00ae) Sarcoma olaratumab pembrolizumab The purpose of this study is to evaluate the safety of olaratumab plus pembrolizumab in participants with previously treated advanced or metastatic soft tissue sarcoma."}
 {"nctId": "NCT06603571", "briefTitle": "A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes", "officialTitle": "A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2024-09-20", "completionDate": "2026-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 350, "briefSummary": "The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.", "conditions": ["Obesity", "Overweight"], "keywords": ["Type 2 Diabetes"], "interventions": [{"type": "DRUG", "name": "LY3841136", "otherNames": []}, {"type": "DRUG", "name": "Tirzepatide", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Obesity", "Overweight", "Diabetes Mellitus, Type 2"], "meshInterventions": ["Tirzepatide"], "hasResults": false, "classifyText": "A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes Obesity Overweight Type 2 Diabetes LY3841136 Tirzepatide Placebo Obesity Overweight Diabetes Mellitus, Type 2 Tirzepatide The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks."}
 {"nctId": "NCT05882032", "briefTitle": "A Study of LY3502970 in Participants With Impaired and Normal Liver Function", "officialTitle": "A Phase 1, Multicenter, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic Impairment", "overallStatus": "COMPLETED", "startDate": "2023-06-13", "completionDate": "2024-11-18", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 29, "briefSummary": "The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of LY3502970 will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.", "conditions": ["Healthy", "Hepatic Insufficiency"], "keywords": ["LY3502970", "Pharmacokinetics Hepatic Impairment", "GLP-1 Receptor Non-peptide agonist (GLP-1 NPA)"], "interventions": [{"type": "DRUG", "name": "LY3502970", "otherNames": []}], "meshConditions": ["Hepatic Insufficiency"], "meshInterventions": ["orforglipron"], "hasResults": false, "classifyText": "A Study of LY3502970 in Participants With Impaired and Normal Liver Function Healthy Hepatic Insufficiency LY3502970 Pharmacokinetics Hepatic Impairment GLP-1 Receptor Non-peptide agonist (GLP-1 NPA) LY3502970 Hepatic Insufficiency orforglipron The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of LY3502970 will also be evaluated. The study may last up to 6 weeks for each participant including the screening period."}
 {"nctId": "NCT00191659", "briefTitle": "Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents", "officialTitle": "A Randomised, Controlled, Open-Label Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents", "overallStatus": "COMPLETED", "startDate": "2004-06", "completionDate": "2006-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 200, "briefSummary": "To test the hypothesis that children/adolescents with ADHD, who are treated with atomoxetine hydrochloride in comparison to standard current therapies have greater improvements in their quality of life.", "conditions": ["Attention Deficit Hyperactivity Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Atomoxetine Hydrochloride", "otherNames": []}], "meshConditions": ["Attention Deficit Disorder with Hyperactivity"], "meshInterventions": ["Atomoxetine Hydrochloride"], "hasResults": false, "classifyText": "Study of Broader Efficacy of Atomoxetine in the Treatment of ADHD in Children/Adolescents Attention Deficit Hyperactivity Disorder Atomoxetine Hydrochloride Attention Deficit Disorder with Hyperactivity Atomoxetine Hydrochloride To test the hypothesis that children/adolescents with ADHD, who are treated with atomoxetine hydrochloride in comparison to standard current therapies have greater improvements in their quality of life."}
 {"nctId": "NCT01807026", "briefTitle": "A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease", "officialTitle": "A Safety, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects and Patients Diagnosed With Alzheimer's Disease", "overallStatus": "COMPLETED", "startDate": "2013-03", "completionDate": "2013-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 36, "briefSummary": "This study is being done for the following reasons:\n\nTo determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF) when one dose is given to healthy participants and participants diagnosed with Alzheimer's disease. It will also look at how safe and tolerable the study drug is when given to healthy participants in higher doses.\n\nThis research study is being conducted in three groups, referred to as Groups (Cohorts) A, B, or C.\n\nGroup A will enroll participants with Alzheimer's disease while Groups B and C will enroll healthy participants.\n\nFor Group A or B, participation in this research study could last up to 34 days. For Group C, participation could last up to 60 days.", "conditions": ["Alzheimer Disease", "Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2886721", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Alzheimer Disease"], "meshInterventions": ["N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide"], "hasResults": true, "classifyText": "A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease Alzheimer Disease Healthy Volunteers LY2886721 Placebo Alzheimer Disease N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide This study is being done for the following reasons:\n\nTo determine the safety of LY2886721 and any side effects that may be associated with it and to see how much of the study drug is in the blood and the cerebrospinal fluid (CSF) when one dose is given to healthy participants and participants diagnosed with Alzheimer's disease. It will also look at how safe and tolerable the study drug is when given to healthy participants in higher doses.\n\nThis research study is being conducted in three groups, referred to as Groups (Cohorts) A, B, or C.\n\nGroup A will enroll participants with Alzheimer's disease while Groups B and C will enroll healthy participants.\n\nFor Group A or B, participation in this research study could last up to 34 days. For Group C, participation could last up to 60 days."}
 {"nctId": "NCT00636818", "briefTitle": "Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)", "officialTitle": "An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-deficit/Hyperactivity Disorder", "overallStatus": "COMPLETED", "startDate": "2008-03", "completionDate": "2008-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 45, "briefSummary": "The primary objective of this clinical study is to assess overall safety and tolerability as measured by discontinuation rate due to adverse events in doses up to 120 mg/day in relation to global clinical studies in adult subjects who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV\u2122) criteria for Attention-Deficit/Hyperactivity Disorder (ADHD).", "conditions": ["Attention Deficit Hyperactivity Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Atomoxetine", "otherNames": ["LY139603", "Strattera"]}], "meshConditions": ["Attention Deficit Disorder with Hyperactivity"], "meshInterventions": ["Atomoxetine Hydrochloride"], "hasResults": true, "classifyText": "Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD) Attention Deficit Hyperactivity Disorder Atomoxetine Attention Deficit Disorder with Hyperactivity Atomoxetine Hydrochloride The primary objective of this clinical study is to assess overall safety and tolerability as measured by discontinuation rate due to adverse events in doses up to 120 mg/day in relation to global clinical studies in adult subjects who meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV\u2122) criteria for Attention-Deficit/Hyperactivity Disorder (ADHD)."}
 {"nctId": "NCT01648582", "briefTitle": "A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus", "officialTitle": "The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea", "overallStatus": "COMPLETED", "startDate": "2012-07", "completionDate": "2014-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 774, "briefSummary": "The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral antihyperglycemic medications (OAM) (metformin and/or a sulfonylurea), in addition to any healthy lifestyle changes recommended by their healthcare providers.", "conditions": ["Type 2 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Insulin glargine", "otherNames": []}, {"type": "DRUG", "name": "Metformin", "otherNames": []}, {"type": "DRUG", "name": "Sulfonylureas", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide", "Insulin Glargine", "Metformin", "Sulfonylurea Compounds"], "hasResults": true, "classifyText": "A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus Dulaglutide Insulin glargine Metformin Sulfonylureas Diabetes Mellitus, Type 2 dulaglutide Insulin Glargine Metformin Sulfonylurea Compounds The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral antihyperglycemic medications (OAM) (metformin and/or a sulfonylurea), in addition to any healthy lifestyle changes recommended by their healthcare providers."}
 {"nctId": "NCT00363415", "briefTitle": "Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer", "officialTitle": "A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin Versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2006-08", "completionDate": "2008-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 908, "briefSummary": "This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin.", "conditions": ["Small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514", "Alimta"]}, {"type": "DRUG", "name": "etoposide", "otherNames": []}, {"type": "DRUG", "name": "carboplatin", "otherNames": []}], "meshConditions": ["Small Cell Lung Carcinoma"], "meshInterventions": ["Pemetrexed", "Etoposide", "Carboplatin"], "hasResults": true, "classifyText": "Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer Small Cell Lung Cancer pemetrexed etoposide carboplatin Small Cell Lung Carcinoma Pemetrexed Etoposide Carboplatin This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus carboplatin. It is anticipated that pemetrexed plus carboplatin will offer similar survival benefits as compared to etoposide plus carboplatin."}
 {"nctId": "NCT00969618", "briefTitle": "A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder", "officialTitle": "Long-Term, Open-Label Safety and Efficacy Study of Atomoxetine Hydrochloride in Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)", "overallStatus": "COMPLETED", "startDate": "2009-11", "completionDate": "2012-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 211, "briefSummary": "The purpose of this study is to assess long-term safety and tolerability in adult patients who have completed a previous atomoxetine study.", "conditions": ["Attention Deficit Hyperactivity Disorder"], "keywords": ["ADHD"], "interventions": [{"type": "DRUG", "name": "Atomoxetine", "otherNames": ["LY139603", "Strattera"]}], "meshConditions": ["Attention Deficit Disorder with Hyperactivity"], "meshInterventions": ["Atomoxetine Hydrochloride"], "hasResults": true, "classifyText": "A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder Attention Deficit Hyperactivity Disorder ADHD Atomoxetine Attention Deficit Disorder with Hyperactivity Atomoxetine Hydrochloride The purpose of this study is to assess long-term safety and tolerability in adult patients who have completed a previous atomoxetine study."}
 {"nctId": "NCT00190710", "briefTitle": "A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer", "officialTitle": "A Randomized Phase III Trial of Paraplatin (Carboplatin) + Gemzar Versus Gemzar Alone in Patients With Advanced Non-Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2004-03", "completionDate": "2007-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 242, "briefSummary": "To determine and compare the median survival produced by combined Gemcitabine plus Paraplatin versus Gemcitabine as a single-agent in patients with NSCLC and a PS equal to 2.", "conditions": ["Non-Small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Gemcitabine", "otherNames": []}, {"type": "DRUG", "name": "Carboplatin", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Gemcitabine", "Carboplatin"], "hasResults": false, "classifyText": "A Trial of Carboplatin and Gemcitabine Versus Gemcitabine Alone in Patients With Non-Small-Cell Lung Cancer Non-Small Cell Lung Cancer Gemcitabine Carboplatin Carcinoma, Non-Small-Cell Lung Gemcitabine Carboplatin To determine and compare the median survival produced by combined Gemcitabine plus Paraplatin versus Gemcitabine as a single-agent in patients with NSCLC and a PS equal to 2."}
 {"nctId": "NCT02117648", "briefTitle": "A Study of LY2835219 in Participants With Cancer", "officialTitle": "Effects of CYP3A Inhibition by Clarithromycin on the Pharmacokinetics of LY2835219 and Its Metabolites in Cancer Patients", "overallStatus": "COMPLETED", "startDate": "2014-04", "completionDate": "2015-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 26, "briefSummary": "The purpose of this study is to assess how the body handles Abemaciclib when it is given with another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from the body. The safety and tolerability of these drugs will be studied.\n\nEach participant will complete 2 study periods in fixed order. After screening, Period 1 will last approximately 8 days and Period 2 will last approximately 15 days. Participants who complete Period 2 may continue to receive Abemaciclib in 28-day cycles until discontinuation criteria are met.", "conditions": ["Neoplasm", "Neoplasm Metastasis"], "keywords": ["advanced cancer", "metastatic cancer"], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Clarithromycin", "otherNames": []}], "meshConditions": ["Neoplasms", "Neoplasm Metastasis"], "meshInterventions": ["abemaciclib", "Clarithromycin"], "hasResults": true, "classifyText": "A Study of LY2835219 in Participants With Cancer Neoplasm Neoplasm Metastasis advanced cancer metastatic cancer Abemaciclib Clarithromycin Neoplasms Neoplasm Metastasis abemaciclib Clarithromycin The purpose of this study is to assess how the body handles Abemaciclib when it is given with another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from the body. The safety and tolerability of these drugs will be studied.\n\nEach participant will complete 2 study periods in fixed order. After screening, Period 1 will last approximately 8 days and Period 2 will last approximately 15 days. Participants who complete Period 2 may continue to receive Abemaciclib in 28-day cycles until discontinuation criteria are met."}
 {"nctId": "NCT06516913", "briefTitle": "A Study of Subcutaneous Injection in Healthy Participants", "officialTitle": "A Randomized, Participant-Blinded Study to Investigate the Effects of Subcutaneous Injection Volume, Injection Rate, and Needle Length on Pain in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2024-07-22", "completionDate": "2024-09-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["NA"], "primaryPurpose": "DEVICE_FEASIBILITY", "enrollment": 32, "briefSummary": "This is a device feasibility study designed to evaluate the practicality of delivering a high-viscosity solution subcutaneously using various injection parameters, including volume, rate, and needle length. The goal is to assess the usability and operational performance of a delivery setup (Havard apparatus syringe pump and related components) to inform design requirements for future large-volume injection devices.\n\nNo active drug is administered in this study, and no health outcomes are being evaluated.\n\nThe study duration is approximately 40 days, including screening, injection assessments, and follow-up.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DEVICE", "name": "Harvard Apparatus syringe pump", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of Subcutaneous Injection in Healthy Participants Healthy Harvard Apparatus syringe pump This is a device feasibility study designed to evaluate the practicality of delivering a high-viscosity solution subcutaneously using various injection parameters, including volume, rate, and needle length. The goal is to assess the usability and operational performance of a delivery setup (Havard apparatus syringe pump and related components) to inform design requirements for future large-volume injection devices.\n\nNo active drug is administered in this study, and no health outcomes are being evaluated.\n\nThe study duration is approximately 40 days, including screening, injection assessments, and follow-up."}
 {"nctId": "NCT02514603", "briefTitle": "A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers", "officialTitle": "A Phase 1 Study of LY2606368 in Japanese Patients With Advanced Solid Tumors", "overallStatus": "COMPLETED", "startDate": "2015-10", "completionDate": "2017-04-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 12, "briefSummary": "The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers.", "conditions": ["Neoplasm"], "keywords": ["Neoplasm metastasis", "Checkpoint Kinase 1", "CHK1", "CHK1 inhibitor"], "interventions": [{"type": "DRUG", "name": "Prexasertib", "otherNames": ["LY2606368"]}], "meshConditions": ["Neoplasms", "Neoplasm Metastasis"], "meshInterventions": ["prexasertib"], "hasResults": false, "classifyText": "A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers Neoplasm Neoplasm metastasis Checkpoint Kinase 1 CHK1 CHK1 inhibitor Prexasertib Neoplasms Neoplasm Metastasis prexasertib The primary purpose of this study is to assess the tolerability of prexasertib in Japanese participants with advanced solid cancers."}
 {"nctId": "NCT00042666", "briefTitle": "A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.", "officialTitle": "A Phase 2 Evaluation of Oral LY317615 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "overallStatus": "COMPLETED", "startDate": "2002-06", "completionDate": "2008-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 55, "briefSummary": "This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma).", "conditions": ["Non-Hodgkin's Lymphoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY317615", "otherNames": ["enzastaurin"]}], "meshConditions": ["Lymphoma, Non-Hodgkin"], "meshInterventions": ["enzastaurin"], "hasResults": true, "classifyText": "A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas. Non-Hodgkin's Lymphoma LY317615 Lymphoma, Non-Hodgkin enzastaurin This study will measure the effectiveness and any side effects of LY317615 in participants with diffuse large B-cell lymphoma (DLBCL: a sub-type of Non-Hodgkins Lymphoma)."}
 {"nctId": "NCT03703466", "briefTitle": "A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer", "officialTitle": "An Open-Label, Randomized Phase 2 Study of the Impact of Food on Tolerability When Receiving Abemaciclib for Patients With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2018-11-28", "completionDate": "2023-03-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 72, "briefSummary": "The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food.", "conditions": ["Metastatic Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["abemaciclib"], "hasResults": true, "classifyText": "A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer Metastatic Breast Cancer Abemaciclib Breast Neoplasms abemaciclib The main purpose of this study is to examine the side effects that participants with metastatic breast cancer experience when taking abemaciclib with or without food."}
 {"nctId": "NCT05327595", "briefTitle": "A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)", "officialTitle": "A Randomized, Double-Blind, Multiple-Ascending Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3549492 in Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2022-05-09", "completionDate": "2024-04-22", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 80, "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in participants with T2DM. Blood tests will be done to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study has two parts. Each participant will enroll in only one part. The study will last either 12 or 13 weeks, depending on part.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3549492", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Atorvastatin", "otherNames": []}, {"type": "DRUG", "name": "Midazolam", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Atorvastatin", "Midazolam"], "hasResults": false, "classifyText": "A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM) Diabetes Mellitus, Type 2 LY3549492 Placebo Atorvastatin Midazolam Diabetes Mellitus, Type 2 Atorvastatin Midazolam The main purpose of this study is to evaluate the safety and tolerability of LY3549492 in participants with T2DM. Blood tests will be done to check how much LY3549492 gets into the bloodstream and how the body handles LY3549492. This study has two parts. Each participant will enroll in only one part. The study will last either 12 or 13 weeks, depending on part."}
 {"nctId": "NCT07485153", "briefTitle": "A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease", "officialTitle": "A Study to Assess the Use of the Somfit, an Ambulatory Electroencephalogram-Based Digital Health Technology, Compared With Polysomnography to Evaluate Sleep Architecture in Individuals With Asymptomatic or Early Alzheimer's Disease", "overallStatus": "NOT_YET_RECRUITING", "startDate": "2026-03", "completionDate": "2026-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "OBSERVATIONAL", "phases": [], "primaryPurpose": null, "enrollment": 35, "briefSummary": "The purpose of this study is to compare the results of two different sleep tests in Alzheimer's patients with no symptoms or early symptoms. Participants will undergo two simultaneous sleep tests (polysomnography) in a sleep laboratory for two nights and one sleep test at home for three nights. For each participant, the study will last at least a week and will last up to three months.", "conditions": ["Alzheimer's Disease", "Early Alzheimer's Disease", "Memory Problems"], "keywords": [], "interventions": [{"type": "DEVICE", "name": "Mobile EEG", "otherNames": ["Somfit"]}, {"type": "DEVICE", "name": "Activity Monitor", "otherNames": ["ActiGraph LEAP Activity Monitor"]}, {"type": "DEVICE", "name": "Sleep Study", "otherNames": ["Polysomnography"]}], "meshConditions": ["Alzheimer Disease", "Memory Disorders"], "meshInterventions": ["Fitness Trackers", "Polysomnography"], "hasResults": false, "classifyText": "A Study to Compare Two Different Sleep Tests in Participants With No Symptoms or Early Symptoms of Alzheimer's Disease Alzheimer's Disease Early Alzheimer's Disease Memory Problems Mobile EEG Activity Monitor Sleep Study Alzheimer Disease Memory Disorders Fitness Trackers Polysomnography The purpose of this study is to compare the results of two different sleep tests in Alzheimer's patients with no symptoms or early symptoms. Participants will undergo two simultaneous sleep tests (polysomnography) in a sleep laboratory for two nights and one sleep test at home for three nights. For each participant, the study will last at least a week and will last up to three months."}
 {"nctId": "NCT02307812", "briefTitle": "Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France", "officialTitle": "Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France", "overallStatus": "APPROVED_FOR_MARKETING", "startDate": null, "completionDate": null, "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "EXPANDED_ACCESS", "phases": [], "primaryPurpose": null, "enrollment": null, "briefSummary": "The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.", "conditions": ["Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Ramucirumab", "otherNames": ["IMC-1121B", "LY3009806"]}, {"type": "DRUG", "name": "Paclitaxel", "otherNames": []}], "meshConditions": ["Stomach Neoplasms"], "meshInterventions": ["Ramucirumab", "Paclitaxel"], "hasResults": false, "classifyText": "Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France Gastric Cancer Gastroesophageal Junction Adenocarcinoma Ramucirumab Paclitaxel Stomach Neoplasms Ramucirumab Paclitaxel The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU."}
 {"nctId": "NCT02304419", "briefTitle": "A Study of Galunisertib on the Immune System in Participants With Cancer", "officialTitle": "Phase 1 Study to Determine the Immunomodulatory Activity of LY2157299 Monohydrate in Patients With Solid Tumors", "overallStatus": "COMPLETED", "startDate": "2015-05", "completionDate": "2016-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 10, "briefSummary": "The main purpose of this study is to learn more about how the study drug called galunisertib affects the immune system in participants with cancer. The study treatment is expected to last about six months for each participant, not including screening or follow-up.", "conditions": ["Neoplasm"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Galunisertib", "otherNames": ["LY2157299"]}], "meshConditions": ["Neoplasms"], "meshInterventions": ["LY-2157299"], "hasResults": false, "classifyText": "A Study of Galunisertib on the Immune System in Participants With Cancer Neoplasm Galunisertib Neoplasms LY-2157299 The main purpose of this study is to learn more about how the study drug called galunisertib affects the immune system in participants with cancer. The study treatment is expected to last about six months for each participant, not including screening or follow-up."}
 {"nctId": "NCT05492201", "briefTitle": "A Study of LY3873862 in Healthy Participants", "officialTitle": "A Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3873862 in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2022-08-11", "completionDate": "2025-04-29", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 84, "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of LY3873862 when administered either in single or multiple doses in healthy participants. The study will also assess how fast LY3873862 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 58, 72, and 72 days for Part A, B, and C, respectively.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3873862", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3873862 in Healthy Participants Healthy LY3873862 Placebo The main purpose of this study is to evaluate the safety and tolerability of LY3873862 when administered either in single or multiple doses in healthy participants. The study will also assess how fast LY3873862 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 58, 72, and 72 days for Part A, B, and C, respectively."}
 {"nctId": "NCT06102512", "briefTitle": "A Study of [14C]-LOXO-783 in Healthy Adult Participants", "officialTitle": "A Phase 1, Open-label Two-part Study of the Absorption, Metabolism, Excretion, and the Absolute Bioavailability of [14C]-LOXO-783 in Healthy Adult Subjects", "overallStatus": "COMPLETED", "startDate": "2023-10-23", "completionDate": "2024-01-17", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Loxo Oncology, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 16, "briefSummary": "The main purpose of this study is to evaluate how much of the study drug, the radioactive substance 14C incorporated LOXO-783 (\\[\u00b9\u2074C\\]-LOXO-783) passes from blood into urine, feces and expired air in healthy adult participants when administered as a single dose. The study will also measure how much of the LOXO-783 and \\[\u00b9\u2074C\\]-LOXO-783 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study is conducted in two parts and will last up to approximately 72 and 61 days for part 1 and 2, respectively.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "[\u00b9\u2074C]-LOXO-783", "otherNames": ["LY3849524"]}, {"type": "DRUG", "name": "LOXO-783", "otherNames": ["LY3849524"]}, {"type": "DRUG", "name": "[\u00b9\u2074C]-LOXO-783", "otherNames": ["LY3849524"]}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of [14C]-LOXO-783 in Healthy Adult Participants Healthy [\u00b9\u2074C]-LOXO-783 LOXO-783 [\u00b9\u2074C]-LOXO-783 The main purpose of this study is to evaluate how much of the study drug, the radioactive substance 14C incorporated LOXO-783 (\\[\u00b9\u2074C\\]-LOXO-783) passes from blood into urine, feces and expired air in healthy adult participants when administered as a single dose. The study will also measure how much of the LOXO-783 and \\[\u00b9\u2074C\\]-LOXO-783 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study is conducted in two parts and will last up to approximately 72 and 61 days for part 1 and 2, respectively."}
 {"nctId": "NCT03848767", "briefTitle": "A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges", "officialTitle": "An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus During Meal Challenges", "overallStatus": "COMPLETED", "startDate": "2019-02-20", "completionDate": "2019-04-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["NA"], "primaryPurpose": "DEVICE_FEASIBILITY", "enrollment": 10, "briefSummary": "The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes. The purpose of this study is to assess the safety of the AID system during meal challenges.", "conditions": ["Type 1 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DEVICE", "name": "AID System", "otherNames": ["LY8888AU"]}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["LY275585"]}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin Lispro"], "hasResults": false, "classifyText": "A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges Type 1 Diabetes Mellitus AID System Insulin Lispro Diabetes Mellitus, Type 1 Insulin Lispro The Automated Insulin Delivery (AID) System is an investigational insulin delivery device being developed for use for participants with diabetes. The purpose of this study is to assess the safety of the AID system during meal challenges."}
 {"nctId": "NCT00190567", "briefTitle": "Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence", "officialTitle": "Biomechanical Effects of Duloxetine on Bladder Function and Sphincter Resistance During the Emptying Phase and on Urethral Function During the Filling Phase of the Micturition Cycle in Women With Pure Genuine Stress Incontinence", "overallStatus": "COMPLETED", "startDate": "2001-10", "completionDate": "2006-04", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Boehringer Ingelheim"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 50, "briefSummary": "Double-blind placebo-controlled study of the biomechanical effects of duloxetine compared with placebo in the treatment of women with pure genuine stress incontinence", "conditions": ["Urinary Stress Incontinence"], "keywords": [], "interventions": [{"type": "DRUG", "name": "duloxetine", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Urinary Incontinence, Stress"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence Urinary Stress Incontinence duloxetine Placebo Urinary Incontinence, Stress Duloxetine Hydrochloride Double-blind placebo-controlled study of the biomechanical effects of duloxetine compared with placebo in the treatment of women with pure genuine stress incontinence"}
 {"nctId": "NCT01369511", "briefTitle": "A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement", "officialTitle": "A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty", "overallStatus": "COMPLETED", "startDate": "2011-07", "completionDate": "2014-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 400, "briefSummary": "The primary objective of this study is to test the hypothesis that appendicular lean body mass (aLBM) will increase after 12 weeks of LY2495655 treatment versus placebo in older participants undergoing elective total hip arthroplasty (eTHA).", "conditions": ["Muscular Atrophy"], "keywords": ["Disuse Atrophy", "Muscle", "Strength", "Arthroplasty", "Hip", "Joint Replacement"], "interventions": [{"type": "DRUG", "name": "LY2495655", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Muscular Atrophy", "Muscular Disorders, Atrophic"], "meshInterventions": ["landogrozumab"], "hasResults": true, "classifyText": "A Study of LY2495655 in Older Participants Undergoing Elective Total Hip Replacement Muscular Atrophy Disuse Atrophy Muscle Strength Arthroplasty Hip Joint Replacement LY2495655 Placebo Muscular Atrophy Muscular Disorders, Atrophic landogrozumab The primary objective of this study is to test the hypothesis that appendicular lean body mass (aLBM) will increase after 12 weeks of LY2495655 treatment versus placebo in older participants undergoing elective total hip arthroplasty (eTHA)."}
 {"nctId": "NCT03952130", "briefTitle": "A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes", "officialTitle": "A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 1 Diabetes", "overallStatus": "COMPLETED", "startDate": "2019-05-29", "completionDate": "2022-01-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 354, "briefSummary": "The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 1 diabetes (T1D).", "conditions": ["Type 1 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY900014", "otherNames": ["Ultra-Rapid Lispro"]}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["LY275585", "Humalog"]}, {"type": "DRUG", "name": "Insulin Glargine", "otherNames": []}, {"type": "DRUG", "name": "Insulin Degludec", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin Lispro", "Insulin Glargine", "insulin degludec"], "hasResults": true, "classifyText": "A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Type 1 Diabetes Mellitus LY900014 Insulin Lispro Insulin Glargine Insulin Degludec Diabetes Mellitus, Type 1 Insulin Lispro Insulin Glargine insulin degludec The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 1 diabetes (T1D)."}
 {"nctId": "NCT07152002", "briefTitle": "A Study of LY4064912 in Healthy Participants and With Overweight or Obesity", "officialTitle": "A Phase 1, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4064912 in Healthy Participants and Participants With Overweight or Obesity", "overallStatus": "RECRUITING", "startDate": "2025-08-28", "completionDate": "2026-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 144, "briefSummary": "The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.", "conditions": ["Overweight or Obesity", "Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY4064912", "otherNames": []}, {"type": "DRUG", "name": "LY4064912", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Overweight", "Obesity"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY4064912 in Healthy Participants and With Overweight or Obesity Overweight or Obesity Healthy LY4064912 LY4064912 Placebo Placebo Overweight Obesity The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body."}
 {"nctId": "NCT05372419", "briefTitle": "A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color", "officialTitle": "An Open-Label, 24-Week Study to Investigate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color", "overallStatus": "COMPLETED", "startDate": "2023-01-12", "completionDate": "2025-02-17", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 90, "briefSummary": "The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color.", "conditions": ["Atopic Dermatitis"], "keywords": ["Eczema"], "interventions": [{"type": "DRUG", "name": "Lebrikizumab", "otherNames": ["LY3650150", "DRM06"]}], "meshConditions": ["Dermatitis, Atopic", "Eczema"], "meshInterventions": ["lebrikizumab"], "hasResults": true, "classifyText": "A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color Atopic Dermatitis Eczema Lebrikizumab Dermatitis, Atopic Eczema lebrikizumab The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atopic dermatitis (AD) and skin of color."}
 {"nctId": "NCT01263119", "briefTitle": "A Study of LY2216684 and Warfarin in Healthy Subjects", "officialTitle": "Effect of LY2216684 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2010-12", "completionDate": "2011-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 18, "briefSummary": "The purpose of this study is to determine how warfarin might affect LY2216684 and how giving LY2216684 might affect warfarin in the body. Information about any side effects that may occur will also be collected.", "conditions": ["Major Depressive Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Warfarin", "otherNames": []}, {"type": "DRUG", "name": "LY2216684", "otherNames": []}], "meshConditions": ["Depressive Disorder, Major"], "meshInterventions": ["Warfarin", "alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol"], "hasResults": true, "classifyText": "A Study of LY2216684 and Warfarin in Healthy Subjects Major Depressive Disorder Warfarin LY2216684 Depressive Disorder, Major Warfarin alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol The purpose of this study is to determine how warfarin might affect LY2216684 and how giving LY2216684 might affect warfarin in the body. Information about any side effects that may occur will also be collected."}
 {"nctId": "NCT00510211", "briefTitle": "An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.", "officialTitle": "An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.", "overallStatus": "COMPLETED", "startDate": "2007-04", "completionDate": "2009-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "OBSERVATIONAL", "phases": [], "primaryPurpose": null, "enrollment": 1131, "briefSummary": "The primary objective of this study is to assess the proportion of schizophrenic patients and the proportion of bipolar patients who discontinue olanzapine within 12 months of treatment in outpatient, ambulatory or community settings", "conditions": ["Schizophrenia", "Bipolar Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "olanzapine", "otherNames": []}], "meshConditions": ["Schizophrenia", "Bipolar Disorder"], "meshInterventions": ["Olanzapine"], "hasResults": false, "classifyText": "An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients. Schizophrenia Bipolar Disorder olanzapine Schizophrenia Bipolar Disorder Olanzapine The primary objective of this study is to assess the proportion of schizophrenic patients and the proportion of bipolar patients who discontinue olanzapine within 12 months of treatment in outpatient, ambulatory or community settings"}
 {"nctId": "NCT00071136", "briefTitle": "Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)", "officialTitle": "Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer", "overallStatus": "COMPLETED", "startDate": "2003-12", "completionDate": "2006-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 48, "briefSummary": "This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer. This treatment is for patients that have not received any prior chemotherapy treatment for lung cancer. The primary goal is to find out if the tumor gets smaller or disappears with this treatment.", "conditions": ["Lung Neoplasms"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": []}, {"type": "DRUG", "name": "gemcitabine", "otherNames": []}], "meshConditions": ["Lung Neoplasms"], "meshInterventions": ["Pemetrexed", "Gemcitabine"], "hasResults": false, "classifyText": "Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Lung Neoplasms pemetrexed gemcitabine Lung Neoplasms Pemetrexed Gemcitabine This is a Phase 2 study of pemetrexed and gemcitabine chemotherapy given once every 14 days to patients with advanced stage non-small cell lung cancer. This treatment is for patients that have not received any prior chemotherapy treatment for lung cancer. The primary goal is to find out if the tumor gets smaller or disappears with this treatment."}
 {"nctId": "NCT00326911", "briefTitle": "Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer", "officialTitle": "A Phase II, Randomized, Open-Label Study of Cetuximab and Bevacizumab Alone or in Combination With Fixed-Dose Rate Gemcitabine as First-Line Therapy of Patients With Metastatic Adenocarcinoma of the Pancreas", "overallStatus": "TERMINATED", "startDate": "2006-05", "completionDate": "2008-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 61, "briefSummary": "Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine", "conditions": ["Metastatic Pancreatic Cancer"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "cetuximab", "otherNames": ["Erbitux\u00ae"]}, {"type": "BIOLOGICAL", "name": "bevacizumab", "otherNames": ["Avastin\u00ae"]}, {"type": "DRUG", "name": "gemcitabine", "otherNames": ["Gemzar\u00ae"]}, {"type": "BIOLOGICAL", "name": "cetuximab", "otherNames": ["Erbitux\u00ae"]}], "meshConditions": ["Pancreatic Neoplasms"], "meshInterventions": ["Cetuximab", "Bevacizumab", "Gemcitabine"], "hasResults": true, "classifyText": "Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer Metastatic Pancreatic Cancer cetuximab bevacizumab gemcitabine cetuximab Pancreatic Neoplasms Cetuximab Bevacizumab Gemcitabine Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine"}
 {"nctId": "NCT00447057", "briefTitle": "Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)", "officialTitle": "A Phase 2 Study of Pemetrexed Versus Pemetrexed Plus Erlotinib in Second-Line Treatment in Patients With Nonsquamous NSCLC", "overallStatus": "COMPLETED", "startDate": "2007-03", "completionDate": "2011-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "PREVENTION", "enrollment": 204, "briefSummary": "This is a multicenter, randomized, Phase 2, open label, parallel trial to evaluate an effect of pemetrexed alone on nonsquamous non-small cell lung cancer (NSCLC) in a second-line setting (such as progression-free survival \\[PFS\\], disease control rate, best response rate, time to treatment failure \\[TTTF\\], overall survival \\[OS\\] and 1-year survival rates) compared to pemetrexed plus erlotinib combination.", "conditions": ["Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy."], "keywords": ["nonsquamous"], "interventions": [{"type": "DRUG", "name": "Pemetrexed", "otherNames": ["LY231514", "Alimta"]}, {"type": "DRUG", "name": "Erlotinib", "otherNames": ["Tarceva"]}, {"type": "DRUG", "name": "Pemetrexed", "otherNames": ["LY231514", "Alimta"]}, {"type": "DRUG", "name": "Erlotinib", "otherNames": ["Tarceva"]}], "meshConditions": [], "meshInterventions": ["Pemetrexed", "Erlotinib Hydrochloride"], "hasResults": true, "classifyText": "Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. nonsquamous Pemetrexed Erlotinib Pemetrexed Erlotinib Pemetrexed Erlotinib Hydrochloride This is a multicenter, randomized, Phase 2, open label, parallel trial to evaluate an effect of pemetrexed alone on nonsquamous non-small cell lung cancer (NSCLC) in a second-line setting (such as progression-free survival \\[PFS\\], disease control rate, best response rate, time to treatment failure \\[TTTF\\], overall survival \\[OS\\] and 1-year survival rates) compared to pemetrexed plus erlotinib combination."}
 {"nctId": "NCT01676701", "briefTitle": "Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)", "officialTitle": "Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate", "overallStatus": "TERMINATED", "startDate": "2012-09", "completionDate": "2013-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 8, "briefSummary": "The purpose of this study is to evaluate the serum concentration of tabalumab after the administration using either prefilled syringe or auto-injector after the initial loading dose and after 12 weeks of treatment. Treatment period is followed by 40 weeks optional safety extension.", "conditions": ["Rheumatoid Arthritis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tabalumab Auto-Injector", "otherNames": ["LY2127399"]}, {"type": "DRUG", "name": "Tabalumab Prefilled Syringe", "otherNames": ["LY2127399"]}], "meshConditions": ["Arthritis, Rheumatoid"], "meshInterventions": ["tabalumab"], "hasResults": true, "classifyText": "Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA) Rheumatoid Arthritis Tabalumab Auto-Injector Tabalumab Prefilled Syringe Arthritis, Rheumatoid tabalumab The purpose of this study is to evaluate the serum concentration of tabalumab after the administration using either prefilled syringe or auto-injector after the initial loading dose and after 12 weeks of treatment. Treatment period is followed by 40 weeks optional safety extension."}
 {"nctId": "NCT00381732", "briefTitle": "A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction", "officialTitle": "A Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tadalafil (2.5mg and 5mg) Administered Once Daily to Men With Erectile Dysfunction", "overallStatus": "COMPLETED", "startDate": "2003-10", "completionDate": "2006-06", "leadSponsor": "Eli Lilly and Company", "collaborators": ["ICOS Corporation"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 280, "briefSummary": "This is a multicenter, randomized, double blind, placebo-controlled, parallel design study to evaluate the efficacy and safety of 2.5mg and 5mg tadalafil taken once daily in men with erectile dysfunction.", "conditions": ["Erectile Dysfunction"], "keywords": ["Impotence", "erectile dysfunction"], "interventions": [{"type": "DRUG", "name": "tadalafil", "otherNames": ["LY450190", "Cialis", "IC351"]}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Erectile Dysfunction"], "meshInterventions": ["Tadalafil"], "hasResults": false, "classifyText": "A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction Erectile Dysfunction Impotence erectile dysfunction tadalafil placebo Erectile Dysfunction Tadalafil This is a multicenter, randomized, double blind, placebo-controlled, parallel design study to evaluate the efficacy and safety of 2.5mg and 5mg tadalafil taken once daily in men with erectile dysfunction."}
 {"nctId": "NCT00190593", "briefTitle": "Raloxifene Use for The Heart", "officialTitle": "Raloxifene Hydrochloride or Placebo in Postmenopausal Women at Risk for Major Coronary Events", "overallStatus": "COMPLETED", "startDate": "1998-06", "completionDate": "2005-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "PREVENTION", "enrollment": 10000, "briefSummary": "The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events.", "conditions": ["Cardiovascular Diseases", "Breast Neoplasms"], "keywords": [], "interventions": [{"type": "DRUG", "name": "raloxifene", "otherNames": []}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Cardiovascular Diseases", "Breast Neoplasms"], "meshInterventions": ["Raloxifene Hydrochloride"], "hasResults": false, "classifyText": "Raloxifene Use for The Heart Cardiovascular Diseases Breast Neoplasms raloxifene placebo Cardiovascular Diseases Breast Neoplasms Raloxifene Hydrochloride The purpose of this study is to determine whether raloxifene compared with placebo lowers the risk of coronary events and reduces the risk of invasive breast cancer in postmenopausal women at risk for major coronary events."}
 {"nctId": "NCT00447421", "briefTitle": "A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy", "officialTitle": "Phase I/II Study of Concurrent Cisplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer", "overallStatus": "TERMINATED", "startDate": "2007-02", "completionDate": "2008-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 9, "briefSummary": "The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer.", "conditions": ["Small Cell Lung Cancer", "Carcinoma, Small Cell", "SCLC"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514", "Alimta"]}, {"type": "DRUG", "name": "cisplatin", "otherNames": []}, {"type": "RADIATION", "name": "radiation", "otherNames": []}], "meshConditions": ["Small Cell Lung Carcinoma", "Carcinoma, Small Cell"], "meshInterventions": ["Pemetrexed", "Cisplatin", "Radiation"], "hasResults": true, "classifyText": "A Study to Treat Small Cell Lung Cancer With a Combination of Cisplatin, Pemetrexed, and Radiotherapy Small Cell Lung Cancer Carcinoma, Small Cell SCLC pemetrexed cisplatin radiation Small Cell Lung Carcinoma Carcinoma, Small Cell Pemetrexed Cisplatin Radiation The purpose of this study is to determine the recommended dose of pemetrexed, cisplatin and radiotherapy in the treatment of patients with Small Cell Lung Cancer."}
 {"nctId": "NCT04294147", "briefTitle": "A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist", "officialTitle": "A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist", "overallStatus": "COMPLETED", "startDate": "2020-10-06", "completionDate": "2021-03-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 65, "briefSummary": "The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill\u2122) in adult participants with migraine who are taking a monoclonal antibody (mAb) calcitonin gene-related peptide (CGRP) antagonist called galcanezumab or erenumab.", "conditions": ["Migraine"], "keywords": ["prevention", "prophylaxis", "headache"], "interventions": [{"type": "DRUG", "name": "Galcanezumab", "otherNames": ["LY2951742"]}, {"type": "DRUG", "name": "Erenumab", "otherNames": []}], "meshConditions": ["Migraine Disorders", "Headache"], "meshInterventions": ["galcanezumab", "erenumab"], "hasResults": true, "classifyText": "A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist Migraine prevention prophylaxis headache Galcanezumab Erenumab Migraine Disorders Headache galcanezumab erenumab The purpose of this study is to measure the gastrointestinal emptying time using the wireless motility capsule (WMC) technology (FDA approved SmartPill\u2122) in adult participants with migraine who are taking a monoclonal antibody (mAb) calcitonin gene-related peptide (CGRP) antagonist called galcanezumab or erenumab."}
 {"nctId": "NCT04184622", "briefTitle": "A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight", "officialTitle": "Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)", "overallStatus": "COMPLETED", "startDate": "2019-12-04", "completionDate": "2024-07-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 2539, "briefSummary": "This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.", "conditions": ["Overweight", "Obesity"], "keywords": ["Metabolism and Nutrition Disorder", "Prediabetes"], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Overweight", "Obesity", "Nutrition Disorders", "Prediabetic State"], "meshInterventions": ["Tirzepatide"], "hasResults": true, "classifyText": "A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight Overweight Obesity Metabolism and Nutrition Disorder Prediabetes Tirzepatide Placebo Overweight Obesity Nutrition Disorders Prediabetic State Tirzepatide This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years."}
 {"nctId": "NCT04165031", "briefTitle": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation", "officialTitle": "A Phase 1/2 Study of LY3499446 Administered to Patients With Advanced Solid Tumors With KRAS G12C Mutation", "overallStatus": "TERMINATED", "startDate": "2019-11-28", "completionDate": "2020-10-30", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 5, "briefSummary": "The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation.", "conditions": ["Advanced Solid Tumor", "Non-Small Cell Lung Cancer", "Colorectal Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3499446", "otherNames": []}, {"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Cetuximab", "otherNames": []}, {"type": "DRUG", "name": "Erlotinib", "otherNames": []}, {"type": "DRUG", "name": "Docetaxel", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Colorectal Neoplasms"], "meshInterventions": ["abemaciclib", "Cetuximab", "Erlotinib Hydrochloride", "Docetaxel"], "hasResults": true, "classifyText": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation Advanced Solid Tumor Non-Small Cell Lung Cancer Colorectal Cancer LY3499446 Abemaciclib Cetuximab Erlotinib Docetaxel Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms abemaciclib Cetuximab Erlotinib Hydrochloride Docetaxel The reason for this study is to see if the study drug LY3499446 is safe and effective in participants with solid tumors with KRAS G12C mutation."}
 {"nctId": "NCT01175824", "briefTitle": "Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies", "officialTitle": "Comparison of Twice-Daily Insulin Lispro Low Mixture Versus Once-Daily Basal Insulin Glargine and Once-Daily Prandial Insulin Lispro as Insulin Intensification Strategies in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine and Metformin and/or Pioglitazone", "overallStatus": "COMPLETED", "startDate": "2011-04", "completionDate": "2012-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 478, "briefSummary": "The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Metabolic Diseases", "Diabetes Mellitus, Type 2", "Glargine", "Diabetes Mellitus", "Insulin LISPRO", "Insulin"], "interventions": [{"type": "DRUG", "name": "Insulin Lispro Low Mixture (LM)", "otherNames": ["Humalog Mix75/25 (75% insulin lispro protamine suspension and 25% insulin lispro injection)"]}, {"type": "DRUG", "name": "Insulin Glargine", "otherNames": []}, {"type": "DRUG", "name": "Prandial Insulin Lispro", "otherNames": ["Humalog", "LY275585"]}], "meshConditions": ["Diabetes Mellitus, Type 2", "Metabolic Diseases", "Diabetes Mellitus", "Insulin Resistance"], "meshInterventions": ["Insulin Lispro", "Insulin Glargine"], "hasResults": true, "classifyText": "Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies Diabetes Mellitus, Type 2 Metabolic Diseases Diabetes Mellitus, Type 2 Glargine Diabetes Mellitus Insulin LISPRO Insulin Insulin Lispro Low Mixture (LM) Insulin Glargine Prandial Insulin Lispro Diabetes Mellitus, Type 2 Metabolic Diseases Diabetes Mellitus Insulin Resistance Insulin Lispro Insulin Glargine The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes."}
 {"nctId": "NCT00421083", "briefTitle": "Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess Efficacy and Safety of Tadalafil (LY450190) in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury", "overallStatus": "COMPLETED", "startDate": "2004-09", "completionDate": "2005-06", "leadSponsor": "Eli Lilly and Company", "collaborators": ["ICOS Corporation"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 180, "briefSummary": "This is a study of the efficacy and safety of on-demand dosing of tadalafil or placebo administered for 12 weeks to men with erectile dysfunction caused by spinal cord injury.", "conditions": ["Erectile Dysfunction", "Spinal Cord Injuries"], "keywords": ["Erectile dysfunction as a result of traumatic spinal cord injury"], "interventions": [{"type": "DRUG", "name": "tadalafil", "otherNames": ["LY450190", "Cialis", "IC351"]}], "meshConditions": ["Erectile Dysfunction", "Spinal Cord Injuries"], "meshInterventions": ["Tadalafil"], "hasResults": false, "classifyText": "Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury Erectile Dysfunction Spinal Cord Injuries Erectile dysfunction as a result of traumatic spinal cord injury tadalafil Erectile Dysfunction Spinal Cord Injuries Tadalafil This is a study of the efficacy and safety of on-demand dosing of tadalafil or placebo administered for 12 weeks to men with erectile dysfunction caused by spinal cord injury."}
 {"nctId": "NCT04768842", "briefTitle": "A Study of Two Different Formulations of LY3209590 in Healthy Participants", "officialTitle": "Comparative Pharmacokinetics of LY3209590 After Administration of a Lyophilized Formulation and a Solution Formulation in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2021-03-03", "completionDate": "2021-09-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 50, "briefSummary": "The main purpose of this study is to look at the amount of the study drug, LY3209590, that gets into the blood stream and how long it takes the body to get rid of LY3209590 when given as different formulations. The tolerability of LY3209590 will also be evaluated and information about any side effects experienced will be collected. The study will last up to 142 days.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3209590", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of Two Different Formulations of LY3209590 in Healthy Participants Healthy LY3209590 The main purpose of this study is to look at the amount of the study drug, LY3209590, that gets into the blood stream and how long it takes the body to get rid of LY3209590 when given as different formulations. The tolerability of LY3209590 will also be evaluated and information about any side effects experienced will be collected. The study will last up to 142 days."}
 {"nctId": "NCT01250873", "briefTitle": "A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline", "officialTitle": "LY2216684 and Sertraline Pharmacokinetic Interaction Study in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2010-11", "completionDate": "2011-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 20, "briefSummary": "LY2216684 is being studied as adjunctive treatment for major depressive disorder (MDD) in participants who are partial responders to selective serotonin reuptake inhibitors (SSRIs). Sertraline is a medication that is widely used to treat MDD and is a known substrate of cytochrome P450s (CYP450s), including CYP450 2D6 (CYP2D6), CYP450 2C19 (CYP2C19), CYPP450 3A4 (CYP3A4), and a modest inhibitor of CYP2D6. Based on the diversity of hepatic metabolic clearance pathways for LY2216684 and its elimination by the kidney, it is expected that CYP2D6 inhibition by sertraline will not result in a substantial change in the pharmacokinetic (PK) profile of LY2216684. LY2216684 is only known to be a moderate inhibitor of CYP2C19, so it is unlikely that coadministration of sertraline with LY2216684 will result in a clinically meaningful change in the PK of sertraline. This study is being conducted to test these hypotheses.", "conditions": ["Major Depressive Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2216684", "otherNames": []}, {"type": "DRUG", "name": "Sertraline", "otherNames": []}], "meshConditions": ["Depressive Disorder, Major"], "meshInterventions": ["alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol", "Sertraline"], "hasResults": true, "classifyText": "A Pharmacokinetic Study of the Coadministration of LY2216684 With Sertraline Major Depressive Disorder LY2216684 Sertraline Depressive Disorder, Major alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol Sertraline LY2216684 is being studied as adjunctive treatment for major depressive disorder (MDD) in participants who are partial responders to selective serotonin reuptake inhibitors (SSRIs). Sertraline is a medication that is widely used to treat MDD and is a known substrate of cytochrome P450s (CYP450s), including CYP450 2D6 (CYP2D6), CYP450 2C19 (CYP2C19), CYPP450 3A4 (CYP3A4), and a modest inhibitor of CYP2D6. Based on the diversity of hepatic metabolic clearance pathways for LY2216684 and its elimination by the kidney, it is expected that CYP2D6 inhibition by sertraline will not result in a substantial change in the pharmacokinetic (PK) profile of LY2216684. LY2216684 is only known to be a moderate inhibitor of CYP2C19, so it is unlikely that coadministration of sertraline with LY2216684 will result in a clinically meaningful change in the PK of sertraline. This study is being conducted to test these hypotheses."}
 {"nctId": "NCT00790790", "briefTitle": "A Study in the Treatment of Osteoarthritis Knee Pain", "officialTitle": "A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the Treatment of Subjects With Osteoarthritis Knee Pain", "overallStatus": "COMPLETED", "startDate": "2008-11", "completionDate": "2010-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 147, "briefSummary": "To gather data on whether a new drug for osteoarthritis knee pain will be safe and have an effect on pain levels.", "conditions": ["Osteoarthritis Knee Pain"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "LY545694 49 mg", "otherNames": []}, {"type": "DRUG", "name": "LY545694 105 mg", "otherNames": []}], "meshConditions": [], "meshInterventions": ["dasolampanel etibutil"], "hasResults": true, "classifyText": "A Study in the Treatment of Osteoarthritis Knee Pain Osteoarthritis Knee Pain Placebo LY545694 49 mg LY545694 105 mg dasolampanel etibutil To gather data on whether a new drug for osteoarthritis knee pain will be safe and have an effect on pain levels."}
 {"nctId": "NCT01606397", "briefTitle": "A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes", "officialTitle": "The Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Doses of LY2409021 in Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2008-03", "completionDate": "2008-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 50, "briefSummary": "The study drug LY2409021 is being evaluated as a possible treatment for diabetes. The primary purpose of this study is to help answer the following research questions, and not to provide treatment for diabetes :\n\n* The safety of LY2409021 and any side effects that might be associated with it following 4 weeks of doses\n* How long it takes the body to absorb and remove LY2409021 following dosing over 4 weeks\n* How daily dosing of LY2409021 affects blood levels of sugar (glucose), insulin and other naturally occurring substances before and after a meal\n* How LY2409021 works when given with metformin\n* How daily dosing of LY2409021 affects the cells that produce insulin", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "LY2409021", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["adomeglivant"], "hasResults": false, "classifyText": "A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 Diabetes Diabetes Mellitus, Type 2 Placebo LY2409021 Diabetes Mellitus, Type 2 adomeglivant The study drug LY2409021 is being evaluated as a possible treatment for diabetes. The primary purpose of this study is to help answer the following research questions, and not to provide treatment for diabetes :\n\n* The safety of LY2409021 and any side effects that might be associated with it following 4 weeks of doses\n* How long it takes the body to absorb and remove LY2409021 following dosing over 4 weeks\n* How daily dosing of LY2409021 affects blood levels of sugar (glucose), insulin and other naturally occurring substances before and after a meal\n* How LY2409021 works when given with metformin\n* How daily dosing of LY2409021 affects the cells that produce insulin"}
 {"nctId": "NCT06876662", "briefTitle": "A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma", "officialTitle": "Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma", "overallStatus": "RECRUITING", "startDate": "2025-05-20", "completionDate": "2032-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 279, "briefSummary": "Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.", "conditions": ["Chronic Lymphocytic Leukemia", "Non-Hodgkin Lymphoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pirtobrutinib", "otherNames": ["LOXO-305", "LY3527727"]}], "meshConditions": ["Leukemia, Lymphocytic, Chronic, B-Cell", "Lymphoma, Non-Hodgkin"], "meshInterventions": ["pirtobrutinib"], "hasResults": false, "classifyText": "A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma Pirtobrutinib Leukemia, Lymphocytic, Chronic, B-Cell Lymphoma, Non-Hodgkin pirtobrutinib Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib."}
 {"nctId": "NCT06937086", "briefTitle": "Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study", "officialTitle": "A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight", "overallStatus": "RECRUITING", "startDate": "2025-06-26", "completionDate": "2028-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 350, "briefSummary": "The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.\n\nParticipation in this study will last up to 61 weeks, including 52 weeks of treatment.", "conditions": ["Ulcerative Colitis", "Obesity or Overweight"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Mirikizumab", "otherNames": ["LY3074828"]}, {"type": "DRUG", "name": "Mirikizumab", "otherNames": ["LY3074828"]}, {"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Colitis, Ulcerative", "Obesity", "Overweight"], "meshInterventions": ["mirikizumab", "Tirzepatide"], "hasResults": false, "classifyText": "Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study Ulcerative Colitis Obesity or Overweight Mirikizumab Mirikizumab Tirzepatide Placebo Colitis, Ulcerative Obesity Overweight mirikizumab Tirzepatide The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight.\n\nParticipation in this study will last up to 61 weeks, including 52 weeks of treatment."}
 {"nctId": "NCT02377752", "briefTitle": "A Study of Olaratumab in Japanese Participants With Advanced Cancer", "officialTitle": "A Phase 1 Study of Olaratumab in Japanese Patients With Advanced Soft Tissue Sarcoma or Advanced Solid Tumors", "overallStatus": "COMPLETED", "startDate": "2015-03-23", "completionDate": "2020-01-14", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 25, "briefSummary": "This study consists of 2 parts (Part A and Part B). The main purpose of Part A is to evaluate safety and side effects of olaratumab in combination with doxorubicin in Japanese participants with a group of rare cancers (advanced solid tumors, especially advanced soft tissue sarcoma \\[STS\\].) The main purpose of Part B is to evaluate how much olaratumab gets into the blood stream of Japanese participants with advanced solid tumors and how long it takes the body to get rid of it.", "conditions": ["Neoplasm"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "Olaratumab", "otherNames": ["LY3012207", "IMC-3G3"]}, {"type": "DRUG", "name": "Doxorubicin", "otherNames": []}], "meshConditions": ["Neoplasms"], "meshInterventions": ["olaratumab", "Doxorubicin"], "hasResults": true, "classifyText": "A Study of Olaratumab in Japanese Participants With Advanced Cancer Neoplasm Olaratumab Doxorubicin Neoplasms olaratumab Doxorubicin This study consists of 2 parts (Part A and Part B). The main purpose of Part A is to evaluate safety and side effects of olaratumab in combination with doxorubicin in Japanese participants with a group of rare cancers (advanced solid tumors, especially advanced soft tissue sarcoma \\[STS\\].) The main purpose of Part B is to evaluate how much olaratumab gets into the blood stream of Japanese participants with advanced solid tumors and how long it takes the body to get rid of it."}
 {"nctId": "NCT00191191", "briefTitle": "To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC)", "officialTitle": "LY231514 500 mg/m2 and LY231514 1000 mg/m2 in Patients With Advanced Non-Small Cell Lung Cancer Who Were Previously Treated With Prior Systemic Anti Cancer Therapy: A Randomized Phase II Trial", "overallStatus": "COMPLETED", "startDate": "2004-10", "completionDate": "2008-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 226, "briefSummary": "To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC).", "conditions": ["Non-small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pemetrexed 500 mg/m2", "otherNames": ["Alimta", "LY231514"]}, {"type": "DRUG", "name": "Pemetrexed 1000 mg/m2", "otherNames": ["Alimta", "LY231514"]}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Pemetrexed"], "hasResults": true, "classifyText": "To Investigate Efficacy and Safety of Pemetrexed as Second or Third Line Therapy in Patients With Non-small Cell Lung Cancer (NSCLC) Non-small Cell Lung Cancer Pemetrexed 500 mg/m2 Pemetrexed 1000 mg/m2 Carcinoma, Non-Small-Cell Lung Pemetrexed To investigate efficacy and safety of pemetrexed as second or third line therapy in patients with non-small cell lung cancer (NSCLC)."}
 {"nctId": "NCT01846702", "briefTitle": "A Study of LY3084077 in Healthy Participants", "officialTitle": "A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3084077 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2013-05", "completionDate": "2013-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 43, "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3084077 in healthy participants. The study will also investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The study is expected to last approximately 8 weeks for each participant.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "LY3084077", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": true, "classifyText": "A Study of LY3084077 in Healthy Participants Healthy Volunteers Placebo LY3084077 The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3084077 in healthy participants. The study will also investigate how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. Information about any side effects that may occur will also be collected. The study is expected to last approximately 8 weeks for each participant."}
 {"nctId": "NCT00191945", "briefTitle": "Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)", "officialTitle": "A Randomized Double-Blind, Placebo-Controlled Clinical Trial of Efficacy and Safety of Atomoxetine up to 12 Weeks in Newly Diagnosed Children and Adolescents Outpatients With Attention-Deficit/Hyperactivity Disorder", "overallStatus": "COMPLETED", "startDate": "2005-05", "completionDate": "2008-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 151, "briefSummary": "Double blinded clinical trial placebo controlled in 153 children (planned enrollment) with recent diagnosis of ADHD. Patients will be randomized to atomoxetine or placebo arm (2:1). The double blinded period will last 12 weeks and the treatment open phase will last up to 1 year, and atomoxetine treatment will be administered.\n\nA gatekeeper strategy will be employed for sequentially testing the secondary objectives.", "conditions": ["Attention Deficit Hyperactivity Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Atomoxetine Hydrochloride", "otherNames": ["LY139603", "Strattera"]}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Attention Deficit Disorder with Hyperactivity"], "meshInterventions": ["Atomoxetine Hydrochloride"], "hasResults": true, "classifyText": "Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) Attention Deficit Hyperactivity Disorder Atomoxetine Hydrochloride placebo Attention Deficit Disorder with Hyperactivity Atomoxetine Hydrochloride Double blinded clinical trial placebo controlled in 153 children (planned enrollment) with recent diagnosis of ADHD. Patients will be randomized to atomoxetine or placebo arm (2:1). The double blinded period will last 12 weeks and the treatment open phase will last up to 1 year, and atomoxetine treatment will be administered.\n\nA gatekeeper strategy will be employed for sequentially testing the secondary objectives."}
 {"nctId": "NCT04591626", "briefTitle": "A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes", "officialTitle": "A Randomized, Double-Blind Trial Comparing the Effect of the Addition of Dulaglutide 1.5 mg Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Patients With Type 2 Diabetes", "overallStatus": "COMPLETED", "startDate": "2020-12-07", "completionDate": "2022-04-28", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 291, "briefSummary": "The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus.", "conditions": ["Type 2 Diabetes Mellitus"], "keywords": ["T2DM", "LY2189265"], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Insulin Glargine", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide", "Insulin Glargine"], "hasResults": true, "classifyText": "A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes Type 2 Diabetes Mellitus T2DM LY2189265 Dulaglutide Placebo Insulin Glargine Diabetes Mellitus, Type 2 dulaglutide Insulin Glargine The main purpose of this study is to evaluate the safety and efficacy of once weekly dulaglutide when added to insulin glargine, with metformin and/or acarbose in Chinese participants with type 2 diabetes mellitus."}
 {"nctId": "NCT00266643", "briefTitle": "Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain", "officialTitle": "A Comparison of Strategies for Switching Patients From Amitriptyline to Duloxetine for the Management of Diabetic Peripheral Neuropathic Pain", "overallStatus": "COMPLETED", "startDate": "2005-12", "completionDate": "2007-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 205, "briefSummary": "This study is to compare the tolerability of different methods for switching from another medication to duloxetine for the management of diabetic nerve pain. The primary objective is to compare the most gradual method with the most abrupt method, to see if they have different tolerability.", "conditions": ["Diabetic Neuropathy, Painful"], "keywords": [], "interventions": [{"type": "DRUG", "name": "duloxetine hydrochloride", "otherNames": []}], "meshConditions": ["Diabetic Neuropathies"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Tolerability of Switching to Duloxetine for the Management of Diabetic Nerve Pain Diabetic Neuropathy, Painful duloxetine hydrochloride Diabetic Neuropathies Duloxetine Hydrochloride This study is to compare the tolerability of different methods for switching from another medication to duloxetine for the management of diabetic nerve pain. The primary objective is to compare the most gradual method with the most abrupt method, to see if they have different tolerability."}
 {"nctId": "NCT00320489", "briefTitle": "Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia", "officialTitle": "A Randomized, Open-label Study Comparing the Effects of Olanzapine Pamoate Depot With Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia", "overallStatus": "COMPLETED", "startDate": "2006-04", "completionDate": "2009-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 524, "briefSummary": "To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine.", "conditions": ["Schizophrenia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "olanzapine", "otherNames": ["LY170053", "Zyprexa"]}, {"type": "DRUG", "name": "olanzapine pamoate depot", "otherNames": []}], "meshConditions": ["Schizophrenia"], "meshInterventions": ["Olanzapine"], "hasResults": true, "classifyText": "Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia Schizophrenia olanzapine olanzapine pamoate depot Schizophrenia Olanzapine To compare the health outcome of patients with schizophrenia, who are at risk for relapse, when treated with a long acting injection form of olanzapine versus treatment with oral olanzapine."}
 {"nctId": "NCT00191490", "briefTitle": "A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer", "officialTitle": "A Multicenter Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel (RP56976, TAXOTERE *) and Gemcitabine and of Cisplatin/Gemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2002-07", "completionDate": "2005-05", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Aventis Pharmaceuticals"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 162, "briefSummary": "Phase II study that will evaluate the activity of gemcitabine as intravesical therapy on the marker lesion in superficial bladder carcinoma at intermediate risk. Primary objective is the evaluation of the pathological complete response after 8 instillation of gemcitabine. 46 patients are requested.", "conditions": ["Carcinoma, Non-Small-Cell Lung"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Gemcitabine", "otherNames": []}, {"type": "DRUG", "name": "docetaxel", "otherNames": []}, {"type": "DRUG", "name": "cisplatin", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Gemcitabine", "Docetaxel", "Cisplatin"], "hasResults": false, "classifyText": "A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Gemcitabine docetaxel cisplatin Carcinoma, Non-Small-Cell Lung Gemcitabine Docetaxel Cisplatin Phase II study that will evaluate the activity of gemcitabine as intravesical therapy on the marker lesion in superficial bladder carcinoma at intermediate risk. Primary objective is the evaluation of the pathological complete response after 8 instillation of gemcitabine. 46 patients are requested."}
 {"nctId": "NCT05609825", "briefTitle": "A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia", "officialTitle": "A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia", "overallStatus": "TERMINATED", "startDate": "2022-11-14", "completionDate": "2024-01-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 41, "briefSummary": "The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either LY3875383 or placebo.The study will be conducted in four parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening.", "conditions": ["Hypertriglyceridemia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3875383", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Hypertriglyceridemia"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3875383 in Healthy Participants and Participants With Hypertriglyceridemia Hypertriglyceridemia LY3875383 Placebo Hypertriglyceridemia The main purpose of this study is to determine the tolerability and side effects related to LY3875383 given as a single injection under the skin to healthy participants and participants with elevated triglyceride (TG) levels.The study will also assess how fast LY3875383 gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either LY3875383 or placebo.The study will be conducted in four parts (A, B, C and D) and may last up to approximately 28 to 56 weeks including screening."}
 {"nctId": "NCT06190691", "briefTitle": "Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants", "officialTitle": "An Open-label, Nonrandomized, Single-dose, Parallel-group, Safety, Tolerance, and Pharmacokinetic Study of LOXO-305 Administered to Fasted Hepatically Impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2020-12-18", "completionDate": "2021-12-30", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Loxo Oncology, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 36, "briefSummary": "The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired liver function and healthy participants. The side effects and tolerability of pirtobrutinib will also be evaluated. Participation could last about 46 days.", "conditions": ["Healthy", "Hepatic Insufficiency"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pirtobrutinib", "otherNames": ["LOXO-305, LY3527727"]}], "meshConditions": ["Hepatic Insufficiency"], "meshInterventions": ["pirtobrutinib"], "hasResults": true, "classifyText": "Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants Healthy Hepatic Insufficiency Pirtobrutinib Hepatic Insufficiency pirtobrutinib The main purpose of this study is to measure how much of pirtobrutinib (LOXO-305) gets into the bloodstream and how long it takes the body to eliminate it in participants with impaired liver function and healthy participants. The side effects and tolerability of pirtobrutinib will also be evaluated. Participation could last about 46 days."}
 {"nctId": "NCT00316225", "briefTitle": "Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen", "officialTitle": "A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid", "overallStatus": "COMPLETED", "startDate": "2006-12", "completionDate": "2009-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 31, "briefSummary": "This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen.", "conditions": ["Non-small Cell Lung Cancer", "Mesothelioma", "Lung Neoplasms"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514", "Alimta"]}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Mesothelioma", "Lung Neoplasms"], "meshInterventions": ["Pemetrexed"], "hasResults": true, "classifyText": "Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen Non-small Cell Lung Cancer Mesothelioma Lung Neoplasms pemetrexed Carcinoma, Non-Small-Cell Lung Mesothelioma Lung Neoplasms Pemetrexed This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen."}
 {"nctId": "NCT01380691", "briefTitle": "A Study of LY2216684 in Healthy Participants", "officialTitle": "A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction of LY2216684 With Alcohol in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2011-06", "completionDate": "2011-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 28, "briefSummary": "This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days.", "conditions": ["Major Depressive Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2216684", "otherNames": ["Edivoxetine"]}, {"type": "DRUG", "name": "Placebo-matching LY2216684", "otherNames": []}, {"type": "DRUG", "name": "Placebo-matching alcoholic beverage", "otherNames": []}, {"type": "DRUG", "name": "Alcoholic beverage", "otherNames": []}], "meshConditions": ["Depressive Disorder, Major"], "meshInterventions": ["alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol", "Alcoholic Beverages"], "hasResults": true, "classifyText": "A Study of LY2216684 in Healthy Participants Major Depressive Disorder LY2216684 Placebo-matching LY2216684 Placebo-matching alcoholic beverage Alcoholic beverage Depressive Disorder, Major alpha-((5-fluoro-2-methoxyphenyl)methyl)-alpha-(tetrahydro-2H-pyran-4-yl)-2-morpholinemethanol Alcoholic Beverages This study will evaluate the pharmacodynamic and pharmacokinetic interaction of LY2216684 with alcohol in healthy participants. This study will run approximately for 34 days."}
 {"nctId": "NCT02778126", "briefTitle": "A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer", "officialTitle": "Disposition of [\u00b9\u2074C]LY2606368 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumours", "overallStatus": "COMPLETED", "startDate": "2016-09-22", "completionDate": "2017-07-27", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 6, "briefSummary": "The main purpose of this study is to evaluate the safety of the study drug known as Prexasertib (LY2606368) in participants with advanced cancer or cancer that has spread to other parts of the body. This study will involve a single dose of \u00b9\u2074C radiolabelled Prexasertib . This means that a radioactive substance, carbon 14, will be incorporated into the study drug. This will provide information about the study drug and its breakdown products and will help determine how much passes from the blood into urine, feces and expired air. After a minimum 14-day washout period following the \\[\u00b9\u2074C\\] Prexasertib dose, participants will be allowed to receive continued access to Prexasertib as outpatients.", "conditions": ["Advanced Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "[\u00b9\u2074C]Prexasertib", "otherNames": ["[\u00b9\u2074C]LY2606368"]}, {"type": "DRUG", "name": "Prexasertib", "otherNames": ["LY2606368"]}], "meshConditions": [], "meshInterventions": ["prexasertib"], "hasResults": false, "classifyText": "A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer Advanced Cancer [\u00b9\u2074C]Prexasertib Prexasertib prexasertib The main purpose of this study is to evaluate the safety of the study drug known as Prexasertib (LY2606368) in participants with advanced cancer or cancer that has spread to other parts of the body. This study will involve a single dose of \u00b9\u2074C radiolabelled Prexasertib . This means that a radioactive substance, carbon 14, will be incorporated into the study drug. This will provide information about the study drug and its breakdown products and will help determine how much passes from the blood into urine, feces and expired air. After a minimum 14-day washout period following the \\[\u00b9\u2074C\\] Prexasertib dose, participants will be allowed to receive continued access to Prexasertib as outpatients."}
 {"nctId": "NCT00191282", "briefTitle": "Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes", "officialTitle": "Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D)", "overallStatus": "COMPLETED", "startDate": "2002-10", "completionDate": "2007-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 1116, "briefSummary": "The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined adjudicated cardiovascular (CV) event (primary outcome defined as CV death, nonfatal myocardial infarction \\[MI\\], nonfatal stroke, coronary revascularization, or hospitalized acute coronary syndrome).", "conditions": ["Diabetes Mellitus, Type 2", "Acute Myocardial Infarction"], "keywords": ["diabetes", "MI", "heart attack"], "interventions": [{"type": "DRUG", "name": "Insulin lispro", "otherNames": ["Humalog"]}, {"type": "DRUG", "name": "Human insulin isophane suspension (NPH)", "otherNames": []}, {"type": "DRUG", "name": "Insulin glargine", "otherNames": []}, {"type": "DRUG", "name": "Human insulin isophane suspension", "otherNames": []}, {"type": "DRUG", "name": "Human insulin 30/70", "otherNames": ["Human insulin 70/30 (in the United States)"]}], "meshConditions": ["Diabetes Mellitus, Type 2", "Diabetes Mellitus", "Myocardial Infarction"], "meshInterventions": ["Insulin Lispro", "Insulin Glargine"], "hasResults": true, "classifyText": "Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes Diabetes Mellitus, Type 2 Acute Myocardial Infarction diabetes MI heart attack Insulin lispro Human insulin isophane suspension (NPH) Insulin glargine Human insulin isophane suspension Human insulin 30/70 Diabetes Mellitus, Type 2 Diabetes Mellitus Myocardial Infarction Insulin Lispro Insulin Glargine The primary objective was to demonstrate a difference between two insulin strategies, one targeting postprandial (PP) hyperglycemia and the other targeting fasting and interprandial hyperglycemia, on time until the first combined adjudicated cardiovascular (CV) event (primary outcome defined as CV death, nonfatal myocardial infarction \\[MI\\], nonfatal stroke, coronary revascularization, or hospitalized acute coronary syndrome)."}
 {"nctId": "NCT00309140", "briefTitle": "An Open Label Study of Oral Enzastaurin in Participants With Cancer", "officialTitle": "An Open-Label Study of Oral Enzastaurin HCl in Patients With Advanced or Metastatic Malignancies", "overallStatus": "COMPLETED", "startDate": "2006-03", "completionDate": "2009-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 23, "briefSummary": "This study will collect further basic safety data on participants with cancer treated with enzastaurin. This study is not open to the public.\n\nThe purpose of the this study is to extend the clinical experience of participants who complete enzastaurin therapy per clinical pharmacology and biopharmaceutics studies conducted by Eli Lilly and Company and who may benefit from continued enzastaurin therapy.", "conditions": ["Neoplasms", "Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "enzastaurin", "otherNames": ["LY317615"]}], "meshConditions": ["Neoplasms"], "meshInterventions": ["enzastaurin"], "hasResults": true, "classifyText": "An Open Label Study of Oral Enzastaurin in Participants With Cancer Neoplasms Cancer enzastaurin Neoplasms enzastaurin This study will collect further basic safety data on participants with cancer treated with enzastaurin. This study is not open to the public.\n\nThe purpose of the this study is to extend the clinical experience of participants who complete enzastaurin therapy per clinical pharmacology and biopharmaceutics studies conducted by Eli Lilly and Company and who may benefit from continued enzastaurin therapy."}
 {"nctId": "NCT06607185", "briefTitle": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "officialTitle": "A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2024-10-21", "completionDate": "2030-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 750, "briefSummary": "The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years.", "conditions": ["Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer", "Colorectal Cancer", "Advanced Solid Tumor", "Metastatic Solid Tumor"], "keywords": ["KRAS", "KRAS mutation", "KRASG12C", "KRASG12D", "KRASG12V", "KRASG12S", "KRASG12A", "KRASG13D", "LY4066434", "Targeted therapy", "Lung cancer", "Pancreas cancer", "Colon cancer", "Rectal cancer", "Colorectal cancer", "Ovarian cancer", "Endometrial cancer", "Cholangiocarcinoma", "Esophageal cancer", "KRAS-mutant tumor", "PanKRAS", "Pan KRAS"], "interventions": [{"type": "DRUG", "name": "LY4066434.", "otherNames": []}, {"type": "DRUG", "name": "Cetuximab", "otherNames": []}, {"type": "DRUG", "name": "Nab paclitaxel", "otherNames": []}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": []}, {"type": "DRUG", "name": "Oxaliplatin", "otherNames": []}, {"type": "DRUG", "name": "Leucovorin", "otherNames": ["Folinic Acid"]}, {"type": "DRUG", "name": "Irinotecan", "otherNames": []}, {"type": "DRUG", "name": "5Fluorouracil", "otherNames": []}, {"type": "DRUG", "name": "Carboplatin", "otherNames": []}, {"type": "DRUG", "name": "Cisplatin", "otherNames": []}, {"type": "DRUG", "name": "Pemetrexed", "otherNames": []}, {"type": "DRUG", "name": "Pembrolizumab", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Colorectal Neoplasms", "Neoplasm Metastasis", "Lung Neoplasms", "Pancreatic Neoplasms", "Colonic Neoplasms", "Rectal Neoplasms", "Ovarian Neoplasms", "Endometrial Neoplasms", "Cholangiocarcinoma", "Esophageal Neoplasms"], "meshInterventions": ["Cetuximab", "Taxes", "Gemcitabine", "Oxaliplatin", "Leucovorin", "Irinotecan", "Fluorouracil", "Carboplatin", "Cisplatin", "Pemetrexed", "pembrolizumab"], "hasResults": false, "classifyText": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors Pancreatic Ductal Adenocarcinoma Non-small Cell Lung Cancer Colorectal Cancer Advanced Solid Tumor Metastatic Solid Tumor KRAS KRAS mutation KRASG12C KRASG12D KRASG12V KRASG12S KRASG12A KRASG13D LY4066434 Targeted therapy Lung cancer Pancreas cancer Colon cancer Rectal cancer Colorectal cancer Ovarian cancer Endometrial cancer Cholangiocarcinoma Esophageal cancer KRAS-mutant tumor PanKRAS Pan KRAS LY4066434. Cetuximab Nab paclitaxel Gemcitabine Oxaliplatin Leucovorin Irinotecan 5Fluorouracil Carboplatin Cisplatin Pemetrexed Pembrolizumab Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Neoplasm Metastasis Lung Neoplasms Pancreatic Neoplasms Colonic Neoplasms Rectal Neoplasms Ovarian Neoplasms Endometrial Neoplasms Cholangiocarcinoma Esophageal Neoplasms Cetuximab Taxes Gemcitabine Oxaliplatin Leucovorin Irinotecan Fluorouracil Carboplatin Cisplatin Pemetrexed pembrolizumab The main purpose of the study is to assess whether the study drug, LY4066434, is safe and tolerable when administered to participants with locally advanced or metastatic solid tumors with certain KRAS mutations. LY4066434 will be given alone or in combination with other treatments. The study will have 2 parts: monotherapy dose escalation and dose optimization. The study is expected to last up to approximately 5 years."}
 {"nctId": "NCT07226843", "briefTitle": "A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers", "officialTitle": "NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies", "overallStatus": "NOT_YET_RECRUITING", "startDate": "2026-04", "completionDate": "2029-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 360, "briefSummary": "The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.", "conditions": ["Lymphoma, Non-Hodgkin's", "Lymphoma, Diffuse Large B-Cell", "Follicular Lymphoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY4584180", "otherNames": []}, {"type": "DRUG", "name": "Rituximab", "otherNames": []}], "meshConditions": ["Lymphoma, Non-Hodgkin", "Lymphoma, Large B-Cell, Diffuse", "Lymphoma, Follicular"], "meshInterventions": ["Rituximab"], "hasResults": false, "classifyText": "A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Follicular Lymphoma LY4584180 Rituximab Lymphoma, Non-Hodgkin Lymphoma, Large B-Cell, Diffuse Lymphoma, Follicular Rituximab The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening."}
 {"nctId": "NCT04451408", "briefTitle": "A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants", "officialTitle": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Participants With Alzheimer's Disease and Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2020-07-07", "completionDate": "2024-11-18", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 139, "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin. The study will also investigate how much LY3372993 gets into the bloodstream and will test the effects of LY3372993. The study will be conducted in two parts. The part A includes participants with AD and part B includes healthy participants. Participation could last up to about 61 weeks and may include up to 31 visits to the study center.", "conditions": ["Alzheimer Disease", "Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3372993", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Alzheimer Disease"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3372993 in Participants With Alzheimer's Disease (AD) and Healthy Participants Alzheimer Disease Healthy LY3372993 Placebo Alzheimer Disease The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in participants with AD, non-Japanese, and Japanese healthy participants who are of first-generation Japanese origin. The study will also investigate how much LY3372993 gets into the bloodstream and will test the effects of LY3372993. The study will be conducted in two parts. The part A includes participants with AD and part B includes healthy participants. Participation could last up to about 61 weeks and may include up to 31 visits to the study center."}
 {"nctId": "NCT01080313", "briefTitle": "Head and Neck Cancer Registry (LORHAN)", "officialTitle": "Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy Other Than Surgical Resection Alone for Newly Diagnosed Head and Neck Cancer", "overallStatus": "COMPLETED", "startDate": "2005-08", "completionDate": "2011-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "OBSERVATIONAL", "phases": [], "primaryPurpose": null, "enrollment": 26000, "briefSummary": "The primary objective of this study is to describe, in detail, patterns of care for head and neck carcinoma patient", "conditions": ["Head and Neck Cancer"], "keywords": [], "interventions": [{"type": "OTHER", "name": "Therapy for head and neck cancer", "otherNames": []}], "meshConditions": ["Head and Neck Neoplasms"], "meshInterventions": ["Therapeutics"], "hasResults": false, "classifyText": "Head and Neck Cancer Registry (LORHAN) Head and Neck Cancer Therapy for head and neck cancer Head and Neck Neoplasms Therapeutics The primary objective of this study is to describe, in detail, patterns of care for head and neck carcinoma patient"}
 {"nctId": "NCT07313813", "briefTitle": "A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus", "officialTitle": "A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Dulaglutide on Retained Gastric Contents Using Gastric Ultrasound in Participants With Type 2 Diabetes Mellitus", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2025-12-29", "completionDate": "2026-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 20, "briefSummary": "The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal.\n\nUltrasound devices will be used to check the stomach content after a test meal.\n\nThe study can last approximately 28 weeks.", "conditions": ["Type 2 Diabetes Mellitus (T2DM)"], "keywords": ["Point of Care Ultrasound (POCUS)"], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide"], "hasResults": false, "classifyText": "A Study to Evaluate the Effect of Fasting Duration and Dulaglutide (LY2189265) Withholding on Gastric Retention in Participants With Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus (T2DM) Point of Care Ultrasound (POCUS) Dulaglutide Diabetes Mellitus, Type 2 dulaglutide The purpose of this study is to evaluate how fasting and stopping the use of Dulaglutide (LY2189265) affect the amount of food and drink that stays in your stomach after a meal.\n\nUltrasound devices will be used to check the stomach content after a test meal.\n\nThe study can last approximately 28 weeks."}
 {"nctId": "NCT05971940", "briefTitle": "A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone", "officialTitle": "A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone", "overallStatus": "COMPLETED", "startDate": "2023-08-09", "completionDate": "2025-04-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 559, "briefSummary": "The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Orforglipron", "otherNames": ["LY3502970"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["orforglipron"], "hasResults": false, "classifyText": "A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone Type 2 Diabetes Orforglipron Placebo Diabetes Mellitus, Type 2 orforglipron The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks."}
 {"nctId": "NCT00088010", "briefTitle": "Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer", "officialTitle": "Effects of Arzoxifene on Vertebral Fracture Incidence and on Invasive Breast Cancer Incidence in Postmenopausal Women With Osteoporosis or With Low Bone Density.", "overallStatus": "COMPLETED", "startDate": "2004-06", "completionDate": "2009-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 9369, "briefSummary": "The purpose of this trial is to study:\n\n* Effects of arzoxifene on bone fractures and bone mass.\n* Effects of arzoxifene on getting breast cancer.\n* Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke.\n* Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health.\n* Effects of arzoxifene on the uterus.\n* The safety of arzoxifene and any side effects.", "conditions": ["Osteoporosis, Postmenopausal"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Arzoxifene", "otherNames": ["LY353381"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Osteoporosis, Postmenopausal"], "meshInterventions": ["LY 353381"], "hasResults": false, "classifyText": "Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer Osteoporosis, Postmenopausal Arzoxifene Placebo Osteoporosis, Postmenopausal LY 353381 The purpose of this trial is to study:\n\n* Effects of arzoxifene on bone fractures and bone mass.\n* Effects of arzoxifene on getting breast cancer.\n* Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke.\n* Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health.\n* Effects of arzoxifene on the uterus.\n* The safety of arzoxifene and any side effects."}
 {"nctId": "NCT05580250", "briefTitle": "A Study of LY3526318 in Healthy Male Japanese Participants", "officialTitle": "A Phase I, Single-Centre Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of LY3526318, and to Investigate the Effect of LY3526318 on Metformin and Simvastatin Pharmacokinetics in Healthy Male Japanese Participants", "overallStatus": "WITHDRAWN", "startDate": "2022-11-22", "completionDate": "2022-12-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 0, "briefSummary": "This is a study of LY3526318 in healthy male Japanese. The main purposes of this study are to:\n\n* Assess how safe and well tolerated LY3526318 is when given by mouth.\n* Measure how LY3526318 affects the kidney and the liver. The study will be conducted in three parts (Part A, Part B, Part C). Participants may only enroll in one part. After screening, the study will last from one to two weeks, depending on part.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3526318", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Iohexol", "otherNames": []}, {"type": "DRUG", "name": "Simvastatin", "otherNames": []}, {"type": "DRUG", "name": "Metformin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Iohexol", "Simvastatin", "Metformin"], "hasResults": false, "classifyText": "A Study of LY3526318 in Healthy Male Japanese Participants Healthy LY3526318 Placebo Iohexol Simvastatin Metformin Iohexol Simvastatin Metformin This is a study of LY3526318 in healthy male Japanese. The main purposes of this study are to:\n\n* Assess how safe and well tolerated LY3526318 is when given by mouth.\n* Measure how LY3526318 affects the kidney and the liver. The study will be conducted in three parts (Part A, Part B, Part C). Participants may only enroll in one part. After screening, the study will last from one to two weeks, depending on part."}
 {"nctId": "NCT07090785", "briefTitle": "A Study of LY4088044 in Healthy Participants", "officialTitle": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4088044 in Healthy Participants.", "overallStatus": "RECRUITING", "startDate": "2025-07-24", "completionDate": "2027-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 104, "briefSummary": "The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it.\n\nThe study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY4088044", "otherNames": []}, {"type": "DRUG", "name": "LY4088044", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY4088044 in Healthy Participants Healthy LY4088044 LY4088044 Placebo Placebo The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it.\n\nThe study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening."}
 {"nctId": "NCT06964776", "briefTitle": "A Study of LY4268989 (MORF-057) in Healthy Participants", "officialTitle": "A Phase 1 Study to Further Investigate the Pharmacokinetics, Safety and Tolerability, Food Effect and Drug-Drug Interaction of LY4268989 (MORF-057) in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2025-05-01", "completionDate": "2026-02-17", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 144, "briefSummary": "The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY4268989", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Midazolam", "otherNames": []}, {"type": "DRUG", "name": "Midazolam", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Midazolam"], "hasResults": false, "classifyText": "A Study of LY4268989 (MORF-057) in Healthy Participants Healthy LY4268989 Placebo Midazolam Midazolam Midazolam The purpose of this study is to measure the body's absorption and processing of the study drug, the study drug's effect on the body, safety, and tolerability with LY4268989 (MORF-57) in healthy participants, including Japanese and Chinese participants"}
 {"nctId": "NCT00191152", "briefTitle": "A Phase III Trial For Patients With Metastatic Breast Cancer", "officialTitle": "Randomized Trial of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd", "overallStatus": "COMPLETED", "startDate": "2002-02", "completionDate": "2008-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 475, "briefSummary": "This is a phase III randomized study between the docetaxel/gemcitabine and docetaxel/ capecitabine doublets, with crossover to the alternate agent. The experimental arm will receive gemcitabine 1000 mg/m2 intravenous (IV) over 30 minutes days 1 and 8 and docetaxel 75 mg/m2 IV day 1 over 1 hour repeated every three weeks. The comparator arm will receive docetaxel 75 mgm/m2 IV day 1 over 1 hour and oral capecitabine 1000 mg/m2 twice daily, days 1 through 14 repeated every three weeks. Patients who progress on the experimental arm, will be treated with capecitabine as dosed on the comparator arm. Patients who progress on the comparator arm will be treated with gemcitabine as dosed on the experimental arm.", "conditions": ["Breast Cancer", "Breast Neoplasms", "Cancer of the Breast"], "keywords": [], "interventions": [{"type": "DRUG", "name": "gemcitabine", "otherNames": ["LY188011", "Gemzar"]}, {"type": "DRUG", "name": "docetaxel", "otherNames": []}, {"type": "DRUG", "name": "capecitabine", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Gemcitabine", "Docetaxel", "Capecitabine"], "hasResults": true, "classifyText": "A Phase III Trial For Patients With Metastatic Breast Cancer Breast Cancer Breast Neoplasms Cancer of the Breast gemcitabine docetaxel capecitabine Breast Neoplasms Gemcitabine Docetaxel Capecitabine This is a phase III randomized study between the docetaxel/gemcitabine and docetaxel/ capecitabine doublets, with crossover to the alternate agent. The experimental arm will receive gemcitabine 1000 mg/m2 intravenous (IV) over 30 minutes days 1 and 8 and docetaxel 75 mg/m2 IV day 1 over 1 hour repeated every three weeks. The comparator arm will receive docetaxel 75 mgm/m2 IV day 1 over 1 hour and oral capecitabine 1000 mg/m2 twice daily, days 1 through 14 repeated every three weeks. Patients who progress on the experimental arm, will be treated with capecitabine as dosed on the comparator arm. Patients who progress on the comparator arm will be treated with gemcitabine as dosed on the experimental arm."}
 {"nctId": "NCT02555449", "briefTitle": "A Study of [\u00b9\u2074C]-LY3202626 in Healthy Male Participants", "officialTitle": "Disposition of [\u00b9\u2074C]-LY3202626 Following Oral Administration in Healthy Male Subjects", "overallStatus": "COMPLETED", "startDate": "2015-09", "completionDate": "2015-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 6, "briefSummary": "The purpose of this study is to measure how much of the specially prepared study drug, LY3202626, containing radiolabeled carbon \\[\u00b9\u2074C\\] gets into the blood stream and how long it takes the body to get rid of it.\n\nInformation about any side effects that may occur will also be collected.\n\nParticipants will stay at a clinical research unit (CRU). The study will last about 28 days (check in to follow-up) for each participant.\n\nThis study is for research purposes only and is not intended to treat any medical condition.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "[\u00b9\u2074C]-LY3202626", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": true, "classifyText": "A Study of [\u00b9\u2074C]-LY3202626 in Healthy Male Participants Healthy [\u00b9\u2074C]-LY3202626 The purpose of this study is to measure how much of the specially prepared study drug, LY3202626, containing radiolabeled carbon \\[\u00b9\u2074C\\] gets into the blood stream and how long it takes the body to get rid of it.\n\nInformation about any side effects that may occur will also be collected.\n\nParticipants will stay at a clinical research unit (CRU). The study will last about 28 days (check in to follow-up) for each participant.\n\nThis study is for research purposes only and is not intended to treat any medical condition."}
 {"nctId": "NCT07357415", "briefTitle": "A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight", "officialTitle": "A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial", "overallStatus": "RECRUITING", "startDate": "2026-01-24", "completionDate": "2028-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 600, "briefSummary": "The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.", "conditions": ["Obesity", "Overweight"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Retatrutide", "otherNames": ["LY3437943"]}], "meshConditions": ["Obesity", "Overweight"], "meshInterventions": ["retatrutide"], "hasResults": false, "classifyText": "A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight Obesity Overweight Retatrutide Obesity Overweight retatrutide The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks."}
 {"nctId": "NCT00036309", "briefTitle": "Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder", "officialTitle": "Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder", "overallStatus": "COMPLETED", "startDate": "2002-05", "completionDate": "2003-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": null, "briefSummary": "The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment.", "conditions": ["Depressive Disorder"], "keywords": ["Major Depressive Disorder", "Diagnostic and Statistical Manual of Mental Disorders Fourth Edition-defined major depressive disorder without psychotic features"], "interventions": [{"type": "DRUG", "name": "Duloxetine Hydrochloride", "otherNames": []}], "meshConditions": ["Depressive Disorder", "Depressive Disorder, Major", "Disease"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Duloxetine Versus Placebo in the Prevention of Relapse of Major Depressive Disorder Depressive Disorder Major Depressive Disorder Diagnostic and Statistical Manual of Mental Disorders Fourth Edition-defined major depressive disorder without psychotic features Duloxetine Hydrochloride Depressive Disorder Depressive Disorder, Major Disease Duloxetine Hydrochloride The purpose of this study is to determine if duloxetine is effective when compared to placebo in preventing recurrence of major depressive disorder in patients who have responded to open-label duloxetine treatment."}
 {"nctId": "NCT05222399", "briefTitle": "A Study of LY3871801 in Healthy Participants", "officialTitle": "Pharmacokinetics of LY3871801 Following Oral Administration of a Crystalline Freebase Tablet and a Solid Dispersion Oral Suspension", "overallStatus": "COMPLETED", "startDate": "2022-02-04", "completionDate": "2022-03-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 15, "briefSummary": "The main purpose of this study is to compare the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it, when given as crystalline freebase tablet (test) and as a solid dispersion oral suspension (reference) in healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3871801 will also be evaluated. The study may last up to approximately 15 days excluding the 28 days of screening period.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3871801", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3871801 in Healthy Participants Healthy LY3871801 The main purpose of this study is to compare the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it, when given as crystalline freebase tablet (test) and as a solid dispersion oral suspension (reference) in healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3871801 will also be evaluated. The study may last up to approximately 15 days excluding the 28 days of screening period."}
 {"nctId": "NCT00703326", "briefTitle": "Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer", "officialTitle": "A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2008-08-06", "completionDate": "2020-11-19", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1144, "briefSummary": "The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer.", "conditions": ["Breast Cancer"], "keywords": ["Metastatic breast cancer", "HER2 negative breast cancer", "locally recurrent breast cancer"], "interventions": [{"type": "BIOLOGICAL", "name": "ramucirumab (IMC-1121B)", "otherNames": ["IMC-1121B", "LY3009806"]}, {"type": "DRUG", "name": "docetaxel", "otherNames": []}, {"type": "OTHER", "name": "Placebo", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Ramucirumab", "Docetaxel"], "hasResults": true, "classifyText": "Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer Breast Cancer Metastatic breast cancer HER2 negative breast cancer locally recurrent breast cancer ramucirumab (IMC-1121B) docetaxel Placebo Breast Neoplasms Ramucirumab Docetaxel The objective of this study is to compare the progression-free survival (PFS) of the drug combination ramucirumab plus docetaxel to placebo plus docetaxel in previously untreated participants with human epidermal growth factor receptor 2 (HER2)-negative, unresectable, locally-recurrent or metastatic breast cancer."}
 {"nctId": "NCT05205447", "briefTitle": "Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants", "officialTitle": "A Phase 1, Two-part, Open-label, Fixed-sequence Study to Evaluate the Effects of Multiple Doses of Itraconazole and Carbamazepine on the Single-dose Pharmacokinetics of LY3410738 in Healthy Adult Subjects", "overallStatus": "TERMINATED", "startDate": "2022-01-05", "completionDate": "2022-04-12", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Loxo Oncology, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 27, "briefSummary": "The main purpose of this study is to learn about how itraconazole and carbamazepine affect the levels of LY3410738 in the blood stream of healthy participants. Participation could last up to 75 days.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3410738", "otherNames": []}, {"type": "DRUG", "name": "Itraconazole", "otherNames": []}, {"type": "DRUG", "name": "Carbamazepine", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Itraconazole", "Carbamazepine"], "hasResults": false, "classifyText": "Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy Participants Healthy LY3410738 Itraconazole Carbamazepine Itraconazole Carbamazepine The main purpose of this study is to learn about how itraconazole and carbamazepine affect the levels of LY3410738 in the blood stream of healthy participants. Participation could last up to 75 days."}
 {"nctId": "NCT00190840", "briefTitle": "A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer", "officialTitle": "Open-Label Single-Arm Phase 2 Study of ALIMTA in Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy", "overallStatus": "COMPLETED", "startDate": "2003-09", "completionDate": "2005-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 186, "briefSummary": "In previous phase 2 studies, pemetrexed has shown antitumor activity in advanced non-small cell lung cancer as a single agent as well as in combination with cisplatin. Since the introduction of vitamin supplementation, pemetrexed has shown good tolerance and high safety. Vitamin supplementation has opened the opportunity to offer patients higher pemetrexed dosing, as has been demonstrated by a recent Phase 1 study. The higher dose with supplementation may increase pemetrexed's efficacy without unduly compromising safety. The present Phase 2 study will use pemetrexed dosing that is tailored to individual patient tolerance, and is an effort to determine the efficacy and safety of this approach in patients with advanced NSCLC who had prior chemotherapy.", "conditions": ["Carcinoma, Non-Small Cell Lung"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Pemetrexed"], "hasResults": false, "classifyText": "A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer Carcinoma, Non-Small Cell Lung pemetrexed Carcinoma, Non-Small-Cell Lung Pemetrexed In previous phase 2 studies, pemetrexed has shown antitumor activity in advanced non-small cell lung cancer as a single agent as well as in combination with cisplatin. Since the introduction of vitamin supplementation, pemetrexed has shown good tolerance and high safety. Vitamin supplementation has opened the opportunity to offer patients higher pemetrexed dosing, as has been demonstrated by a recent Phase 1 study. The higher dose with supplementation may increase pemetrexed's efficacy without unduly compromising safety. The present Phase 2 study will use pemetrexed dosing that is tailored to individual patient tolerance, and is an effort to determine the efficacy and safety of this approach in patients with advanced NSCLC who had prior chemotherapy."}
 {"nctId": "NCT00191867", "briefTitle": "Clinical Trial of Teriparatide in Japan", "officialTitle": "Assessment of Dose Response of LY333334 in Japanese Postmenopausal Women With Osteoporosis", "overallStatus": "COMPLETED", "startDate": "2005-02", "completionDate": "2006-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 160, "briefSummary": "The purpose of this study is to assess the Efficacy and Safety of Teriparatide in Japanese Postmenopausal Women with Osteoporosis.", "conditions": ["Osteoporosis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Teriparatide", "otherNames": []}], "meshConditions": ["Osteoporosis"], "meshInterventions": ["Teriparatide"], "hasResults": false, "classifyText": "Clinical Trial of Teriparatide in Japan Osteoporosis Teriparatide Osteoporosis Teriparatide The purpose of this study is to assess the Efficacy and Safety of Teriparatide in Japanese Postmenopausal Women with Osteoporosis."}
 {"nctId": "NCT00350792", "briefTitle": "Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients", "officialTitle": "A Phase II Trial Pemetrexed Carboplatin as First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly Patients", "overallStatus": "COMPLETED", "startDate": "2006-08", "completionDate": "2009-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 62, "briefSummary": "A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer", "conditions": ["Non Small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514", "Alimta"]}, {"type": "DRUG", "name": "carboplatin", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Pemetrexed", "Carboplatin"], "hasResults": true, "classifyText": "Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients Non Small Cell Lung Cancer pemetrexed carboplatin Carcinoma, Non-Small-Cell Lung Pemetrexed Carboplatin A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer"}
 {"nctId": "NCT01140347", "briefTitle": "A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib", "officialTitle": "A Multicenter, Randomized, Double-Blind, Phase 3 Study of Ramucirumab (IMC-1121B) Drug Product and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)", "overallStatus": "COMPLETED", "startDate": "2010-10", "completionDate": "2015-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 565, "briefSummary": "This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.\n\nApproximately 544 participants, at least 18 years of age, with Child-Pugh score \\< 7 and diagnosed with hepatocellular carcinoma will be randomized. Participants must have received sorafenib as first-line systemic treatment for hepatocellular carcinoma (HCC), and must have discontinued sorafenib prior to entering the study.\n\nHypothesis: This sample size will allow differentiation of the expected increase in median overall survival (OS), from 8 months in the placebo arm to 10.67 months in the ramucirumab arm.\n\nUpon registration and completion of screening procedures, eligible participants with HCC who have disease progression during or following first-line therapy with sorafenib, or were intolerant to this agent, will be randomized to receive either ramucirumab DP or placebo.\n\nThe treatment regimen will be continued until radiographic or symptomatic progression, the development of unacceptable toxicity, noncompliance or withdrawal of consent by the participant, or investigator decision.", "conditions": ["Hepatocellular Carcinoma"], "keywords": ["Hepatocellular carcinoma (HCC)", "recombinant human immunoglobulin G", "subclass 1 (IgG1) monoclonal antibody (MAb)", "Hepatocellular Carcinoma (HCC) following First-Line Therapy With Sorafenib"], "interventions": [{"type": "BIOLOGICAL", "name": "Placebo", "otherNames": []}, {"type": "BIOLOGICAL", "name": "Ramucirumab DP (IMC-1121B)", "otherNames": ["IMC-1121B", "LY3009806"]}, {"type": "OTHER", "name": "BSC", "otherNames": []}], "meshConditions": ["Carcinoma, Hepatocellular"], "meshInterventions": ["Ramucirumab"], "hasResults": true, "classifyText": "A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib Hepatocellular Carcinoma Hepatocellular carcinoma (HCC) recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody (MAb) Hepatocellular Carcinoma (HCC) following First-Line Therapy With Sorafenib Placebo Ramucirumab DP (IMC-1121B) BSC Carcinoma, Hepatocellular Ramucirumab This is a Phase 3 multicenter, randomized study evaluating the safety and efficacy of ramucirumab DP plus BSC as a double-blind, placebo-controlled (placebo plus BSC) comparison.\n\nApproximately 544 participants, at least 18 years of age, with Child-Pugh score \\< 7 and diagnosed with hepatocellular carcinoma will be randomized. Participants must have received sorafenib as first-line systemic treatment for hepatocellular carcinoma (HCC), and must have discontinued sorafenib prior to entering the study.\n\nHypothesis: This sample size will allow differentiation of the expected increase in median overall survival (OS), from 8 months in the placebo arm to 10.67 months in the ramucirumab arm.\n\nUpon registration and completion of screening procedures, eligible participants with HCC who have disease progression during or following first-line therapy with sorafenib, or were intolerant to this agent, will be randomized to receive either ramucirumab DP or placebo.\n\nThe treatment regimen will be con"}
 {"nctId": "NCT05536804", "briefTitle": "A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes", "officialTitle": "Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance Imaging", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2023-02-08", "completionDate": "2026-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 140, "briefSummary": "We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D).\n\nThe study will last about 56 weeks and include up to 12 visits.", "conditions": ["Overweight", "Obesity", "Chronic Kidney Disease", "Type 2 Diabetes", "T2D"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Overweight", "Obesity", "Renal Insufficiency, Chronic", "Diabetes Mellitus, Type 2"], "meshInterventions": ["Tirzepatide"], "hasResults": false, "classifyText": "A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Overweight Obesity Chronic Kidney Disease Type 2 Diabetes T2D Tirzepatide Placebo Overweight Obesity Renal Insufficiency, Chronic Diabetes Mellitus, Type 2 Tirzepatide We are doing this study to learn more about how tirzepatide may help fight chronic kidney disease in people with obesity with or without type 2 diabetes (T2D).\n\nThe study will last about 56 weeks and include up to 12 visits."}
 {"nctId": "NCT01751399", "briefTitle": "A Single Dose Study of LY2605541 in Participants With Liver Impairment", "officialTitle": "A Single Dose Pharmacokinetic Study of LY2605541 in Subjects With Hepatic Impairment", "overallStatus": "COMPLETED", "startDate": "2012-12", "completionDate": "2013-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 35, "briefSummary": "The primary purpose of this study is to help answer the following research questions:\n\n* To evaluate how much of the study drug (LY2605541) is in the blood of participants with varying degrees of liver impairment compared to those with normal liver function\n* To assess the safety of LY2605541 and any side effects that might be associated with it", "conditions": ["Healthy Volunteers", "Hepatic Insufficiency", "Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2605541", "otherNames": []}], "meshConditions": ["Hepatic Insufficiency", "Diabetes Mellitus, Type 2"], "meshInterventions": ["LY2605541"], "hasResults": true, "classifyText": "A Single Dose Study of LY2605541 in Participants With Liver Impairment Healthy Volunteers Hepatic Insufficiency Diabetes Mellitus, Type 2 LY2605541 Hepatic Insufficiency Diabetes Mellitus, Type 2 LY2605541 The primary purpose of this study is to help answer the following research questions:\n\n* To evaluate how much of the study drug (LY2605541) is in the blood of participants with varying degrees of liver impairment compared to those with normal liver function\n* To assess the safety of LY2605541 and any side effects that might be associated with it"}
 {"nctId": "NCT01836198", "briefTitle": "The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream", "officialTitle": "Effects of Potent Inhibition of CYP2C8, CYP2J2, and CYP3A4, Using Gemfibrozil, Ketoconazole, and Clarithromycin as Probes, on the Pharmacokinetics of LY2409021 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2013-05", "completionDate": "2013-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 30, "briefSummary": "The purpose of this study is to examine the effect of gemfibrozil, ketoconazole, and clarithromycin on how much LY2409021 is found in the bloodstream and how long the body takes to get rid of it. The study is split into two parts, Part A and Part B. Participants in Part A are divided into two cohorts (groups). Each cohort will participate in two study periods. Period 1 involves a single dose of LY2409021. Period 2 involves either gemfibrozil or ketoconazole given daily for 21 days with LY2409021 given once on Day 4. Part A will last for 51 days and will also involve screening within 27 days of the start of the study. Part B is only open to participants who successfully completed Part A of the study. Participants in Part B will receive clarithromycin given daily for 21 days with LY2409021 given once on Day 4. Part B will last for 29 days and will also involve screening within 27 days of the start of the study.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2409021", "otherNames": []}, {"type": "DRUG", "name": "Gemfibrozil", "otherNames": []}, {"type": "DRUG", "name": "Ketoconazole", "otherNames": []}, {"type": "DRUG", "name": "Clarithromycin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["adomeglivant", "Gemfibrozil", "Ketoconazole", "Clarithromycin"], "hasResults": true, "classifyText": "The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream Healthy Volunteers LY2409021 Gemfibrozil Ketoconazole Clarithromycin adomeglivant Gemfibrozil Ketoconazole Clarithromycin The purpose of this study is to examine the effect of gemfibrozil, ketoconazole, and clarithromycin on how much LY2409021 is found in the bloodstream and how long the body takes to get rid of it. The study is split into two parts, Part A and Part B. Participants in Part A are divided into two cohorts (groups). Each cohort will participate in two study periods. Period 1 involves a single dose of LY2409021. Period 2 involves either gemfibrozil or ketoconazole given daily for 21 days with LY2409021 given once on Day 4. Part A will last for 51 days and will also involve screening within 27 days of the start of the study. Part B is only open to participants who successfully completed Part A of the study. Participants in Part B will receive clarithromycin given daily for 21 days with LY2409021 given once on Day 4. Part B will last for 29 days and will also involve screening within 27 days of the start of the study."}
 {"nctId": "NCT02020616", "briefTitle": "A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes", "officialTitle": "Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus", "overallStatus": "TERMINATED", "startDate": "2013-12", "completionDate": "2015-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 60, "briefSummary": "The purpose of this study is to investigate the safety and effectiveness of the study drug known as LY3053102 in participants with Type 2 diabetes mellitus. The study drug will be given in different doses as an injection under the skin. The study is expected to last up to 6 months for each participant. Participants may remain on stable-dose metformin as prescribed by their personal physician.", "conditions": ["Type 2 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3053102", "otherNames": []}, {"type": "DRUG", "name": "Exenatide ER", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Metformin", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Metformin"], "hasResults": true, "classifyText": "A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes Type 2 Diabetes Mellitus LY3053102 Exenatide ER Placebo Metformin Diabetes Mellitus, Type 2 Metformin The purpose of this study is to investigate the safety and effectiveness of the study drug known as LY3053102 in participants with Type 2 diabetes mellitus. The study drug will be given in different doses as an injection under the skin. The study is expected to last up to 6 months for each participant. Participants may remain on stable-dose metformin as prescribed by their personal physician."}
 {"nctId": "NCT00370292", "briefTitle": "Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "officialTitle": "Pemetrexed Monochemotherapy in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer. A Pilot Study to Define the Best Dosing Schedule for a Planned Phase II Randomized Trial", "overallStatus": "COMPLETED", "startDate": "2006-09", "completionDate": "2008-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 19, "briefSummary": "Patients affected by non-small cell lung cancer (NSCLC) will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles. Pemetrexed is an enhancer of some biomolecules involved in the gemcitabine mechanism of action. Purpose of the trial is to monitor the blood values of these biomolecules at different time intervals, to optimize the synergism between pemetrexed and gemcitabine.", "conditions": ["Non Small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pemetrexed - Before Protocol Amendment", "otherNames": ["LY231514", "Alimta"]}, {"type": "DRUG", "name": "Pemetrexed - After Protocol Amendment", "otherNames": ["LY231514", "Alimta"]}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Pemetrexed"], "hasResults": true, "classifyText": "Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Non Small Cell Lung Cancer Pemetrexed - Before Protocol Amendment Pemetrexed - After Protocol Amendment Carcinoma, Non-Small-Cell Lung Pemetrexed Patients affected by non-small cell lung cancer (NSCLC) will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles. Pemetrexed is an enhancer of some biomolecules involved in the gemcitabine mechanism of action. Purpose of the trial is to monitor the blood values of these biomolecules at different time intervals, to optimize the synergism between pemetrexed and gemcitabine."}
 {"nctId": "NCT00191932", "briefTitle": "Switching to Duloxetine From Other Antidepressants", "officialTitle": "Switching to Duloxetine From Other Antidepressants: A Regional Multicentre Trial Comparing Two Switching Techniques", "overallStatus": "COMPLETED", "startDate": "2004-08", "completionDate": "2006-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 360, "briefSummary": "A multicentre, randomised, open label study of out-patients with major depression who have failed to respond adequately to antidepressant treatment for their current episode of depression. The study compares outcomes associated with two methods of switching from current antidepressant to duloxetine", "conditions": ["Major Depressive Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": []}], "meshConditions": ["Depressive Disorder, Major"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Switching to Duloxetine From Other Antidepressants Major Depressive Disorder Duloxetine Depressive Disorder, Major Duloxetine Hydrochloride A multicentre, randomised, open label study of out-patients with major depression who have failed to respond adequately to antidepressant treatment for their current episode of depression. The study compares outcomes associated with two methods of switching from current antidepressant to duloxetine"}
 {"nctId": "NCT03861039", "briefTitle": "A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes", "officialTitle": "A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)", "overallStatus": "COMPLETED", "startDate": "2019-03-30", "completionDate": "2021-02-16", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 443, "briefSummary": "The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes.", "conditions": ["Type 2 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Oral antihyperglycemic medication (OAM)", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Tirzepatide"], "hasResults": true, "classifyText": "A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Type 2 Diabetes Mellitus Tirzepatide Oral antihyperglycemic medication (OAM) Diabetes Mellitus, Type 2 Tirzepatide The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes."}
 {"nctId": "NCT05882045", "briefTitle": "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease", "officialTitle": "A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2023-05-30", "completionDate": "2026-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1800, "briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.", "conditions": ["Obesity", "Cardiovascular Diseases"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Retatrutide", "otherNames": ["LY3437943"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Obesity", "Cardiovascular Diseases"], "meshInterventions": ["retatrutide"], "hasResults": false, "classifyText": "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease Obesity Cardiovascular Diseases Retatrutide Placebo Obesity Cardiovascular Diseases retatrutide The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks."}
 {"nctId": "NCT01445119", "briefTitle": "A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas", "officialTitle": "A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas", "overallStatus": "COMPLETED", "startDate": "2007-01", "completionDate": "2013-07", "leadSponsor": "Eli Lilly and Company", "collaborators": ["National Cancer Institute (NCI)"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 58, "briefSummary": "This study will evaluate the safety and effectiveness of Enzastaurin, an experimental drug that may prevent the growth of tumor vessels, in combination with Carboplatin, for patients who have a glioma, a type of brain tumor. Carboplatin is used for treating many kinds of cancers, though not recurrent gliomas. Tumor growth involves new cancer cell formation and accumulation, requiring a blood supply. Research shows that brain tumor cells can produce substances that stimulate new blood vessel formation. This study will look into whether the combination of drugs can stop that process.\n\nPatients ages 18 and older who have recurring gliomas, who are not pregnant or breast feeding, and who do not have serious diseases may be eligible for this study. About 96 patients will participate for 1 year. They will have a physical examination, give blood and urine samples for analysis, and undergo magnetic resonance imaging (MRI) or computed tomography (CT) scans regarding tumor growth, and perhaps an electrocardiogram. Patients may also undergo a dynamic MRI with spectroscopy or PET scan (positron emission tomography), to distinguish a live tumor from a dying one. Researchers are studying patients taking a certain type of antiseizure medicine and patients who are not taking it because some antiseizure medicines may change the way the body handles a drug such as Enzastaurin. There will be two groups of participants, with 16 to 48 each. Group A is not taking enzyme-inducing antiseizure drugs, and Group B is taking such drugs. In Groups A and B are four dose levels, with 4 to12 patients at each level. Patients' doctors will tell them which group they belong to and how much Enzastaurin and Carboplatin they will take. Treatment consists of Enzastaurin every day for 5 weeks in Cycle 1 only and for 4 weeks beginning with Cycle 2 (each 4-week period as a cycle). Patients take Enzastaurin within 30 minutes after a meal. History, physical, and neurological examinations are repeated at the end of Cycle 1 and then every 4 weeks. Patients will have a repeat head MRI or CT scan before each cycle. If they tolerate the drugs without serious side effects and the tumor is not growing, they may continue with another cycle of Enzastaurin, taking the tablets every day, and Carboplatin being infused on Day 8 of Cycle 1 and on Day 1 of each additional cycle. Routine lab tests are done regularly. Patients will continue the 4-week cycles of treatment for as long as they have no serious side effects and there are no signs of tumor growth. Side effects of Enzastaurin may be fatigue, constipation, cough, and nausea. In men, there may be a decrease in sperm count. Carboplatin can lead to low counts in blood cells and platelets, and there may also be an allergic reaction. Vomiting is a likely side effect. At injection sites, there may be redness, swelling, and pain.\n\nThis study may or may not have a direct benefit for participants. However, information gained may help the sponsor of the study, Eli Lilly and Company, and may help patients in the future who have gliomas.", "conditions": ["Recurrent Gliomas"], "keywords": ["Brain", "Tumor", "Radiation", "Antiangiogenesis", "Chemotherapy", "Brain Tumor", "Glioma"], "interventions": [{"type": "DRUG", "name": "Enzastaurin (LY317615)", "otherNames": []}, {"type": "DRUG", "name": "Carboplatin", "otherNames": []}], "meshConditions": ["Glioma", "Neoplasms", "Brain Neoplasms"], "meshInterventions": ["enzastaurin", "Carboplatin"], "hasResults": false, "classifyText": "A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas Recurrent Gliomas Brain Tumor Radiation Antiangiogenesis Chemotherapy Brain Tumor Glioma Enzastaurin (LY317615) Carboplatin Glioma Neoplasms Brain Neoplasms enzastaurin Carboplatin This study will evaluate the safety and effectiveness of Enzastaurin, an experimental drug that may prevent the growth of tumor vessels, in combination with Carboplatin, for patients who have a glioma, a type of brain tumor. Carboplatin is used for treating many kinds of cancers, though not recurrent gliomas. Tumor growth involves new cancer cell formation and accumulation, requiring a blood supply. Research shows that brain tumor cells can produce substances that stimulate new blood vessel formation. This study will look into whether the combination of drugs can stop that process.\n\nPatients ages 18 and older who have recurring gliomas, who are not pregnant or breast feeding, and who do not have serious diseases may be eligible for this study. About 96 patients will participate for 1 year. They will have a physical examination, give blood and urine samples for analysis, and undergo magnetic resonance imaging (MRI) or computed tomography (CT) scans regarding tumor growth, and perhaps an"}
 {"nctId": "NCT03311724", "briefTitle": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes", "officialTitle": "A Phase 2, Double-Blind, Placebo-Controlled, 3-Month Trial of LY3298176 Versus Placebo in Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2017-10-19", "completionDate": "2018-04-24", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 111, "briefSummary": "The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Tirzepatide"], "hasResults": true, "classifyText": "A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Type 2 Diabetes Tirzepatide Placebo Diabetes Mellitus, Type 2 Tirzepatide The purpose of this study is to determine the efficacy of tirzepatide in participants with type 2 diabetes."}
 {"nctId": "NCT00192023", "briefTitle": "An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).", "officialTitle": "An Italian Randomised, Double-blind Placebo Controlled Study of the Efficacy of Atomoxetine Hydrochloride in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder", "overallStatus": "COMPLETED", "startDate": "2004-10", "completionDate": "2008-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 139, "briefSummary": "The study is a phase IIIb multicentre, randomised, placebo controlled, trial in paediatric patients with Attention-Deficit/Hyperactivity (ADHD) and Oppositional Defiant Disorder (ODD). The primary aim of the study is to evaluate the efficacy of atomoxetine in improving ADHD and ODD symptoms in patients non responders to a previous psychological intervention with parent support. Moreover, the potential role of atomoxetine in treating other psychiatric comorbid conditions associated with ADHD and ODD will be assessed.", "conditions": ["Attention Deficit Hyperactivity Disorder", "Oppositional Defiant Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "atomoxetine 0.5 mg/kg/day", "otherNames": ["LY139603", "Strattera"]}, {"type": "DRUG", "name": "placebo", "otherNames": []}, {"type": "DRUG", "name": "atomoxetine 1.2 mg/kg/day", "otherNames": ["LY139603", "Strattera"]}, {"type": "DRUG", "name": "atomoxetine 1.2-1.4 mg/kg/day", "otherNames": ["LY139603", "Strattera"]}], "meshConditions": ["Attention Deficit Disorder with Hyperactivity", "Oppositional Defiant Disorder"], "meshInterventions": ["Atomoxetine Hydrochloride"], "hasResults": true, "classifyText": "An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). Attention Deficit Hyperactivity Disorder Oppositional Defiant Disorder atomoxetine 0.5 mg/kg/day placebo atomoxetine 1.2 mg/kg/day atomoxetine 1.2-1.4 mg/kg/day Attention Deficit Disorder with Hyperactivity Oppositional Defiant Disorder Atomoxetine Hydrochloride The study is a phase IIIb multicentre, randomised, placebo controlled, trial in paediatric patients with Attention-Deficit/Hyperactivity (ADHD) and Oppositional Defiant Disorder (ODD). The primary aim of the study is to evaluate the efficacy of atomoxetine in improving ADHD and ODD symptoms in patients non responders to a previous psychological intervention with parent support. Moreover, the potential role of atomoxetine in treating other psychiatric comorbid conditions associated with ADHD and ODD will be assessed."}
 {"nctId": "NCT00191620", "briefTitle": "Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer.", "officialTitle": "Randomized Phase II Study of Cisplatin + Gemcitabine Administered Either as Short Infusion or at a Fixed Dose Rate in Non-Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2004-03", "completionDate": "2006-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 64, "briefSummary": "The purposes of this study are to determine:\n\nHow standard gemcitabine plus cisplatin compares to fixed dose rate of gemcitabine plus cisplatin in the treatment of non-small cell lung cancer.\n\nThe safety of standard gemcitabine plus cisplatin and any side effects that might be associated with it as compared to a fixed dose rate of gemcitabine plus cisplatin.", "conditions": ["Non-Small-Cell Lung Carcinoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Gemcitabine", "otherNames": []}, {"type": "DRUG", "name": "cisplatin", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Gemcitabine", "Cisplatin"], "hasResults": false, "classifyText": "Study Comparing Short Infusion Vs. Fixed Dose of Cisplatin + Gemcitabine in Non Small Cell Lung Cancer. Non-Small-Cell Lung Carcinoma Gemcitabine cisplatin Carcinoma, Non-Small-Cell Lung Gemcitabine Cisplatin The purposes of this study are to determine:\n\nHow standard gemcitabine plus cisplatin compares to fixed dose rate of gemcitabine plus cisplatin in the treatment of non-small cell lung cancer.\n\nThe safety of standard gemcitabine plus cisplatin and any side effects that might be associated with it as compared to a fixed dose rate of gemcitabine plus cisplatin."}
 {"nctId": "NCT02248480", "briefTitle": "A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan", "officialTitle": "Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Osteoarthritis and Knee Pain in Japan", "overallStatus": "COMPLETED", "startDate": "2014-10", "completionDate": "2015-06", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Shionogi"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 354, "briefSummary": "The main purpose of this study is to evaluate the efficacy of the study drug known as duloxetine in participants with chronic osteoarthritis (OA) and knee pain in Japan.", "conditions": ["Osteoarthritis of the Knee"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": ["LY248686"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Osteoarthritis, Knee"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": true, "classifyText": "A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan Osteoarthritis of the Knee Duloxetine Placebo Osteoarthritis, Knee Duloxetine Hydrochloride The main purpose of this study is to evaluate the efficacy of the study drug known as duloxetine in participants with chronic osteoarthritis (OA) and knee pain in Japan."}
 {"nctId": "NCT01460368", "briefTitle": "A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart", "officialTitle": "A Placebo- and Positive-Controlled Study of the Electrophysiological Effects of a Supratherapeutic Dose of LY2409021 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2011-10", "completionDate": "2012-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 67, "briefSummary": "Part A: The purpose of Part A of the study is to look at the electrocardiogram (ECG) effects due to blood sugar changes after a meal compared to when LY2409021 is also given with a meal.\n\nPart B: The purpose of Part B is to evaluate the effect of LY2409021, when given at a dose level much higher than what would normally be given, on the electrical activity of the heart as measured by ECG in relation to placebo and moxifloxacin.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2409021", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Moxifloxacin", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["adomeglivant", "Moxifloxacin"], "hasResults": true, "classifyText": "A Study on the Effects of LY2409021 on the Electrical Impulses of the Heart Diabetes Mellitus, Type 2 LY2409021 Placebo Moxifloxacin Diabetes Mellitus, Type 2 adomeglivant Moxifloxacin Part A: The purpose of Part A of the study is to look at the electrocardiogram (ECG) effects due to blood sugar changes after a meal compared to when LY2409021 is also given with a meal.\n\nPart B: The purpose of Part B is to evaluate the effect of LY2409021, when given at a dose level much higher than what would normally be given, on the electrical activity of the heart as measured by ECG in relation to placebo and moxifloxacin."}
 {"nctId": "NCT00162318", "briefTitle": "A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer", "officialTitle": "A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2005-03", "completionDate": "2006-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 30, "briefSummary": "The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.", "conditions": ["Non-Small-Cell Lung Carcinoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Cetuximab + Gefitinib", "otherNames": ["Erbitux"]}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Cetuximab", "Gefitinib"], "hasResults": false, "classifyText": "A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Non-Small-Cell Lung Carcinoma Cetuximab + Gefitinib Carcinoma, Non-Small-Cell Lung Cetuximab Gefitinib The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer."}
 {"nctId": "NCT02260648", "briefTitle": "A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia", "officialTitle": "A Double-Blind Efficacy and Safety Study of Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia", "overallStatus": "TERMINATED", "startDate": "2015-01", "completionDate": "2015-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 149, "briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of the study drug known as evacetrapib when administered in combination with atorvastatin for 12 weeks in Japanese participants with primary hypercholesterolemia.", "conditions": ["Hypercholesterolemia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Evacetrapib", "otherNames": ["LY2484595"]}, {"type": "DRUG", "name": "Ezetimibe", "otherNames": []}, {"type": "DRUG", "name": "Atorvastatin", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Hypercholesterolemia"], "meshInterventions": ["evacetrapib", "Ezetimibe", "Atorvastatin"], "hasResults": true, "classifyText": "A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia Hypercholesterolemia Evacetrapib Ezetimibe Atorvastatin Placebo Hypercholesterolemia evacetrapib Ezetimibe Atorvastatin The main purpose of this study is to evaluate the efficacy and safety of the study drug known as evacetrapib when administered in combination with atorvastatin for 12 weeks in Japanese participants with primary hypercholesterolemia."}
 {"nctId": "NCT00191074", "briefTitle": "Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature", "officialTitle": "Phase III Study of Humatrope in Non-Growth Hormone Deficient Children With Short Stature", "overallStatus": "COMPLETED", "startDate": "2001-02", "completionDate": "2006-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 11, "briefSummary": "After approval of amendment (g), patients who were still receiving study drug at the time were scheduled for a study visit. In addition, patients who had discontinued early from the core, blinded phase of the study were contacted.\n\nAll of these patients were offered the opportunity to enter the unblinded extension phase (if they met eligibility criteria) and continue somatropin treatment (regardless of initial treatment randomization) until they reached final height.", "conditions": ["Growth Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "somatropin, rDNA origin, for injection", "otherNames": []}], "meshConditions": ["Growth Disorders"], "meshInterventions": ["Human Growth Hormone", "WW Domain-Containing Oxidoreductase"], "hasResults": false, "classifyText": "Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature Growth Disorder somatropin, rDNA origin, for injection Growth Disorders Human Growth Hormone WW Domain-Containing Oxidoreductase After approval of amendment (g), patients who were still receiving study drug at the time were scheduled for a study visit. In addition, patients who had discontinued early from the core, blinded phase of the study were contacted.\n\nAll of these patients were offered the opportunity to enter the unblinded extension phase (if they met eligibility criteria) and continue somatropin treatment (regardless of initial treatment randomization) until they reached final height."}
 {"nctId": "NCT03343587", "briefTitle": "A Study of LY3375880 in Healthy Participants", "officialTitle": "A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3375880 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2017-11-17", "completionDate": "2018-11-16", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 80, "briefSummary": "The purpose of this study is to evaluate how well LY3375880 (study drug) is tolerated in healthy participants and what side effects may occur. The study drug will be administered either subcutaneously (SC) under the skin or intravenously (IV) into a vein in the arm.\n\nThis is a two-part study. Participants will enroll in only one part. Part one will last about 16 weeks including screening and follow-up. This part will include 2 nights at the study site. Part two will last about 20 weeks including screening and follow-up. This part will include 2 nights at the study site for each dose.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3375880 IV", "otherNames": []}, {"type": "DRUG", "name": "LY3375880 SC", "otherNames": []}, {"type": "DRUG", "name": "Placebo IV", "otherNames": []}, {"type": "DRUG", "name": "Placebo SC", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3375880 in Healthy Participants Healthy LY3375880 IV LY3375880 SC Placebo IV Placebo SC The purpose of this study is to evaluate how well LY3375880 (study drug) is tolerated in healthy participants and what side effects may occur. The study drug will be administered either subcutaneously (SC) under the skin or intravenously (IV) into a vein in the arm.\n\nThis is a two-part study. Participants will enroll in only one part. Part one will last about 16 weeks including screening and follow-up. This part will include 2 nights at the study site. Part two will last about 20 weeks including screening and follow-up. This part will include 2 nights at the study site for each dose."}
 {"nctId": "NCT06045221", "briefTitle": "A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin", "officialTitle": "A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)", "overallStatus": "COMPLETED", "startDate": "2023-09-22", "completionDate": "2025-08-22", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1698, "briefSummary": "The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Orforglipron", "otherNames": ["LY3502970"]}, {"type": "DRUG", "name": "Semaglutide", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["orforglipron", "semaglutide"], "hasResults": false, "classifyText": "A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin Type 2 Diabetes Orforglipron Semaglutide Diabetes Mellitus, Type 2 orforglipron semaglutide The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks."}
 {"nctId": "NCT01432938", "briefTitle": "A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants", "officialTitle": "The Effect of Dulaglutide (LY2189265) on the Pharmacokinetics and Pharmacodynamics of Single Dose Warfarin in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2011-09", "completionDate": "2011-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 28, "briefSummary": "Warfarin is a commonly used drug to prevent the blood from clotting. The purpose of this study is to determine if dulaglutide (LY2189265) affects how warfarin works. The study involves two different treatments (Treatment 1: warfarin; Treatment 2: dulaglutide + warfarin) separated by a minimum washout period of 24 days. In Treatment 1, the participant will receive 10 milligrams (mg) of warfarin on Day 1. In Treatment 2, the participant will receive a 1.5-mg dose of dulaglutide (LY2189265) as an injection on Day 1 and then a 10 mg dose of warfarin on Day 3. Participants will be randomly assigned into different treatment sequences. Participants in Treatment Sequence A will receive Treatment 1 then Treatment 2. Participants in Treatment Sequence B will receive Treatment 2 then Treatment 1.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "dulaglutide", "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Warfarin", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide", "Warfarin"], "hasResults": true, "classifyText": "A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants Diabetes Mellitus, Type 2 dulaglutide Warfarin Diabetes Mellitus, Type 2 dulaglutide Warfarin Warfarin is a commonly used drug to prevent the blood from clotting. The purpose of this study is to determine if dulaglutide (LY2189265) affects how warfarin works. The study involves two different treatments (Treatment 1: warfarin; Treatment 2: dulaglutide + warfarin) separated by a minimum washout period of 24 days. In Treatment 1, the participant will receive 10 milligrams (mg) of warfarin on Day 1. In Treatment 2, the participant will receive a 1.5-mg dose of dulaglutide (LY2189265) as an injection on Day 1 and then a 10 mg dose of warfarin on Day 3. Participants will be randomly assigned into different treatment sequences. Participants in Treatment Sequence A will receive Treatment 1 then Treatment 2. Participants in Treatment Sequence B will receive Treatment 2 then Treatment 1."}
 {"nctId": "NCT01490632", "briefTitle": "A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of Baricitinib in Patients With Moderate-to-Severe Plaque Psoriasis", "overallStatus": "COMPLETED", "startDate": "2011-12", "completionDate": "2014-08", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Incyte Corporation"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 271, "briefSummary": "This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments.", "conditions": ["Psoriasis", "Skin Diseases", "Skin Diseases, Papulosquamous"], "keywords": ["Moderate", "Severe", "Plaque", "Chronic"], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104", "INCB028050"]}], "meshConditions": ["Psoriasis", "Skin Diseases", "Skin Diseases, Papulosquamous", "Lymphoma, Follicular", "Plaque, Amyloid", "Bronchiolitis Obliterans Syndrome"], "meshInterventions": ["baricitinib"], "hasResults": true, "classifyText": "A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis Psoriasis Skin Diseases Skin Diseases, Papulosquamous Moderate Severe Plaque Chronic Placebo Baricitinib Psoriasis Skin Diseases Skin Diseases, Papulosquamous Lymphoma, Follicular Plaque, Amyloid Bronchiolitis Obliterans Syndrome baricitinib This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index (PASI) score and routine safety assessments."}
 {"nctId": "NCT01064687", "briefTitle": "A Study in Participants With Type 2 Diabetes Mellitus", "officialTitle": "A Randomized, Placebo-Controlled Comparison of the Effects of Two Doses of LY2189265 or Exenatide on Glycemic Control in Patients With Type 2 Diabetes on Stable Doses of Metformin and Pioglitazone (AWARD-1: Assessment of Weekly Administration of LY2189265 in Diabetes-1)", "overallStatus": "COMPLETED", "startDate": "2010-02", "completionDate": "2012-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 978, "briefSummary": "The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes. The participants must also be taking metformin and pioglitazone.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2189265", "otherNames": ["Dulaglutide"]}, {"type": "DRUG", "name": "Exenatide", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Metformin", "otherNames": []}, {"type": "DRUG", "name": "Pioglitazone", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide", "Exenatide", "Metformin", "Pioglitazone"], "hasResults": true, "classifyText": "A Study in Participants With Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2 LY2189265 Exenatide Placebo Metformin Pioglitazone Diabetes Mellitus, Type 2 dulaglutide Exenatide Metformin Pioglitazone The purpose of this study is to determine if LY2189265 is effective and safe in reducing hemoglobin A1c (HbA1c), as compared to placebo (no medicine), or exenatide in participants with Type 2 Diabetes. The participants must also be taking metformin and pioglitazone."}
 {"nctId": "NCT01632306", "briefTitle": "A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer", "officialTitle": "Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy", "overallStatus": "TERMINATED", "startDate": "2013-03", "completionDate": "2015-06", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Mayo Clinic"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 13, "briefSummary": "Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer.", "conditions": ["Pancreatic Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2090314", "otherNames": []}, {"type": "DRUG", "name": "FOLFOX", "otherNames": ["FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin)"]}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": ["Gemzar", "LY188011"]}, {"type": "DRUG", "name": "Nab-paclitaxel", "otherNames": []}], "meshConditions": ["Pancreatic Neoplasms"], "meshInterventions": ["3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione", "Folfox protocol", "Leucovorin", "Fluorouracil", "Oxaliplatin", "Gemcitabine", "130-nm albumin-bound paclitaxel"], "hasResults": true, "classifyText": "A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer Pancreatic Cancer LY2090314 FOLFOX Gemcitabine Nab-paclitaxel Pancreatic Neoplasms 3-(9-fluoro-2-(piperidin-1-ylcarbonyl)-1,2,3,4-tetrahydro(1,4)diazepino(6,7,1-hi)indol-7-yl)-4-imidazo(1,2-a)pyridin-3-yl-1H-pyrrole-2,5-dione Folfox protocol Leucovorin Fluorouracil Oxaliplatin Gemcitabine 130-nm albumin-bound paclitaxel Purpose of this phase I/II study is to test how well LY2090314 works in combination with different chemotherapies in treating participants with metastatic pancreatic cancer."}
 {"nctId": "NCT00415155", "briefTitle": "A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma", "officialTitle": "An Open Label, Single Arm, Phase 1b/2 Study With Pharmacokinetic Sampling to Evaluate LY2181308 in Patients With Advanced Hepatocellular Carcinoma", "overallStatus": "WITHDRAWN", "startDate": "2008-08", "completionDate": "2011-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 60, "briefSummary": "The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308.", "conditions": ["Hepatocellular Carcinoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2181308", "otherNames": []}], "meshConditions": ["Carcinoma, Hepatocellular"], "meshInterventions": ["LY 2181308"], "hasResults": false, "classifyText": "A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma LY2181308 Carcinoma, Hepatocellular LY 2181308 The primary objective of this study is to estimate the time to progressive disease for patients with advanced hepatocellular cancer who receive LY2181308."}
 {"nctId": "NCT00149214", "briefTitle": "Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens", "officialTitle": "A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel, Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2005-09", "completionDate": "2011-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 257, "briefSummary": "An open-label randomized Phase II study in order to explore two different sequential anthracycline-based neoadjuvant treatment regimens in female patients with primary, operable breast cancer (T2-T4/N0-2/M0).", "conditions": ["Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514, Alimta"]}, {"type": "DRUG", "name": "cyclophosphamide", "otherNames": []}, {"type": "DRUG", "name": "doxorubicin", "otherNames": []}, {"type": "DRUG", "name": "docetaxel", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Pemetrexed", "Cyclophosphamide", "Doxorubicin", "Docetaxel"], "hasResults": true, "classifyText": "Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens Breast Cancer pemetrexed cyclophosphamide doxorubicin docetaxel Breast Neoplasms Pemetrexed Cyclophosphamide Doxorubicin Docetaxel An open-label randomized Phase II study in order to explore two different sequential anthracycline-based neoadjuvant treatment regimens in female patients with primary, operable breast cancer (T2-T4/N0-2/M0)."}
 {"nctId": "NCT01687478", "briefTitle": "A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression", "officialTitle": "A Study to Assess the Short-Term Efficacy and Safety of Olanzapine and Fluoxetine Compared to Placebo and Fluoxetine for Nonpsychotic Treatment-Resistant Depression", "overallStatus": "TERMINATED", "startDate": "2012-09", "completionDate": "2015-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 176, "briefSummary": "The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.", "conditions": ["Treatment Resistant Depression"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Olanzapine", "otherNames": ["LY170053", "Zyprexa"]}, {"type": "DRUG", "name": "Fluoxetine", "otherNames": ["LY110140", "Prozac"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Depressive Disorder, Treatment-Resistant"], "meshInterventions": ["Olanzapine", "Fluoxetine"], "hasResults": true, "classifyText": "A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression Treatment Resistant Depression Olanzapine Fluoxetine Placebo Depressive Disorder, Treatment-Resistant Olanzapine Fluoxetine The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants."}
 {"nctId": "NCT01454284", "briefTitle": "A Study in Participants With Type I Diabetes Mellitus", "officialTitle": "The Impact of LY2605541 Versus Insulin Glargine for Patients With Type 1 Diabetes Mellitus Treated With Preprandial Insulin Lispro: a Double-Blind, Randomized, 52-week Study", "overallStatus": "COMPLETED", "startDate": "2012-01", "completionDate": "2014-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1114, "briefSummary": "The purpose of this study is:\n\n* To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment.\n* To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52 weeks of treatment.\n* To compare the number of participants on LY2605541 reaching blood sugar targets without low blood sugar episodes at night to those taking insulin glargine after 52 weeks of treatment.\n* To compare the rate of low blood sugar episodes on LY2605541 with insulin glargine during 52 weeks of treatment", "conditions": ["Diabetes Mellitus, Type 1"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Glargine", "otherNames": []}, {"type": "DRUG", "name": "LY2605541", "otherNames": []}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["LY275585", "Humalog"]}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin Glargine", "LY2605541", "Insulin Lispro"], "hasResults": true, "classifyText": "A Study in Participants With Type I Diabetes Mellitus Diabetes Mellitus, Type 1 Glargine LY2605541 Insulin Lispro Diabetes Mellitus, Type 1 Insulin Glargine LY2605541 Insulin Lispro The purpose of this study is:\n\n* To compare blood sugar control on LY2605541 with insulin glargine after 52 weeks of treatment.\n* To compare the rate of nocturnal low blood sugar episodes on LY2605541 with insulin glargine during 52 weeks of treatment.\n* To compare the number of participants on LY2605541 reaching blood sugar targets without low blood sugar episodes at night to those taking insulin glargine after 52 weeks of treatment.\n* To compare the rate of low blood sugar episodes on LY2605541 with insulin glargine during 52 weeks of treatment"}
 {"nctId": "NCT03270644", "briefTitle": "A Study of Lasmiditan and Propranolol in Healthy Participants", "officialTitle": "Effect of Lasmiditan on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Propranolol", "overallStatus": "COMPLETED", "startDate": "2017-08-31", "completionDate": "2017-11-22", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 44, "briefSummary": "This study will assess the effects on heart rate and blood pressure when a single dose of lasmiditan is administered with a daily dose of propranolol. This study will also measure how much lasmiditan gets into the bloodstream after taking lasmiditan alone and after taking it together with propranolol. The study will also look at how well both drugs are tolerated. Information about any side effects that may occur will be collected.\n\nThis study will last approximately 45 days including screening. This study will require 13 days/12 nights in a Clinical Research Unit (CRU) followed by 1 follow-up appointment approximately 7 days after the last dose. Screening is required within 28 days prior to the start of the study.\n\nThis study is for research purposes only and is not intended to treat any medical condition.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Lasmiditan", "otherNames": ["LY573144"]}, {"type": "DRUG", "name": "Propranolol", "otherNames": []}], "meshConditions": [], "meshInterventions": ["lasmiditan", "Propranolol"], "hasResults": true, "classifyText": "A Study of Lasmiditan and Propranolol in Healthy Participants Healthy Lasmiditan Propranolol lasmiditan Propranolol This study will assess the effects on heart rate and blood pressure when a single dose of lasmiditan is administered with a daily dose of propranolol. This study will also measure how much lasmiditan gets into the bloodstream after taking lasmiditan alone and after taking it together with propranolol. The study will also look at how well both drugs are tolerated. Information about any side effects that may occur will be collected.\n\nThis study will last approximately 45 days including screening. This study will require 13 days/12 nights in a Clinical Research Unit (CRU) followed by 1 follow-up appointment approximately 7 days after the last dose. Screening is required within 28 days prior to the start of the study.\n\nThis study is for research purposes only and is not intended to treat any medical condition."}
 {"nctId": "NCT01107899", "briefTitle": "Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes", "officialTitle": "Recovery of Platelet Function After a Loading Dose of Prasugrel or Clopidogrel in Aspirin-Treated Subjects Presenting With Symptoms of Acute Coronary Syndromes", "overallStatus": "TERMINATED", "startDate": "2009-10", "completionDate": "2010-12", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Daiichi Sankyo Co., Ltd."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 29, "briefSummary": "To investigate how platelets recover to normal function in subjects who have symptoms of a heart attack or unstable angina and who get a loading dose of prasugrel or clopidogrel for planned coronary angiography.", "conditions": ["Acute Coronary Syndromes"], "keywords": ["Acute Coronary Syndromes", "Angina", "Platelet Function", "Coronary Angiography", "Clinical Symptoms of Angina", "Positive Stress Test"], "interventions": [{"type": "DRUG", "name": "clopidogrel", "otherNames": []}, {"type": "DRUG", "name": "prasugrel", "otherNames": ["Efient\u00ae", "Effient\u00ae", "LY640315", "CS747"]}], "meshConditions": ["Acute Coronary Syndrome", "Angina Pectoris"], "meshInterventions": ["Clopidogrel", "Prasugrel Hydrochloride"], "hasResults": true, "classifyText": "Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes Acute Coronary Syndromes Acute Coronary Syndromes Angina Platelet Function Coronary Angiography Clinical Symptoms of Angina Positive Stress Test clopidogrel prasugrel Acute Coronary Syndrome Angina Pectoris Clopidogrel Prasugrel Hydrochloride To investigate how platelets recover to normal function in subjects who have symptoms of a heart attack or unstable angina and who get a loading dose of prasugrel or clopidogrel for planned coronary angiography."}
 {"nctId": "NCT05086289", "briefTitle": "Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain", "officialTitle": "Randomized Placebo-controlled Phase 2 Clinical Trial to Evaluate LY3526318 for the Treatment of Chronic Low Back Pain", "overallStatus": "COMPLETED", "startDate": "2021-10-25", "completionDate": "2022-06-17", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 159, "briefSummary": "The purpose of this study is to test whether LY3526318 is efficacious and safe in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.", "conditions": ["Chronic Low-back Pain"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3526318", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": true, "classifyText": "Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain Chronic Low-back Pain LY3526318 Placebo The purpose of this study is to test whether LY3526318 is efficacious and safe in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain."}
 {"nctId": "NCT04088396", "briefTitle": "A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)", "officialTitle": "Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.", "overallStatus": "RECRUITING", "startDate": "2020-02-12", "completionDate": "2026-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 58, "briefSummary": "The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib.", "conditions": ["Systemic Juvenile Idiopathic Arthritis"], "keywords": ["Systemic", "Fever", "Flare", "sJIA", "JIA"], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104"]}, {"type": "DRUG", "name": "Tocilizumab", "otherNames": []}], "meshConditions": ["Arthritis, Juvenile", "Fever"], "meshInterventions": ["baricitinib", "tocilizumab"], "hasResults": false, "classifyText": "A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) Systemic Juvenile Idiopathic Arthritis Systemic Fever Flare sJIA JIA Baricitinib Tocilizumab Arthritis, Juvenile Fever baricitinib tocilizumab The reason for this study is to see if the study drug baricitinib is safe and effective in participants from 1 year to less than 18 years old with systemic juvenile idiopathic arthritis (sJIA). Participants are assigned to 1 of 2 cohorts. In cohort 1, participants will receive baricitinib or tocilizumab reference. In cohort 2, participants will receive baricitinib."}
 {"nctId": "NCT00192062", "briefTitle": "A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer", "officialTitle": "A Phase II Trial of Gemcitabine (Gemzar) Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2004-07", "completionDate": "2007-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 80, "briefSummary": "This is a Phase II study of gemcitabine- Vinorelbine combination in a 3-weekly schedule as first line chemotherapy in patients with metastatic breast cancer. Eighty patients with measurable disease will be enrolled in the study. Gemcitabine will be used at 1000 mg/m2, vinorelbine at 25mg/m2. Every cycle, vinorelbine will be administered before gemcitabine. After the initial dose, modifications of Gemcitabine and vinorelbine doses are allowed based on patient toxicity\n\nStudy therapy may continue until:\n\n* There is evidence of progressive disease\n* The patient experiences unacceptable toxicity.\n* The investigator decides that the patient should be discontinued\n* The patient requests discontinuation\n* The patient has received 6 cycles of the regimen(if the physician decides to continue after 6 cycles-this will be done after consultation with the sponsor)\n* Discontinuation from study therapy is indicated according to the protocol It's the investigator's responsibility to strictly stick to the protocol procedures. It needs to be discussed with Lilly medical designee in advance when any special situation occurs which has not been defined in protocol.\n\nAfter patients discontinue from study therapy, they proceed to the post-study follow up phase of the study. Assessments to take place during this phase are outlined in the protocol.", "conditions": ["Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "gemcitabine", "otherNames": []}, {"type": "DRUG", "name": "vinorelbine", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Gemcitabine", "Vinorelbine"], "hasResults": false, "classifyText": "A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer Breast Cancer gemcitabine vinorelbine Breast Neoplasms Gemcitabine Vinorelbine This is a Phase II study of gemcitabine- Vinorelbine combination in a 3-weekly schedule as first line chemotherapy in patients with metastatic breast cancer. Eighty patients with measurable disease will be enrolled in the study. Gemcitabine will be used at 1000 mg/m2, vinorelbine at 25mg/m2. Every cycle, vinorelbine will be administered before gemcitabine. After the initial dose, modifications of Gemcitabine and vinorelbine doses are allowed based on patient toxicity\n\nStudy therapy may continue until:\n\n* There is evidence of progressive disease\n* The patient experiences unacceptable toxicity.\n* The investigator decides that the patient should be discontinued\n* The patient requests discontinuation\n* The patient has received 6 cycles of the regimen(if the physician decides to continue after 6 cycles-this will be done after consultation with the sponsor)\n* Discontinuation from study therapy is indicated according to the protocol It's the investigator's responsibility to strictly stick to "}
 {"nctId": "NCT06238479", "briefTitle": "A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors", "officialTitle": "A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Recurrent, Advanced or Metastatic Solid Tumors", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2024-03-05", "completionDate": "2027-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 490, "briefSummary": "The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.", "conditions": ["Metastatic Solid Tumor", "Recurrent Solid Tumor", "Advanced Solid Tumor", "Urinary Bladder Neoplasm", "Triple Negative Breast Cancer", "Non-small Cell Lung Cancer", "Esophageal Cancer", "Pancreatic Cancer", "Ovarian Cancer", "Cervical Cancer", "Head and Neck Squamous Cell Carcinoma", "Prostate Cancer", "Renal Pelvis Cancer", "Bladder Cancer"], "keywords": ["Bladder Cancer", "Bladder Neoplasm", "Bladder Urothelial Carcinoma", "Urinary Bladder Cancer", "Urinary Tract Cancer", "Urothelial Neoplasms", "Renal Pelvis Cancer", "Ureter Cancer", "Nectin-4", "Antibody Drug Conjugate (ADC)"], "interventions": [{"type": "DRUG", "name": "LY4101174", "otherNames": []}], "meshConditions": ["Neoplasm Metastasis", "Urinary Bladder Neoplasms", "Triple Negative Breast Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Esophageal Neoplasms", "Pancreatic Neoplasms", "Ovarian Neoplasms", "Uterine Cervical Neoplasms", "Squamous Cell Carcinoma of Head and Neck", "Prostatic Neoplasms", "Urologic Neoplasms", "Ureteral Neoplasms"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors Metastatic Solid Tumor Recurrent Solid Tumor Advanced Solid Tumor Urinary Bladder Neoplasm Triple Negative Breast Cancer Non-small Cell Lung Cancer Esophageal Cancer Pancreatic Cancer Ovarian Cancer Cervical Cancer Head and Neck Squamous Cell Carcinoma Prostate Cancer Renal Pelvis Cancer Bladder Cancer Bladder Cancer Bladder Neoplasm Bladder Urothelial Carcinoma Urinary Bladder Cancer Urinary Tract Cancer Urothelial Neoplasms Renal Pelvis Cancer Ureter Cancer Nectin-4 Antibody Drug Conjugate (ADC) LY4101174 Neoplasm Metastasis Urinary Bladder Neoplasms Triple Negative Breast Neoplasms Carcinoma, Non-Small-Cell Lung Esophageal Neoplasms Pancreatic Neoplasms Ovarian Neoplasms Uterine Cervical Neoplasms Squamous Cell Carcinoma of Head and Neck Prostatic Neoplasms Urologic Neoplasms Ureteral Neoplasms The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years."}
 {"nctId": "NCT02672423", "briefTitle": "A Study of Abemaciclib in Healthy Participants", "officialTitle": "A Bioequivalence Study Comparing Abemaciclib Capsule and Tablet Formulations and Effect of Food on Abemaciclib Tablet Pharmacokinetics in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2016-02", "completionDate": "2016-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 127, "briefSummary": "The purpose of this study is to measure how much abemaciclib gets into the blood stream and how long it takes the body to get rid of it when given as capsules versus a tablet(s). The effect of a high fat meal on the tablet formulation will also be evaluated. In addition, the tolerability of abemaciclib tablet and capsule formulations will be evaluated. Information about any side effects that may occur will also be collected.\n\nThis study has 3 parts. Parts A and C will last about 44 days including follow-up. Part B will last about 60 days including follow-up. Screening may occur up to 28 days before the first dose of study drug. Participants are only allowed to enroll in one part.\n\nThis study is for research purposes only and is not intended to treat any medical condition.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Abemaciclib Capsules (Reference Formulation)", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Abemaciclib Tablet (Test Formulation)", "otherNames": ["LY2835219"]}], "meshConditions": [], "meshInterventions": ["abemaciclib"], "hasResults": true, "classifyText": "A Study of Abemaciclib in Healthy Participants Healthy Abemaciclib Capsules (Reference Formulation) Abemaciclib Tablet (Test Formulation) abemaciclib The purpose of this study is to measure how much abemaciclib gets into the blood stream and how long it takes the body to get rid of it when given as capsules versus a tablet(s). The effect of a high fat meal on the tablet formulation will also be evaluated. In addition, the tolerability of abemaciclib tablet and capsule formulations will be evaluated. Information about any side effects that may occur will also be collected.\n\nThis study has 3 parts. Parts A and C will last about 44 days including follow-up. Part B will last about 60 days including follow-up. Screening may occur up to 28 days before the first dose of study drug. Participants are only allowed to enroll in one part.\n\nThis study is for research purposes only and is not intended to treat any medical condition."}
 {"nctId": "NCT01624259", "briefTitle": "A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes", "officialTitle": "A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)", "overallStatus": "COMPLETED", "startDate": "2012-06", "completionDate": "2013-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 599, "briefSummary": "The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2189265", "otherNames": ["Dulaglutide"]}, {"type": "DRUG", "name": "Liraglutide", "otherNames": []}, {"type": "DRUG", "name": "Metformin", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide", "Liraglutide", "Metformin"], "hasResults": true, "classifyText": "A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes Type 2 Diabetes LY2189265 Liraglutide Metformin Diabetes Mellitus, Type 2 dulaglutide Liraglutide Metformin The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin."}
 {"nctId": "NCT03456713", "briefTitle": "A Study of LY3074828 in Healthy Participants", "officialTitle": "A Safety, Tolerability, and Pharmacokinetic Study of 1- and 2-mL Injections of LY3074828 Solution Using Investigational Pre-filled Syringes and Investigational Autoinjectors in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2018-03-06", "completionDate": "2018-08-13", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 72, "briefSummary": "The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828, when given as a solution formulation in different devices. The tolerability of LY3074828 will also be evaluated and information about any side effects experienced will be collected.\n\nScreening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be approximately 13 weeks, not including screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "LY3074828", "otherNames": []}], "meshConditions": [], "meshInterventions": ["mirikizumab"], "hasResults": true, "classifyText": "A Study of LY3074828 in Healthy Participants Healthy LY3074828 mirikizumab The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828, when given as a solution formulation in different devices. The tolerability of LY3074828 will also be evaluated and information about any side effects experienced will be collected.\n\nScreening is required within 28 days prior to the start of the study. For each participant, the total duration of the clinical trial will be approximately 13 weeks, not including screening."}
 {"nctId": "NCT00377520", "briefTitle": "A Trial for Patients With Advanced/Recurrent Endometrial Cancer", "officialTitle": "A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma", "overallStatus": "COMPLETED", "startDate": "2006-09", "completionDate": "2008-09", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Gynecologic Oncology Group"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 27, "briefSummary": "The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma.", "conditions": ["Neoplasms", "Neoplasms by Site", "Urogenital Neoplasms", "Genital Neoplasms, Female", "Uterine Neoplasms", "Endometrial Neoplasms", "Cancer of Endometrium", "Endometrial Cancer", "Cancer of the Endometrium", "Endometrium Cancer", "Neoplasms, Endometrial"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514", "Alimta"]}], "meshConditions": ["Neoplasms", "Neoplasms by Site", "Urogenital Neoplasms", "Genital Neoplasms, Female", "Uterine Neoplasms", "Endometrial Neoplasms"], "meshInterventions": ["Pemetrexed"], "hasResults": true, "classifyText": "A Trial for Patients With Advanced/Recurrent Endometrial Cancer Neoplasms Neoplasms by Site Urogenital Neoplasms Genital Neoplasms, Female Uterine Neoplasms Endometrial Neoplasms Cancer of Endometrium Endometrial Cancer Cancer of the Endometrium Endometrium Cancer Neoplasms, Endometrial pemetrexed Neoplasms Neoplasms by Site Urogenital Neoplasms Genital Neoplasms, Female Uterine Neoplasms Endometrial Neoplasms Pemetrexed The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma."}
 {"nctId": "NCT01997411", "briefTitle": "Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes", "officialTitle": "Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes", "overallStatus": "COMPLETED", "startDate": "2013-11", "completionDate": "2015-01", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Jaeb Center for Health Research", "Locemia Solutions ULC"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 48, "briefSummary": "The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection. In addition, the safety and tolerability of glucagon given nasally was evaluated.", "conditions": ["Diabetes Mellitus, Type 1"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Nasal Glucagon", "otherNames": ["AMG504-1", "LY900018"]}, {"type": "DRUG", "name": "Intramuscular Glucagon", "otherNames": ["GlucaGen HypoKit"]}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": [], "hasResults": true, "classifyText": "Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes Diabetes Mellitus, Type 1 Nasal Glucagon Intramuscular Glucagon Diabetes Mellitus, Type 1 The purpose of this study was to assess how glucagon administered nasally, using a nasal dosing delivery device, works in children and adolescents compared with commercially-available glucagon given by injection. In addition, the safety and tolerability of glucagon given nasally was evaluated."}
 {"nctId": "NCT02783599", "briefTitle": "A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma", "officialTitle": "A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy", "overallStatus": "COMPLETED", "startDate": "2016-10-11", "completionDate": "2018-07-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 51, "briefSummary": "The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS).", "conditions": ["Soft Tissue Sarcoma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Olaratumab", "otherNames": ["LY3012207"]}, {"type": "DRUG", "name": "Doxorubicin", "otherNames": []}, {"type": "RADIATION", "name": "External Beam Radiotherapy", "otherNames": []}], "meshConditions": ["Sarcoma"], "meshInterventions": ["olaratumab", "Doxorubicin"], "hasResults": true, "classifyText": "A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma Soft Tissue Sarcoma Olaratumab Doxorubicin External Beam Radiotherapy Sarcoma olaratumab Doxorubicin The purpose of this study is to evaluate potential biomarkers and method of action, efficacy and safety of olaratumab in participants with soft tissue sarcoma (STS)."}
 {"nctId": "NCT03841630", "briefTitle": "A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants", "officialTitle": "A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3437943 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2019-03-13", "completionDate": "2019-07-25", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 45, "briefSummary": "This study is being conducted to determine the side effects related to LY3437943 given as a single injection under the skin to healthy participants. Blood tests will be performed to check how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3437943 or placebo. The study will last up to approximately 71 days for each participant, including screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3437943", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": ["retatrutide"], "hasResults": false, "classifyText": "A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants Healthy LY3437943 Placebo retatrutide This study is being conducted to determine the side effects related to LY3437943 given as a single injection under the skin to healthy participants. Blood tests will be performed to check how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3437943 or placebo. The study will last up to approximately 71 days for each participant, including screening."}
 {"nctId": "NCT01097707", "briefTitle": "A Study in Men With Benign Prostatic Hyperplasia", "officialTitle": "A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men With Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH)", "overallStatus": "TERMINATED", "startDate": "2010-04", "completionDate": "2011-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 414, "briefSummary": "The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)", "conditions": ["Benign Prostatic Hyperplasia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY500307", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Prostatic Hyperplasia"], "meshInterventions": ["erteberel"], "hasResults": true, "classifyText": "A Study in Men With Benign Prostatic Hyperplasia Benign Prostatic Hyperplasia LY500307 Placebo Prostatic Hyperplasia erteberel The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)"}
 {"nctId": "NCT05440136", "briefTitle": "A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants", "officialTitle": "A Single-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3462817 in Healthy Japanese and Non-Japanese Participants", "overallStatus": "COMPLETED", "startDate": "2022-06-28", "completionDate": "2023-03-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 33, "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of LY3462817 in healthy Japanese and non-Japanese participants. The study will also assess how fast LY3462817 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 12 weeks.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3462817 (SC)", "otherNames": []}, {"type": "DRUG", "name": "Placebo (SC)", "otherNames": []}, {"type": "DRUG", "name": "LY3462817 (IV)", "otherNames": []}, {"type": "DRUG", "name": "Placebo (IV)", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants Healthy LY3462817 (SC) Placebo (SC) LY3462817 (IV) Placebo (IV) The main purpose of this study is to evaluate the safety and tolerability of LY3462817 in healthy Japanese and non-Japanese participants. The study will also assess how fast LY3462817 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 12 weeks."}
 {"nctId": "NCT00035971", "briefTitle": "EVA: Evista Alendronate Comparison", "officialTitle": null, "overallStatus": "COMPLETED", "startDate": null, "completionDate": null, "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": null, "briefSummary": "The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures", "conditions": ["Osteoporosis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "raloxifene HCI and alendronate Na", "otherNames": []}], "meshConditions": ["Osteoporosis"], "meshInterventions": [], "hasResults": false, "classifyText": "EVA: Evista Alendronate Comparison Osteoporosis raloxifene HCI and alendronate Na Osteoporosis The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures"}
 {"nctId": "NCT00191100", "briefTitle": "Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix", "officialTitle": "Phase 3 Randomized Comparison of Concurrent Gemcitabine, Cisplatin, and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Cancer of the Cervix Stages IIB to IVA", "overallStatus": "COMPLETED", "startDate": "2002-05", "completionDate": "2008-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 515, "briefSummary": "The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by adjuvant gemcitabine and cisplatin and the other half will receive cisplatin along with radiation therapy without adjuvant therapy.", "conditions": ["Cancer of Cervix"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Gemcitabine", "otherNames": ["LY188011", "Gemzar"]}, {"type": "DRUG", "name": "Cisplatin", "otherNames": []}, {"type": "RADIATION", "name": "Brachytherapy", "otherNames": []}, {"type": "RADIATION", "name": "Pelvic radiation", "otherNames": []}], "meshConditions": ["Uterine Cervical Neoplasms"], "meshInterventions": ["Gemcitabine", "Cisplatin", "Brachytherapy"], "hasResults": true, "classifyText": "Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix Cancer of Cervix Gemcitabine Cisplatin Brachytherapy Pelvic radiation Uterine Cervical Neoplasms Gemcitabine Cisplatin Brachytherapy The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by adjuvant gemcitabine and cisplatin and the other half will receive cisplatin along with radiation therapy without adjuvant therapy."}
 {"nctId": "NCT04975295", "briefTitle": "A Study of LY3361237 in Participants With Psoriasis", "officialTitle": "A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Participants With Psoriasis", "overallStatus": "COMPLETED", "startDate": "2021-07-27", "completionDate": "2022-11-29", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 21, "briefSummary": "The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis. LY3361237 will be administered by injections just under the skin. The study will last up to 41 weeks and may include up to 15 visits to the study center.", "conditions": ["Psoriasis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3361237", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Psoriasis"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3361237 in Participants With Psoriasis Psoriasis LY3361237 Placebo Psoriasis The main purpose of this study is to learn more about the safety and tolerability of LY3361237 and any side effects that might be associated with it when given to participants with psoriasis. LY3361237 will be administered by injections just under the skin. The study will last up to 41 weeks and may include up to 15 visits to the study center."}
 {"nctId": "NCT01134107", "briefTitle": "Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use", "officialTitle": "A Double-Blind, Randomized, Crossover Trial of CSII Reservoir In-use Comparing Insulin Lispro Formulation to Insulin Aspart in Patients With Type 1 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2010-11", "completionDate": "2011-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 133, "briefSummary": "Patients will continue to use their current insulin pump for this study. Patients will receive insulin lispro and insulin aspart during this study. One medication will be taken for 12 weeks and then the other medication for 12 weeks. Neither the patient nor the study doctor will know which medication is being taken at any time. The order in which the two medications are taken will be determined by chance.", "conditions": ["Diabetes Mellitus, Type 1"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Insulin Lispro 6 Day (6D)", "otherNames": ["Insulin Lispro Formulation", "Humalog", "LY275585"]}, {"type": "DRUG", "name": "Insulin Aspart 6 Day (6D)", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Insulin Lispro", "Insulin Aspart"], "hasResults": true, "classifyText": "Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use Diabetes Mellitus, Type 1 Insulin Lispro 6 Day (6D) Insulin Aspart 6 Day (6D) Diabetes Mellitus, Type 1 Insulin Lispro Insulin Aspart Patients will continue to use their current insulin pump for this study. Patients will receive insulin lispro and insulin aspart during this study. One medication will be taken for 12 weeks and then the other medication for 12 weeks. Neither the patient nor the study doctor will know which medication is being taken at any time. The order in which the two medications are taken will be determined by chance."}
 {"nctId": "NCT00190957", "briefTitle": "Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse", "officialTitle": "Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse: A Randomized, Placebo-Controlled Trial", "overallStatus": "COMPLETED", "startDate": "2004-08", "completionDate": "2006-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 140, "briefSummary": "Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse", "conditions": ["ADHD", "Comorbid Alcohol Abuse"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Atomoxetine", "otherNames": []}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Attention Deficit Disorder with Hyperactivity"], "meshInterventions": ["Atomoxetine Hydrochloride"], "hasResults": false, "classifyText": "Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse ADHD Comorbid Alcohol Abuse Atomoxetine placebo Attention Deficit Disorder with Hyperactivity Atomoxetine Hydrochloride Atomoxetine Treatment of Adults with ADHD and Comorbid Alcohol Abuse"}
 {"nctId": "NCT00191828", "briefTitle": "A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme", "officialTitle": "A Prospective/Parallel Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme", "overallStatus": "COMPLETED", "startDate": "2003-03", "completionDate": "2005-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 60, "briefSummary": "Olanzapine is an atypical antipsychotic agent indicated for the treatment of schizophrenia and moderate to severe manic episode.\n\nOlanzapine is among the many antipsychotic agents associated with weight gain . The mechanism for antipsychotic drug-related weight gain is not known, although antagonism of serotonin receptors, especially the 5HT2C , and histamine receptors has been hypothesized.\n\nThe purpose of this study is to observe the efficacy of a psychoeducational programme in managing the increased weight as a side effect of the olanzapine treatment.\n\nInterventions to prevent weight gain associated with olanzapine should at least include periodic monitoring and recommendations for changes in diet and physical activity.\n\nThis is a phase IV, randomised, parallel study of subjects previously treated with olanzapine as antipsychotic monotherapy, which have shown an increase of B.M.I. \\>7% from the beginning of antipsychotic treatment (assessed during the routine visits). For the first 12 weeks of the trial approximately 60 outpatients, enrolled in one site during a period of one year, will be randomised in a 1:1 ratio into 2 treatment groups: olanzapine + psychoeducational programme or olanzapine alone. In the following 12 weeks of the study all patients undergo the psychoeducational programme. The efficacy of this programme will be assessed monitoring the mean difference from baseline to endpoint in total body weight and BMI.", "conditions": ["Weight Gain"], "keywords": [], "interventions": [{"type": "DRUG", "name": "olanzapine", "otherNames": []}], "meshConditions": ["Weight Gain"], "meshInterventions": ["Olanzapine"], "hasResults": false, "classifyText": "A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational Programme Weight Gain olanzapine Weight Gain Olanzapine Olanzapine is an atypical antipsychotic agent indicated for the treatment of schizophrenia and moderate to severe manic episode.\n\nOlanzapine is among the many antipsychotic agents associated with weight gain . The mechanism for antipsychotic drug-related weight gain is not known, although antagonism of serotonin receptors, especially the 5HT2C , and histamine receptors has been hypothesized.\n\nThe purpose of this study is to observe the efficacy of a psychoeducational programme in managing the increased weight as a side effect of the olanzapine treatment.\n\nInterventions to prevent weight gain associated with olanzapine should at least include periodic monitoring and recommendations for changes in diet and physical activity.\n\nThis is a phase IV, randomised, parallel study of subjects previously treated with olanzapine as antipsychotic monotherapy, which have shown an increase of B.M.I. \\>7% from the beginning of antipsychotic treatment (assessed during the routine visits). For the first "}
 {"nctId": "NCT00670319", "briefTitle": "Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis", "officialTitle": "Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis", "overallStatus": "COMPLETED", "startDate": "1994-11", "completionDate": "1999-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 7705, "briefSummary": "To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures.", "conditions": ["Osteoporosis, Postmenopausal"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Raloxifene HCL", "otherNames": ["Evista", "LY139481"]}, {"type": "DRUG", "name": "Raloxifene HCL", "otherNames": ["Evista", "LY139481"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Osteoporosis, Postmenopausal"], "meshInterventions": ["Raloxifene Hydrochloride"], "hasResults": false, "classifyText": "Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis Osteoporosis, Postmenopausal Raloxifene HCL Raloxifene HCL Placebo Osteoporosis, Postmenopausal Raloxifene Hydrochloride To study the effect of long-term treatment with raloxifene, compared with placebo, on the rate of new vertebral fractures in osteoporotic postmenopausal women with and without existing vertebral fractures."}
 {"nctId": "NCT01477567", "briefTitle": "A First-in-Human Study of LY3009385 in Healthy Participants", "officialTitle": "A Single Ascending Dose (SAD) Study of LY3009385 in Healthy Volunteers", "overallStatus": "COMPLETED", "startDate": "2011-11", "completionDate": "2012-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 40, "briefSummary": "The main purpose of this study is to determine the safety of LY3009385 in healthy participants. The study drug is given as a single dose, by injections under the skin. Side effects will be documented. This study is approximately 28 days not including screening. Screening is required within 28 days prior to the start of the study.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3009385", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": [], "hasResults": true, "classifyText": "A First-in-Human Study of LY3009385 in Healthy Participants Diabetes Mellitus, Type 2 LY3009385 Placebo Diabetes Mellitus, Type 2 The main purpose of this study is to determine the safety of LY3009385 in healthy participants. The study drug is given as a single dose, by injections under the skin. Side effects will be documented. This study is approximately 28 days not including screening. Screening is required within 28 days prior to the start of the study."}
 {"nctId": "NCT01469000", "briefTitle": "A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)", "officialTitle": "A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations", "overallStatus": "COMPLETED", "startDate": "2012-02", "completionDate": "2017-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 195, "briefSummary": "The purpose of this study is to compare the combination of pemetrexed and gefitinib versus gefitinib alone, in terms of progression-free survival. This study is in participants who have stage IV non squamous NSCLC with activating epidermal growth factor mutations and who have not had any previous chemotherapy for stage IV disease.", "conditions": ["Carcinoma, Non Small Cell Lung"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Gefitinib", "otherNames": ["Iressa"]}, {"type": "DRUG", "name": "Pemetrexed", "otherNames": ["Alimta"]}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Gefitinib", "Pemetrexed"], "hasResults": true, "classifyText": "A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) Carcinoma, Non Small Cell Lung Gefitinib Pemetrexed Carcinoma, Non-Small-Cell Lung Gefitinib Pemetrexed The purpose of this study is to compare the combination of pemetrexed and gefitinib versus gefitinib alone, in terms of progression-free survival. This study is in participants who have stage IV non squamous NSCLC with activating epidermal growth factor mutations and who have not had any previous chemotherapy for stage IV disease."}
 {"nctId": "NCT06180967", "briefTitle": "A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants", "officialTitle": "A Phase I, Open Label, Fixed-sequence Drug Interaction Study to Investigate the Effect of Multiple Oral Doses of LOXO-305 on the Pharmacokinetics of a Single Dose of Intravenous and Oral Midazolam (CYP3A4 Substrate) in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2020-09-03", "completionDate": "2020-10-20", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Loxo Oncology, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 15, "briefSummary": "The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on how fast different formulations of midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. The study will also access how much endogenous coproporphyrins I and III as biomarkers of OATP1B1 and OATP1B3 is in the bloodstream and how the body handles and eliminates them following single and multiple oral doses of Pirtobrutinib. Safety and tolerability of Pirtobrutinib will also be evaluated. For each participant, the total duration of the study will be 59 days, including screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Midazolam Syrup", "otherNames": []}, {"type": "DRUG", "name": "Midazolam Solution", "otherNames": []}, {"type": "DRUG", "name": "Pirtobrutinib", "otherNames": ["LOXO-305", "LY3527727"]}], "meshConditions": [], "meshInterventions": ["pirtobrutinib"], "hasResults": true, "classifyText": "A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants Healthy Midazolam Syrup Midazolam Solution Pirtobrutinib pirtobrutinib The main purpose of this study is to assess the effect of Pirtobrutinib (LOXO-305) on how fast different formulations of midazolam gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. The study will also access how much endogenous coproporphyrins I and III as biomarkers of OATP1B1 and OATP1B3 is in the bloodstream and how the body handles and eliminates them following single and multiple oral doses of Pirtobrutinib. Safety and tolerability of Pirtobrutinib will also be evaluated. For each participant, the total duration of the study will be 59 days, including screening."}
 {"nctId": "NCT05931380", "briefTitle": "A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease", "officialTitle": "A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Japanese Adult Participants With Obesity Disease", "overallStatus": "COMPLETED", "startDate": "2023-07-31", "completionDate": "2025-06-19", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 238, "briefSummary": "The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.", "conditions": ["Obesity"], "keywords": ["Overweight", "Metabolism and Nutrition Disorder"], "interventions": [{"type": "DRUG", "name": "Orforglipron", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Obesity", "Overweight", "Nutrition Disorders"], "meshInterventions": ["orforglipron"], "hasResults": false, "classifyText": "A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease Obesity Overweight Metabolism and Nutrition Disorder Orforglipron Placebo Obesity Overweight Nutrition Disorders orforglipron The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems."}
 {"nctId": "NCT07046923", "briefTitle": "A Study of LY4175408 in Participants With Advanced Cancer", "officialTitle": "A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors", "overallStatus": "RECRUITING", "startDate": "2025-07-28", "completionDate": "2030-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 240, "briefSummary": "The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.", "conditions": ["Carcinoma, Non-Small-Cell Lung", "Small Cell Lung Carcinoma", "Endometrial Neoplasms", "Neoplasm Metastasis", "Triple Negative Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY4175408", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Small Cell Lung Carcinoma", "Endometrial Neoplasms", "Neoplasm Metastasis", "Triple Negative Breast Neoplasms"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY4175408 in Participants With Advanced Cancer Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma Endometrial Neoplasms Neoplasm Metastasis Triple Negative Breast Cancer LY4175408 Carcinoma, Non-Small-Cell Lung Small Cell Lung Carcinoma Endometrial Neoplasms Neoplasm Metastasis Triple Negative Breast Neoplasms The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years."}
 {"nctId": "NCT02614261", "briefTitle": "Evaluation of Galcanezumab in the Prevention of Chronic Migraine", "officialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study", "overallStatus": "COMPLETED", "startDate": "2015-11-30", "completionDate": "2021-07-14", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1117, "briefSummary": "The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine.", "conditions": ["Chronic Migraine"], "keywords": ["prevention", "prophylaxis", "headache"], "interventions": [{"type": "DRUG", "name": "Galcanezumab", "otherNames": ["LY2951742"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Headache"], "meshInterventions": ["galcanezumab"], "hasResults": true, "classifyText": "Evaluation of Galcanezumab in the Prevention of Chronic Migraine Chronic Migraine prevention prophylaxis headache Galcanezumab Placebo Headache galcanezumab The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with chronic migraine."}
 {"nctId": "NCT01168973", "briefTitle": "A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy", "officialTitle": "A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy", "overallStatus": "COMPLETED", "startDate": "2010-12", "completionDate": "2016-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1253, "briefSummary": "The purpose of the study is to compare the survival of participants who receive chemotherapy and ramucirumab versus chemotherapy alone as second line treatment for NSCLC after prior first line platinum-based chemotherapy.", "conditions": ["Non-Small Cell Lung Cancer"], "keywords": ["second line", "non small cell lung cancer", "NSCLC", "phase 3", "ramucirumab", "lung cancer", "docetaxel", "taxotere"], "interventions": [{"type": "BIOLOGICAL", "name": "Ramucirumab", "otherNames": ["IMC 1121B", "LY3009806"]}, {"type": "DRUG", "name": "Placebo (for Ramucirumab)", "otherNames": []}, {"type": "DRUG", "name": "Docetaxel", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Lung Neoplasms"], "meshInterventions": ["Ramucirumab", "Docetaxel"], "hasResults": true, "classifyText": "A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy Non-Small Cell Lung Cancer second line non small cell lung cancer NSCLC phase 3 ramucirumab lung cancer docetaxel taxotere Ramucirumab Placebo (for Ramucirumab) Docetaxel Carcinoma, Non-Small-Cell Lung Lung Neoplasms Ramucirumab Docetaxel The purpose of the study is to compare the survival of participants who receive chemotherapy and ramucirumab versus chemotherapy alone as second line treatment for NSCLC after prior first line platinum-based chemotherapy."}
 {"nctId": "NCT01421459", "briefTitle": "A Study in Adults With Type 2 Diabetes", "officialTitle": "A Prospective, Randomized, Double-Blind Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 2 Study", "overallStatus": "COMPLETED", "startDate": "2011-09", "completionDate": "2012-09", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Boehringer Ingelheim"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 759, "briefSummary": "The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Diabetes", "Type 2 Diabetes"], "interventions": [{"type": "DRUG", "name": "LY2963016", "otherNames": []}, {"type": "DRUG", "name": "Lantus", "otherNames": []}, {"type": "DRUG", "name": "OAMs", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2", "Diabetes Mellitus"], "meshInterventions": ["LY2963016 insulin glargine", "Insulin Glargine"], "hasResults": true, "classifyText": "A Study in Adults With Type 2 Diabetes Diabetes Mellitus, Type 2 Diabetes Type 2 Diabetes LY2963016 Lantus OAMs Diabetes Mellitus, Type 2 Diabetes Mellitus LY2963016 insulin glargine Insulin Glargine The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications."}
 {"nctId": "NCT01821703", "briefTitle": "A Study of LY3045697 After Multiple Oral Dosing in Healthy Participants", "officialTitle": "A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3045697 After Multiple Oral Dosing in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2013-05", "completionDate": "2013-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": null, "enrollment": 24, "briefSummary": "The purpose of this study is to investigate the safety and tolerability of LY3045697 after multiple doses and to determine how long LY3045697 remains in the body. Each participant is expected to complete 3 dosing periods. At least 7 days will pass between dosing periods.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3045697", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Spironolactone", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Spironolactone"], "hasResults": false, "classifyText": "A Study of LY3045697 After Multiple Oral Dosing in Healthy Participants Healthy Volunteers LY3045697 Placebo Spironolactone Placebo Spironolactone The purpose of this study is to investigate the safety and tolerability of LY3045697 after multiple doses and to determine how long LY3045697 remains in the body. Each participant is expected to complete 3 dosing periods. At least 7 days will pass between dosing periods."}
 {"nctId": "NCT05565742", "briefTitle": "A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]", "officialTitle": "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a)", "overallStatus": "COMPLETED", "startDate": "2022-10-20", "completionDate": "2024-10-17", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 320, "briefSummary": "The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.", "conditions": ["Lipoprotein Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3819469", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": true, "classifyText": "A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)] Lipoprotein Disorder LY3819469 Placebo The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months."}
 {"nctId": "NCT00857454", "briefTitle": "A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations", "officialTitle": "A Phase III Open-label Extension of the MTE08 Trial (A Phase III Open-label Titration Trial to Evaluate the Effectiveness and Safety of Different Doses of a Dermal Application of Testosterone MD-Lotion\u00ae (Cutaneous Solution) in Hypogonadal Men) to Evaluate Skin-safety", "overallStatus": "COMPLETED", "startDate": "2008-10", "completionDate": "2009-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 71, "briefSummary": "Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety events for a further two months of continuous use of the Testosterone MD-Lotion\u00ae (cutaneous solution) after completion of the MTE08 (NCT00702650) trial.", "conditions": ["Hypogonadism"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Testosterone MD-Lotion", "otherNames": ["LY900011", "Axiron"]}], "meshConditions": ["Hypogonadism"], "meshInterventions": ["Testosterone Propionate"], "hasResults": true, "classifyText": "A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations Hypogonadism Testosterone MD-Lotion Hypogonadism Testosterone Propionate Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will assess the occurrence of skin safety events for a further two months of continuous use of the Testosterone MD-Lotion\u00ae (cutaneous solution) after completion of the MTE08 (NCT00702650) trial."}
 {"nctId": "NCT00095199", "briefTitle": "Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer", "officialTitle": "Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy", "overallStatus": "COMPLETED", "startDate": "2005-01", "completionDate": "2011-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 939, "briefSummary": "This trial is a multicenter, open-label, randomized, Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy. Patients will receive either Docetaxel or Pemetrexed as chemotherapy at the investigator's choice. Within each chemotherapy group, patients will be randomized to receive Cetuximab plus chemotherapy or chemotherapy alone (Cetuximab \\& Pemetrexed or Pemetrexed alone; Cetuximab \\& Docetaxel or Docetaxel alone).", "conditions": ["Non Small Cell Lung Cancer"], "keywords": ["Recurrent or Progressive Non-Small Cell Lung Cancer", "Second-line therapy", "Docetaxel", "Pemetrexed", "Cetuximab", "Failed platinum-based therapy", "NSCLC"], "interventions": [{"type": "DRUG", "name": "Pemetrexed", "otherNames": ["Alimta", "LY231514"]}, {"type": "BIOLOGICAL", "name": "Cetuximab", "otherNames": ["Erbitux", "LY2939777"]}, {"type": "DRUG", "name": "Docetaxel", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Recurrence"], "meshInterventions": ["Pemetrexed", "Cetuximab", "Docetaxel"], "hasResults": true, "classifyText": "Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer Non Small Cell Lung Cancer Recurrent or Progressive Non-Small Cell Lung Cancer Second-line therapy Docetaxel Pemetrexed Cetuximab Failed platinum-based therapy NSCLC Pemetrexed Cetuximab Docetaxel Carcinoma, Non-Small-Cell Lung Recurrence Pemetrexed Cetuximab Docetaxel This trial is a multicenter, open-label, randomized, Phase III study in patients with recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial platinum-based chemotherapy. Patients will receive either Docetaxel or Pemetrexed as chemotherapy at the investigator's choice. Within each chemotherapy group, patients will be randomized to receive Cetuximab plus chemotherapy or chemotherapy alone (Cetuximab \\& Pemetrexed or Pemetrexed alone; Cetuximab \\& Docetaxel or Docetaxel alone)."}
 {"nctId": "NCT06039826", "briefTitle": "A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese", "officialTitle": "A Phase 1 Study to Investigate the Effect of LY3437943 on the Pharmacokinetics of the Combined Oral Contraceptive Ethinyl Estradiol and Drospirenone in Female Participants", "overallStatus": "COMPLETED", "startDate": "2023-09-12", "completionDate": "2024-07-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 46, "briefSummary": "The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant.", "conditions": ["Overweight"], "keywords": ["Pharmacokinetics", "Obesity", "Oral Contraceptive"], "interventions": [{"type": "DRUG", "name": "LY3437943", "otherNames": []}, {"type": "DRUG", "name": "Ethinyl Estradiol", "otherNames": []}, {"type": "DRUG", "name": "Drospirenone", "otherNames": []}], "meshConditions": ["Overweight", "Obesity"], "meshInterventions": ["retatrutide", "Ethinyl Estradiol", "drospirenone"], "hasResults": false, "classifyText": "A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese Overweight Pharmacokinetics Obesity Oral Contraceptive LY3437943 Ethinyl Estradiol Drospirenone Overweight Obesity retatrutide Ethinyl Estradiol drospirenone The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of combined oral contraceptive (COC) ethinyl estradiol and drospirenone in the blood stream in postmenopausal female participants who are overweight or obese. The safety and tolerability of LY3437943 when administered with COC will also be evaluated. This study will last up to approximately 29 weeks for each participant."}
 {"nctId": "NCT00993421", "briefTitle": "A Weight Loss Study in Overweight Men and Women", "officialTitle": "LY377604 + Sibutramine Hydrochloride Monohydrate: A Phase 2 Weight Loss Efficacy Study in Overweight/Obese Men and Women", "overallStatus": "TERMINATED", "startDate": "2009-10", "completionDate": "2010-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 343, "briefSummary": "The purpose of this study is to determine if LY377604 + sibutramine work better than LY377604 or sibutramine alone in the treatment of obesity.", "conditions": ["Obesity"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY377604", "otherNames": []}, {"type": "DRUG", "name": "Sibutramine", "otherNames": []}, {"type": "DRUG", "name": "Metoprolol", "otherNames": []}, {"type": "DRUG", "name": "Placebo sibutramine", "otherNames": []}, {"type": "DRUG", "name": "Placebo Metoprolol", "otherNames": []}, {"type": "DRUG", "name": "Placebo LY377604", "otherNames": []}], "meshConditions": ["Obesity"], "meshInterventions": ["sibutramine", "Metoprolol"], "hasResults": true, "classifyText": "A Weight Loss Study in Overweight Men and Women Obesity LY377604 Sibutramine Metoprolol Placebo sibutramine Placebo Metoprolol Placebo LY377604 Obesity sibutramine Metoprolol The purpose of this study is to determine if LY377604 + sibutramine work better than LY377604 or sibutramine alone in the treatment of obesity."}
 {"nctId": "NCT02124148", "briefTitle": "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer", "officialTitle": "A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors", "overallStatus": "COMPLETED", "startDate": "2014-06-18", "completionDate": "2020-02-13", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 167, "briefSummary": "The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple parts (A, B, C, D and E). Participants will only enroll in one part.", "conditions": ["Neoplasm Metastasis", "Colorectal Neoplasms", "Breast Cancer"], "keywords": ["cancer"], "interventions": [{"type": "DRUG", "name": "Prexasertib", "otherNames": ["LY2606368"]}, {"type": "DRUG", "name": "Cisplatin", "otherNames": []}, {"type": "DRUG", "name": "Cetuximab", "otherNames": ["Erbitux"]}, {"type": "DRUG", "name": "G-CSF", "otherNames": []}, {"type": "DRUG", "name": "Pemetrexed", "otherNames": ["Alimta"]}, {"type": "DRUG", "name": "Fluorouracil", "otherNames": []}, {"type": "DRUG", "name": "LY3023414", "otherNames": []}, {"type": "DRUG", "name": "Leucovorin", "otherNames": []}], "meshConditions": ["Neoplasm Metastasis", "Colorectal Neoplasms", "Breast Neoplasms", "Neoplasms"], "meshInterventions": ["prexasertib", "Cisplatin", "Cetuximab", "Granulocyte Colony-Stimulating Factor", "Pemetrexed", "Fluorouracil", "LY3023414", "Leucovorin"], "hasResults": false, "classifyText": "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer Neoplasm Metastasis Colorectal Neoplasms Breast Cancer cancer Prexasertib Cisplatin Cetuximab G-CSF Pemetrexed Fluorouracil LY3023414 Leucovorin Neoplasm Metastasis Colorectal Neoplasms Breast Neoplasms Neoplasms prexasertib Cisplatin Cetuximab Granulocyte Colony-Stimulating Factor Pemetrexed Fluorouracil LY3023414 Leucovorin The main purpose of this study is to investigate the safety of prexasertib in combination with other anti-cancer drugs (cisplatin, cetuximab, pemetrexed, fluorouracil or LY3023414) in participants with advanced cancer or cancer that has spread to another part of the body. The study has multiple parts (A, B, C, D and E). Participants will only enroll in one part."}
 {"nctId": "NCT00191334", "briefTitle": "Gemcitabine in Ovarian Cancer", "officialTitle": "Phase II Study of Gemcitabine Plus Cisplatin as First-Line Therapy in Patients With Epithelial Ovarian Cancer", "overallStatus": "COMPLETED", "startDate": "2004-12", "completionDate": "2007-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 50, "briefSummary": "The primary endpoint of this study is to assess the objective tumor response rate in patients with advanced epithelial ovarian cancer receiving combination of Gemcitabine at a dose 1250 mg/m2 (Day 1 and 8) with Cisplatin 75 mg/m2 (Day 1) as first-line treatment", "conditions": ["Ovarian Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "gemcitabine", "otherNames": ["LY188011", "Gemzar"]}, {"type": "DRUG", "name": "cisplatin", "otherNames": []}], "meshConditions": ["Ovarian Neoplasms"], "meshInterventions": ["Gemcitabine", "Cisplatin"], "hasResults": true, "classifyText": "Gemcitabine in Ovarian Cancer Ovarian Cancer gemcitabine cisplatin Ovarian Neoplasms Gemcitabine Cisplatin The primary endpoint of this study is to assess the objective tumor response rate in patients with advanced epithelial ovarian cancer receiving combination of Gemcitabine at a dose 1250 mg/m2 (Day 1 and 8) with Cisplatin 75 mg/m2 (Day 1) as first-line treatment"}
 {"nctId": "NCT03267732", "briefTitle": "A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)", "officialTitle": "A Phase 1 Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of AM0010 in Healthy Adult Subjects", "overallStatus": "COMPLETED", "startDate": "2017-09-05", "completionDate": "2017-10-30", "leadSponsor": "Eli Lilly and Company", "collaborators": ["ARMO BioSciences"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "OTHER", "enrollment": 24, "briefSummary": "To evaluate the pharmacokinetics of single and multiple doses of pegilodecakin in healthy participants.", "conditions": ["Healthy Adult Subjects"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "Pegilodecakin", "otherNames": ["LY3500518", "AM0010"]}], "meshConditions": [], "meshInterventions": ["pegilodecakin", "AM0010"], "hasResults": false, "classifyText": "A Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) Healthy Adult Subjects Pegilodecakin pegilodecakin AM0010 To evaluate the pharmacokinetics of single and multiple doses of pegilodecakin in healthy participants."}
 {"nctId": "NCT00125892", "briefTitle": "A Study of Duloxetine in the Treatment of Fibromyalgia", "officialTitle": "A 1-Year Safety Study of Duloxetine in Patients With Fibromyalgia Syndrome", "overallStatus": "COMPLETED", "startDate": "2005-07", "completionDate": "2007-03", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Boehringer Ingelheim"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 320, "briefSummary": "This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.", "conditions": ["Fibromyalgia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "duloxetine", "otherNames": []}], "meshConditions": ["Fibromyalgia"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "A Study of Duloxetine in the Treatment of Fibromyalgia Fibromyalgia duloxetine Fibromyalgia Duloxetine Hydrochloride This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients."}
 {"nctId": "NCT02973100", "briefTitle": "A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy", "officialTitle": "A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy", "overallStatus": "COMPLETED", "startDate": "2016-12", "completionDate": "2017-08-14", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 318, "briefSummary": "The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide"], "hasResults": true, "classifyText": "A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy Type 2 Diabetes Dulaglutide Placebo Diabetes Mellitus, Type 2 dulaglutide The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy."}
 {"nctId": "NCT00520481", "briefTitle": "Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer", "officialTitle": "Phase 2 Single Arm, Open-Label Study of IMC-A12 in Asymptomatic, Chemotherapy-Na\u00efve Patients With Metastatic Androgen-Independent Prostate Cancer", "overallStatus": "COMPLETED", "startDate": "2007-08", "completionDate": "2013-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 41, "briefSummary": "This single arm, multicenter, open-label, Phase II study will enroll chemotherapy-naive participants with metastatic, histologically-confirmed adenocarcinoma of the prostate (stage M1 D2). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Non-surgically castrated participants must continue the use of luteinizing hormone-releasing hormone (LHRH) agonists during protocol treatment.", "conditions": ["Adenocarcinoma of the Prostate"], "keywords": ["prostate cancer"], "interventions": [{"type": "DRUG", "name": "IMC-A12 (Cixutumumab)", "otherNames": ["Cixutumumab", "LY3012217"]}], "meshConditions": ["Prostatic Neoplasms"], "meshInterventions": ["cixutumumab"], "hasResults": true, "classifyText": "Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer Adenocarcinoma of the Prostate prostate cancer IMC-A12 (Cixutumumab) Prostatic Neoplasms cixutumumab This single arm, multicenter, open-label, Phase II study will enroll chemotherapy-naive participants with metastatic, histologically-confirmed adenocarcinoma of the prostate (stage M1 D2). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met. Non-surgically castrated participants must continue the use of luteinizing hormone-releasing hormone (LHRH) agonists during protocol treatment."}
 {"nctId": "NCT05901311", "briefTitle": "A Study of [14C]-LY3537982 in Healthy Participants", "officialTitle": "A Phase I, Open-label, Two-part Study of the Absorption, Metabolism, Excretion, and the Absolute Bioavailability of [14C]-LY3537982 in Healthy Adult Subjects", "overallStatus": "COMPLETED", "startDate": "2023-06-05", "completionDate": "2023-08-10", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Loxo Oncology, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 16, "briefSummary": "The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in healthy participants. This study will involve a single dose of 14C radiolabeled LY3537982. This means that a radioactive tracer substance, C14, will be incorporated into the study drug LY3537982 to investigate the study drug and its breakdown products and to find out how much of these passes from blood into urine, feces and expired air. The study will also evaluate the safety and tolerability of LY3537982. The study will be conducted in two parts. The study will last up to 71 days and 61 days for part 1 and 2, respectively.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3537982", "otherNames": ["Olomorasib"]}, {"type": "DRUG", "name": "[\u00b9\u2074C]-LY3537982", "otherNames": []}, {"type": "DRUG", "name": "[\u00b9\u2074C]-LY3537982", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of [14C]-LY3537982 in Healthy Participants Healthy LY3537982 [\u00b9\u2074C]-LY3537982 [\u00b9\u2074C]-LY3537982 The main purpose of this study is to conduct blood tests to measure how much LY3537982 is in the bloodstream and how the body handles and eliminates LY3537982 in healthy participants. This study will involve a single dose of 14C radiolabeled LY3537982. This means that a radioactive tracer substance, C14, will be incorporated into the study drug LY3537982 to investigate the study drug and its breakdown products and to find out how much of these passes from blood into urine, feces and expired air. The study will also evaluate the safety and tolerability of LY3537982. The study will be conducted in two parts. The study will last up to 71 days and 61 days for part 1 and 2, respectively."}
 {"nctId": "NCT05048719", "briefTitle": "A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus", "officialTitle": "A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2021-09-15", "completionDate": "2022-09-30", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 383, "briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3502970", "otherNames": []}, {"type": "DRUG", "name": "Dulaglutide", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["orforglipron", "dulaglutide"], "hasResults": true, "classifyText": "A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus Type 2 Diabetes LY3502970 Dulaglutide Placebo Placebo Diabetes Mellitus, Type 2 orforglipron dulaglutide The main purpose of this study is to evaluate the efficacy and safety of LY3502970 in participants with type 2 diabetes (T2D) who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin. This study will last about 30 weeks."}
 {"nctId": "NCT03715192", "briefTitle": "A Safety Study of LY3462817 in Healthy Participants", "officialTitle": "Single-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3462817", "overallStatus": "COMPLETED", "startDate": "2018-12-13", "completionDate": "2019-12-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 64, "briefSummary": "This study is being conducted to determine how safe and how well tolerated LY3462817 is when given intravenously (IV) (into a vein) and subcutaneously (SC) (just under the skin) to healthy participants. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive 1 dose of LY3462817 or placebo. The study will last about 16 weeks, including screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "LY3462817 IV", "otherNames": []}, {"type": "BIOLOGICAL", "name": "LY3462817 SC", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Safety Study of LY3462817 in Healthy Participants Healthy LY3462817 IV LY3462817 SC Placebo This study is being conducted to determine how safe and how well tolerated LY3462817 is when given intravenously (IV) (into a vein) and subcutaneously (SC) (just under the skin) to healthy participants. Blood tests will be done to check how much LY3462817 is in the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive 1 dose of LY3462817 or placebo. The study will last about 16 weeks, including screening."}
 {"nctId": "NCT00836693", "briefTitle": "Effect of Tadalafil Once a Day in Men With Erectile Dysfunction", "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy and Safety of Tadalafil (LY450190) Once a Day in Subjects With Erectile Dysfunction Who Are Na\u00efve to PDE5 Inhibitors", "overallStatus": "COMPLETED", "startDate": "2009-01", "completionDate": "2010-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 217, "briefSummary": "The primary aim of this study is to assess the efficacy and safety of tadalafil 5 mg administered once a day in patients with erectile dysfunction (ED) who are na\u00efve to PDE5 (phosphodiesterase type 5) inhibitors. Patients may be dose reduced to 2.5mg based on tolerability.", "conditions": ["Erectile Dysfunction"], "keywords": ["Erectile Dysfunction"], "interventions": [{"type": "DRUG", "name": "tadalafil", "otherNames": ["Cialis", "LY450190"]}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Erectile Dysfunction"], "meshInterventions": ["Tadalafil"], "hasResults": true, "classifyText": "Effect of Tadalafil Once a Day in Men With Erectile Dysfunction Erectile Dysfunction Erectile Dysfunction tadalafil placebo Erectile Dysfunction Tadalafil The primary aim of this study is to assess the efficacy and safety of tadalafil 5 mg administered once a day in patients with erectile dysfunction (ED) who are na\u00efve to PDE5 (phosphodiesterase type 5) inhibitors. Patients may be dose reduced to 2.5mg based on tolerability."}
 {"nctId": "NCT03381547", "briefTitle": "A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518)", "officialTitle": "An Open Label, Randomized, Single Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetics of Different Dose Levels and Dose Formulations of AM0010 in Healthy Adult Subjects", "overallStatus": "COMPLETED", "startDate": "2017-12-18", "completionDate": "2018-02-11", "leadSponsor": "Eli Lilly and Company", "collaborators": ["ARMO BioSciences"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "OTHER", "enrollment": 12, "briefSummary": "To evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants.", "conditions": ["Healthy Adult Subjects"], "keywords": [], "interventions": [{"type": "BIOLOGICAL", "name": "Pegilodecakin", "otherNames": ["LY3500518", "AM0010"]}], "meshConditions": [], "meshInterventions": ["pegilodecakin", "AM0010"], "hasResults": false, "classifyText": "A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Participants After Dosing With Pegilodecakin (LY3500518) Healthy Adult Subjects Pegilodecakin pegilodecakin AM0010 To evaluate the pharmacokinetics of different dose levels and dose formulations of pegilodecakin in healthy adult participants."}
 {"nctId": "NCT07483099", "briefTitle": "A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease", "officialTitle": "A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared With Mirikizumab in Adults With Moderately to Severely Active Crohn's Disease", "overallStatus": "NOT_YET_RECRUITING", "startDate": "2026-04", "completionDate": "2028-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 60, "briefSummary": "The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.", "conditions": ["Crohn Disease"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY4395089", "otherNames": []}, {"type": "DRUG", "name": "Mirikizumab - Intravenous (IV)", "otherNames": ["LY3074828"]}, {"type": "DRUG", "name": "Mirikizumab - Subcutaneous (SC)", "otherNames": ["LY3074828"]}], "meshConditions": ["Crohn Disease"], "meshInterventions": ["mirikizumab"], "hasResults": false, "classifyText": "A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease Crohn Disease LY4395089 Mirikizumab - Intravenous (IV) Mirikizumab - Subcutaneous (SC) Crohn Disease mirikizumab The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks."}
 {"nctId": "NCT03099109", "briefTitle": "A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors", "officialTitle": "A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors", "overallStatus": "COMPLETED", "startDate": "2017-04-12", "completionDate": "2023-08-30", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 209, "briefSummary": "The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participants with advanced relapsed/refractory solid tumors.", "conditions": ["Solid Tumor"], "keywords": ["TIM-3", "PD-L1"], "interventions": [{"type": "DRUG", "name": "LY3321367", "otherNames": []}, {"type": "DRUG", "name": "LY3300054", "otherNames": []}], "meshConditions": [], "meshInterventions": ["LY3321367", "LY3300054"], "hasResults": false, "classifyText": "A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors Solid Tumor TIM-3 PD-L1 LY3321367 LY3300054 LY3321367 LY3300054 The purpose of this study is to evaluate the safety of the study drug known as LY3321367, an anti-T-cell immunoglobulin and mucin-domain domain-containing molecule-3 (TIM-3) antibody administered alone or in combination with LY3300054, an anti-programmed death ligand 1 (PD-L1) antibody, in participants with advanced relapsed/refractory solid tumors."}
 {"nctId": "NCT00749216", "briefTitle": "Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease", "officialTitle": "Multiple-Dose Safety in Japanese Subjects With Mild-to-Moderate Alzheimer's Disease", "overallStatus": "COMPLETED", "startDate": "2008-09", "completionDate": "2009-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 33, "briefSummary": "The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple dosing Solanezumab in subjects with mild-to-moderate AD in Japanese population.", "conditions": ["Alzheimer's Disease"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Solanezumab", "otherNames": ["LY2062430"]}], "meshConditions": ["Alzheimer Disease"], "meshInterventions": ["solanezumab"], "hasResults": false, "classifyText": "Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease Alzheimer's Disease Solanezumab Alzheimer Disease solanezumab The purpose of this study is to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of multiple dosing Solanezumab in subjects with mild-to-moderate AD in Japanese population."}
 {"nctId": "NCT00762034", "briefTitle": "A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer", "officialTitle": "Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2008-12", "completionDate": "2014-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 939, "briefSummary": "This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer.", "conditions": ["Non-small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pemetrexed", "otherNames": ["Alimta", "LY231514"]}, {"type": "DRUG", "name": "Pemetrexed", "otherNames": ["Alimta", "LY231514"]}, {"type": "DRUG", "name": "Paclitaxel", "otherNames": []}, {"type": "DRUG", "name": "Carboplatin", "otherNames": []}, {"type": "BIOLOGICAL", "name": "Bevacizumab", "otherNames": []}, {"type": "BIOLOGICAL", "name": "Bevacizumab", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Pemetrexed", "Paclitaxel", "Carboplatin", "Bevacizumab"], "hasResults": true, "classifyText": "A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer Non-small Cell Lung Cancer Pemetrexed Pemetrexed Paclitaxel Carboplatin Bevacizumab Bevacizumab Carcinoma, Non-Small-Cell Lung Pemetrexed Paclitaxel Carboplatin Bevacizumab This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer."}
 {"nctId": "NCT00699998", "briefTitle": "A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects", "officialTitle": "A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed", "overallStatus": "COMPLETED", "startDate": "2008-06", "completionDate": "2012-04", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Daiichi Sankyo Co., Ltd.", "Duke Clinical Research Institute"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 9326, "briefSummary": "This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is, patients who are not managed with acute coronary revascularization).", "conditions": ["Acute Coronary Syndrome"], "keywords": ["ACS"], "interventions": [{"type": "DRUG", "name": "Clopidogrel", "otherNames": []}, {"type": "DRUG", "name": "Prasugrel", "otherNames": ["LY640315", "Effient", "Efient", "CS-747"]}, {"type": "DRUG", "name": "Commercially-available Aspirin", "otherNames": []}], "meshConditions": ["Acute Coronary Syndrome"], "meshInterventions": ["Clopidogrel", "Prasugrel Hydrochloride"], "hasResults": true, "classifyText": "A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects Acute Coronary Syndrome ACS Clopidogrel Prasugrel Commercially-available Aspirin Acute Coronary Syndrome Clopidogrel Prasugrel Hydrochloride This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is, patients who are not managed with acute coronary revascularization)."}
 {"nctId": "NCT00604214", "briefTitle": "Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock", "officialTitle": "A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of Drotrecogin Alfa (Activated) Administered as a Continuous 96-hr Infusion to Adult Patients With Septic Shock", "overallStatus": "COMPLETED", "startDate": "2008-03", "completionDate": "2012-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1696, "briefSummary": "The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients receiving the current standard of care for septic shock. This study will also assess the effectiveness of drotrecogin alfa (activated) in reducing 28-day mortality in patients with septic shock and concomitant severe protein C deficiency.", "conditions": ["Sepsis"], "keywords": ["Sepsis", "Septic shock"], "interventions": [{"type": "DRUG", "name": "Drotrecogin alfa (activated)", "otherNames": ["LY203638", "Xigris"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Sepsis", "Shock, Septic"], "meshInterventions": ["drotrecogin alfa activated"], "hasResults": true, "classifyText": "Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock Sepsis Sepsis Septic shock Drotrecogin alfa (activated) Placebo Sepsis Shock, Septic drotrecogin alfa activated The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients receiving the current standard of care for septic shock. This study will also assess the effectiveness of drotrecogin alfa (activated) in reducing 28-day mortality in patients with septic shock and concomitant severe protein C deficiency."}
 {"nctId": "NCT01089621", "briefTitle": "A Study for Adolescents With Fibromyalgia Syndrome", "officialTitle": "An Open-label Feasibility Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome: A Pilot Study", "overallStatus": "WITHDRAWN", "startDate": "2010-03", "completionDate": "2010-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 0, "briefSummary": "The purpose of this study is to evaluate the possibility of conducting a larger study in adolescents with fibromyalgia syndrome.", "conditions": ["Fibromyalgia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": ["Cymbalta", "LY248686"]}], "meshConditions": ["Fibromyalgia"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "A Study for Adolescents With Fibromyalgia Syndrome Fibromyalgia Duloxetine Fibromyalgia Duloxetine Hydrochloride The purpose of this study is to evaluate the possibility of conducting a larger study in adolescents with fibromyalgia syndrome."}
 {"nctId": "NCT02525744", "briefTitle": "A Study of a New LY900014 Formulation in Healthy Participants", "officialTitle": "Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel LY900014 Formulation", "overallStatus": "COMPLETED", "startDate": "2015-08", "completionDate": "2015-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 24, "briefSummary": "This study evaluates a new formulation of LY900014, a drug that lowers blood sugar. It is administered by injection under the skin of the abdomen. The study will be conducted in healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of different doses of LY900014 on blood sugar levels. Side effects and tolerability will be documented. The study will last for about 8 to 9 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY900014", "otherNames": ["Ultra-Rapid Lispro"]}, {"type": "DRUG", "name": "Insulin Lispro (Humalog)", "otherNames": ["LY275585", "Humalog"]}], "meshConditions": [], "meshInterventions": ["Insulin Lispro"], "hasResults": true, "classifyText": "A Study of a New LY900014 Formulation in Healthy Participants Healthy LY900014 Insulin Lispro (Humalog) Insulin Lispro This study evaluates a new formulation of LY900014, a drug that lowers blood sugar. It is administered by injection under the skin of the abdomen. The study will be conducted in healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of different doses of LY900014 on blood sugar levels. Side effects and tolerability will be documented. The study will last for about 8 to 9 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study."}
 {"nctId": "NCT01929707", "briefTitle": "A Study of LY3050258 in Healthy Participants", "officialTitle": "A Single-Dose, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of LY3050258", "overallStatus": "COMPLETED", "startDate": "2013-08", "completionDate": "2013-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 38, "briefSummary": "The main purpose of this study is to evaluate the safety and how well the body will handle a single dose of increasing strength of study drug LY3050258. Each participant will receive LY3050258 or placebo once, in each of 2 dosing periods. At least 7 days will pass between doses. This study will last approximately 45 days for each participant. Screening is required within 28 days before the start of the study.", "conditions": ["Healthy Participants"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3050258", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": true, "classifyText": "A Study of LY3050258 in Healthy Participants Healthy Participants LY3050258 Placebo The main purpose of this study is to evaluate the safety and how well the body will handle a single dose of increasing strength of study drug LY3050258. Each participant will receive LY3050258 or placebo once, in each of 2 dosing periods. At least 7 days will pass between doses. This study will last approximately 45 days for each participant. Screening is required within 28 days before the start of the study."}
 {"nctId": "NCT06627088", "briefTitle": "A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants", "officialTitle": "A Phase 1, Open-label, Two-part Study of the Absorption, Metabolism, Excretion, and Bioavailability of LY4100511 (DC-853) Following Administration of [14C]-LY4100511 in Healthy Male Participants", "overallStatus": "COMPLETED", "startDate": "2024-08-23", "completionDate": "2024-12-31", "leadSponsor": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 24, "briefSummary": "The study has two parts, Part A and Part B. The purpose of Part A is to determine the absorption, metabolism, and excretion (AME) of \\[14C\\]-LY4100511 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants after a single oral dose of LY4100511. The purpose of Part B is to determine the absolute bioavailability of LY4100511 in humans, to further analyze the rate and routes of excretion, including the mass balance, and to further investigate the pharmacokinetics (PK) of \\[14C\\]-LY4100511, LY4100511, and TRA.", "conditions": ["Healthy"], "keywords": ["LY4100511", "DC-853"], "interventions": [{"type": "DRUG", "name": "LY4100511 (DC-853)", "otherNames": []}, {"type": "DRUG", "name": "[14C]-LY4100511 (DC-853) Administered oral dose", "otherNames": []}, {"type": "DRUG", "name": "LY4100511 (DC-853)", "otherNames": []}, {"type": "DRUG", "name": "[14C]-LY4100511 (DC-853)", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male Participants Healthy LY4100511 DC-853 LY4100511 (DC-853) [14C]-LY4100511 (DC-853) Administered oral dose LY4100511 (DC-853) [14C]-LY4100511 (DC-853) The study has two parts, Part A and Part B. The purpose of Part A is to determine the absorption, metabolism, and excretion (AME) of \\[14C\\]-LY4100511 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants after a single oral dose of LY4100511. The purpose of Part B is to determine the absolute bioavailability of LY4100511 in humans, to further analyze the rate and routes of excretion, including the mass balance, and to further investigate the pharmacokinetics (PK) of \\[14C\\]-LY4100511, LY4100511, and TRA."}
 {"nctId": "NCT04039503", "briefTitle": "A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin", "officialTitle": "Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin", "overallStatus": "COMPLETED", "startDate": "2019-08-30", "completionDate": "2021-01-13", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 475, "briefSummary": "The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications. The study will last approximately 47 weeks and may include about 23 visits.", "conditions": ["Type 2 Diabetes"], "keywords": ["glucose-dependent insulinotropic polypeptide (GIP)", "glucagon-like peptide-1 (GLP-1)", "GIP/GLP-1 dual receptor agonist", "T2DM"], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Tirzepatide"], "hasResults": true, "classifyText": "A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin Type 2 Diabetes glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) GIP/GLP-1 dual receptor agonist T2DM Tirzepatide Placebo Diabetes Mellitus, Type 2 Tirzepatide The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin. Participants will administer tirzepatide or placebo along with their previous glucose lowering medications. The study will last approximately 47 weeks and may include about 23 visits."}
 {"nctId": "NCT05869903", "briefTitle": "A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities", "officialTitle": "A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2023-06-05", "completionDate": "2027-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 3127, "briefSummary": "This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.", "conditions": ["Obesity", "Overweight", "Overweight or Obesity"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Orforglipron", "otherNames": ["LY3502970"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Obesity", "Overweight"], "meshInterventions": ["orforglipron"], "hasResults": false, "classifyText": "A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities Obesity Overweight Overweight or Obesity Orforglipron Placebo Obesity Overweight orforglipron This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years."}
 {"nctId": "NCT06229366", "briefTitle": "[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer", "officialTitle": "[Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer (ACCEL)", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2024-04-03", "completionDate": "2032-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 142, "briefSummary": "ACCEL is a multicenter, open label phase Ia/Ib/II study of \\[Ac-225\\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.", "conditions": ["Prostate Cancer", "Metastatic Castration-resistant Prostate Cancer", "Oligometastatic Prostate Carcinoma", "Hormone Sensitive Prostate Cancer"], "keywords": ["mCRPC", "OmHSPC", "Prostatic Neoplasms", "Genital Neoplasms, Male", "Castration Resistant Prostate Cancer", "Hormone Sensitive Prostate Cancer", "Oligometastatic Prostate Cancer", "[225Ac]-PSMA-62", "Ac-225-PSMA-62", "Actinium", "Radioligand Therapy", "Radiopharmaceuticals", "Urogenital Neoplasm"], "interventions": [{"type": "DRUG", "name": "[Ac-225]-PSMA-62 (mCRPC)", "otherNames": []}, {"type": "DRUG", "name": "[Ac-225]-PSMA-62 (OmHSPC)", "otherNames": []}], "meshConditions": ["Prostatic Neoplasms", "Genital Neoplasms, Male", "Urogenital Neoplasms"], "meshInterventions": [], "hasResults": false, "classifyText": "[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer Prostate Cancer Metastatic Castration-resistant Prostate Cancer Oligometastatic Prostate Carcinoma Hormone Sensitive Prostate Cancer mCRPC OmHSPC Prostatic Neoplasms Genital Neoplasms, Male Castration Resistant Prostate Cancer Hormone Sensitive Prostate Cancer Oligometastatic Prostate Cancer [225Ac]-PSMA-62 Ac-225-PSMA-62 Actinium Radioligand Therapy Radiopharmaceuticals Urogenital Neoplasm [Ac-225]-PSMA-62 (mCRPC) [Ac-225]-PSMA-62 (OmHSPC) Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms ACCEL is a multicenter, open label phase Ia/Ib/II study of \\[Ac-225\\]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer."}
 {"nctId": "NCT00686959", "briefTitle": "Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer", "officialTitle": "Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology", "overallStatus": "COMPLETED", "startDate": "2008-09", "completionDate": "2014-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 598, "briefSummary": "This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.", "conditions": ["Non Small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pemetrexed", "otherNames": ["Alimta", "LY231514"]}, {"type": "DRUG", "name": "Cisplatin", "otherNames": []}, {"type": "DRUG", "name": "Etoposide", "otherNames": []}, {"type": "DRUG", "name": "Vinorelbine", "otherNames": []}, {"type": "DRUG", "name": "Paclitaxel", "otherNames": []}, {"type": "DRUG", "name": "Carboplatin", "otherNames": []}, {"type": "RADIATION", "name": "Thoracic Radiation Therapy (TRT)", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Pemetrexed", "Cisplatin", "Etoposide", "Vinorelbine", "Paclitaxel", "Carboplatin"], "hasResults": true, "classifyText": "Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer Non Small Cell Lung Cancer Pemetrexed Cisplatin Etoposide Vinorelbine Paclitaxel Carboplatin Thoracic Radiation Therapy (TRT) Carcinoma, Non-Small-Cell Lung Pemetrexed Cisplatin Etoposide Vinorelbine Paclitaxel Carboplatin This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology."}
 {"nctId": "NCT02735980", "briefTitle": "A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer", "officialTitle": "A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2016-05-11", "completionDate": "2019-02-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 133, "briefSummary": "The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life.", "conditions": ["Small Cell Lung Cancer"], "keywords": ["SCLC", "LY2606368", "CHK1"], "interventions": [{"type": "DRUG", "name": "Prexasertib", "otherNames": ["LY2606368"]}], "meshConditions": ["Small Cell Lung Carcinoma"], "meshInterventions": ["prexasertib"], "hasResults": true, "classifyText": "A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer Small Cell Lung Cancer SCLC LY2606368 CHK1 Prexasertib Small Cell Lung Carcinoma prexasertib The purpose of this study is to evaluate the safety and efficacy of prexasertib when given to participants with extensive stage disease small cell lung cancer (ED-SCLC). The study will evaluate how the body processes the drug and how the drug affects the body. The study will also evaluate the association between tumor response and the participant's perceived quality of life."}
 {"nctId": "NCT01818245", "briefTitle": "A Study of LY2605541 in Healthy Participants and in the Elderly", "officialTitle": "Effect of Injection Site on the Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of LY2605541 in Healthy Subjects, and Impact of Body Mass Index and Age on the Pharmacokinetics of LY2605541", "overallStatus": "COMPLETED", "startDate": "2013-03", "completionDate": "2013-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 52, "briefSummary": "This study will include 2 groups (cohorts) of participants:\n\nIn Cohort A, this study will look at the amount of LY2605541 that is present in the body after it is injected in 3 different locations in the body of the same participant. At least 16 days will pass between each injection.\n\nIn Cohort B, the study will look at how the body absorbs, distributes, and disposes of LY2605541 in participants aged 65 and over.\n\nParticipants may enroll in only one cohort.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2605541", "otherNames": []}], "meshConditions": [], "meshInterventions": ["LY2605541"], "hasResults": true, "classifyText": "A Study of LY2605541 in Healthy Participants and in the Elderly Healthy Volunteers LY2605541 LY2605541 This study will include 2 groups (cohorts) of participants:\n\nIn Cohort A, this study will look at the amount of LY2605541 that is present in the body after it is injected in 3 different locations in the body of the same participant. At least 16 days will pass between each injection.\n\nIn Cohort B, the study will look at how the body absorbs, distributes, and disposes of LY2605541 in participants aged 65 and over.\n\nParticipants may enroll in only one cohort."}
 {"nctId": "NCT00071695", "briefTitle": "Duloxetine vs. Active Comparator in the Treatment of Patients With Depression", "officialTitle": "Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder", "overallStatus": "COMPLETED", "startDate": "2003-07", "completionDate": "2004-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 320, "briefSummary": "How duloxetine compares to a medication currently available for the treatment of patients diagnosed with depression", "conditions": ["Depression"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine Hydrochloride", "otherNames": []}, {"type": "DRUG", "name": "Venlafaxine Extended Release", "otherNames": []}], "meshConditions": ["Depression"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Duloxetine vs. Active Comparator in the Treatment of Patients With Depression Depression Duloxetine Hydrochloride Venlafaxine Extended Release Depression Duloxetine Hydrochloride How duloxetine compares to a medication currently available for the treatment of patients diagnosed with depression"}
 {"nctId": "NCT00486005", "briefTitle": "Weight Gain Management in Patients With Schizophrenia", "officialTitle": "Weight Gain Management in Patients With Schizophrenia During Treatment With Olanzapine in Association With Nizatidine", "overallStatus": "COMPLETED", "startDate": "2003-02", "completionDate": "2003-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 74, "briefSummary": "Evaluate the efficacy of nizatidine in reducing/limiting weight gain in patients with schizophrenia who have been under treatment with olanzapine for at least two months and evaluate the treatment effects on the Eating Inventory, BPRS, number of treatment, emergent adverse events, changes in vital signs, laboratory results and extrapyramidal effects.", "conditions": ["Schizophrenia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Olanzapine Hydrochloride", "otherNames": []}, {"type": "DRUG", "name": "Nizatidine", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Schizophrenia"], "meshInterventions": ["olanzapine-fluoxetine combination", "Nizatidine"], "hasResults": false, "classifyText": "Weight Gain Management in Patients With Schizophrenia Schizophrenia Olanzapine Hydrochloride Nizatidine Placebo Schizophrenia olanzapine-fluoxetine combination Nizatidine Evaluate the efficacy of nizatidine in reducing/limiting weight gain in patients with schizophrenia who have been under treatment with olanzapine for at least two months and evaluate the treatment effects on the Eating Inventory, BPRS, number of treatment, emergent adverse events, changes in vital signs, laboratory results and extrapyramidal effects."}
 {"nctId": "NCT00415194", "briefTitle": "A Study for Patients With Head and Neck Cancer", "officialTitle": "A Randomized Phase 3 Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer", "overallStatus": "COMPLETED", "startDate": "2006-12", "completionDate": "2010-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 795, "briefSummary": "This study will compare the effects of pemetrexed plus cisplatin versus cisplatin alone in head and neck cancer patients.", "conditions": ["Head and Neck Neoplasms"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": ["Alimta", "LY231514"]}, {"type": "DRUG", "name": "cisplatin", "otherNames": []}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Head and Neck Neoplasms"], "meshInterventions": ["Pemetrexed", "Cisplatin"], "hasResults": true, "classifyText": "A Study for Patients With Head and Neck Cancer Head and Neck Neoplasms pemetrexed cisplatin placebo Head and Neck Neoplasms Pemetrexed Cisplatin This study will compare the effects of pemetrexed plus cisplatin versus cisplatin alone in head and neck cancer patients."}
 {"nctId": "NCT00869986", "briefTitle": "A Study for Patients With Relapsing Remitting Multiple Sclerosis", "officialTitle": "A Double Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis", "overallStatus": "COMPLETED", "startDate": "2006-11", "completionDate": "2009-09", "leadSponsor": "Eli Lilly and Company", "collaborators": ["BioMS Technology Corp."], "studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 218, "briefSummary": "The purpose of this study is to test if dirucotide is safe and effective in treating patients with relapsing remitting multiple sclerosis.", "conditions": ["Relapsing Remitting Multiple Sclerosis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "dirucotide", "otherNames": ["MBP8298", "LY2820671"]}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Multiple Sclerosis, Relapsing-Remitting"], "meshInterventions": ["MBP-8298"], "hasResults": false, "classifyText": "A Study for Patients With Relapsing Remitting Multiple Sclerosis Relapsing Remitting Multiple Sclerosis dirucotide placebo Multiple Sclerosis, Relapsing-Remitting MBP-8298 The purpose of this study is to test if dirucotide is safe and effective in treating patients with relapsing remitting multiple sclerosis."}
 {"nctId": "NCT01577355", "briefTitle": "A Study of LY2784544 in Healthy Male Subjects", "officialTitle": "Disposition of [14C]-LY2784544 Following Oral Administration in Healthy Male Subjects", "overallStatus": "COMPLETED", "startDate": "2012-04", "completionDate": "2012-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 8, "briefSummary": "This is a single dose study of radiolabelled LY2784544 in healthy male subjects to study the absorption, distribution, metabolism and excretion of LY2784544. This study is for research purposes only and is not intended to treat any medical condition.", "conditions": ["Healthy Male Volunteers"], "keywords": [], "interventions": [{"type": "RADIATION", "name": "Drug", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Pharmaceutical Preparations"], "hasResults": false, "classifyText": "A Study of LY2784544 in Healthy Male Subjects Healthy Male Volunteers Drug Pharmaceutical Preparations This is a single dose study of radiolabelled LY2784544 in healthy male subjects to study the absorption, distribution, metabolism and excretion of LY2784544. This study is for research purposes only and is not intended to treat any medical condition."}
 {"nctId": "NCT07219966", "briefTitle": "A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder", "officialTitle": "A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)", "overallStatus": "RECRUITING", "startDate": "2025-10-15", "completionDate": "2028-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1100, "briefSummary": "The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.", "conditions": ["Alcohol Use Disorder"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3537031", "otherNames": ["Brenipatide"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Alcoholism"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of Brenipatide in Participants With Moderate-to-Severe Alcohol Use Disorder Alcohol Use Disorder LY3537031 Placebo Alcoholism The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks."}
 {"nctId": "NCT02443883", "briefTitle": "A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer", "officialTitle": "Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma", "overallStatus": "COMPLETED", "startDate": "2015-07-07", "completionDate": "2019-06-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 164, "briefSummary": "The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following prior chemotherapy.", "conditions": ["Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma"], "keywords": ["stomach cancer"], "interventions": [{"type": "DRUG", "name": "Ramucirumab", "otherNames": ["LY3009806", "IMC-1121B"]}], "meshConditions": ["Stomach Neoplasms"], "meshInterventions": ["Ramucirumab"], "hasResults": true, "classifyText": "A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Gastric Adenocarcinoma Gastroesophageal Junction Adenocarcinoma stomach cancer Ramucirumab Stomach Neoplasms Ramucirumab The main purpose of this study was to evaluate the safety and pharmacokinetics of administering various dose regimens of ramucirumab in participants with advanced gastric cancer whose disease has progressed during or following prior chemotherapy."}
 {"nctId": "NCT05932446", "briefTitle": "A Study to Compare Two Formulations of LY3819469 in Healthy Participants", "officialTitle": "A Single Dose Study to Assess the Pharmacokinetics of 2 Formulations of LY3819469 in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2023-06-30", "completionDate": "2023-11-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 27, "briefSummary": "The main purpose of this study is to assess two formulations of LY3819469 based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3819469 will also be evaluated.\n\nScreening is required within 28 days prior to the enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening and follow-up periods.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3819469", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study to Compare Two Formulations of LY3819469 in Healthy Participants Healthy LY3819469 The main purpose of this study is to assess two formulations of LY3819469 based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to healthy participants. The information about any adverse effects experienced will be collected and the tolerability of LY3819469 will also be evaluated.\n\nScreening is required within 28 days prior to the enrolment. For each participant, the total duration of the clinical trial will be about 17 weeks including screening and follow-up periods."}
 {"nctId": "NCT00035061", "briefTitle": "A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium", "officialTitle": null, "overallStatus": "COMPLETED", "startDate": null, "completionDate": null, "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": null, "briefSummary": "Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.", "conditions": ["Urologic Neoplasms", "Metastases, Neoplasm"], "keywords": ["Bladder Cancer", "Metastatic", "Recurrent", "Transitional cell carcinoma of the urothelium"], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": []}], "meshConditions": ["Urologic Neoplasms", "Neoplasm Metastasis", "Urinary Bladder Neoplasms", "Recurrence"], "meshInterventions": ["Pemetrexed"], "hasResults": false, "classifyText": "A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium Urologic Neoplasms Metastases, Neoplasm Bladder Cancer Metastatic Recurrent Transitional cell carcinoma of the urothelium pemetrexed Urologic Neoplasms Neoplasm Metastasis Urinary Bladder Neoplasms Recurrence Pemetrexed Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body."}
 {"nctId": "NCT02759107", "briefTitle": "A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)", "officialTitle": "A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2016-05-11", "completionDate": "2017-06-26", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 142, "briefSummary": "The main purposes of this study are to determine:\n\n* The safety of tirzepatide and any side effects that might be associated with it.\n* How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it.\n* How tirzepatide affects the levels of blood sugar.\n\nThis study includes 3 parts (A, B and C). Part A involves a single dose of tirzepatide taken as a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in duration, including screening. Parts B and C involve 4 doses of tirzepatide taken once weekly (over 4 weeks) as a SC injection just under the skin and is approximately 12-14 weeks in duration, including screening. Each participant will enroll in only one part.\n\nThis study is for research purposes only, and is not intended to treat any medical condition.", "conditions": ["Healthy", "Type 2 Diabetes Mellitus (T2DM)"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Dulaglutide", "otherNames": ["Trulicity\u00ae"]}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Tirzepatide", "dulaglutide"], "hasResults": true, "classifyText": "A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM) Healthy Type 2 Diabetes Mellitus (T2DM) Tirzepatide Placebo Dulaglutide Diabetes Mellitus, Type 2 Tirzepatide dulaglutide The main purposes of this study are to determine:\n\n* The safety of tirzepatide and any side effects that might be associated with it.\n* How much tirzepatide gets into the bloodstream and how long it takes the body to get rid of it.\n* How tirzepatide affects the levels of blood sugar.\n\nThis study includes 3 parts (A, B and C). Part A involves a single dose of tirzepatide taken as a subcutaneous (SC) injection just under the skin and will be approximately 10 weeks in duration, including screening. Parts B and C involve 4 doses of tirzepatide taken once weekly (over 4 weeks) as a SC injection just under the skin and is approximately 12-14 weeks in duration, including screening. Each participant will enroll in only one part.\n\nThis study is for research purposes only, and is not intended to treat any medical condition."}
 {"nctId": "NCT01024244", "briefTitle": "A Study of LY2599506 in Patients With Type 2 Diabetes", "officialTitle": "A 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2599506 in Patients With Type 2 Diabetes Mellitus Treated With Diet and Exercise, With or Without Metformin", "overallStatus": "TERMINATED", "startDate": "2009-12", "completionDate": "2010-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 78, "briefSummary": "The purpose of this study is to help answer the following questions:\n\n* To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks.\n* To evaluate the safety of LY2599506 in participants with diabetes.\n* To determine if LY2599506 has the ability to control blood sugar in participants with diabetes.\n* To determine how much LY2599506 should be given to participants.\n* To determine if LY2599506 has an effect on a participant's weight.\n\nThe study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow-up period.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "LY2599506", "otherNames": ["Glucokinase Activator"]}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["glucokinase activator compound 50"], "hasResults": true, "classifyText": "A Study of LY2599506 in Patients With Type 2 Diabetes Diabetes Mellitus, Type 2 Placebo LY2599506 Diabetes Mellitus, Type 2 glucokinase activator compound 50 The purpose of this study is to help answer the following questions:\n\n* To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks.\n* To evaluate the safety of LY2599506 in participants with diabetes.\n* To determine if LY2599506 has the ability to control blood sugar in participants with diabetes.\n* To determine how much LY2599506 should be given to participants.\n* To determine if LY2599506 has an effect on a participant's weight.\n\nThe study design consists of 4 study periods: a screening period, a 4-week dose adjustment period, an 8-week treatment period, and a 4-week follow-up period."}
 {"nctId": "NCT01373164", "briefTitle": "A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer", "officialTitle": "A Phase 1b/2 Study With Gemcitabine and LY2157299 for Patients With Metastatic Cancer (Phase 1b) and Advanced or Metastatic Unresectable Pancreatic Cancer (Phase 2)", "overallStatus": "COMPLETED", "startDate": "2011-06", "completionDate": "2016-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 170, "briefSummary": "Phase 1b: To determine the safe and tolerable dose of galunisertib in combination with gemcitabine in patients with solid malignancy\n\nPhase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of galunisertib and gemcitabine with that of gemcitabine plus placebo.", "conditions": ["Neoplasms", "Neoplasm Metastasis", "Pancreatic Cancer"], "keywords": ["Neoplasms", "Neoplasm Metastasis", "Pancreatic Cancer"], "interventions": [{"type": "DRUG", "name": "Galunisertib", "otherNames": ["LY2157299"]}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": ["Gemzar", "LY188011"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Neoplasms", "Neoplasm Metastasis", "Pancreatic Neoplasms"], "meshInterventions": ["LY-2157299", "Gemcitabine"], "hasResults": true, "classifyText": "A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer Neoplasms Neoplasm Metastasis Pancreatic Cancer Neoplasms Neoplasm Metastasis Pancreatic Cancer Galunisertib Gemcitabine Placebo Neoplasms Neoplasm Metastasis Pancreatic Neoplasms LY-2157299 Gemcitabine Phase 1b: To determine the safe and tolerable dose of galunisertib in combination with gemcitabine in patients with solid malignancy\n\nPhase 2a: To compare the overall survival (OS) of patients with Stage II to IV unresectable pancreatic cancer when treated with a combination of galunisertib and gemcitabine with that of gemcitabine plus placebo."}
 {"nctId": "NCT01750853", "briefTitle": "A Study of LY3045697 in Healthy Participants", "officialTitle": "A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3045697 After Single Oral Dosing in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2013-01", "completionDate": "2013-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 27, "briefSummary": "The purpose of this study is to investigate the safety and tolerability of LY3045697 after a single dose, and to determine how long LY3045697 remains in the body. Two cohorts (groups) of 9 participants each will participate in 3 dosing periods. These participants will receive placebo in one period only. A third cohort of 9 will participate in 2 dosing periods and participants will receive either 2 dose levels of LY3045697 or 1 dose level of LY3045697 and placebo by the end of both periods.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3045697", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3045697 in Healthy Participants Healthy Volunteers LY3045697 Placebo The purpose of this study is to investigate the safety and tolerability of LY3045697 after a single dose, and to determine how long LY3045697 remains in the body. Two cohorts (groups) of 9 participants each will participate in 3 dosing periods. These participants will receive placebo in one period only. A third cohort of 9 will participate in 2 dosing periods and participants will receive either 2 dose levels of LY3045697 or 1 dose level of LY3045697 and placebo by the end of both periods."}
 {"nctId": "NCT04086745", "briefTitle": "A Study of Baricitinib in Participants With Rheumatoid Arthritis", "officialTitle": "A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis", "overallStatus": "COMPLETED", "startDate": "2020-02-14", "completionDate": "2025-05-19", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Incyte Corporation"], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 1317, "briefSummary": "This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).", "conditions": ["Rheumatoid Arthritis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104"]}, {"type": "DRUG", "name": "TNF Inhibitor", "otherNames": ["Etanercept", "Adalimumab"]}], "meshConditions": ["Arthritis, Rheumatoid"], "meshInterventions": ["baricitinib", "Tumor Necrosis Factor Inhibitors", "Etanercept", "Adalimumab"], "hasResults": false, "classifyText": "A Study of Baricitinib in Participants With Rheumatoid Arthritis Rheumatoid Arthritis Baricitinib TNF Inhibitor Arthritis, Rheumatoid baricitinib Tumor Necrosis Factor Inhibitors Etanercept Adalimumab This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA)."}
 {"nctId": "NCT00061477", "briefTitle": "Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma", "officialTitle": "ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial", "overallStatus": "COMPLETED", "startDate": "2002-12", "completionDate": "2006-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 48, "briefSummary": "The purposes of this study are to determine:\n\n1. The safety of Pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs.\n2. Whether Pemetrexed plus Gemcitabine can help patients with mesothelioma live longer.\n3. Whether Pemetrexed plus Gemcitabine can make the tumor smaller or disappear, and for how long.\n4. To see if patients feel better while taking Pemetrexed plus Gemcitabine.", "conditions": ["Mesothelioma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pemetrexed", "otherNames": []}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": []}], "meshConditions": ["Mesothelioma"], "meshInterventions": ["Pemetrexed", "Gemcitabine"], "hasResults": false, "classifyText": "Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma Mesothelioma Pemetrexed Gemcitabine Mesothelioma Pemetrexed Gemcitabine The purposes of this study are to determine:\n\n1. The safety of Pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs.\n2. Whether Pemetrexed plus Gemcitabine can help patients with mesothelioma live longer.\n3. Whether Pemetrexed plus Gemcitabine can make the tumor smaller or disappear, and for how long.\n4. To see if patients feel better while taking Pemetrexed plus Gemcitabine."}
 {"nctId": "NCT06937411", "briefTitle": "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants", "officialTitle": "A Phase I, Randomized, Double-Blinded, Placebo-Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending and Multiple Ascending Doses of DC-853 in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2023-02-13", "completionDate": "2023-10-30", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 88, "briefSummary": "The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy participants.\n\nParticipation could last up to 7 weeks", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY4100511", "otherNames": ["DC-853"]}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants Healthy LY4100511 The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy participants.\n\nParticipation could last up to 7 weeks"}
 {"nctId": "NCT00190853", "briefTitle": "Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence", "officialTitle": "Effect of Duloxetine on Valsalva Leak Point Pressure and Quantitative Rhabdosphincter Electromyography Measures in Women With Stress Urinary Incontinence", "overallStatus": "COMPLETED", "startDate": "2005-01", "completionDate": "2006-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 93, "briefSummary": "Biomechanical and electrophysiological effects of duloxetine in the treatment of women with urinary stress incontinence", "conditions": ["Urinary Stress Incontinence"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": []}], "meshConditions": ["Urinary Incontinence, Stress"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Biomechanical and Electrophysiological Effects of Duloxetine in the Treatment of Women With Urinary Stress Incontinence Urinary Stress Incontinence Duloxetine Urinary Incontinence, Stress Duloxetine Hydrochloride Biomechanical and electrophysiological effects of duloxetine in the treatment of women with urinary stress incontinence"}
 {"nctId": "NCT01646177", "briefTitle": "A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)", "officialTitle": "A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period", "overallStatus": "COMPLETED", "startDate": "2012-07-28", "completionDate": "2019-07-22", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1346, "briefSummary": "This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.", "conditions": ["Psoriasis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "50 mg etanercept", "otherNames": []}, {"type": "DRUG", "name": "80 mg ixekizumab", "otherNames": ["LY2439821"]}], "meshConditions": ["Psoriasis"], "meshInterventions": ["Etanercept", "ixekizumab"], "hasResults": true, "classifyText": "A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3) Psoriasis Placebo 50 mg etanercept 80 mg ixekizumab Psoriasis Etanercept ixekizumab This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis."}
 {"nctId": "NCT01107912", "briefTitle": "Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease", "officialTitle": "A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease", "overallStatus": "COMPLETED", "startDate": "2010-03", "completionDate": "2011-10", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Daiichi Sankyo Co., Ltd."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 155, "briefSummary": "The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.", "conditions": ["Coronary Artery Disease"], "keywords": ["Platelet function"], "interventions": [{"type": "DRUG", "name": "prasugrel", "otherNames": ["Efient", "Effient", "LY640315", "CS747"]}, {"type": "DRUG", "name": "clopidogrel", "otherNames": []}], "meshConditions": ["Coronary Artery Disease"], "meshInterventions": ["Prasugrel Hydrochloride", "Clopidogrel"], "hasResults": true, "classifyText": "Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease Coronary Artery Disease Platelet function prasugrel clopidogrel Coronary Artery Disease Prasugrel Hydrochloride Clopidogrel The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients."}
 {"nctId": "NCT00805441", "briefTitle": "A Study in the Treatment of Alcohol Dependence.", "officialTitle": "A Phase 2 Study of LY686017 Compared With Placebo for the Treatment of Alcohol Dependence", "overallStatus": "COMPLETED", "startDate": "2008-12", "completionDate": "2009-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 190, "briefSummary": "H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with placebo in a 12-week trial that includes Medical Management. This study is an outpatient study in which approximately 180 alcohol dependent subjects will be enrolled. Subjects will be randomized in a 1:1 fashion to LY686017 or placebo, and will receive once daily dosing for twelve weeks.", "conditions": ["Alcohol Dependence"], "keywords": ["Alcoholic"], "interventions": [{"type": "DRUG", "name": "LY686017", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Alcoholism"], "meshInterventions": ["LY686017"], "hasResults": true, "classifyText": "A Study in the Treatment of Alcohol Dependence. Alcohol Dependence Alcoholic LY686017 Placebo Alcoholism LY686017 H8R-MC-HJAQ is a Phase 2, parallel, double-blind, randomized study comparing LY686017 with placebo in a 12-week trial that includes Medical Management. This study is an outpatient study in which approximately 180 alcohol dependent subjects will be enrolled. Subjects will be randomized in a 1:1 fashion to LY686017 or placebo, and will receive once daily dosing for twelve weeks."}
 {"nctId": "NCT07100119", "briefTitle": "A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis", "officialTitle": "A Multiple Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally Administered LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis", "overallStatus": "RECRUITING", "startDate": "2025-08-05", "completionDate": "2027-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 32, "briefSummary": "The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it.", "conditions": ["ALS (Amyotrophic Lateral Sclerosis)"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY4256984", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Amyotrophic Lateral Sclerosis"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis ALS (Amyotrophic Lateral Sclerosis) LY4256984 Placebo Amyotrophic Lateral Sclerosis The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it."}
 {"nctId": "NCT02941601", "briefTitle": "A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Na\u00efve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)", "officialTitle": "A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Na\u00efve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)", "overallStatus": "WITHDRAWN", "startDate": "2016-11", "completionDate": "2019-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 0, "briefSummary": "The main purpose of this study is to evaluate the effectiveness and safety of gemcitabine-carboplatin plus necitumumab in chemotherapy-na\u00efve participants with locally advanced or metastatic squamous non-small cell lung cancer.", "conditions": ["Locally Advanced Squamous Non-Small Cell Lung Cancer", "Metastatic Squamous Non-Small Cell Lung Cancer"], "keywords": ["Thoracic Neoplasms", "Lung Diseases", "Lung Cancer", "Respiratory Tract Diseases", "Respiratory Tract Neoplasms", "Antineoplastic Agents", "Monoclonal Antibodies"], "interventions": [{"type": "DRUG", "name": "Necitumumab", "otherNames": ["LY3012211"]}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": ["LY188011"]}, {"type": "DRUG", "name": "Carboplatin", "otherNames": []}], "meshConditions": ["Thoracic Neoplasms", "Lung Diseases", "Lung Neoplasms", "Respiratory Tract Diseases", "Respiratory Tract Neoplasms"], "meshInterventions": ["necitumumab", "Gemcitabine", "Carboplatin"], "hasResults": false, "classifyText": "A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Na\u00efve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Locally Advanced Squamous Non-Small Cell Lung Cancer Metastatic Squamous Non-Small Cell Lung Cancer Thoracic Neoplasms Lung Diseases Lung Cancer Respiratory Tract Diseases Respiratory Tract Neoplasms Antineoplastic Agents Monoclonal Antibodies Necitumumab Gemcitabine Carboplatin Thoracic Neoplasms Lung Diseases Lung Neoplasms Respiratory Tract Diseases Respiratory Tract Neoplasms necitumumab Gemcitabine Carboplatin The main purpose of this study is to evaluate the effectiveness and safety of gemcitabine-carboplatin plus necitumumab in chemotherapy-na\u00efve participants with locally advanced or metastatic squamous non-small cell lung cancer."}
 {"nctId": "NCT00044863", "briefTitle": "Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma", "officialTitle": "A Phase II Multicenter Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma", "overallStatus": "COMPLETED", "startDate": "2002-08", "completionDate": "2005-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 250, "briefSummary": "This is a phase II, multicenter, target enrollment of 250 evaluable patients, open-label study of cetuximab in patients with refractory, metastatic colorectal carcinoma. Based on prior studies, we predict that 70 to 75% of patients will be EGFR-positive. Patients must have documented failure after receiving either at least two chemotherapy regimens for metastatic disease or adjuvant therapy plus one chemotherapy regimen for metastatic disease provided that the patient progressed within 6 months of completing adjuvant therapy. Prior chemotherapy must have included irinotecan, oxaliplatin, and a fluoropyrimidine.\n\nPatients will receive an initial dose of cetuximab, 400 mg/m2, intravenously (i.v.) over 120 minutes, followed by weekly treatment with cetuximab, 250 mg/m2 i.v. over 60 minutes. Patients who experience unacceptable toxicity or who have progressive disease will not receive further cetuximab therapy.\n\nPatients will be evaluated for a tumor response at a minimum of every 6 weeks while on cetuximab therapy. Patients with stable disease or a partial or complete response may continue to receive weekly cetuximab therapy, unless they are dose-delayed or discontinued because of toxicity. Patients who have a partial or complete response must have a confirmatory tumor assessment no less than 4 weeks after the initial evaluation demonstrating a response.\n\nIn addition, there is a pharmacokinetic companion protocol which will determine the trough and peak levels of cetuximab in 25 patients enrolled in the study at four to eight centers. A pharmacologic serum sample for the determination of levels of cetuximab will be obtained prior to the initial, fourth and sixth cetuximab infusions and 1 hour following the completion of the initial, fourth and sixth cetuximab infusions in the first course; and prior to and 1 hour post the completion of the first cetuximab infusion of each subsequent course of therapy. A course of therapy is defined as six weekly infusions of cetuximab monotherapy. ImClone will perform the pharmacokinetic analyses.", "conditions": ["Colorectal Neoplasms", "Metastases, Neoplasm"], "keywords": ["EGFr", "Metastatic Colorectal Carcinoma"], "interventions": [{"type": "BIOLOGICAL", "name": "Erbitux (Cetuximab)", "otherNames": []}], "meshConditions": ["Colorectal Neoplasms", "Neoplasm Metastasis"], "meshInterventions": ["Cetuximab"], "hasResults": false, "classifyText": "Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma Colorectal Neoplasms Metastases, Neoplasm EGFr Metastatic Colorectal Carcinoma Erbitux (Cetuximab) Colorectal Neoplasms Neoplasm Metastasis Cetuximab This is a phase II, multicenter, target enrollment of 250 evaluable patients, open-label study of cetuximab in patients with refractory, metastatic colorectal carcinoma. Based on prior studies, we predict that 70 to 75% of patients will be EGFR-positive. Patients must have documented failure after receiving either at least two chemotherapy regimens for metastatic disease or adjuvant therapy plus one chemotherapy regimen for metastatic disease provided that the patient progressed within 6 months of completing adjuvant therapy. Prior chemotherapy must have included irinotecan, oxaliplatin, and a fluoropyrimidine.\n\nPatients will receive an initial dose of cetuximab, 400 mg/m2, intravenously (i.v.) over 120 minutes, followed by weekly treatment with cetuximab, 250 mg/m2 i.v. over 60 minutes. Patients who experience unacceptable toxicity or who have progressive disease will not receive further cetuximab therapy.\n\nPatients will be evaluated for a tumor response at a minimum of every 6 weeks "}
 {"nctId": "NCT01644500", "briefTitle": "A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus", "officialTitle": "The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2012-07", "completionDate": "2014-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 737, "briefSummary": "The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to glimepiride in participants with type 2 diabetes mellitus who have inadequate glycemic control with oral antihyperglycemic medication (OAM) or are OAM-na\u00efve.", "conditions": ["Type 2 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Glimepiride", "otherNames": []}, {"type": "DRUG", "name": "Placebo as Capsules", "otherNames": []}, {"type": "DRUG", "name": "Placebo as SC Injection", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide", "glimepiride", "Capsules"], "hasResults": true, "classifyText": "A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus Dulaglutide Glimepiride Placebo as Capsules Placebo as SC Injection Diabetes Mellitus, Type 2 dulaglutide glimepiride Capsules The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to glimepiride in participants with type 2 diabetes mellitus who have inadequate glycemic control with oral antihyperglycemic medication (OAM) or are OAM-na\u00efve."}
 {"nctId": "NCT07533019", "briefTitle": "A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo", "officialTitle": "A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo", "overallStatus": "NOT_YET_RECRUITING", "startDate": "2026-04-14", "completionDate": "2027-09-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 60, "briefSummary": "The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.\n\nThe study will last approximately 48 weeks, including screening.", "conditions": ["Vitiligo", "Non-Segmental Vitiligo (NSV)"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY4005130", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Vitiligo"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY4005130 in Adult Participants With Non-Segmental Vitiligo Vitiligo Non-Segmental Vitiligo (NSV) LY4005130 Placebo Vitiligo The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo (NSV) when compared with placebo. The study drug will be administered intravenously (IV) (into a vein in the arm).\n\nBlood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.\n\nThe study will last approximately 48 weeks, including screening."}
 {"nctId": "NCT00190619", "briefTitle": "Efficacy and Safety of Duloxetine", "officialTitle": "Efficacy and Safety of Duloxetine Compared With Placebo in Subjects Electing Surgery for Severe Pure Genuine Stress Incontinence", "overallStatus": "COMPLETED", "startDate": "2001-05", "completionDate": "2006-05", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Boehringer Ingelheim"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 100, "briefSummary": "The purpose of this study is to monitor the long term safety and efficacy of duloxetine in the treatment of severe pure genuine stress incontinence.", "conditions": ["Urinary Stress Incontinence"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Urinary Incontinence, Stress"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Efficacy and Safety of Duloxetine Urinary Stress Incontinence Duloxetine Placebo Urinary Incontinence, Stress Duloxetine Hydrochloride The purpose of this study is to monitor the long term safety and efficacy of duloxetine in the treatment of severe pure genuine stress incontinence."}
 {"nctId": "NCT02963766", "briefTitle": "A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes", "officialTitle": "A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)", "overallStatus": "COMPLETED", "startDate": "2016-12-29", "completionDate": "2022-01-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 154, "briefSummary": "The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.", "conditions": ["Type 2 Diabetes"], "keywords": ["Pediatrics"], "interventions": [{"type": "DRUG", "name": "Dulaglutide", "otherNames": ["LY2189265"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["dulaglutide"], "hasResults": true, "classifyText": "A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes Type 2 Diabetes Pediatrics Dulaglutide Placebo Diabetes Mellitus, Type 2 dulaglutide The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks."}
 {"nctId": "NCT01236105", "briefTitle": "Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject", "officialTitle": "Evaluation of the Impact of Activated Charcoal and Time of Dose on the Absorption of LY2624803 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2010-10", "completionDate": "2010-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 21, "briefSummary": "The purpose of this study is to determine the effect of activated charcoal and dosing time on the absorption of LY2624803 in healthy subjects. In this crossover study, there are three treatments with a washout period of at least 7 days in between treatments. Each subject will participate in all three treatments with random assignment to the treatment sequence.", "conditions": ["Insomnia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2624803", "otherNames": []}, {"type": "OTHER", "name": "Activated Charcoal", "otherNames": []}], "meshConditions": ["Sleep Initiation and Maintenance Disorders"], "meshInterventions": ["Charcoal"], "hasResults": true, "classifyText": "Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject Insomnia LY2624803 Activated Charcoal Sleep Initiation and Maintenance Disorders Charcoal The purpose of this study is to determine the effect of activated charcoal and dosing time on the absorption of LY2624803 in healthy subjects. In this crossover study, there are three treatments with a washout period of at least 7 days in between treatments. Each subject will participate in all three treatments with random assignment to the treatment sequence."}
 {"nctId": "NCT04634253", "briefTitle": "A Study of LY3462817 in Participants With Rheumatoid Arthritis", "officialTitle": "A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants With Moderately to Severely Active Rheumatoid Arthritis", "overallStatus": "COMPLETED", "startDate": "2021-01-04", "completionDate": "2022-06-29", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 98, "briefSummary": "The reason for this study is to see if the study drug LY3462817 is safe and effective in participants with moderately to severely active rheumatoid arthritis (RA).", "conditions": ["Rheumatoid Arthritis"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "LY3462817", "otherNames": []}], "meshConditions": ["Arthritis, Rheumatoid"], "meshInterventions": [], "hasResults": true, "classifyText": "A Study of LY3462817 in Participants With Rheumatoid Arthritis Rheumatoid Arthritis Placebo LY3462817 Arthritis, Rheumatoid The reason for this study is to see if the study drug LY3462817 is safe and effective in participants with moderately to severely active rheumatoid arthritis (RA)."}
 {"nctId": "NCT00207077", "briefTitle": "Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors", "officialTitle": "A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies", "overallStatus": "COMPLETED", "startDate": "2005-08", "completionDate": "2007-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 33, "briefSummary": "The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).", "conditions": ["Neoplasms"], "keywords": ["Advanced Solid Tumors"], "interventions": [{"type": "DRUG", "name": "Cetuximab + Erlotinib", "otherNames": ["Erbitux"]}], "meshConditions": ["Neoplasms"], "meshInterventions": ["Cetuximab", "Erlotinib Hydrochloride"], "hasResults": false, "classifyText": "Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors Neoplasms Advanced Solid Tumors Cetuximab + Erlotinib Neoplasms Cetuximab Erlotinib Hydrochloride The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib)."}
 {"nctId": "NCT02451930", "briefTitle": "A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC", "officialTitle": "An Open-Label, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of the Combination of Necitumumab With Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2015-09-04", "completionDate": "2019-09-17", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Merck Sharp & Dohme LLC"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 71, "briefSummary": "The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV non-small cell lung cancer (NSCLC).", "conditions": ["Stage IV Non-Small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Necitumumab", "otherNames": ["LY3012211"]}, {"type": "DRUG", "name": "Pembrolizumab", "otherNames": ["MK3475"]}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["necitumumab", "pembrolizumab"], "hasResults": true, "classifyText": "A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC Stage IV Non-Small Cell Lung Cancer Necitumumab Pembrolizumab Carcinoma, Non-Small-Cell Lung necitumumab pembrolizumab The main purpose of this study is to evaluate the safety and efficacy of the combination of necitumumab with pembrolizumab in participants with stage IV non-small cell lung cancer (NSCLC)."}
 {"nctId": "NCT01087970", "briefTitle": "A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer", "officialTitle": "Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck", "overallStatus": "COMPLETED", "startDate": "2010-08", "completionDate": "2013-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 69, "briefSummary": "The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.", "conditions": ["Head and Neck Neoplasms"], "keywords": ["Pharynx", "Larynx", "Nose", "Parathyroid"], "interventions": [{"type": "DRUG", "name": "Pemetrexed", "otherNames": ["Alimta", "LY231514"]}, {"type": "DRUG", "name": "Cetuximab", "otherNames": ["Erbitux"]}, {"type": "DRUG", "name": "Carboplatin", "otherNames": []}, {"type": "DRUG", "name": "Cisplatin", "otherNames": []}], "meshConditions": ["Head and Neck Neoplasms", "Laryngeal Diseases"], "meshInterventions": ["Pemetrexed", "Cetuximab", "Carboplatin", "Cisplatin"], "hasResults": true, "classifyText": "A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Head and Neck Neoplasms Pharynx Larynx Nose Parathyroid Pemetrexed Cetuximab Carboplatin Cisplatin Head and Neck Neoplasms Laryngeal Diseases Pemetrexed Cetuximab Carboplatin Cisplatin The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck."}
 {"nctId": "NCT02857270", "briefTitle": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer", "officialTitle": "A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer", "overallStatus": "COMPLETED", "startDate": "2016-09-29", "completionDate": "2022-10-24", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 210, "briefSummary": "The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.", "conditions": ["Advanced Cancer", "Metastatic Melanoma", "Metastatic Non-small Cell Lung Cancer", "Colorectal Cancer"], "keywords": ["MAPK", "RAS", "BRAF"], "interventions": [{"type": "DRUG", "name": "LY3214996", "otherNames": []}, {"type": "DRUG", "name": "Midazolam", "otherNames": []}, {"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Nab-paclitaxel", "otherNames": []}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": []}, {"type": "DRUG", "name": "Encorafenib", "otherNames": []}, {"type": "DRUG", "name": "Cetuximab", "otherNames": []}], "meshConditions": ["Melanoma", "Carcinoma, Non-Small-Cell Lung", "Colorectal Neoplasms"], "meshInterventions": ["LY3214996", "Midazolam", "abemaciclib", "130-nm albumin-bound paclitaxel", "Gemcitabine", "encorafenib", "Cetuximab"], "hasResults": false, "classifyText": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer Advanced Cancer Metastatic Melanoma Metastatic Non-small Cell Lung Cancer Colorectal Cancer MAPK RAS BRAF LY3214996 Midazolam Abemaciclib Nab-paclitaxel Gemcitabine Encorafenib Cetuximab Melanoma Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms LY3214996 Midazolam abemaciclib 130-nm albumin-bound paclitaxel Gemcitabine encorafenib Cetuximab The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer."}
 {"nctId": "NCT03765502", "briefTitle": "A Study Comparing User Experience of Different Delivery Devices for Glucagon", "officialTitle": "A Simulation Study Comparing Successful Administration, Time to Administer, and User Experience of Ready-to-Use Nasal Glucagon With Reconstitutable Injectable Glucagon", "overallStatus": "COMPLETED", "startDate": "2018-11-19", "completionDate": "2019-01-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "OTHER", "enrollment": 99, "briefSummary": "The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies. The study will be carried out using medical manikins to simulate real life scenarios. No drug will be administered to humans. Part A will last approximately 17 days for Trained Users and Participants with Diabetes (PWD). Part B will last approximately nine (9) days for Untrained Users. Each part will be separated by approximately 7 days.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DEVICE", "name": "Nasal Glucagon Device (NG)", "otherNames": []}, {"type": "DEVICE", "name": "GEK", "otherNames": []}, {"type": "DRUG", "name": "IM Glucagon", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": true, "classifyText": "A Study Comparing User Experience of Different Delivery Devices for Glucagon Healthy Nasal Glucagon Device (NG) GEK IM Glucagon The purpose of the study is to learn more about different devices for delivering glucagon during simulations of severe hypoglycemic (low blood sugar) emergencies. The study will be carried out using medical manikins to simulate real life scenarios. No drug will be administered to humans. Part A will last approximately 17 days for Trained Users and Participants with Diabetes (PWD). Part B will last approximately nine (9) days for Untrained Users. Each part will be separated by approximately 7 days."}
 {"nctId": "NCT03247790", "briefTitle": "A Study of Lasmiditan in Participants With Migraine", "officialTitle": "An Open-Label, Two-Period Study to Evaluate the Pharmacokinetics of Lasmiditan in Migraineurs During Acute Migraine Attacks and During Inter-Ictal Periods", "overallStatus": "COMPLETED", "startDate": "2017-08-16", "completionDate": "2018-01-15", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 16, "briefSummary": "The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.\n\nInformation about any side effects that may occur will also be collected.\n\nThis study includes two study periods. Each study period requires an overnight stay in the Clinical Research Unit (CRU) for at least one night (and up to three nights), followed by up to two outpatient appointments. This study will last approximately 5-6 weeks (not including screening).\n\nFollow-up is required four to seven days after last dose of investigational drug. Screening is required within 28 days prior to the start of the study.\n\nThis study is for research purposes only and is not intended to treat any medical condition.", "conditions": ["Migraine Disorders"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Lasmiditan", "otherNames": ["LY573144"]}], "meshConditions": ["Migraine Disorders"], "meshInterventions": ["lasmiditan"], "hasResults": true, "classifyText": "A Study of Lasmiditan in Participants With Migraine Migraine Disorders Lasmiditan Migraine Disorders lasmiditan The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.\n\nInformation about any side effects that may occur will also be collected.\n\nThis study includes two study periods. Each study period requires an overnight stay in the Clinical Research Unit (CRU) for at least one night (and up to three nights), followed by up to two outpatient appointments. This study will last approximately 5-6 weeks (not including screening).\n\nFollow-up is required four to seven days after last dose of investigational drug. Screening is required within 28 days prior to the start of the study.\n\nThis study is for research purposes only and is not intended to treat any medical condition."}
 {"nctId": "NCT03898791", "briefTitle": "A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer", "officialTitle": "Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2019-07-16", "completionDate": "2021-03-30", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 48, "briefSummary": "The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer.", "conditions": ["Small Cell Lung Cancer"], "keywords": ["aurora kinase A", "kinase", "aurora A", "aurora kinase inhibitor", "aurora kinase A inhibitor", "kinase inhibitor", "AURKA", "AurA"], "interventions": [{"type": "DRUG", "name": "LY3295668 Erbumine", "otherNames": []}], "meshConditions": ["Small Cell Lung Carcinoma", "Epilepsy"], "meshInterventions": ["LY3295668 erbumine"], "hasResults": false, "classifyText": "A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer Small Cell Lung Cancer aurora kinase A kinase aurora A aurora kinase inhibitor aurora kinase A inhibitor kinase inhibitor AURKA AurA LY3295668 Erbumine Small Cell Lung Carcinoma Epilepsy LY3295668 erbumine The purpose of this study is to determine the recommended phase 2 dose of LY3295668 erbumine in participants with platinum-sensitive, extensive-stage small-cell lung cancer."}
 {"nctId": "NCT00190983", "briefTitle": "A Trial for Patients With Advanced/Recurrent Cervical Cancer", "officialTitle": "A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix", "overallStatus": "COMPLETED", "startDate": "2005-02", "completionDate": "2007-10", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Gynecologic Oncology Group"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 29, "briefSummary": "This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer.", "conditions": ["Cervical Intraepithelial Neoplasia", "Uterine Neoplasms", "Genital Neoplasms, Female"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pemetrexed", "otherNames": []}], "meshConditions": ["Uterine Cervical Dysplasia", "Uterine Neoplasms", "Genital Neoplasms, Female"], "meshInterventions": ["Pemetrexed"], "hasResults": true, "classifyText": "A Trial for Patients With Advanced/Recurrent Cervical Cancer Cervical Intraepithelial Neoplasia Uterine Neoplasms Genital Neoplasms, Female Pemetrexed Uterine Cervical Dysplasia Uterine Neoplasms Genital Neoplasms, Female Pemetrexed This phase II trial is studying the antitumor activity of single agent pemetrexed 900mg/m2 IV over 10 minutes in patients with recurrent cervical cancer."}
 {"nctId": "NCT05338489", "briefTitle": "A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants", "officialTitle": "A 2-Part, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Multiple Doses of Itraconazole and Rifampin on the Single-Dose Pharmacokinetics of LOXO-292 in Healthy Adult Subjects", "overallStatus": "COMPLETED", "startDate": "2018-05-11", "completionDate": "2018-08-22", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Loxo Oncology, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 24, "briefSummary": "The main purpose of this study is to assess the effect of itraconazole and rifampin on how fast selpercatinib gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study is conducted in two parts and it will last up to 54 days (part 1) and 59 days (part 2), respectively, inclusive of screening period.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Selpercatinib", "otherNames": ["LY3527723", "LOXO-292"]}, {"type": "DRUG", "name": "Itraconazole", "otherNames": []}, {"type": "DRUG", "name": "Rifampin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["selpercatinib", "Itraconazole", "Rifampin"], "hasResults": true, "classifyText": "A Study of Effects of Itraconazole and Rifampin on Selpercatinib (LY3527723) in Healthy Participants Healthy Selpercatinib Itraconazole Rifampin selpercatinib Itraconazole Rifampin The main purpose of this study is to assess the effect of itraconazole and rifampin on how fast selpercatinib gets into the blood stream and how long it takes the body to remove it when administered in healthy participants. Information about safety and tolerability will be collected. The study is conducted in two parts and it will last up to 54 days (part 1) and 59 days (part 2), respectively, inclusive of screening period."}
 {"nctId": "NCT00251550", "briefTitle": "Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma", "officialTitle": "Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma", "overallStatus": "COMPLETED", "startDate": "2005-10", "completionDate": "2006-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 12, "briefSummary": "To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma.", "conditions": ["Malignant Pleural Mesotherioma"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pemetrexed", "otherNames": []}, {"type": "DRUG", "name": "Cisplatin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Pemetrexed", "Cisplatin"], "hasResults": false, "classifyText": "Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma Malignant Pleural Mesotherioma Pemetrexed Cisplatin Pemetrexed Cisplatin To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma."}
 {"nctId": "NCT02224846", "briefTitle": "A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction", "officialTitle": "Postmarketing Surveillance Study: A Randomized, Open-Label, 3-Month Interventional Study of Tadalafil Effectiveness (2.5 mg and 5 mg) and Long-Term Safety Administered Once Daily in Chinese Men With Erectile Dysfunction", "overallStatus": "COMPLETED", "startDate": "2014-10", "completionDate": "2017-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 635, "briefSummary": "The purpose of this study is to evaluate the safety and effectiveness of the study drug, taken once daily, known as tadalafil in Chinese participants with erectile dysfunction (ED). The study will last about up to 25 months for each participant.", "conditions": ["Erectile Dysfunction"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tadalafil", "otherNames": ["LY450190"]}], "meshConditions": ["Erectile Dysfunction"], "meshInterventions": ["Tadalafil"], "hasResults": true, "classifyText": "A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction Erectile Dysfunction Tadalafil Erectile Dysfunction Tadalafil The purpose of this study is to evaluate the safety and effectiveness of the study drug, taken once daily, known as tadalafil in Chinese participants with erectile dysfunction (ED). The study will last about up to 25 months for each participant."}
 {"nctId": "NCT05292040", "briefTitle": "A Study of LY3857210 in Healthy Participants", "officialTitle": "An Adaptive Design, Phase 1, Open-label Study to Investigate Receptor Occupancy in Brain After Single Oral Doses of LY3857210 as Measured by Positron Emission Tomography (PET) With the Radioligand [18F]-LY3818850 in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2022-03-17", "completionDate": "2022-12-14", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 10, "briefSummary": "The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand \\[18F\\]-LY3818850 in healthy participants. The safety and tolerability of LY3857210 will also be evaluated. The study will last up to approximately 6 weeks for each participant and may include up to four visits to the study center.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3857210", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3857210 in Healthy Participants Healthy LY3857210 The main purpose of this study is to evaluate the presence of study drug LY3857210 in the brain measured by positron emission tomography (PET) with the radioligand \\[18F\\]-LY3818850 in healthy participants. The safety and tolerability of LY3857210 will also be evaluated. The study will last up to approximately 6 weeks for each participant and may include up to four visits to the study center."}
 {"nctId": "NCT02102490", "briefTitle": "A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread", "officialTitle": "A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2014-06-10", "completionDate": "2018-10-22", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 132, "briefSummary": "The main purpose of this study is to evaluate whether the study drug known as abemaciclib is effective in treating participants with breast cancer who have already tried other drug treatments.", "conditions": ["Metastatic Breast Cancer"], "keywords": ["Endocrine Therapy, Taxane, MONARCH 1"], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["abemaciclib"], "hasResults": true, "classifyText": "A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread Metastatic Breast Cancer Endocrine Therapy, Taxane, MONARCH 1 Abemaciclib Breast Neoplasms abemaciclib The main purpose of this study is to evaluate whether the study drug known as abemaciclib is effective in treating participants with breast cancer who have already tried other drug treatments."}
 {"nctId": "NCT04050670", "briefTitle": "A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes", "officialTitle": "Effect of Injection Site on the Relative Bioavailability of a Single Dose of Tirzepatide in Subjects With Low and High Body Mass Indices", "overallStatus": "COMPLETED", "startDate": "2019-09-13", "completionDate": "2020-04-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 54, "briefSummary": "The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of tirzepatide will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 20 weeks, including screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}], "meshConditions": [], "meshInterventions": ["Tirzepatide"], "hasResults": true, "classifyText": "A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes Healthy Tirzepatide Tirzepatide The purpose of this study is to compare the amount of tirzepatide that gets into the blood stream and how long it takes the body to get rid of it, when injected under the skin of the upper arm and thigh compared to the abdomen. The study will be conducted in healthy males and females with different body sizes. The tolerability of tirzepatide will be evaluated and information about any side effects experienced will be collected. For each participant, the study will last about 20 weeks, including screening."}
 {"nctId": "NCT00133380", "briefTitle": "A Study in People With High Cholesterol", "officialTitle": "PPAR Alpha (LY518674): A Phase 2 Study of the Combinatorial Effect of LY518674 and Atorvastatin in Subjects With Hypercholesterolemia", "overallStatus": "COMPLETED", "startDate": "2005-07", "completionDate": "2006-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 300, "briefSummary": "The purposes of this study are to determine:\n\n* The safety of the study medication and any side effects that might be associated with it\n* Whether the study medication can help patients with high levels of \"bad\" cholesterol (low-density lipoprotein-cholesterol \\[LDL-C\\]), alone or in combination with additional study medication", "conditions": ["Hypercholesterolemia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "PPAR alpha", "otherNames": []}, {"type": "DRUG", "name": "atorvastatin", "otherNames": []}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Hypercholesterolemia"], "meshInterventions": ["PPAR alpha", "Atorvastatin"], "hasResults": false, "classifyText": "A Study in People With High Cholesterol Hypercholesterolemia PPAR alpha atorvastatin placebo Hypercholesterolemia PPAR alpha Atorvastatin The purposes of this study are to determine:\n\n* The safety of the study medication and any side effects that might be associated with it\n* Whether the study medication can help patients with high levels of \"bad\" cholesterol (low-density lipoprotein-cholesterol \\[LDL-C\\]), alone or in combination with additional study medication"}
 {"nctId": "NCT00804570", "briefTitle": "A Study for the Treatment of Alcohol Dependence", "officialTitle": "A Phase 2 Study of LY2196044 Compared With Placebo in the Treatment of Alcohol Dependence", "overallStatus": "COMPLETED", "startDate": "2008-11", "completionDate": "2010-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 375, "briefSummary": "The Primary objective of this study is to test whether LY2196044 can reduce the number of heavy drinking days per month in people with alcohol dependence. Each subject will undergo a screening and assessment period (including medication washout) prior to randomization into a 16 week double blind treatment period.", "conditions": ["Alcohol Dependence"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2196044", "otherNames": []}, {"type": "DRUG", "name": "placebo", "otherNames": []}], "meshConditions": ["Alcoholism"], "meshInterventions": ["LY2196044"], "hasResults": true, "classifyText": "A Study for the Treatment of Alcohol Dependence Alcohol Dependence LY2196044 placebo Alcoholism LY2196044 The Primary objective of this study is to test whether LY2196044 can reduce the number of heavy drinking days per month in people with alcohol dependence. Each subject will undergo a screening and assessment period (including medication washout) prior to randomization into a 16 week double blind treatment period."}
 {"nctId": "NCT00520923", "briefTitle": "A Study for Patients With Schizophrenia", "officialTitle": "A Multi-Center, Inpatient, Phase 2, Double-blind, Placebo-Controlled Dose Ranging Study of LY2140023 in Patients With DSM-IV Schizophrenia", "overallStatus": "COMPLETED", "startDate": "2007-09", "completionDate": "2008-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 654, "briefSummary": "The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to patients with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.", "conditions": ["Schizophrenia"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2140023", "otherNames": []}, {"type": "DRUG", "name": "LY2140023", "otherNames": []}, {"type": "DRUG", "name": "LY2140023", "otherNames": []}, {"type": "DRUG", "name": "LY2140023", "otherNames": []}, {"type": "DRUG", "name": "Olanzapine", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Schizophrenia"], "meshInterventions": ["LY 2140023", "Olanzapine"], "hasResults": false, "classifyText": "A Study for Patients With Schizophrenia Schizophrenia LY2140023 LY2140023 LY2140023 LY2140023 Olanzapine Placebo Placebo Schizophrenia LY 2140023 Olanzapine The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to patients with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo."}
 {"nctId": "NCT07215559", "briefTitle": "A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes", "officialTitle": "A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes", "overallStatus": "RECRUITING", "startDate": "2025-10-16", "completionDate": "2027-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 200, "briefSummary": "The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.", "conditions": ["Obesity", "Overweight", "Diabetes Mellitus, Type 2"], "keywords": ["GIP", "Amylin"], "interventions": [{"type": "DRUG", "name": "Macupatide", "otherNames": ["LY3532226"]}, {"type": "DRUG", "name": "Eloralintide", "otherNames": ["LY3841136"]}, {"type": "DRUG", "name": "Macupatide Placebo", "otherNames": []}, {"type": "DRUG", "name": "Eloralintide Placebo", "otherNames": []}], "meshConditions": ["Obesity", "Overweight", "Diabetes Mellitus, Type 2"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes Obesity Overweight Diabetes Mellitus, Type 2 GIP Amylin Macupatide Eloralintide Macupatide Placebo Eloralintide Placebo Obesity Overweight Diabetes Mellitus, Type 2 The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks."}
 {"nctId": "NCT01139788", "briefTitle": "A Study of LY2624587 in Patients With Advanced Cancer", "officialTitle": "A Phase 1 Study of LY2624587 in Patients With Advanced Cancer", "overallStatus": "COMPLETED", "startDate": "2010-06", "completionDate": "2011-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 56, "briefSummary": "Study CXBA is a multicenter nonrandomized, dose escalation, open-label, Phase 1 study of intravenous LY2624587 in patients with advanced or metastatic cancer for which no treatment of higher priority exists.", "conditions": ["Metastatic Cancer"], "keywords": ["Cancer"], "interventions": [{"type": "DRUG", "name": "LY2624587", "otherNames": []}], "meshConditions": ["Neoplasm Metastasis", "Neoplasms"], "meshInterventions": ["LY2624587"], "hasResults": false, "classifyText": "A Study of LY2624587 in Patients With Advanced Cancer Metastatic Cancer Cancer LY2624587 Neoplasm Metastasis Neoplasms LY2624587 Study CXBA is a multicenter nonrandomized, dose escalation, open-label, Phase 1 study of intravenous LY2624587 in patients with advanced or metastatic cancer for which no treatment of higher priority exists."}
 {"nctId": "NCT05963022", "briefTitle": "A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)", "officialTitle": "A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 Diabetes", "overallStatus": "COMPLETED", "startDate": "2023-08-21", "completionDate": "2024-10-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 206, "briefSummary": "The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.", "conditions": ["Type 2 Diabetes"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["Tirzepatide"], "hasResults": true, "classifyText": "A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) Type 2 Diabetes Tirzepatide Placebo Diabetes Mellitus, Type 2 Tirzepatide The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes."}
 {"nctId": "NCT02737072", "briefTitle": "A Study of LY2510924 and Durvalumab in Participants With Solid Tumors", "officialTitle": "A Phase 1a/1b Study of CXCR4 Peptide Antagonist (LY2510924) Administered in Combination With the Anti-PD-L1 Antibody, Durvalumab (MEDI4736), in Advanced Refractory Solid Tumors", "overallStatus": "TERMINATED", "startDate": "2016-09", "completionDate": "2017-09-25", "leadSponsor": "Eli Lilly and Company", "collaborators": ["AstraZeneca"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 9, "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory solid tumors.", "conditions": ["Solid Tumor"], "keywords": ["immuno-oncology"], "interventions": [{"type": "DRUG", "name": "LY2510924", "otherNames": []}, {"type": "DRUG", "name": "Durvalumab", "otherNames": []}], "meshConditions": [], "meshInterventions": ["LY2510924", "durvalumab"], "hasResults": true, "classifyText": "A Study of LY2510924 and Durvalumab in Participants With Solid Tumors Solid Tumor immuno-oncology LY2510924 Durvalumab LY2510924 durvalumab The main purpose of this study is to evaluate the safety and tolerability of chemokine (C-X-C Motif) receptor 4 (CXCR4) peptide antagonist LY2510924 and durvalumab for phase 1a and 1b in participants with advanced refractory solid tumors."}
 {"nctId": "NCT07346495", "briefTitle": "A Study of Remternetug (LY3372993) in Healthy Chinese Participants", "officialTitle": "A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of Remternetug in Healthy Chinese Participants", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2026-01-31", "completionDate": "2027-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 24, "briefSummary": "The study will evaluate the safety and tolerability of remternetug when given subcutaneously (SC) (under the skin) to healthy Chinese participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 25 weeks, including screening period.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3372993", "otherNames": ["Remternetug"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of Remternetug (LY3372993) in Healthy Chinese Participants Healthy LY3372993 Placebo The study will evaluate the safety and tolerability of remternetug when given subcutaneously (SC) (under the skin) to healthy Chinese participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to 25 weeks, including screening period."}
 {"nctId": "NCT00670501", "briefTitle": "Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis", "officialTitle": "Effects of LY333334 in the Treatment of Postmenopausal Women With Osteoporosis", "overallStatus": "COMPLETED", "startDate": "1996-08", "completionDate": "1999-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 1637, "briefSummary": "The primary objective of this study is to demonstrate a reduction in the proportion of new vertebral fractures in postmenopausal women with osteoporosis following 3-years of treatment with 20 and 40 mcg/day of teriparatide plus calcium and vitamin D compared with calcium and vitamin D alone.", "conditions": ["Osteoporosis, Postmenopausal"], "keywords": [], "interventions": [{"type": "DRUG", "name": "teriparatide", "otherNames": ["LY333334", "Forteo", "Forsteo"]}, {"type": "DRUG", "name": "teriparatide", "otherNames": ["LY333334", "Forteo", "Forsteo"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Calcium Supplement", "otherNames": []}, {"type": "DRUG", "name": "Vitamin D Supplement", "otherNames": []}], "meshConditions": ["Osteoporosis, Postmenopausal"], "meshInterventions": ["Teriparatide"], "hasResults": false, "classifyText": "Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis Osteoporosis, Postmenopausal teriparatide teriparatide Placebo Calcium Supplement Vitamin D Supplement Osteoporosis, Postmenopausal Teriparatide The primary objective of this study is to demonstrate a reduction in the proportion of new vertebral fractures in postmenopausal women with osteoporosis following 3-years of treatment with 20 and 40 mcg/day of teriparatide plus calcium and vitamin D compared with calcium and vitamin D alone."}
 {"nctId": "NCT05067270", "briefTitle": "A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus", "officialTitle": "A Study to Investigate Local Infusion Site Pain After Infusion of Excipients Across Infusion Sites and Infusion Depths", "overallStatus": "COMPLETED", "startDate": "2021-10-22", "completionDate": "2021-12-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 40, "briefSummary": "The main purpose of this study is to evaluate the effect of excipients sodium citrate and treprostinil without insulin on local infusion site pain in participants with type 1 diabetes mellitus (T1DM) on continuous subcutaneous insulin infusion (CSII). The study may last up to 36 days including a screening period and 3 visits.", "conditions": ["Type 1 Diabetes Mellitus"], "keywords": ["Humalog - Insulin lispro", "Citrate", "Infusion Site Pain", "Excipients"], "interventions": [{"type": "DRUG", "name": "Sodium Citrate", "otherNames": []}, {"type": "DRUG", "name": "Treprostinil", "otherNames": []}, {"type": "DRUG", "name": "Humalog diluent", "otherNames": []}, {"type": "DRUG", "name": "Magnesium Chloride", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["Sodium Citrate", "treprostinil", "Magnesium Chloride"], "hasResults": true, "classifyText": "A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus Humalog - Insulin lispro Citrate Infusion Site Pain Excipients Sodium Citrate Treprostinil Humalog diluent Magnesium Chloride Diabetes Mellitus, Type 1 Sodium Citrate treprostinil Magnesium Chloride The main purpose of this study is to evaluate the effect of excipients sodium citrate and treprostinil without insulin on local infusion site pain in participants with type 1 diabetes mellitus (T1DM) on continuous subcutaneous insulin infusion (CSII). The study may last up to 36 days including a screening period and 3 visits."}
 {"nctId": "NCT00494377", "briefTitle": "Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression", "officialTitle": "Duloxetine Versus Duloxetine Plus Non-Pharmacological Intervention in the Treatment of Depression", "overallStatus": "COMPLETED", "startDate": "2004-02", "completionDate": "2005-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 940, "briefSummary": "The primary purpose of this study is to determine if duloxetine plus non-drug intervention is more effective than duloxetine alone in patients with depression.", "conditions": ["Depression"], "keywords": [], "interventions": [{"type": "DRUG", "name": "duloxetine", "otherNames": []}], "meshConditions": ["Depression"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": false, "classifyText": "Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression Depression duloxetine Depression Duloxetine Hydrochloride The primary purpose of this study is to determine if duloxetine plus non-drug intervention is more effective than duloxetine alone in patients with depression."}
 {"nctId": "NCT01341457", "briefTitle": "A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors", "officialTitle": "A Phase 1 Dose-Escalation Study of LY2603618 in Combination With Gemcitabine in Japanese Patients With Solid Tumors", "overallStatus": "COMPLETED", "startDate": "2011-05", "completionDate": "2016-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 17, "briefSummary": "The primary objective of this study is to evaluate the safety and tolerability of LY2603618 in combination with the standard dose of gemcitabine up to the global recommended dose of LY2603618 in Japanese participants with solid advanced or metastatic tumors.", "conditions": ["Solid Tumors"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2603618", "otherNames": []}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": ["LY188011"]}], "meshConditions": [], "meshInterventions": ["LY2603618", "Gemcitabine"], "hasResults": true, "classifyText": "A Study of LY2603618 in Combination With Gemcitabine in Participants With Solid Tumors Solid Tumors LY2603618 Gemcitabine LY2603618 Gemcitabine The primary objective of this study is to evaluate the safety and tolerability of LY2603618 in combination with the standard dose of gemcitabine up to the global recommended dose of LY2603618 in Japanese participants with solid advanced or metastatic tumors."}
 {"nctId": "NCT02614716", "briefTitle": "A Study of LY3090106 in Participants With Sj\u00f6gren's Syndrome (SS)", "officialTitle": "A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sj\u00f6gren's Syndrome", "overallStatus": "COMPLETED", "startDate": "2015-12-10", "completionDate": "2018-09-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 32, "briefSummary": "The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sj\u00f6gren's Syndrome (SS). The study will also evaluate how much of the study drug gets into the blood stream and how long it takes the body to remove it.", "conditions": ["Sj\u00f6gren's Syndrome"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3090106", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Sjogren's Syndrome"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3090106 in Participants With Sj\u00f6gren's Syndrome (SS) Sj\u00f6gren's Syndrome LY3090106 Placebo Sjogren's Syndrome The main purpose of this study is to learn more about the safety and side effects of the study drug known as LY3090106 in participants with Sj\u00f6gren's Syndrome (SS). The study will also evaluate how much of the study drug gets into the blood stream and how long it takes the body to remove it."}
 {"nctId": "NCT06037252", "briefTitle": "A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity", "officialTitle": "A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and Obesity", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2023-09-21", "completionDate": "2026-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 414, "briefSummary": "The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.", "conditions": ["Type 2 Diabetes", "Obesity"], "keywords": ["Diabetes Mellitus", "Glucose Metabolism Disorders", "Metabolic Disease", "Endocrine System Diseases", "Overnutrition", "Nutrition Disorders", "Body Weight", "Tirzepatide", "Incretins"], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2", "Obesity", "Diabetes Mellitus", "Glucose Metabolism Disorders", "Metabolic Diseases", "Endocrine System Diseases", "Overnutrition", "Nutrition Disorders", "Body Weight"], "meshInterventions": ["Tirzepatide"], "hasResults": false, "classifyText": "A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity Type 2 Diabetes Obesity Diabetes Mellitus Glucose Metabolism Disorders Metabolic Disease Endocrine System Diseases Overnutrition Nutrition Disorders Body Weight Tirzepatide Incretins Tirzepatide Placebo Diabetes Mellitus, Type 2 Obesity Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Overnutrition Nutrition Disorders Body Weight Tirzepatide The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks."}
 {"nctId": "NCT04749914", "briefTitle": "A Study of Lasmiditan in Healthy Volunteers", "officialTitle": "An Open-Label, 2-Part Study to Investigate the Effect of Lasmiditan on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Volunteers", "overallStatus": "COMPLETED", "startDate": "2021-02-15", "completionDate": "2021-07-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 97, "briefSummary": "The main purpose of the study is to investigate the blood concentrations of dabigatran etexilate and rosuvastatin when taken alone compared to when taken together with lasmiditan in healthy participants. The safety and tolerability of dabigatran etexilate or rosuvastatin in combination with lasmiditan will also be evaluated in healthy participants. The study has two parts. Each part will last up to 17 days, not including screening.", "conditions": ["Healthy"], "keywords": ["Drug Interaction Study"], "interventions": [{"type": "DRUG", "name": "Lasmiditan", "otherNames": ["LY573144"]}, {"type": "DRUG", "name": "Dabigatran Etexilate", "otherNames": []}, {"type": "DRUG", "name": "Rosuvastatin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["lasmiditan", "Dabigatran", "Rosuvastatin Calcium"], "hasResults": true, "classifyText": "A Study of Lasmiditan in Healthy Volunteers Healthy Drug Interaction Study Lasmiditan Dabigatran Etexilate Rosuvastatin lasmiditan Dabigatran Rosuvastatin Calcium The main purpose of the study is to investigate the blood concentrations of dabigatran etexilate and rosuvastatin when taken alone compared to when taken together with lasmiditan in healthy participants. The safety and tolerability of dabigatran etexilate or rosuvastatin in combination with lasmiditan will also be evaluated in healthy participants. The study has two parts. Each part will last up to 17 days, not including screening."}
 {"nctId": "NCT03720548", "briefTitle": "A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD)", "officialTitle": "A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3372993 in Healthy Subjects and Patients With Alzheimer's Disease", "overallStatus": "COMPLETED", "startDate": "2018-11-05", "completionDate": "2019-05-14", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 36, "briefSummary": "The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD.\n\nThe study has two parts:\n\n* Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks;\n* Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days.", "conditions": ["Alzheimer Disease"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3372993", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Alzheimer Disease"], "meshInterventions": [], "hasResults": false, "classifyText": "A Study of LY3372993 in Healthy Participants and Participants With Alzheimer's Disease (AD) Alzheimer Disease LY3372993 Placebo Alzheimer Disease The main purpose of this study is to evaluate the safety and tolerability of LY3372993 in healthy participants and participants with AD. The study will also investigate how much LY3372993 gets into the bloodstream and test the effects of LY3372993 in participants with AD.\n\nThe study has two parts:\n\n* Part A - Healthy participants will receive LY3372993 or placebo. Part A will last up to 17 weeks;\n* Part B - Participants with AD will receive LY3372993 or placebo. Part B will last about 317 days."}
 {"nctId": "NCT00839332", "briefTitle": "A Study for Participants With Pancreatic Cancer", "officialTitle": "A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Gemcitabine in Patients With Pancreatic Cancer", "overallStatus": "COMPLETED", "startDate": "2009-02", "completionDate": "2013-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 157, "briefSummary": "The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study. The Phase 2 portion of the study evaluated whether LY2603618, when administered 24 hours after gemcitabine therapy, was an effective treatment for participants with pancreatic cancer.", "conditions": ["Pancreatic Neoplasms"], "keywords": ["Pancreas", "metastatic cancer", "advanced cancer", "Pancreatic cancer"], "interventions": [{"type": "DRUG", "name": "LY2603618", "otherNames": []}, {"type": "DRUG", "name": "Gemcitabine", "otherNames": ["Gemzar", "LY188011"]}], "meshConditions": ["Pancreatic Neoplasms", "Neoplasm Metastasis"], "meshInterventions": ["LY2603618", "Gemcitabine"], "hasResults": true, "classifyText": "A Study for Participants With Pancreatic Cancer Pancreatic Neoplasms Pancreas metastatic cancer advanced cancer Pancreatic cancer LY2603618 Gemcitabine Pancreatic Neoplasms Neoplasm Metastasis LY2603618 Gemcitabine The purpose of the Phase 1 portion of this study was to determine the dose of LY2603618 that can be safely administered 24 hours after gemcitabine treatment. This dose was then used for the Phase 2 portion of the study. The Phase 2 portion of the study evaluated whether LY2603618, when administered 24 hours after gemcitabine therapy, was an effective treatment for participants with pancreatic cancer."}
 {"nctId": "NCT06047548", "briefTitle": "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities", "officialTitle": "A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Once Weekly 5 mg and/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)", "overallStatus": "COMPLETED", "startDate": "2023-09-20", "completionDate": "2026-01-20", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 441, "briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction.", "conditions": ["Overweight", "Obesity"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Overweight", "Obesity"], "meshInterventions": ["Tirzepatide"], "hasResults": false, "classifyText": "A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities Overweight Obesity Tirzepatide Placebo Overweight Obesity Tirzepatide The main purpose of this study is to evaluate the efficacy and safety of tirzepatide for the maintenance of body weight reduction."}
 {"nctId": "NCT00082212", "briefTitle": "A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma", "officialTitle": "A Phase II Trial of Single-agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma", "overallStatus": "TERMINATED", "startDate": "2004-11", "completionDate": "2007-06", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Bristol-Myers Squibb"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 25, "briefSummary": "The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma.", "conditions": ["Ovarian Cancer"], "keywords": ["ovarian", "primary peritoneal cancer", "Persistent or Recurrent Ovarian Cancer", "Primary Peritoneal Carcinoma"], "interventions": [{"type": "BIOLOGICAL", "name": "Cetuximab", "otherNames": ["Erbitux"]}], "meshConditions": ["Ovarian Neoplasms"], "meshInterventions": ["Cetuximab"], "hasResults": false, "classifyText": "A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma Ovarian Cancer ovarian primary peritoneal cancer Persistent or Recurrent Ovarian Cancer Primary Peritoneal Carcinoma Cetuximab Ovarian Neoplasms Cetuximab The purpose of this study is to determine the overall response rate, time to progression, and 1 yr survival with cetuximab in patients with ovarian or primary peritoneal carcinoma."}
 {"nctId": "NCT05611671", "briefTitle": "A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC", "officialTitle": "A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-2)", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2022-11-21", "completionDate": "2026-08", "leadSponsor": "Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 280, "briefSummary": "This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).", "conditions": ["Inflammatory Bowel Diseases", "Colitis, Ulcerative"], "keywords": ["Ulcerative Colitis (UC)", "Inflammatory Bowel Disease (IBD)", "a4b7", "Moderate-to-severe", "Integrin", "EMERALD"], "interventions": [{"type": "DRUG", "name": "MORF-057", "otherNames": ["LY4268989"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Inflammatory Bowel Diseases", "Colitis, Ulcerative"], "meshInterventions": [], "hasResults": true, "classifyText": "A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC Inflammatory Bowel Diseases Colitis, Ulcerative Ulcerative Colitis (UC) Inflammatory Bowel Disease (IBD) a4b7 Moderate-to-severe Integrin EMERALD MORF-057 Placebo Inflammatory Bowel Diseases Colitis, Ulcerative This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC)."}
 {"nctId": "NCT00061464", "briefTitle": "Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.", "officialTitle": "ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase II Clinical Trial", "overallStatus": "COMPLETED", "startDate": "2003-02", "completionDate": "2006-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 48, "briefSummary": "The purposes of this study are to determine:\n\n1. The safety of pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs.\n2. Whether pemetrexed plus Gemcitabine can help patients with non-small cell lung cancer live longer.\n3. Whether pemetrexed plus Gemcitabine can make the tumor smaller or disappear, and for how long.\n4. To see if patients feel better while taking pemetrexed plus Gemcitabine.", "conditions": ["Carcinoma, Non-Small-Cell Lung"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": []}, {"type": "DRUG", "name": "gemcitabine", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["Pemetrexed", "Gemcitabine"], "hasResults": false, "classifyText": "Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy. Carcinoma, Non-Small-Cell Lung pemetrexed gemcitabine Carcinoma, Non-Small-Cell Lung Pemetrexed Gemcitabine The purposes of this study are to determine:\n\n1. The safety of pemetrexed plus Gemcitabine and any side effects that might be associated with the combination of these two drugs.\n2. Whether pemetrexed plus Gemcitabine can help patients with non-small cell lung cancer live longer.\n3. Whether pemetrexed plus Gemcitabine can make the tumor smaller or disappear, and for how long.\n4. To see if patients feel better while taking pemetrexed plus Gemcitabine."}
 {"nctId": "NCT00848081", "briefTitle": "A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers", "officialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Efficacy of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant Alpha1-Adrenergic Blocker Therapy", "overallStatus": "COMPLETED", "startDate": "2009-03", "completionDate": "2009-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 318, "briefSummary": "The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such as urinary frequency, urgency, and a feeling that the bladder is not completely emptied after urination).", "conditions": ["Benign Prostatic Hyperplasia"], "keywords": ["Prostate", "BPH", "Benign Prostatic Hyperplasia", "BPH-LUTS", "LUTS", "Phosphodiesterase Inhibitors", "tadalafil", "alpha blockers"], "interventions": [{"type": "DRUG", "name": "Tadalafil", "otherNames": ["LY450190", "Cialis"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Prostatic Hyperplasia"], "meshInterventions": ["Tadalafil"], "hasResults": true, "classifyText": "A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers Benign Prostatic Hyperplasia Prostate BPH Benign Prostatic Hyperplasia BPH-LUTS LUTS Phosphodiesterase Inhibitors tadalafil alpha blockers Tadalafil Placebo Prostatic Hyperplasia Tadalafil The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such as urinary frequency, urgency, and a feeling that the bladder is not completely emptied after urination)."}
 {"nctId": "NCT05445232", "briefTitle": "A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants", "officialTitle": "A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes", "overallStatus": "COMPLETED", "startDate": "2022-07-08", "completionDate": "2023-02-24", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 32, "briefSummary": "The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.", "conditions": ["Obesity"], "keywords": ["Overweight", "Obesity", "Drug Interaction", "Cocktail", "Pharmacokinetic"], "interventions": [{"type": "DRUG", "name": "LY3437943", "otherNames": []}, {"type": "DRUG", "name": "Midazolam", "otherNames": []}, {"type": "DRUG", "name": "Warfarin", "otherNames": []}, {"type": "DRUG", "name": "Caffeine", "otherNames": []}], "meshConditions": ["Obesity", "Overweight"], "meshInterventions": ["retatrutide", "Midazolam", "Warfarin", "Caffeine"], "hasResults": false, "classifyText": "A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants Obesity Overweight Obesity Drug Interaction Cocktail Pharmacokinetic LY3437943 Midazolam Warfarin Caffeine Obesity Overweight retatrutide Midazolam Warfarin Caffeine The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant."}
 {"nctId": "NCT00087698", "briefTitle": "Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma", "officialTitle": "A Multicenter Phase II Trial of Neo-Adjuvant Pemetrexed (Alimta) Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma", "overallStatus": "COMPLETED", "startDate": "2003-09", "completionDate": "2008-02", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 77, "briefSummary": "This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored.", "conditions": ["Pleural Neoplasms"], "keywords": [], "interventions": [{"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514", "Alimta"]}, {"type": "DRUG", "name": "cisplatin", "otherNames": []}], "meshConditions": ["Pleural Neoplasms"], "meshInterventions": ["Pemetrexed", "Cisplatin"], "hasResults": true, "classifyText": "Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma Pleural Neoplasms pemetrexed cisplatin Pleural Neoplasms Pemetrexed Cisplatin This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery. Following surgery, all eligible patients will receive radiation to the chest. How patients respond, whether the cancer returns and if so, where, will also be monitored."}
 {"nctId": "NCT00044187", "briefTitle": "The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder", "officialTitle": "The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder", "overallStatus": "COMPLETED", "startDate": "2001-04", "completionDate": "2003-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 130, "briefSummary": "Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine.\n\nThe purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.", "conditions": ["Schizophrenia", "Psychotic Disorders", "Bipolar Disorder"], "keywords": ["schizoaffective disorder", "schizophreniform disorder", "bipolar I disorder"], "interventions": [{"type": "DRUG", "name": "Sibutramine", "otherNames": []}], "meshConditions": ["Schizophrenia", "Psychotic Disorders", "Bipolar Disorder"], "meshInterventions": ["sibutramine"], "hasResults": false, "classifyText": "The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder Schizophrenia Psychotic Disorders Bipolar Disorder schizoaffective disorder schizophreniform disorder bipolar I disorder Sibutramine Schizophrenia Psychotic Disorders Bipolar Disorder sibutramine Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine.\n\nThe purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine."}
 {"nctId": "NCT06194214", "briefTitle": "A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants", "officialTitle": "A Phase I, Open-label, Fixed-sequence, Drug Interaction Study to Investigate the Effect of Single and Multiple Oral Doses of LOXO-305 on the Pharmacokinetics of Multiple Oral Doses of Digoxin (P-Glycoprotein Substrate) in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2021-03-11", "completionDate": "2021-06-09", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Loxo Oncology, Inc."], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 16, "briefSummary": "The main purpose of this study is to evaluate the effect of Pirtobrutinib (LOXO-305) on multiple oral doses of digoxin (P-gp substrate) when administered as single and multiple doses by collecting the blood samples and conducting the blood tests to measure how much digoxin is in the bloodstream and how the body handles and eliminates it in healthy participants. The study will also evaluate the safety and tolerability of Pirtobrutinib. Participants will stay in this study for up to 58 days, including screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Pirtobrutinib", "otherNames": ["LOXO-305", "LY3527727"]}, {"type": "DRUG", "name": "Digoxin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["pirtobrutinib", "Digoxin"], "hasResults": true, "classifyText": "A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants Healthy Pirtobrutinib Digoxin pirtobrutinib Digoxin The main purpose of this study is to evaluate the effect of Pirtobrutinib (LOXO-305) on multiple oral doses of digoxin (P-gp substrate) when administered as single and multiple doses by collecting the blood samples and conducting the blood tests to measure how much digoxin is in the bloodstream and how the body handles and eliminates it in healthy participants. The study will also evaluate the safety and tolerability of Pirtobrutinib. Participants will stay in this study for up to 58 days, including screening."}
 {"nctId": "NCT04178733", "briefTitle": "A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants", "officialTitle": "A Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of LY3493269 in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2020-01-10", "completionDate": "2020-05-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 33, "briefSummary": "This study is being conducted to determine the side effects related to LY3493269 given as a single injection to healthy participants. Blood tests will be performed to check how much LY3493269 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3493269 or placebo. The study will last up to approximately 71 days for each participant, including screening.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3493269 - SC", "otherNames": []}, {"type": "DRUG", "name": "Placebo - SC", "otherNames": []}, {"type": "DRUG", "name": "LY3493269 - IV", "otherNames": []}], "meshConditions": [], "meshInterventions": [], "hasResults": true, "classifyText": "A Safety Study of LY3493269 Given as a Single Injection in Healthy Participants Healthy LY3493269 - SC Placebo - SC LY3493269 - IV This study is being conducted to determine the side effects related to LY3493269 given as a single injection to healthy participants. Blood tests will be performed to check how much LY3493269 gets into the bloodstream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of LY3493269 or placebo. The study will last up to approximately 71 days for each participant, including screening."}
 {"nctId": "NCT03375463", "briefTitle": "A Study of Tirzepatide (LY3298176) in Healthy Participants", "officialTitle": "Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2017-12-19", "completionDate": "2018-12-27", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 52, "briefSummary": "This study has four parts. Each participant will enroll in one part.\n\nPart A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC) (just under the skin). Part A will measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it.\n\nPart B: The purpose of Part B is to evaluate the safety and tolerability of tirzepatide intravenous (IV) formulation when administered into a vein.\n\nPart C: The purpose of Part C is to evaluate the safety and tolerability of tirzepatide following multiple SC weekly doses of a solution.\n\nPart D: The purpose of Part D is to evaluate the safety and tolerability of tirzepatide following single IV bolus dose of lyophilized formulation.\n\nThis study will last approximately 70 days for each part (Part A, Part B or Part D) and 92 days for Part C. This does not include screening. Screening is required within 28 days prior to the start of the study.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Tirzepatide", "otherNames": ["LY3298176"]}], "meshConditions": [], "meshInterventions": ["Tirzepatide"], "hasResults": true, "classifyText": "A Study of Tirzepatide (LY3298176) in Healthy Participants Healthy Tirzepatide Tirzepatide Placebo Tirzepatide Tirzepatide This study has four parts. Each participant will enroll in one part.\n\nPart A: The purpose of Part A is to compare study drug tirzepatide solution formulation to a powder formulation mixed with water and given subcutaneously (SC) (just under the skin). Part A will measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it.\n\nPart B: The purpose of Part B is to evaluate the safety and tolerability of tirzepatide intravenous (IV) formulation when administered into a vein.\n\nPart C: The purpose of Part C is to evaluate the safety and tolerability of tirzepatide following multiple SC weekly doses of a solution.\n\nPart D: The purpose of Part D is to evaluate the safety and tolerability of tirzepatide following single IV bolus dose of lyophilized formulation.\n\nThis study will last approximately 70 days for each part (Part A, Part B or Part D) and 92 days for Part C. This does not include screening. Screening is required within 28 days prior to t"}
 {"nctId": "NCT01175811", "briefTitle": "A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus", "officialTitle": "A Comparison of Premixed and Basal-Bolus Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus With Inadequate Glycaemic Control on Twice-daily Premixed Insulin", "overallStatus": "COMPLETED", "startDate": "2011-02", "completionDate": "2012-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 402, "briefSummary": "The purpose of the study is to compare the effects on overall glycaemic control of two insulin intensification therapies.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": ["Metabolic Diseases", "Diabetes Mellitus, Type 2", "Glargine", "Diabetes Mellitus", "Insulin LISPRO", "Insulin"], "interventions": [{"type": "DRUG", "name": "Insulin Lispro Premix", "otherNames": ["Humalog Mix25", "Humalog Mix50", "LY275585"]}, {"type": "DRUG", "name": "Insulin Glargine", "otherNames": []}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": ["Humalog", "LY275585"]}], "meshConditions": ["Diabetes Mellitus, Type 2", "Metabolic Diseases", "Diabetes Mellitus", "Insulin Resistance"], "meshInterventions": ["insulin lispro, isophane insulin lispro drug combination (25:75)", "Insulin Lispro", "Insulin Glargine"], "hasResults": true, "classifyText": "A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus Diabetes Mellitus, Type 2 Metabolic Diseases Diabetes Mellitus, Type 2 Glargine Diabetes Mellitus Insulin LISPRO Insulin Insulin Lispro Premix Insulin Glargine Insulin Lispro Diabetes Mellitus, Type 2 Metabolic Diseases Diabetes Mellitus Insulin Resistance insulin lispro, isophane insulin lispro drug combination (25:75) Insulin Lispro Insulin Glargine The purpose of the study is to compare the effects on overall glycaemic control of two insulin intensification therapies."}
 {"nctId": "NCT01810432", "briefTitle": "Study of Food on Evacetrapib (LY2484595) in Healthy Participants", "officialTitle": "Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2013-03", "completionDate": "2013-06", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 40, "briefSummary": "The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given to healthy participants. Information about any side effects that may occur will also be collected.\n\nThe study has 2 periods. In each period, participants will take the study drug for 10 days, either with or without a meal. There is a minimum 14-day washout between each period.\n\nThis study is approximately 50 days, not including screening. Screening is required within 28 days prior to the start of the study.", "conditions": ["Healthy Volunteers"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Evacetrapib", "otherNames": ["LY2484595"]}, {"type": "OTHER", "name": "High-fat Meal", "otherNames": []}], "meshConditions": [], "meshInterventions": ["evacetrapib"], "hasResults": true, "classifyText": "Study of Food on Evacetrapib (LY2484595) in Healthy Participants Healthy Volunteers Evacetrapib High-fat Meal evacetrapib The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it when given to healthy participants. Information about any side effects that may occur will also be collected.\n\nThe study has 2 periods. In each period, participants will take the study drug for 10 days, either with or without a meal. There is a minimum 14-day washout between each period.\n\nThis study is approximately 50 days, not including screening. Screening is required within 28 days prior to the start of the study."}
 {"nctId": "NCT01137006", "briefTitle": "An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma", "officialTitle": "An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated", "overallStatus": "COMPLETED", "startDate": "2010-06", "completionDate": "2012-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 27, "briefSummary": "A dose-escalation study designed to determine the safety, maximum tolerated dose (MTD), anti-melanoma activity, antibody blood levels and progression-free survival (PFS) in participants with malignant melanoma receiving IMC-20D7S either every 2 weeks or every 3 weeks.", "conditions": ["Malignant Melanoma"], "keywords": ["Melanoma", "Phase I", "antibody", "melanin", "tyrosinase related protein 1", "glycoprotein", "20D7S"], "interventions": [{"type": "BIOLOGICAL", "name": "IMC-20D7S (Cohort 1A)", "otherNames": ["LY3012215"]}, {"type": "BIOLOGICAL", "name": "IMC-20D7S (Cohort 2A)", "otherNames": ["LY3012215"]}, {"type": "BIOLOGICAL", "name": "IMC-20D7S (Cohort 3A)", "otherNames": ["LY3012215"]}, {"type": "BIOLOGICAL", "name": "IMC-20D7S (Cohort 4A)", "otherNames": ["LY3012215"]}, {"type": "BIOLOGICAL", "name": "IMC-20D7S (Cohort 1B)", "otherNames": ["LY3012215"]}, {"type": "BIOLOGICAL", "name": "IMC-20D7S (Cohort 2B)", "otherNames": ["LY3012215"]}, {"type": "BIOLOGICAL", "name": "IMC-20D7S (Cohort 3B)", "otherNames": ["LY3012215"]}], "meshConditions": ["Melanoma"], "meshInterventions": [], "hasResults": true, "classifyText": "An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma Malignant Melanoma Melanoma Phase I antibody melanin tyrosinase related protein 1 glycoprotein 20D7S IMC-20D7S (Cohort 1A) IMC-20D7S (Cohort 2A) IMC-20D7S (Cohort 3A) IMC-20D7S (Cohort 4A) IMC-20D7S (Cohort 1B) IMC-20D7S (Cohort 2B) IMC-20D7S (Cohort 3B) Melanoma A dose-escalation study designed to determine the safety, maximum tolerated dose (MTD), anti-melanoma activity, antibody blood levels and progression-free survival (PFS) in participants with malignant melanoma receiving IMC-20D7S either every 2 weeks or every 3 weeks."}
 {"nctId": "NCT00420381", "briefTitle": "Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer", "officialTitle": "A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Carcinoma", "overallStatus": "COMPLETED", "startDate": "2007-01", "completionDate": "2014-12", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Gynecologic Oncology Group"], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 28, "briefSummary": "The purpose is to assess the efficacy and toxicity of the study agent, enzastaurin, in participants with recurrent or persistent ovarian cancer.", "conditions": ["Ovarian Cancer", "Neoplasms", "Carcinoma"], "keywords": ["Recurrent Cancer"], "interventions": [{"type": "DRUG", "name": "enzastaurin", "otherNames": ["LY317615"]}], "meshConditions": ["Ovarian Neoplasms", "Neoplasms", "Carcinoma", "Recurrence"], "meshInterventions": ["enzastaurin"], "hasResults": true, "classifyText": "Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer Ovarian Cancer Neoplasms Carcinoma Recurrent Cancer enzastaurin Ovarian Neoplasms Neoplasms Carcinoma Recurrence enzastaurin The purpose is to assess the efficacy and toxicity of the study agent, enzastaurin, in participants with recurrent or persistent ovarian cancer."}
 {"nctId": "NCT00641719", "briefTitle": "A Long-term Study for the Treatment of Painful Diabetic Neuropathy", "officialTitle": "A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain - Extension Phase", "overallStatus": "COMPLETED", "startDate": "2008-03", "completionDate": "2010-03", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Shionogi"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 258, "briefSummary": "The purpose of the study is to investigate safety and efficacy of duloxetine for patients with painful diabetic neuropathy at long-term use.", "conditions": ["Diabetic Neuropathies"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Duloxetine hydrochloride", "otherNames": ["LY248686", "Cymbalta"]}, {"type": "DRUG", "name": "Duloxetine hydrochloride", "otherNames": ["LY248686", "Cymbalta"]}], "meshConditions": ["Diabetic Neuropathies"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": true, "classifyText": "A Long-term Study for the Treatment of Painful Diabetic Neuropathy Diabetic Neuropathies Duloxetine hydrochloride Duloxetine hydrochloride Diabetic Neuropathies Duloxetine Hydrochloride The purpose of the study is to investigate safety and efficacy of duloxetine for patients with painful diabetic neuropathy at long-term use."}
 {"nctId": "NCT00074828", "briefTitle": "New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery", "officialTitle": "A Comparison of the Oral Anticoagulant LY517717 Difumarate to Subcutaneous Enoxaparin for the Prevention of Venous Thromboembolic Events (VTE) Post-Total Hip Replacement (THR) and Post-Total Knee Replacement (TKR) Surgery", "overallStatus": "COMPLETED", "startDate": "2003-12", "completionDate": "2005-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "PREVENTION", "enrollment": 511, "briefSummary": "LY517717 (a capsule given by mouth) is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs. Leg and lung blood clots occur commonly after patients have surgery to replace a hip or knee joint. These clots often occur while patients are in bed in the hospital after hip or knee joint surgery. The purpose of this study is to test if different dose strengths (amount of drug in the capsules) of LY517717 can prevent blood clots from forming and to determine if LY517717 is safe. This study will compare LY517717 to enoxaparin, another blood thinner. Enoxaparin is one of the standard medications given after hip or knee joint surgery.", "conditions": ["Total Knee Replacement", "Total Hip Replacement"], "keywords": ["elective", "primary unilateral"], "interventions": [{"type": "DRUG", "name": "LY517717", "otherNames": []}, {"type": "DRUG", "name": "enoxaparin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["LY517717", "Enoxaparin"], "hasResults": false, "classifyText": "New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery Total Knee Replacement Total Hip Replacement elective primary unilateral LY517717 enoxaparin LY517717 Enoxaparin LY517717 (a capsule given by mouth) is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs. Leg and lung blood clots occur commonly after patients have surgery to replace a hip or knee joint. These clots often occur while patients are in bed in the hospital after hip or knee joint surgery. The purpose of this study is to test if different dose strengths (amount of drug in the capsules) of LY517717 can prevent blood clots from forming and to determine if LY517717 is safe. This study will compare LY517717 to enoxaparin, another blood thinner. Enoxaparin is one of the standard medications given after hip or knee joint surgery."}
 {"nctId": "NCT07483073", "briefTitle": "A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease", "officialTitle": "A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease", "overallStatus": "NOT_YET_RECRUITING", "startDate": "2026-04", "completionDate": "2028-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 60, "briefSummary": "Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 62 weeks.", "conditions": ["Colitis, Ulcerative", "Crohn Disease"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Mirikizumab - Intravenous (IV)", "otherNames": ["LY3074828"]}, {"type": "DRUG", "name": "Mirikizumab - Subcutaneous (SC)", "otherNames": ["LY3074828"]}, {"type": "DRUG", "name": "LY4395089", "otherNames": []}], "meshConditions": ["Colitis, Ulcerative", "Crohn Disease"], "meshInterventions": ["mirikizumab"], "hasResults": false, "classifyText": "A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease Colitis, Ulcerative Crohn Disease Mirikizumab - Intravenous (IV) Mirikizumab - Subcutaneous (SC) LY4395089 Colitis, Ulcerative Crohn Disease mirikizumab Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 62 weeks."}
 {"nctId": "NCT01534273", "briefTitle": "A Study of LY2886721 in Healthy Participants", "officialTitle": "Single- and Multiple-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2012-02", "completionDate": "2012-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 30, "briefSummary": "The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the body.", "conditions": ["Healthy Volunteers"], "keywords": ["Mild Cognitive Impairment"], "interventions": [{"type": "DRUG", "name": "LY2886721", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Cognitive Dysfunction"], "meshInterventions": ["N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide"], "hasResults": true, "classifyText": "A Study of LY2886721 in Healthy Participants Healthy Volunteers Mild Cognitive Impairment LY2886721 Placebo Cognitive Dysfunction N-(3-(2-amino-4a,5,7,7a-tetrahydro-4H-furo(3,4-d)(1,3)thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide The purpose of this phase I study in healthy participants will be to evaluate the safety and tolerability of LY2886721 single and multiple doses, to evaluate how the body handles the drug, and to evaluate the drug's effect on the body."}
 {"nctId": "NCT00191373", "briefTitle": "A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease", "officialTitle": "Phase II Study of Gemcitabine and Trastuzumab Therapy in Patients With HER2 Overexpressing Metastatic Breast Cancer", "overallStatus": "COMPLETED", "startDate": "2002-03", "completionDate": "2007-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 66, "briefSummary": "This phase II trial that includes Gemcitabine 1,250mg/m2 to be administered over approximately 30 minutes on days 1 and 8, every 21 days and Trastuzumab 8 mg/kg IV to be administered over 90 minutes on day 1 of the first cycle, then 6mg/kg as a 30 minute infusion administered on subsequent cycles.", "conditions": ["Breast Neoplasms", "Cancer of the Breast", "Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Gemcitabine", "otherNames": []}, {"type": "DRUG", "name": "Trastuzumab", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Gemcitabine", "Trastuzumab"], "hasResults": false, "classifyText": "A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease Breast Neoplasms Cancer of the Breast Breast Cancer Gemcitabine Trastuzumab Breast Neoplasms Gemcitabine Trastuzumab This phase II trial that includes Gemcitabine 1,250mg/m2 to be administered over approximately 30 minutes on days 1 and 8, every 21 days and Trastuzumab 8 mg/kg IV to be administered over 90 minutes on day 1 of the first cycle, then 6mg/kg as a 30 minute infusion administered on subsequent cycles."}
 {"nctId": "NCT00191854", "briefTitle": "Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line", "officialTitle": "Randomized Phase II Study of Biweekly Gemcitabine-Paclitaxel, Biweekly Gemcitabine-Carboplatin and Biweekly Gemcitabine-Cisplatin as First-Line Treatment in Metastatic Breast Cancer After Anthracycline Failure", "overallStatus": "COMPLETED", "startDate": "2005-03", "completionDate": "2009-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 147, "briefSummary": "The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined. The primary objective of this study is to compare the response rates of the gemcitabine-paclitaxel, gemcitabine-carboplatin, and gemcitabine-cisplatin combinations when administered on a biweekly schedule in metastatic breast cancer.", "conditions": ["Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "gemcitabine", "otherNames": ["LY188011", "Gemzar"]}, {"type": "DRUG", "name": "paclitaxel", "otherNames": []}, {"type": "DRUG", "name": "carboplatin", "otherNames": []}, {"type": "DRUG", "name": "cisplatin", "otherNames": []}], "meshConditions": ["Breast Neoplasms"], "meshInterventions": ["Gemcitabine", "Paclitaxel", "Carboplatin", "Cisplatin"], "hasResults": true, "classifyText": "Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line Breast Cancer gemcitabine paclitaxel carboplatin cisplatin Breast Neoplasms Gemcitabine Paclitaxel Carboplatin Cisplatin The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined. The primary objective of this study is to compare the response rates of the gemcitabine-paclitaxel, gemcitabine-carboplatin, and gemcitabine-cisplatin combinations when administered on a biweekly schedule in metastatic breast cancer."}
 {"nctId": "NCT02779751", "briefTitle": "A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer", "officialTitle": "A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2016-11-14", "completionDate": "2026-12", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Merck Sharp & Dohme LLC"], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "TREATMENT", "enrollment": 100, "briefSummary": "The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.", "conditions": ["Non Small Cell Lung Cancer", "Breast Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Abemaciclib", "otherNames": ["LY2835219"]}, {"type": "DRUG", "name": "Pembrolizumab", "otherNames": []}, {"type": "DRUG", "name": "Anastrozole", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung", "Breast Neoplasms"], "meshInterventions": ["abemaciclib", "pembrolizumab", "Anastrozole"], "hasResults": false, "classifyText": "A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Non Small Cell Lung Cancer Breast Cancer Abemaciclib Pembrolizumab Anastrozole Carcinoma, Non-Small-Cell Lung Breast Neoplasms abemaciclib pembrolizumab Anastrozole The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer."}
 {"nctId": "NCT03899259", "briefTitle": "A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata", "officialTitle": "A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata", "overallStatus": "COMPLETED", "startDate": "2019-07-08", "completionDate": "2024-11-19", "leadSponsor": "Eli Lilly and Company", "collaborators": ["Incyte Corporation"], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 606, "briefSummary": "The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA).", "conditions": ["Alopecia Areata"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Baricitinib", "otherNames": ["LY3009104"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Alopecia Areata"], "meshInterventions": ["baricitinib"], "hasResults": true, "classifyText": "A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Alopecia Areata Baricitinib Placebo Alopecia Areata baricitinib The reason for this study is to see if baricitinib is safe and effective in adults with severe or very severe alopecia areata (AA)."}
 {"nctId": "NCT02091362", "briefTitle": "A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus", "officialTitle": "The Effect of LY2409021 on Blood Pressure and Pulse Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Subjects With Type 2 Diabetes Mellitus", "overallStatus": "COMPLETED", "startDate": "2014-03", "completionDate": "2015-01", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 270, "briefSummary": "The main purpose of the trial is to determine the effect of a study drug known as LY2409021 on blood pressure and pulse rate in participants with type 2 diabetes mellitus (T2DM) when compared to placebo. The study has two periods. Each participant will receive LY2409021 or placebo in each period. At least 4 weeks will pass between periods. The study will last about 23 weeks for each participant. Participants may remain on stable dose metformin, as prescribed by their personal physician.", "conditions": ["Type 2 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY2409021", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Metformin", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["adomeglivant", "Metformin"], "hasResults": true, "classifyText": "A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus Type 2 Diabetes Mellitus LY2409021 Placebo Metformin Diabetes Mellitus, Type 2 adomeglivant Metformin The main purpose of the trial is to determine the effect of a study drug known as LY2409021 on blood pressure and pulse rate in participants with type 2 diabetes mellitus (T2DM) when compared to placebo. The study has two periods. Each participant will receive LY2409021 or placebo in each period. At least 4 weeks will pass between periods. The study will last about 23 weeks for each participant. Participants may remain on stable dose metformin, as prescribed by their personal physician."}
 {"nctId": "NCT00003669", "briefTitle": "Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer", "officialTitle": "Phase II Nonrandomized Study of LY353381-HC1 in Patients With Recurrent or Advanced Endometrial Cancer", "overallStatus": "COMPLETED", "startDate": "1998-11", "completionDate": "2001-04", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": null, "briefSummary": "RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using arzoxifene hydrochloride may fight the endometrial cancer by blocking the use of estrogen by the tumor cells\n\nPURPOSE: This phase II trial is studying how well arzoxifene hydrochloride works in treating women with recurrent, advanced, or metastatic endometrial cancer.", "conditions": ["Endometrial Cancer"], "keywords": ["stage IV endometrial carcinoma", "recurrent endometrial carcinoma"], "interventions": [{"type": "DRUG", "name": "arzoxifene hydrochloride", "otherNames": []}], "meshConditions": ["Endometrial Neoplasms"], "meshInterventions": [], "hasResults": false, "classifyText": "Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer Endometrial Cancer stage IV endometrial carcinoma recurrent endometrial carcinoma arzoxifene hydrochloride Endometrial Neoplasms RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using arzoxifene hydrochloride may fight the endometrial cancer by blocking the use of estrogen by the tumor cells\n\nPURPOSE: This phase II trial is studying how well arzoxifene hydrochloride works in treating women with recurrent, advanced, or metastatic endometrial cancer."}
 {"nctId": "NCT01118780", "briefTitle": "A Study of Duloxetine in Elderly Generalized Anxiety Disorder", "officialTitle": "Duloxetine Versus Placebo in the Treatment of Elderly Patients With Generalized Anxiety Disorder", "overallStatus": "COMPLETED", "startDate": "2010-10", "completionDate": "2012-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "primaryPurpose": "TREATMENT", "enrollment": 291, "briefSummary": "The purpose of this study is to test the safety and efficacy of duloxetine versus placebo in elderly patients suffering from generalized anxiety disorder (GAD).", "conditions": ["Generalized Anxiety Disorder"], "keywords": ["GAD", "Generalized Anxiety Disorder", "Anxiety"], "interventions": [{"type": "DRUG", "name": "Duloxetine", "otherNames": ["Cymbalta", "Duloxetine Hydrochloride", "LY248686"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Generalized Anxiety Disorder", "Anxiety Disorders"], "meshInterventions": ["Duloxetine Hydrochloride"], "hasResults": true, "classifyText": "A Study of Duloxetine in Elderly Generalized Anxiety Disorder Generalized Anxiety Disorder GAD Generalized Anxiety Disorder Anxiety Duloxetine Placebo Generalized Anxiety Disorder Anxiety Disorders Duloxetine Hydrochloride The purpose of this study is to test the safety and efficacy of duloxetine versus placebo in elderly patients suffering from generalized anxiety disorder (GAD)."}
 {"nctId": "NCT00827242", "briefTitle": "Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily", "officialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multinational Study to Evaluate the Efficacy and Safety of Daily Tadalafil for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia", "overallStatus": "COMPLETED", "startDate": "2009-01", "completionDate": "2009-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 325, "briefSummary": "The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full, etc.)", "conditions": ["Benign Prostatic Hyperplasia"], "keywords": ["Signs and Symptoms", "Prostatic Hyperplasia", "Hyperplasia", "Genital Diseases, Male", "Prostatic Diseases", "BPH-LUTS"], "interventions": [{"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "tadalafil", "otherNames": ["Cialis", "LY450190"]}], "meshConditions": ["Prostatic Hyperplasia", "Signs and Symptoms", "Hyperplasia", "Genital Diseases, Male", "Prostatic Diseases"], "meshInterventions": ["Tadalafil"], "hasResults": true, "classifyText": "Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily Benign Prostatic Hyperplasia Signs and Symptoms Prostatic Hyperplasia Hyperplasia Genital Diseases, Male Prostatic Diseases BPH-LUTS Placebo tadalafil Prostatic Hyperplasia Signs and Symptoms Hyperplasia Genital Diseases, Male Prostatic Diseases Tadalafil The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your bladder is still full, etc.)"}
 {"nctId": "NCT00363766", "briefTitle": "Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer", "officialTitle": "A Phase 2 Study of LY573636-Sodium Administered as an Intravenous Infusion on Day 1 of a 21-Day Cycle as Third-line Treatment in Patients With Unresectable, Metastatic Non-Small Cell Lung Cancer", "overallStatus": "COMPLETED", "startDate": "2006-09", "completionDate": "2008-10", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 52, "briefSummary": "The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for metastatic non-small cell lung cancer. Patients will receive an intravenous infusion of study drug once every 21 days. Computed tomography (CT)-scans will be done before the first dose and then after every other treatment.", "conditions": ["Non-Small-Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY573636-sodium", "otherNames": ["Tasisulam"]}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide"], "hasResults": true, "classifyText": "Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer Non-Small-Cell Lung Cancer LY573636-sodium Carcinoma, Non-Small-Cell Lung N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments for metastatic non-small cell lung cancer. Patients will receive an intravenous infusion of study drug once every 21 days. Computed tomography (CT)-scans will be done before the first dose and then after every other treatment."}
 {"nctId": "NCT02614196", "briefTitle": "Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study", "officialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study", "overallStatus": "COMPLETED", "startDate": "2015-12-04", "completionDate": "2018-10-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 986, "briefSummary": "The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.", "conditions": ["Migraine"], "keywords": ["prevention", "prophylaxis", "headache"], "interventions": [{"type": "DRUG", "name": "Galcanezumab", "otherNames": ["LY2951742"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Migraine Disorders", "Headache"], "meshInterventions": ["galcanezumab"], "hasResults": true, "classifyText": "Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study Migraine prevention prophylaxis headache Galcanezumab Placebo Migraine Disorders Headache galcanezumab The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine."}
 {"nctId": "NCT00036062", "briefTitle": "A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury", "officialTitle": "A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury", "overallStatus": "COMPLETED", "startDate": "2001-08", "completionDate": "2002-12", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1", "PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 600, "briefSummary": "The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.", "conditions": ["Respiratory Distress Syndrome, Adult", "Acute Lung Injury"], "keywords": ["Sivelestat", "acute lung injury"], "interventions": [{"type": "DRUG", "name": "Sivelestat", "otherNames": []}], "meshConditions": ["Respiratory Distress Syndrome", "Acute Lung Injury"], "meshInterventions": ["sivelestat"], "hasResults": false, "classifyText": "A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury Respiratory Distress Syndrome, Adult Acute Lung Injury Sivelestat acute lung injury Sivelestat Respiratory Distress Syndrome Acute Lung Injury sivelestat The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury."}
 {"nctId": "NCT03182920", "briefTitle": "A Study of Lasmiditan in Healthy Participants", "officialTitle": "Effect of Age on the Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2017-06-16", "completionDate": "2017-08-14", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 35, "briefSummary": "The purpose of this study is to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it by comparing the results of healthy elderly participants to those of healthy young participants. The tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected.\n\nThis study will last up to approximately 19 days, not including screening. This study requires either one (Group 2) or two (Group 1) stays at the clinic each of at least four days/three nights. Participants will return for a follow-up seven days after last dose of study drug. Screening is required within 28 days prior to Day 1.\n\nThis study is for research purposes only and is not intended to treat any medical condition.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Lasmiditan", "otherNames": ["LY573144"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": [], "meshInterventions": ["lasmiditan"], "hasResults": true, "classifyText": "A Study of Lasmiditan in Healthy Participants Healthy Lasmiditan Placebo lasmiditan The purpose of this study is to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it by comparing the results of healthy elderly participants to those of healthy young participants. The tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected.\n\nThis study will last up to approximately 19 days, not including screening. This study requires either one (Group 2) or two (Group 1) stays at the clinic each of at least four days/three nights. Participants will return for a follow-up seven days after last dose of study drug. Screening is required within 28 days prior to Day 1.\n\nThis study is for research purposes only and is not intended to treat any medical condition."}
 {"nctId": "NCT06297603", "briefTitle": "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)", "officialTitle": "A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes, Moderate or Severe Renal Impairment With Inadequate Glycemic Control on Basal Insulin With or Without Metformin and/or SGLT2 Inhibitor", "overallStatus": "ACTIVE_NOT_RECRUITING", "startDate": "2024-03-15", "completionDate": "2026-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 320, "briefSummary": "The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits.", "conditions": ["Type 2 Diabetes"], "keywords": ["Glucose Metabolism Disorders", "Metabolic Diseases", "Endocrine System Diseases", "Diabetes Mellitus", "Diabetes Mellitus, Type 2", "Kidney Disease", "Renal Insufficiency Chronic"], "interventions": [{"type": "DRUG", "name": "Retatrutide", "otherNames": ["LY3437943"]}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2", "Glucose Metabolism Disorders", "Metabolic Diseases", "Endocrine System Diseases", "Diabetes Mellitus", "Kidney Diseases", "Renal Insufficiency, Chronic"], "meshInterventions": ["retatrutide"], "hasResults": false, "classifyText": "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) Type 2 Diabetes Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Diabetes Mellitus Diabetes Mellitus, Type 2 Kidney Disease Renal Insufficiency Chronic Retatrutide Placebo Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Diabetes Mellitus Kidney Diseases Renal Insufficiency, Chronic retatrutide The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and renal impairment, with inadequate glycemic control on basal insulin alone or a combination of basal insulin with or without metformin and/or sodium-glucose cotransporter-2 (SGLT2) inhibitor. The study will last about 14 months and may include up to 22 visits."}
 {"nctId": "NCT06280703", "briefTitle": "A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM)", "officialTitle": "A Four-Part, Randomized, Double-Blind (Part A) and Open-Label (Part B, Part C, and Part D), Multi-Dose, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus", "overallStatus": "RECRUITING", "startDate": "2024-05-15", "completionDate": "2026-09", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 118, "briefSummary": "The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec.\n\nThe study will also evaluate the safety and tolerability of LY3938577 and information about any side effects experienced will be collected.\n\nThe study will be conducted in four parts (A, B, C, and D). Healthy participants in Part A Period 1 will receive a single dose of LY3938577 or a placebo given via intravenous (IV) infusion. In Part A Period 2, participants will receive a single subcutaneous (SC) dose of either LY3938577 or placebo. Participants in Part B with Type 1 Diabetes Mellitus (T1DM) will receive single doses of either LY3938577 or Insulin Degludec given via IV infusion. Participants in Part C with Type 1 Diabetes Mellitus (T1DM) will receive two doses of either LY3938577 or Insulin Degludec administered SC. Participants in Part D with Type 1 Diabetes Mellitus (T1DM) will be evaluated in 2 periods, with Period 1 administered pre-study basal insulin and lispro mealtime insulin to establish insulin needs, and Period 2 administered lispro mealtime insulin and daily doses of LY3938577.\n\nThe study will last up to approximately 11 weeks for Part A, 10 weeks for Part B, 13 weeks for Part C, and 10 weeks for Part D , including screening period.", "conditions": ["Healthy", "Type 1 Diabetes Mellitus"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3938577", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Insulin Degludec", "otherNames": []}, {"type": "DRUG", "name": "Insulin Lispro", "otherNames": []}, {"type": "DRUG", "name": "LY3938577", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}, {"type": "DRUG", "name": "Insulin Degludec", "otherNames": []}, {"type": "DRUG", "name": "Basal Insulin", "otherNames": []}, {"type": "DRUG", "name": "Lispro Prandial Insulin", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 1"], "meshInterventions": ["insulin degludec", "Insulin Lispro"], "hasResults": false, "classifyText": "A Study of LY3938577 in Healthy Participants and Participants With Type 1 Diabetes Mellitus (T1DM) Healthy Type 1 Diabetes Mellitus LY3938577 Placebo Insulin Degludec Insulin Lispro LY3938577 Placebo Insulin Degludec Basal Insulin Lispro Prandial Insulin Diabetes Mellitus, Type 1 insulin degludec Insulin Lispro The main purpose of this study is to look at the amount of the study drug LY3938577 that gets into the blood stream and how long it takes the body to get rid of it. At a later stage of this study (part B and C) the blood sugar lowering effect and the duration of action of LY3938577 will be evaluated compared to Insulin Degludec.\n\nThe study will also evaluate the safety and tolerability of LY3938577 and information about any side effects experienced will be collected.\n\nThe study will be conducted in four parts (A, B, C, and D). Healthy participants in Part A Period 1 will receive a single dose of LY3938577 or a placebo given via intravenous (IV) infusion. In Part A Period 2, participants will receive a single subcutaneous (SC) dose of either LY3938577 or placebo. Participants in Part B with Type 1 Diabetes Mellitus (T1DM) will receive single doses of either LY3938577 or Insulin Degludec given via IV infusion. Participants in Part C with Type 1 Diabetes Mellitus (T1DM) will receive two d"}
 {"nctId": "NCT02575703", "briefTitle": "A Study of [\u00b9\u2074C]-LY3023414 in Healthy Participants", "officialTitle": "Disposition of [\u00b9\u2074C]-LY3023414 Following Oral Administration in Healthy Subjects", "overallStatus": "COMPLETED", "startDate": "2015-10", "completionDate": "2015-11", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 8, "briefSummary": "This type of study is called a radiolabeled study. For this study, LY3023414 has been specially prepared to contain the radioactive carbon atom \\[\u00b9\u2074C\\]. \\[\u00b9\u2074C\\] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study drug does not change how the drug works but helps to identify when the drug appears in the blood, urine, breath, and stool after it is given. The study will last about 15 days for each participant, not including screening. Screening is required within 28 days prior to enrollment. This study is for research purposes only and is not intended to treat any medical condition.", "conditions": ["Healthy"], "keywords": [], "interventions": [{"type": "DRUG", "name": "[\u00b9\u2074C]-LY3023414", "otherNames": []}], "meshConditions": [], "meshInterventions": ["LY3023414"], "hasResults": false, "classifyText": "A Study of [\u00b9\u2074C]-LY3023414 in Healthy Participants Healthy [\u00b9\u2074C]-LY3023414 LY3023414 This type of study is called a radiolabeled study. For this study, LY3023414 has been specially prepared to contain the radioactive carbon atom \\[\u00b9\u2074C\\]. \\[\u00b9\u2074C\\] is a naturally occurring radioactive form of the element carbon. Adding a low dose of radiation to the study drug does not change how the drug works but helps to identify when the drug appears in the blood, urine, breath, and stool after it is given. The study will last about 15 days for each participant, not including screening. Screening is required within 28 days prior to enrollment. This study is for research purposes only and is not intended to treat any medical condition."}
 {"nctId": "NCT06503679", "briefTitle": "A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants", "officialTitle": "A Phase 1, Single-center, Open-label, Fixed-sequence, Crossover Study to Evaluate the Effect of LY4100511 (DC-853) on the Single-dose Pharmacokinetics of Midazolam, Repaglinide, Digoxin, and Rosuvastatin in Healthy Participants", "overallStatus": "COMPLETED", "startDate": "2024-07-16", "completionDate": "2024-12-31", "leadSponsor": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 49, "briefSummary": "The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.", "conditions": ["Healthy"], "keywords": ["LY4100511", "DC-853"], "interventions": [{"type": "DRUG", "name": "LY4100511 (DC-853) Dose 1", "otherNames": []}, {"type": "DRUG", "name": "LY4100511 (DC-853) Dose 2", "otherNames": []}, {"type": "DRUG", "name": "LY4100511 (DC-853) Dose 3", "otherNames": []}, {"type": "DRUG", "name": "Midazolam", "otherNames": []}, {"type": "DRUG", "name": "Repaglinide", "otherNames": []}, {"type": "DRUG", "name": "Digoxin", "otherNames": []}, {"type": "DRUG", "name": "Rosuvastatin", "otherNames": []}], "meshConditions": [], "meshInterventions": ["Midazolam", "repaglinide", "Digoxin", "Rosuvastatin Calcium"], "hasResults": false, "classifyText": "A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants Healthy LY4100511 DC-853 LY4100511 (DC-853) Dose 1 LY4100511 (DC-853) Dose 2 LY4100511 (DC-853) Dose 3 Midazolam Repaglinide Digoxin Rosuvastatin Midazolam repaglinide Digoxin Rosuvastatin Calcium The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants."}
 {"nctId": "NCT03928379", "briefTitle": "A Study of LY3305677 in Participants With Type 2 Diabetes", "officialTitle": "A Multiple-Ascending Dose Study in Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677", "overallStatus": "COMPLETED", "startDate": "2019-10-27", "completionDate": "2021-07-08", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 24, "briefSummary": "The main purpose of this study is to learn more about the safety and side effects of LY3305677 when it is given as an injection just under the skin to participants with type 2 diabetes. The study will last about 20 weeks for each participant, not including screening.", "conditions": ["Diabetes Mellitus, Type 2"], "keywords": [], "interventions": [{"type": "DRUG", "name": "LY3305677", "otherNames": []}, {"type": "DRUG", "name": "Placebo", "otherNames": []}], "meshConditions": ["Diabetes Mellitus, Type 2"], "meshInterventions": ["mazdutide"], "hasResults": false, "classifyText": "A Study of LY3305677 in Participants With Type 2 Diabetes Diabetes Mellitus, Type 2 LY3305677 Placebo Diabetes Mellitus, Type 2 mazdutide The main purpose of this study is to learn more about the safety and side effects of LY3305677 when it is given as an injection just under the skin to participants with type 2 diabetes. The study will last about 20 weeks for each participant, not including screening."}
 {"nctId": "NCT00308750", "briefTitle": "First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)", "officialTitle": "A Randomized, Open-label Phase II Study of Pemetrexed (Alimta) Plus Carboplatin With or Without Enzastaurin Hydrochloride, or Docetaxel Plus Carboplatin as First Line Treatment in Patients With Advanced Stage Non-small Cell Lung Cancer (NSCLC)", "overallStatus": "COMPLETED", "startDate": "2006-03", "completionDate": "2009-07", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "primaryPurpose": "TREATMENT", "enrollment": 218, "briefSummary": "The purposes of this study are to determine:\n\nThe safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or docetaxel with carboplatin and any side effects that might be associated with the combination of these drugs.\n\nWhether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can help participants with non-small cell lung cancer (NSCLC) live longer, compared with the combination of docetaxel and carboplatin.\n\nWhether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can make your tumor smaller or disappear, and for how long, compared with the combination of docetaxel and carboplatin.\n\nThe effects of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin or docetaxel with carboplatin have on your disease related symptoms.\n\nThe relation of smoking history and hormone replacement therapy (for women only) may have to your lung cancer treatment results.\n\nThe effects of certain genes and proteins in samples of your blood and tumor tissue in order to learn more about NSCLC and how enzastaurin works in the body.", "conditions": ["Non-Small Cell Lung Cancer"], "keywords": [], "interventions": [{"type": "DRUG", "name": "enzastaurin", "otherNames": ["LY317615"]}, {"type": "DRUG", "name": "pemetrexed", "otherNames": ["LY231514", "Alimta"]}, {"type": "DRUG", "name": "docetaxel", "otherNames": []}, {"type": "DRUG", "name": "carboplatin", "otherNames": []}], "meshConditions": ["Carcinoma, Non-Small-Cell Lung"], "meshInterventions": ["enzastaurin", "Pemetrexed", "Docetaxel", "Carboplatin"], "hasResults": true, "classifyText": "First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Non-Small Cell Lung Cancer enzastaurin pemetrexed docetaxel carboplatin Carcinoma, Non-Small-Cell Lung enzastaurin Pemetrexed Docetaxel Carboplatin The purposes of this study are to determine:\n\nThe safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or docetaxel with carboplatin and any side effects that might be associated with the combination of these drugs.\n\nWhether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can help participants with non-small cell lung cancer (NSCLC) live longer, compared with the combination of docetaxel and carboplatin.\n\nWhether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can make your tumor smaller or disappear, and for how long, compared with the combination of docetaxel and carboplatin.\n\nThe effects of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin or docetaxel with carboplatin have on your disease related symptoms.\n\nThe relation of smoking history and hormone replacement therapy (for women only) may have to your lung cancer treatment results.\n\nThe"}
 {"nctId": "NCT01742091", "briefTitle": "A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women", "officialTitle": "A Multiple Dose Study of LY2541546 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Postmenopausal Women", "overallStatus": "COMPLETED", "startDate": "2009-09", "completionDate": "2010-03", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "primaryPurpose": "BASIC_SCIENCE", "enrollment": 59, "briefSummary": "The purpose of this study is to assess the safety and side effects of multiple doses of LY2541546 in postmenopausal women when given subcutaneously (injection just under the skin) and intravenously (directly into a vein). The study will also test how long it takes the study drug to get into the body, how long it takes the body to get rid of it, the overall effect of the study drug on the body, and whether antibodies to the study drug are formed.", "conditions": ["Healthy"], "keywords": ["Postmenopausal females", "Volunteers"], "interventions": [{"type": "DRUG", "name": "LY2541546 - SC", "otherNames": ["Blosozumab"]}, {"type": "DRUG", "name": "LY2541546 - IV", "otherNames": ["Blosozumab"]}, {"type": "DRUG", "name": "Placebo - SC", "otherNames": []}, {"type": "DRUG", "name": "Placebo - IV", "otherNames": []}], "meshConditions": [], "meshInterventions": ["blosozumab"], "hasResults": true, "classifyText": "A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women Healthy Postmenopausal females Volunteers LY2541546 - SC LY2541546 - IV Placebo - SC Placebo - IV blosozumab The purpose of this study is to assess the safety and side effects of multiple doses of LY2541546 in postmenopausal women when given subcutaneously (injection just under the skin) and intravenously (directly into a vein). The study will also test how long it takes the study drug to get into the body, how long it takes the body to get rid of it, the overall effect of the study drug on the body, and whether antibodies to the study drug are formed."}
 {"nctId": "NCT00191360", "briefTitle": "Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency", "officialTitle": "Extended Clinical Study of LY137998 [Somatropin (Recombinant DNA Origin)] in Adults With Growth Hormone Deficiency", "overallStatus": "COMPLETED", "startDate": "2003-01", "completionDate": "2006-05", "leadSponsor": "Eli Lilly and Company", "collaborators": [], "studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "primaryPurpose": "TREATMENT", "enrollment": 68, "briefSummary": "To evaluate long-term safety of growth hormone replacement in adult patients with growth hormone deficiency", "conditions": ["Adult Growth Hormone Deficiency"], "keywords": [], "interventions": [{"type": "DRUG", "name": "Somatropin", "otherNames": []}], "meshConditions": ["Dwarfism, Pituitary"], "meshInterventions": ["Human Growth Hormone"], "hasResults": false, "classifyText": "Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency Adult Growth Hormone Deficiency Somatropin Dwarfism, Pituitary Human Growth Hormone To evaluate long-term safety of
No results found